

**(19) World Intellectual Property
Organization
International Bureau**



(43) International Publication Date
2 September 2004 (02.09.2004)


PCT

(10) International Publication Number
WO 2004/074498 A2

- | | |
|--|--|
| <p>(51) International Patent Classification⁷:
C12N 9/10, 5/10, 15/81</p> <p>(21) International Application Number:
PCT/US2004/005132</p> <p>(22) International Filing Date: 20 February 2004 (20.02.2004)</p> <p>(25) Filing Language: English</p> <p>(26) Publication Language: English</p> <p>(30) Priority Data:
10/371,877 20 February 2003 (20.02.2003) US
10/616,082 8 July 2003 (08.07.2003) US</p> <p>(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier applications:
US 10/371,877 (CIP)
Filed on 20 February 2003 (20.02.2003)
US 10/616,082 (CIP)
Filed on 8 July 2003 (08.07.2003)</p> | <p>(71) Applicants and
(72) Inventors: HAMILTON, Stephen, R. [GB/US]; 11 Rocky Hill Road #211, Enfield, NH 03748 (US). GERN-GROSS, Tillman, U. [AT/US]; 2 Parkway, Hanover, NH 03755 (US). WILDT, Stefan [DE/US]; 32 Parkhurst Street, Lebanon, NH 03766 (US). CHOL, Byung-Kwon [KR/US]; 24 Hazen Street, Norwich, VT 05055 (US). NETT, Juergen, Hermann [DE/US]; P.O. Box 808, Grantham, NH 03753 (US). BOBROWICZ, Piotr [PL/US]; 292 Woodhaven Dr., 9B, White River Junction, VT 05001 (US). DAVIDSON, Robert, C. [US/US]; 37 Landing Road # 2, Enfield, NH 03748 (US).</p> <p>(74) Agents: HALEY, James, F. et al.; c/o Fish & Neave, 1251 Avenue of the Americas, New York, NY 10020 (US).</p> <p>(81) Designated States (<i>unless otherwise indicated, for every kind of national protection available</i>): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,</p> |
|--|--|

[Continued on next page]

- (54) Title: EXPRESSION OF CLASS 2 MANNOSIDASE AND CLASS III MANNOSIDASE IN LOWER EUKARYOTIC CELLS



(57) Abstract: A method for producing human-like glycoproteins by expressing a Class 2 α -mannosidase having a substrate specificity for Man α 1,3 and Man α 1,6 glycosidic linkages in a lower eukaryote is disclosed. Hydrolysis of these linkages on oligosaccharides produces substrates for further N-glycan processing in the secretory pathway.

WO 2004/074498 A2



KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW.

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

- (84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

EXPRESSION OF CLASS 2 MANNOSIDASE AND CLASS III
MANNOSIDASE IN LOWER EUKARYOTIC CELLS

CROSS REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority to U.S. Application No. 10/616, 082
5 which is a continuation-in-part of U. S. Application No. 10/371,877, filed on Feb.
20, 2003, which is a continuation-in-part of U. S. Application No. 09/892,591,
filed June 27, 2001, which claims the benefit under 35 U.S.C. §119(e) of U.S.
Provisional Application No. 60/214,358, filed June 28, 2000, U.S. Provisional
Application No. 60/215,638, filed June 30, 2000, and U.S. Provisional Application
10 No. 60/279,997, filed March 30, 2001, each of which is incorporated herein by
reference in its entirety.

FIELD OF THE INVENTION

[0002] The present invention relates to the field of protein glycosylation in lower
15 eukaryotes, specifically the introduction of a mannosidase enzyme having substrate
specificity for hydrolysis of Man α 1,3 and/or Man α 1,6 glycosidic linkages. The
present invention further relates to novel host cells comprising genes encoding a
mannosidase enzyme and N-glycan or N-glycan-containing intermediates produced
as a result of the hydrolysis.

20

BACKGROUND OF THE INVENTION

Glycosylation Pathways in Humans and Lower Eukaryotes

[0003] After DNA is transcribed and translated into a protein, further post-
translational processing involves the attachment of sugar residues, a process known

as glycosylation. Different organisms produce different glycosylation enzymes (glycosyltransferases and glycosidases), and have different substrates (nucleotide sugars) available, so that the glycosylation patterns as well as composition of the individual oligosaccharides, even of the same protein, will be different depending on the host system in which the particular protein is being expressed. Bacteria typically do not glycosylate proteins, and if so only in a very unspecific manner (Moens and Vanderleyden, 1997 *Arch Microbiol.* 168(3):169-175). Lower eukaryotes such as filamentous fungi and yeast add primarily mannose and mannosylphosphate sugars. The resulting glycan is known as a "high-mannose" type glycan or a mannan. Plant cells and insect cells (such as Sf9 cells) glycosylate proteins in yet another way. By contrast, in higher eukaryotes such as humans, the nascent oligosaccharide side chain may be trimmed to remove several mannose residues and elongated with additional sugar residues that typically are not found in the *N*-glycans of lower eukaryotes. See, e.g., R.K. Bretthauer, et al. *Biotechnology and Applied Biochemistry*, 1999, 30, 193-200; W. Martinet, et al. *Biotechnology Letters*, 1998, 20, 1171-1177; S. Weikert, et al. *Nature Biotechnology*, 1999, 17, 1116-1121; M. Malissard, et al. *Biochemical and Biophysical Research Communications*, 2000, 267, 169-173; Jarvis, et al., *Current Opinion in Biotechnology*, 1998, 9:528-533; and M. Takeuchi, *Trends in Glycoscience and Glycotechnology*, 1997, 9, S29-S35.

[0004] Synthesis of a mammalian-type oligosaccharide structure begins with a set of sequential reactions in the course of which sugar residues are added and removed while the protein moves along the secretory pathway in the host organism. The enzymes which reside along the glycosylation pathway of the host organism or cell determine the resulting glycosylation patterns of secreted proteins. Thus, the resulting glycosylation pattern of proteins expressed in lower eukaryotic host cells differs substantially from the glycosylation pattern of proteins expressed in higher eukaryotes such as humans and other mammals (Bretthauer, 1999). The structure of a typical fungal *N*-glycan is shown in Figure 1A.

[0005] The early steps of human glycosylation can be divided into at least two different phases: (i) lipid-linked Glc₃Man₉GlcNAc₂ oligosaccharides are assembled by a sequential set of reactions at the membrane of the endoplasmic reticulum (ER)

and (ii) the transfer of this oligosaccharide from the lipid anchor dolichyl pyrophosphate onto *de novo* synthesized protein.* The site of the specific transfer is defined by an asparagine (Asn) residue in the sequence Asn-Xaa-Ser/Thr where Xaa can be any amino acid except proline (Gavel and von Heijne, 1990 *Protein Eng.* 3:433-42). Further processing by glucosidases and mannosidases occurs in the ER before the nascent glycoprotein is transferred to the early Golgi apparatus, where additional mannose residues are removed by Golgi specific alpha (α -1,2-) mannosidases. Processing continues as the protein proceeds through the Golgi. In the medial Golgi, a number of modifying enzymes, including *N*-
5 acetylglucosaminyl Transferases (GnTI, GnTII, GnTIII, GnTIV and GnTV),
mannosidase II and fucosyltransferases, add and remove specific sugar residues. Finally, in the trans-Golgi, galactosyltransferases (GalT) and sialyltransferases (ST) produce a glycoprotein structure that is released from the Golgi. It is this structure, characterized by bi-, tri- and tetra-antennary structures, containing galactose,
10 fucose, N-acetylglucosamine and a high degree of terminal sialic acid, that gives
15 glycoproteins their human characteristics. The structure of a typical human *N*-glycan is shown in Figure 1B.

[0006] In nearly all eukaryotes, glycoproteins are derived from a common lipid-linked oligosaccharide precursor Glc₃Man₉GlcNAc₂-dolichol-pyrophosphate.
20 Within the endoplasmic reticulum, synthesis and processing of dolichol pyrophosphate bound oligosaccharides are identical between all known eukaryotes. However, further processing of the core oligosaccharide by fungal cells, e.g., yeast, once it has been transferred to a peptide leaving the ER and entering the Golgi, differs significantly from humans as it moves along the secretory pathway and
25 involves the addition of several mannose sugars.

[0007] In yeast, these steps are catalyzed by Golgi residing mannosyl-transferases, like Och1p, Mnt1p and Mnn1p, which sequentially add mannose sugars to the core oligosaccharide. The resulting structure is undesirable for the production of human-like proteins and it is thus desirable to reduce or eliminate
30 mannosyltransferase activity. Mutants of *S.cerevisiae*, deficient in mannosyl-transferase activity (for example *och1* or *mnn9* mutants) have been shown to be

non-lethal and display reduced mannose content in the oligosaccharide of yeast glycoproteins, thus more closely resembling oligosaccharides of higher eukaryotes.

Sugar Nucleotide Precursors

- 5 [0008] The *N*-glycans of animal glycoproteins typically include galactose, fucose, and terminal sialic acid. These sugars are not found on glycoproteins produced in yeast and filamentous fungi. In humans, the full range of nucleotide sugar precursors (e.g. UDP-*N*-acetylglucosamine, UDP-*N*-acetylgalactosamine, CMP-*N*-acetylneuraminic acid, UDP-galactose, GDP-fucose, etc.) are synthesized
- 10 in the cytosol and transported into the Golgi, where they are attached to the core oligosaccharide by glycosyltransferases. (Sommers and Hirschberg, 1981 *J. Cell Biol.* 91(2): A406-A406; Sommers and Hirschberg 1982 *J. Biol. Chem.* 257(18): 811-817; Perez and Hirschberg 1987 *Methods in Enzymology* 138: 709-715).
- [0009] Glycosyl transfer reactions typically yield a side product which is a
- 15 nucleoside diphosphate or monophosphate. While monophosphates can be directly exported in exchange for nucleoside triphosphate sugars by an antiport mechanism, diphosphonucleosides (e.g. GDP) have to be cleaved by phosphatases (e.g. GDPase) to yield nucleoside monophosphates and inorganic phosphate prior to being exported. This reaction is important for efficient glycosylation; for example,
- 20 GDPase from *Saccharomyces cerevisiae* (*S.cerevisiae*) has been found to be necessary for mannosylation. However that GDPase has 90% reduced activity toward UDP (Berninsone et al., 1994 *J. Biol. Chem.* 269(1):207-211). Lower eukaryotes typically lack UDP-specific diphosphatase activity in the Golgi since they do not utilize UDP-sugar precursors for Golgi-based glycoprotein synthesis.
- 25 *Schizosaccharomyces pombe*, a yeast found to add galactose residues to cell wall polysaccharides (from UDP-galactose) has been found to have specific UDPase activity, indicating the potential requirement for such an enzyme (Berninsone et al. (1994) *J. Biol. Chem.* 269(1):207-211). UDP is known to be a potent inhibitor of glycosyltransferases and the removal of this glycosylation side product may be
- 30 important to prevent glycosyl-transferase inhibition in the lumen of the Golgi (Khatara et al., 1974). See Berninsone, P., et al. 1995. *J. Biol. Chem.* 270(24):

14564-14567; Beaudet, L., et al. 1998 *Abc Transporters: Biochemical, Cellular, and Molecular Aspects*. 292: 397-413.

- 5 **Sequential Processing of N-glycans by Compartmentalized Enzyme Activities**
[0010] Sugar transferases and glycosidases (e.g., mannosidases) line the inner (luminal) surface of the ER and Golgi apparatus and thereby provide a "catalytic" surface that allows for the sequential processing of glycoproteins as they proceed through the ER and Golgi network. The multiple compartments of the cis, medial, and trans Golgi and the trans-Golgi Network (TGN), provide the different localities in which the ordered sequence of glycosylation reactions can take place. As a glycoprotein proceeds from synthesis in the ER to full maturation in the late Golgi or TGN, it is sequentially exposed to different glycosidases, mannosidases and glycosyltransferases such that a specific carbohydrate structure may be synthesized. Much work has been dedicated to revealing the exact mechanism by which these enzymes are retained and anchored to their respective organelle. The evolving picture is complex but evidence suggests that stem region, membrane spanning region and cytoplasmic tail, individually or in concert, direct enzymes to the membrane of individual organelles and thereby localize the associated catalytic domain to that locus (see, e.g., Gleeson, P.A. (1998) *Histochem. Cell Biol.* 109, 517-532).
- 15 [0011] In some cases, these specific interactions were found to function across species. For example, the membrane spanning domain of $\alpha 2,6$ -ST from rats, an enzyme known to localize in the trans-Golgi of the animal, was shown to also localize a reporter gene (invertase) in the yeast Golgi (Schwientek et al. (1995) *J. Biol. Chem.* 270(10):5483-9). However, the very same membrane spanning domain as part of a full-length $\alpha 2,6$ -ST was retained in the ER and not further transported to the Golgi of yeast (Krezdorn et al. (1994) *Eur. J. Biochem.* 220(3):809-17). A full length GalT from humans was not even synthesized in yeast, despite demonstrably high transcription levels. In contrast, the transmembrane region of the same human GalT fused to an invertase reporter was able to direct localization to the yeast Golgi, albeit at low production levels.
- 20
- 25
- 30

Schwientek and co-workers have shown that fusing 28 amino acids of a yeast mannosyltransferase (*MNT1*), a region containing a cytoplasmic tail, a transmembrane region and eight amino acids of the stem region, to the catalytic domain of human GalT are sufficient for Golgi localization of an active GalT.

- 5 Other galactosyltransferases appear to rely on interactions with enzymes resident in particular organelles because, after removal of their transmembrane region, they are still able to localize properly.

[0012] Improper localization of a glycosylation enzyme may prevent proper functioning of the enzyme in the pathway. For example, *Aspergillus nidulans*,
10 which has numerous α -1,2-mannosidases (Eades and Hintz, 2000 *Gene* 255(1):25-34), does not add GlcNAc to Man₅GlcNAc₂ when transformed with the rabbit GnTI gene, despite a high overall level of GnTI activity (Kalsner et al. (1995) *Glycoconj. J.* 12(3):360-370). GnTI, although actively expressed, may be incorrectly localized such that the enzyme is not in contact with both of its
15 substrates: UDP-GlcNAc and a productive Man₅GlcNAc₂ substrate (not all Man₅GlcNAc₂ structures are productive; see below). Alternatively, the host organism may not provide an adequate level of UDP-GlcNAc in the Golgi or the enzyme may be properly localized but nevertheless inactive in its new environment. In addition, Man₅GlcNAc₂ structures present in the host cell may
20 differ in structure from Man₅GlcNAc₂ found in mammals. Maras and coworkers found that about one third of the N-glycans from cellobiohydrolase I (CBHI) obtained from *T.reesei* can be trimmed to Man₅GlcNAc₂ by *A.saitoi* 1,2 mannosidase *in vitro*. Fewer than 1% of those N-glycans, however, could serve as a productive substrate for GnTI. Maras et al., 1997, *Eur. J. Biochem.* 249, 701-
25 707. The mere presence of Man₅GlcNAc₂, therefore, does not assure that further *in vivo* processing of Man₅GlcNAc₂ can be achieved. It is formation of a productive, GnTI-reactive Man₅GlcNAc₂ structure that is required. Although Man₅GlcNAc₂ could be produced in the cell (about 27 mol %), only a small fraction could be converted to Man₅GlcNAc₂ (less than about 5%, see Chiba WO
30 01/14522).

[0013] To date, there is no reliable way of predicting whether a particular heterologously expressed glycosyltransferase or mannosidase in a lower eukaryote

will be (1) sufficiently translated, (2) catalytically active or (3) located to the proper organelle within the secretory pathway. Because all three of these are necessary to affect glycosylation patterns in lower eukaryotes, a systematic scheme to achieve the desired catalytic function and proper retention of enzymes in the absence of predictive tools, which are currently not available, would be desirable.

Production of Therapeutic Glycoproteins

[0014] A significant number of proteins isolated from humans or animals are post-translationally modified, with glycosylation being one of the most significant modifications. An estimated 70% of all therapeutic proteins are glycosylated and thus currently rely on a production system (i.e., host cell) that is able to glycosylate in a manner similar to humans. Several studies have shown that glycosylation plays an important role in determining the (1) immunogenicity, (2) pharmacokinetic properties, (3) trafficking and (4) efficacy of therapeutic proteins. It is thus not surprising that substantial efforts by the pharmaceutical industry have been directed at developing processes to obtain glycoproteins that are as "humanoid" or "human-like" as possible. To date, most glycoproteins are made in a mammalian host system. This may involve the genetic engineering of such mammalian cells to enhance the degree of sialylation (i.e., terminal addition of sialic acid) of proteins expressed by the cells, which is known to improve pharmacokinetic properties of such proteins. Alternatively, one may improve the degree of sialylation by *in vitro* addition of such sugars using known glycosyltransferases and their respective nucleotide sugars (e.g., 2,3-sialyltransferase and CMP-sialic acid).

[0015] While most higher eukaryotes carry out glycosylation reactions that are similar to those found in humans, recombinant human proteins expressed in the above mentioned host systems invariably differ from their "natural" human counterpart (Raju et al. (2000) *Glycobiology* 10(5): 477-486). Extensive development work has thus been directed at finding ways to improve the "human character" of proteins made in these expression systems. This includes the optimization of fermentation conditions and the genetic modification of protein expression hosts by introducing genes encoding enzymes involved in the formation

of human-like glycoforms. Goochee et al. (1999) *Biotechnology* 9(12):1347-55; Andersen and Goochee (1994) *Curr Opin Biotechnol.* 5(5):546-49; Werner et al. (1998) *Arzneimittelforschung.* 48(8):870-80; Weikert et al. (1999) *Nat Biotechnol.* 17(11):1116-21; Yang and Butler (2000) *Biotech. Bioeng.* 68:370-80. Inherent
5 problems associated with all mammalian expression systems have not been solved.

Glycoprotein Production Using Eukaryotic Microorganisms

[0016] Although the core oligosaccharide structure transferred to a protein in the endoplasmic reticulum is basically identical in mammals and lower eukaryotes,
10 substantial differences have been found in the subsequent processing reactions which occur in the Golgi apparatus of fungi and mammals. In fact, even amongst different lower eukaryotes there exist a great variety of glycosylation structures. This has historically prevented the use of lower eukaryotes as hosts for the production of recombinant human glycoproteins despite otherwise notable
15 advantages over mammalian expression systems.

[0017] Therapeutic glycoproteins produced in a microorganism host such as yeast utilizing the endogenous host glycosylation pathway differ structurally from those produced in mammalian cells and typically show greatly reduced therapeutic efficacy. Such glycoproteins are typically immunogenic in humans and show a
20 reduced half-life (and thus bioactivity) *in vivo* after administration (Takeuchi (1997) *Trends in Glycoscience and Glycotechnology* 9, S29-S35). Specific receptors in humans and animals (i.e., macrophage mannose receptors) can recognize terminal mannose residues and promote the rapid clearance of the foreign glycoprotein from the bloodstream. Additional adverse effects may
25 include changes in protein folding, solubility, susceptibility to proteases, trafficking, transport, compartmentalization, secretion, recognition by other proteins or factors, antigenicity, or allergenicity.

[0018] Yeast and filamentous fungi have both been successfully used for the production of recombinant proteins, both intracellular and secreted (Cereghino, J.
30 L. and J. M. Cregg 2000 *FEMS Microbiology Reviews* 24(1): 45-66; Harkki, A., et al. 1989 *Bio-Technology* 7(6): 596; Berka, R. M., et al. 1992 *Abstr.Papers Amer. Chem.Soc.* 203: 121-BIOT; Svetina, M., et al. 2000 *J. Biotechnol.* 76(2-3): 245-

251). Various yeasts, such as *K. lactis*, *Pichia pastoris*, *Pichia methanolica*, and *Hansenula polymorpha*, have played particularly important roles as eukaryotic expression systems because they are able to grow to high cell densities and secrete large quantities of recombinant protein. Likewise, filamentous fungi, such as
5 *Aspergillus niger*, *Fusarium sp.*, *Neurospora crassa* and others, have been used to efficiently produce glycoproteins at the industrial scale. However, as noted above, glycoproteins expressed in any of these eukaryotic microorganisms differ substantially in *N*-glycan structure from those in animals. This has prevented the use of yeast or filamentous fungi as hosts for the production of many therapeutic
10 glycoproteins.

[0019] Although glycosylation in yeast and fungi is very different than in humans, some common elements are shared. The first step, the transfer of the core oligosaccharide structure to the nascent protein, is highly conserved in all eukaryotes including yeast, fungi, plants and humans (compare Figures 1A and
15 1B). Subsequent processing of the core oligosaccharide, however, differs significantly in yeast and involves the addition of several mannose sugars. This step is catalyzed by mannosyltransferases residing in the Golgi (e.g. *OCH1*, *MNT1*, *MNN1*, etc.), which sequentially add mannose sugars to the core oligosaccharide. The resulting structure is undesirable for the production of humanoid proteins and it is thus desirable to reduce or eliminate mannosyltransferase activity. Mutants of
20 *S.cerevisiae* deficient in mannosyltransferase activity (e.g. *och1* or *mnn9* mutants) have shown to be non-lethal and display a reduced mannose content in the oligosaccharide of yeast glycoproteins. Other oligosaccharide processing enzymes, such as mannosylphosphate transferases, may also have to be eliminated
25 depending on the host's particular endogenous glycosylation pattern. After reducing undesired endogenous glycosylation reactions, the formation of complex *N*-glycans has to be engineered into the host system. This requires the stable expression of several enzymes and sugar-nucleotide transporters. Moreover, one has to localize these enzymes so that a sequential processing of the maturing
30 glycosylation structure is ensured.

[0020] Several efforts have been made to modify the glycosylation pathways of eukaryotic microorganisms to provide glycoproteins more suitable for use as

mammalian therapeutic agents. For example, several glycosyltransferases have been separately cloned and expressed in *S. cerevisiae* (GalT, GnTI), *Aspergillus nidulans* (GnTI) and other fungi (Yoshida et al. (1999) *Glycobiology* 9(1):53-8, , Kalsner et al. (1995) *Glycoconj. J.* 12(3):360-370). However, *N*-glycans

5 resembling those made in human cells were not obtained.

[0021] Yeasts produce a variety of mannosyltransferases (e.g., 1,3-mannosyltransferases such as *MNN1* in *S. cerevisiae*; Graham and Emr, 1991 *J. Cell. Biol.* 114(2):207-218), 1,2-mannosyltransferases (e.g. *KTR/KRE* family from *S.cerevisiae*), 1,6-mannosyltransferases (e.g., *OCH1* from *S.cerevisiae*),
10 mannosylphosphate transferases and their regulators (e.g., *MNN4* and *MNN6* from *S.cerevisiae*) and additional enzymes that are involved in endogenous glycosylation reactions. Many of these genes have been deleted individually giving rise to viable organisms having altered glycosylation profiles. Examples are shown in Table 1.

15 **Table 1. Examples of yeast strains having altered mannosylation**

Strain	<i>N</i> -glycan (wild type)	Mutation	<i>N</i> -glycan (mutant)	Reference
<i>S. pombe</i>	Man ₈ GlcNAc ₂	OCH1	Man ₈ GlcNAc ₂	Yoko-o et al., 2001 <i>FEBS Lett.</i> 489(1):75-80
<i>S.cerevisiae</i>	Man ₉ GlcNAc ₂	OCH1/MNN1	Man ₈ GlcNAc ₂	Nakanishi-Shindo et al., 1993 <i>J. Biol. Chem.</i> 268(35):26338-26345
<i>S.cerevisiae</i>	Man ₉ GlcNAc ₂	OCH1/MNN1/MNN4	Man ₈ GlcNAc ₂	Chiba et al., 1998 <i>J. Biol. Chem.</i> 273, 26298-26304
<i>P.pastoris</i>	Hyperglycosylated	OCH1 (complete deletion)	Not hyperglycosylated	Welfide, Japanese Application Publication No. 8-336387
<i>P.pastoris</i>	Man ₈ GlcNAc ₂	OCH1 (disruption)	Man ₈ GlcNAc ₂	Contreras et al. WO 02/00856 A2

[0022] Japanese Patent Application Publication No. 8-336387 discloses the deletion of an *OCH1* homolog in *Pichia pastoris*. In *S.cerevisiae*, *OCH1* encodes a 1,6-mannosyltransferase, which adds a mannose to the glycan structure
20 Man₈GlcNAc₂ to yield Man₉GlcNAc₂. The Man₉GlcNAc₂ structure, which contains three 1,6 mannose residues, is then a substrate for further 1,2-, 1,6-, and

1,3- mannosyltransferases *in vivo*, leading to the hypermannosylated glycoproteins that are characteristic for *S.cerevisiae* and which typically may have 30-40 mannose residues per *N*-glycan. Because the Och1p initiates the transfer of 1,6 mannose to the Man₈GlcNAc₂ core, it is often referred to as the “initiating 1,6 mannosyltransferase” to distinguish it from other 1,6 mannosyltransferases acting later in the Golgi. In an *och1 mnn1 mnn4* mutant strain of *S.cerevisiae*, proteins glycosylated with Man₈GlcNAc₂ accumulate and hypermannosylation does not occur. However, Man₈GlcNAc₂ is not a substrate for mammalian glycosyltransferases, such as human UDP-GlcNAc transferase I, and accordingly, the use of that mutant strain, in itself, is not useful for producing mammalian-like proteins, i.e., with complex or hybrid glycosylation patterns.

[0023] One can trim Man₈GlcNAc₂ structures to a Man₅GlcNAc₂ isomer in *S.cerevisiae* (although high efficiency trimming greater than 50% *in vivo* has yet to be demonstrated) by engineering a fungal mannosidase from *A. saitoi* into the endoplasmic reticulum (ER). The shortcomings of this approach are two-fold: (1) it is not clear whether the Man₅GlcNAc₂ structures formed are in fact formed *in vivo* (rather than having been secreted and further modified by mannosidases outside the cell); and (2) it is not clear whether any Man₅GlcNAc₂ structures formed, if in fact formed *in vivo*, are the correct isoform to be a productive substrate for subsequent *N*-glycan modification by GlcNAc transferase I (Maras et al., 1997, *Eur. J. Biochem.* 249, 701-707).

[0024] With the objective of providing a more human-like glycoprotein derived from a fungal host, U.S. Patent No. 5,834,251 discloses a method for producing a hybrid glycoprotein derived from *Trichoderma reesei*. A hybrid *N*-glycan has only mannose residues on the Man α 1-6 arm of the core mannose structure and one or two complex antennae on the Man α 1-3 arm. While this structure has utility, the method has the disadvantage that numerous enzymatic steps must be performed *in vitro*, which is costly and time-consuming. Isolated enzymes are expensive to prepare and need costly substrates (e.g. UDP-GlcNAc). The method also does not allow for the production of complex glycans on a desired protein.

Intracellular Mannosidase Activity Involved in N-glycan Trimming

- [0025] Alpha-1,2-mannosidase activity is required for the trimming of $\text{Man}_8\text{GlcNAc}_2$ to form $\text{Man}_5\text{GlcNAc}_2$, which is a major intermediate for complex N-glycan formation in mammals. Previous work has shown that truncated murine, fungal and human α -1,2-mannosidase can be expressed in the methylotropic yeast *P.pastoris* and display $\text{Man}_8\text{GlcNAc}_2$ to $\text{Man}_5\text{GlcNAc}_2$ trimming activity (Lal et al., *Glycobiology* 1998 Oct;8(10):981-95; Tremblay et al., *Glycobiology* 1998 Jun;8(6):585-95, Callewaert et al. (2001) *FEBS Lett.* 503(2-3):173-8). However, to date, no reports exist that show the high level *in vivo* trimming of $\text{Man}_8\text{GlcNAc}_2$ to $\text{Man}_5\text{GlcNAc}_2$ on a secreted glycoprotein from *P.pastoris*.
- [0026] Moreover, the mere presence of an α -1,2-mannosidase in the cell does not, by itself, ensure proper intracellular trimming of $\text{Man}_8\text{GlcNAc}_2$ to $\text{Man}_5\text{GlcNAc}_2$. (See, e.g., Contreras et al. WO 02/00856 A2, in which an HDEL tagged mannosidase of *T. reesei* is localized primarily in the ER and co-expressed with an influenza haemagglutinin (HA) reporter protein on which virtually no $\text{Man}_5\text{GlcNAc}_2$ could be detected. See also Chiba et al. (1998) *J. Biol. Chem.* 273(41): 26298-26304, in which a chimeric α -1,2-mannosidase/Och1p transmembrane domain fusion localized in the ER, early Golgi and cytosol of *S.cerevisiae*, had no mannosidase trimming activity). Accordingly, mere localization of a mannosidase in the ER or Golgi is insufficient to ensure activity of the respective enzyme in that targeted organelle. (See also, Martinet et al. (1998) *Biotech. Letters* 20(12): 1171-1177, showing that α -1,2-mannosidase from *T. reesei*, while localizing intracellularly, increased rather than decreased the extent of mannosylation). To date, there is no report that demonstrates the intracellular localization of an active heterologous α -1,2- mannosidase in either yeast or fungi using a transmembrane localization sequence.
- [0027] While it is useful to engineer strains that are able to produce $\text{Man}_5\text{GlcNAc}_2$ as the primary N-glycan structure, any attempt to further modify these high mannose precursor structures to more closely resemble human glycans requires additional *in vivo* or *in vitro* steps. Methods to further humanize glycans from fungal and yeast sources *in vitro* are described in U.S. Pat. No. 5,834,251 (*supra*). If $\text{Man}_5\text{GlcNAc}_2$ is to be further humanized *in vivo*, one has to ensure that

the generated Man₅GlcNAc₂ structures are, in fact, generated intracellularly and not the product of mannosidase activity in the medium. Complex N-glycan formation in yeast or fungi will require high levels of Man₅GlcNAc₂ to be generated within the cell because only intracellular Man₅GlcNAc₂ glycans can be further processed to hybrid and complex N-glycans *in vivo*. In addition, one has to demonstrate that the majority of Man₅GlcNAc₂ structures generated are in fact a substrate for GnTI and thus allow the formation of hybrid and complex N-glycans. [0028] Accordingly, the need exists for methods to produce glycoproteins characterized by a high intracellular Man₅GlcNAc₂ content which can be further processed into human-like glycoprotein structures in non-human eukaryotic host cells, and particularly in yeast and filamentous fungi.

Class 2 Mannosidases

[0029] A number of class 2 mannosidases have been purified and characterized: mouse mannosidase II, human mannosidase II and *Drosophila* mannosidase II (Figure 24 shows a phylogenetic tree of the classes of mannosidases). It has been found that Class 2 mannosidase enzymes are responsible for the hydrolysis of α 1,3 and α 1,6 mannose glycosidic linkages on N-linked oligosaccharides generally localized in the Golgi. At least five types of Class 2 mannosidases have been identified, namely: (1) Golgi α -mannosidase II; (2) Golgi α -mannosidase IIx; (3) lysosomal α -mannosidase; (4) cytosolic α -mannosidase; and (5) an enzyme characterized from mouse and pig sperm or epididymal tissues. Moremen K.W., *Biochimica Biophysica Acta* 1573 (2002) 225-235.

[0030] Human congenital dyserythropoietic anemia type II has been associated with the lack of functional α -mannosidase II gene as exhibited in mice. Chui *et al.* *Cell* 1997 Jul 11;90(1):157-67. This genetic defect is referred to as HEMPAS (hereditary erythroblastic multinuclearity with positive acidified serum lysis test), and further research is underway to study the role of α -mannosidase II. For example, a mutation of a single gene encoding α -mannosidase II has been shown to result in a systemic autoimmune disease similar to human systemic lupus erythematosus. Chui *et al.*, *Proc. Natl. Acad. Sci. USA* 2001 98:1142-1147.

[0031] The importance of the enzymatic activity in glycoprotein formation has been well-established; however, efficient expression of such activity for the production of therapeutic glycoproteins has not been accomplished in lower eukaryotic cells.

5 (1) *Golgi α -mannosidase II*

[0032] The Golgi α -mannosidase II (EC. 3.2.1.114) is a Type II transmembrane protein, approximately 125 kDa in size, composed of a short N-terminal cytoplasmic tail, a single-span transmembrane domain connected by a stalk segment to a large luminal C-terminal catalytic portion. Moremen and Touster, *J. Biol. Chem.*, 260, 6654-6662; Moremen and Touster, *J. Biol. Chem.*, 261, 10945-10951. The function of the mannosidase II is essential in the processing of N-glycans in the secretory pathway. In mammalian cells, it has been established that this particular enzyme hydrolyzes the Man α 1,3 and Man α 1,6 glycosidic linkages on the substrate GlcNAcMan₅GlcNAc₂. Subsequent N-glycan processing is catalyzed by other glycosylation enzymes (e.g. N-acetylglucosaminyltransferases, galactosyltransferases, sialyltransferases) to produce the desired glycoforms with their substrates (UDP-GlcNAc, UDP-GalNAc, CMP-Sialic acid) and their respective transporters. See, e.g., WO 02/00879, which is incorporated by reference herein in its entirety.

[0033] A partial clone encoding the Golgi α -mannosidase II has been isolated from a rat liver λ gt11 cDNA library. Moremen, KW. *Proc. Natl. Acad. Sci. USA* 1989 Jul;86(14):5276-80. The mouse Golgi α -mannosidase II and the human α -mannosidase II have also been characterized and expressed in COS cells. Moremen and Robbins, *J. Cell. Biol.* 1991 Dec;115(6):1521-34. Research conducted on Golgi α -mannosidase II enzyme shows that there is considerable similarity within the C-terminal domain of this class of enzyme. In addition, substrate specificity studies show that the hydrolysis of the α 1,3 and/or α 1,6 glycosidic linkages by the Golgi α -mannosidase II enzyme requires a terminal GlcNAc on the oligosaccharide substrate.

[0034] The *Drosophila melanogaster* Golgi α -mannosidase II has been isolated using the murine Golgi α -mannosidase II cDNA and is shown to have considerable similarity to regions from other α -mannosidases. Foster *et al. Gene* 154 (1995)

183-186. Previous work has shown that the *Drosophila* and mouse cDNA sequences translate amino acid sequences of 41% identity and 61% similarity. Expression of the *Drosophila* Golgi α -mannosidase II sequence in CHOP cells (CHO cells stably expressing polyoma large T-antigen) was shown to be active and was also shown to localize mainly in the Golgi apparatus. Rabouille *et al.* *J. Cell. Sci.* 1999 Oct;112 (Pt 19):3319-30.

(2) *Golgi α -mannosidase IIx*

[0035] The gene encoding the human α -mannosidase IIx (α -mannosidase II isotype) has been characterized. Ogawa *et al.* *Eur. J. Biochem.* 242, 446-453 (1996). Overexpression of the α -mannosidase IIx enzyme leads to the conversion of $\text{Man}_6\text{GlcNAc}_2$ to $\text{Man}_4\text{GlcNAc}_2$ in CHO cells. Oh-eda *et al.* *Eur. J. Biochem.* 268, 1280-1288 (2001). The two types of mannosidases (II and IIx) are closely related to the processing of N-glycans in the Golgi. This Golgi α -mannosidase IIx has 66% identity to α -mannosidase II and has similar catalytic activity of hydrolyzing the $\text{Man}\alpha 1,6$ and $\text{Man}\alpha 1,3$ of the $\text{Man}_6\text{GlcNAc}_2$ oligosaccharide. More recent studies revealed an obvious phenotype of infertility in α -mannosidase IIx-deficient male mice. *Biochim Biophys Acta.* 2002 Dec 19;1573(3):382-7. One study found that α -mannosidase IIx-deficient mouse testis showed reduced levels of GlcNAc-terminated complex type N-glycans.

(3) *Lysosomal α -mannosidase*

[0036] Another type of Class 2 mannosidase is found in the lysosome of eukaryotic cells and is involved in glycoprotein catabolism (breakdown). Unlike the Golgi mannosidase II enzyme, which has a neutral pH optimum, the lysosomal mannosidase II has a low pH optimum (pH 4.5), has broad natural substrate specificity, is active toward the synthetic substrate *p*-nitrophenyl- α -mannosidase and is sensitive to inhibition by swainsonine. Daniel *et al.*, (1994) *Glycobiology* 4, 551-566; Moremen *et al.*, (1994) *Glycobiology* 4, 113-125. Structurally, the lysosomal α -mannosidase has an N-terminal signal sequence in place of the cytoplasmic tail, transmembrane domain, and stem region of the Golgi enzyme. Moremen, K.W., *Biochimica Biophysica Acta* 1573 (2002) 225-235. The human lysosomal α -mannosidase (EC 3.2.1.24) has been cloned and expressed in *Pichia*

pastoris. Liao *et al.*, *J Biol Chem* 1996 Nov 8;271(45):28348-58. Based on regions of amino acid sequence conservation between the lysosomal α -mannosidase from *Dictyostelium discoideum* and the murine Golgi α -mannosidase II (a glycoprotein that processes α 1,3/1,6-mannosidase activity) a cDNA encoding the murine lysosomal α -mannosidase was cloned. Merkle *et al.*, *Biochim Biophys Acta* 1997 Aug 29;1336(2):132-46. A deficiency in the lysosomal α -mannosidase results in a human genetic disease termed α -mannosidosis.

(4) Cytosolic α -mannosidase

[0037] The cytosolic α -mannosidase II is less similar to the other Class 2 mannosidases and appears to prefer Co^{2+} over Zn^{2+} for catalytic activity. Moremen, K.W., *Biochimica Biophysica Acta* 1573 (2002) 225-235. Like the lysosomal α -mannosidase II, it is involved in the catabolism of glycoproteins. The cytosolic α -mannosidase II catabolizes the improperly folded glycoproteins in the lumen of the ER that have been retro-translocated into the cytoplasm for proteolytic disposal. Duvet *et al.*, *Biochem. J.* 335 (1998) 389-396; Grard *et al.*, *Biochem. J.* 316 (1996) 787-792. Structurally, this enzyme has no cleavable signal sequence or transmembrane domain.

[0038] Additional mannosidases that exhibit characteristics of Class 2 mannosidases have been described but have yet to be cloned for direct comparison by sequence alignment. Moremen, K.W., *Biochimica Biophysica Acta* 1573 (2002) 225-235.

Class III Mannosidases

[0039] Class III mannosidases, which are also involved in trimming of the $\text{Man}\alpha$ 1,3 and $\text{Man}\alpha$ 1,6 glycosidic linkages of an oligosaccharide, e.g. converting $\text{Man}_5\text{GlcNAc}_2$ to $\text{Man}_3\text{GlcNAc}_2$, have been recently cloned and identified. To date only two members of this class of proteins are known. The first member identified was from an anemic mouse that was deficient in the classic Golgi mannosidase II activity but possessed an alternative mechanism for converting $\text{Man}_5\text{GlcNAc}_2$ directly to $\text{Man}_3\text{GlcNAc}_2$, which was independent of the presence of GlcNAc on the core mannose-1,3 branch (D. Chui, *et al. Cell* 1997 90:157-167). This class III mannosidase has yet to be cloned but a protein with similar activity has been

cloned from Sf9 cells (Z. Kowar, *et al. J. Biol. Chem.* 2001 276(19):16335-16340). The only member of the class III mannosidases to be cloned and characterized originates from lepidopteran insect cell line Sf9 (D. Jarvis, *et al. Glycobiology* 1997 7:113-127). This Sf9 Golgi mannosidase III converts Man₅GlcNAc₂ to
5 Man₃GlcNAc₂, and, unlike the Golgi mannosidase II, does not process GlcNAcMan₅GlcNAc₂. A unique feature of this class of mannosidases is that, in addition to possessing Man α 1,3/1,6 activity, they also possess α -1,2 mannosidase activity like a class I Golgi mannosidase. Furthermore, like the Golgi mannosidase I enzymes, this Sf9 mannosidase III trims Man₈GlcNAc₂ more efficiently than
10 Man₉GlcNAc₂.
[0040] Given the utility of the mannosidase enzyme activities in processing N-glycans, it would be desirable to have a method for producing human-like glycoproteins in lower eukaryotic host cells comprising the step of expressing a catalytically active α -mannosidase II having substrate specificity for Man α 1,3 and
15 Man α 1,6 on an oligosaccharide.

Summary of the Invention

[0041] The invention provides a method for producing a human-like glycoprotein in a lower eukaryotic host cell comprising the step of expressing a catalytically
20 active fragment of a Class 2 or a Class III mannosidase enzyme.

[0042] One embodiment of the invention provides a method for producing a human-like glycoprotein in a lower eukaryotic host cell comprising the step of expressing in the cell a mannosidase enzymatic activity that is capable of hydrolyzing an oligosaccharide substrate comprising either or both a Man α 1,3 and
25 Man α 1,6 glycosidic linkage to the extent that at least 10% of the Man α 1,3 and/or Man α 1,6 linkages of the substrate are hydrolyzed *in vivo*.

[0043] Another embodiment of the invention provides a method for producing a desired N-glycan in a lower eukaryotic host cell comprising the step of expressing in the cell a mannosidase enzymatic activity that is capable of hydrolyzing *in vivo*
30 an oligosaccharide substrate comprising either or both a Man α 1,3 and Man α 1,6 glycosidic linkage wherein the desired N-glycan is produced within the host cell at a yield of at least 10 mole percent.

[0044] Preferably, the desired N-glycan produced is selected from the group consisting of $\text{Man}_3\text{GlcNAc}_2$, $\text{GlcNAcMan}_3\text{GlcNAc}_2$ and $\text{Man}_4\text{GlcNAc}_2$. In another preferred embodiment, the desired N-glycan is characterized as having at least the oligosaccharide branch $\text{Man}\alpha 1,3 (\text{Man}\alpha 1,6) \text{Man}\beta 1,4\text{-GlcNAc } \beta 1,4\text{-GlcNAc } \beta 1\text{-Asn}$. The glycoprotein is preferably isolated from the host cell. In yet another preferred embodiment, the mannosidase enzymatic activity is capable of hydrolyzing *in vivo* both $\text{Man}\alpha 1,3$ and $\text{Man}\alpha 1,6$ linkages of an oligosaccharide substrate comprising a $\text{Man}\alpha 1,3$ and $\text{Man}\alpha 1,6$ glycosidic linkage.

[0045] In another preferred embodiment, the oligosaccharide substrate is characterized as $\text{Man}\alpha 1,3 (\text{Man}\alpha 1,6 \text{Man}\alpha 1,6) \text{Man}\beta 1,4\text{-GlcNAc } \beta 1,4\text{-GlcNAc-Asn}$; $\text{Man}\alpha 1,3 (\text{Man}\alpha 1,3 \text{Man}\alpha 1,6) \text{Man}\beta 1,4\text{-GlcNAc } \beta 1,4\text{-GlcNAc-Asn}$; $\text{GlcNAc}\beta 1,2 \text{Man}\alpha 1,3 (\text{Man}\alpha 1,6 \text{Man}\alpha 1,6) \text{Man}\beta 1,4\text{-GlcNAc } \beta 1,4\text{-GlcNAc-Asn}$; $\text{GlcNAc}\beta 1,2 \text{Man}\alpha 1,3 (\text{Man}\alpha 1,3 \text{Man}\alpha 1,6) \text{Man}\beta 1,4\text{-GlcNAc } \beta 1,4\text{-GlcNAc-Asn}$; $\text{Man}\alpha 1,3 (\text{Man}\alpha 1,3 \text{Man}\alpha 1,6 \text{Man}\alpha 1,6) \text{Man}\beta 1,4\text{-GlcNAc } \beta 1,4\text{-GlcNAc-Asn}$; $\text{GlcNAc}\beta 1,2 \text{Man}\alpha 1,3 (\text{Man}\alpha 1,3 \text{Man}\alpha 1,6 \text{Man}\alpha 1,6) \text{Man}\beta 1,4\text{-GlcNAc } \beta 1,4\text{-GlcNAc-Asn}$; $\text{Man}\alpha 1,2 \text{Man}\alpha 1,3 (\text{Man}\alpha 1,3 \text{Man}\alpha 1,6 \text{Man}\alpha 1,6) \text{Man}\beta 1,4\text{-GlcNAc } \beta 1,4\text{-GlcNAc-Asn}$; $\text{Man}\alpha 1,2 \text{Man}\alpha 1,3 (\text{Man}\alpha 1,3 \text{Man}\alpha 1,6) \text{Man}\beta 1,4\text{-GlcNAc } \beta 1,4\text{-GlcNAc-Asn}$; $\text{Man}\alpha 1,2 \text{Man}\alpha 1,3 (\text{Man}\alpha 1,6 \text{Man}\alpha 1,6) \text{Man}\beta 1,4\text{-GlcNAc } \beta 1,4\text{-GlcNAc-Asn}$ or high mannan.

[0046] In a preferred embodiment, the mannosidase activity is characterized as a Class 2 mannosidase activity. In a more preferred embodiment, the Class 2 mannosidase activity has a substrate specificity for $\text{GlcNAc}\beta 1,2 \text{Man}\alpha 1,3 (\text{Man}\alpha 1,6 \text{Man}\alpha 1,6) \text{Man}\beta 1,4\text{-GlcNAc } \beta 1,4\text{-GlcNAc-Asn}$; $\text{GlcNAc}\beta 1,2 \text{Man}\alpha 1,3 (\text{Man}\alpha 1,3 \text{Man}\alpha 1,6) \text{Man}\beta 1,4\text{-GlcNAc } \beta 1,4\text{-GlcNAc-Asn}$; or $\text{GlcNAc}\beta 1,2 \text{Man}\alpha 1,3 (\text{Man}\alpha 1,3 \text{Man}\alpha 1,6 \text{Man}\alpha 1,6) \text{Man}\beta 1,4\text{-GlcNAc } \beta 1,4\text{-GlcNAc-Asn}$. In an even more preferred embodiment, the Class 2 mannosidase activity is one which is normally found in the Golgi apparatus of a higher eukaryotic host cell.

[0047] In another preferred embodiment, the mannosidase activity is characterized as a Class IIx mannosidase activity. In a more preferred embodiment, the Class IIx mannosidase activity has a substrate specificity for $\text{Man}\alpha 1,3 (\text{Man}\alpha 1,6 \text{Man}\alpha 1,6) \text{Man}\beta 1,4\text{-GlcNAc } \beta 1,4\text{-GlcNAc-Asn}$; $\text{Man}\alpha 1,3$

(Man α 1,3 Man α 1,6) Man β 1,4-GlcNAc β 1,4-GlcNAc-Asn; or Man α 1,2 Man α 1,3
(Man α 1,3 Man α 1,6 Man α 1,6) Man β 1,4-GlcNAc β 1,4-GlcNAc-Asn.

[0048] In yet another preferred embodiment, the mannosidase activity is characterized as a Class III mannosidase activity. In a more preferred

5 embodiment, the Class III mannosidase activity has a substrate specificity for
(Man α 1,6 Man α 1,6) Man β 1,4-GlcNAc β 1,4-GlcNAc-Asn; (Man α 1,3 Man α 1,6)
Man β 1,4-GlcNAc β 1,4-GlcNAc-Asn; or high mannans.

[0049] In any one of the above embodiments, the mannosidase activity is preferably overexpressed. In another preferred embodiment, the mannosidase is
10 further capable of hydrolyzing a Man α 1,2 linkage. The mannosidase activities of
the invention preferably have a pH optimum of from about 5.0 to about 8.0.

[0050] In another embodiment the mannosidase activity is localized within the secretory pathway of the host cell. Preferably, the mannosidase activity is expressed from a polypeptide localized within at least one of the ER, Golgi
15 apparatus or the trans golgi network of the host cell.

[0051] In one preferred embodiment, the mannosidase activity is expressed from a nucleic acid encoding a polypeptide comprising a mannosidase catalytic domain fused to a cellular targeting signal peptide. In a more preferred embodiment, the mannosidase activity is expressed from a nucleic acid comprising sequences that
20 encode a mannosidase catalytic domain native to the host cell. In another more preferred embodiment, the mannosidase activity is expressed from a nucleic acid comprising sequences that encode a mannosidase catalytic domain heterologous to the host cell.

[0052] In another preferred embodiment, the mannosidase enzymatic activity is
25 selected from the group consisting of *Arabidopsis thaliana* Mannosidase II, *C. elegans* Mannosidase II, *Ciona intestinalis* mannosidase II, *Drosophila* mannosidase II, Human mannosidase II, Mouse mannosidase II, Rat mannosidase II, Human mannosidase IIx, Insect cell mannosidase III, Human lysosomal mannosidase II and Human cytoplasmic mannosidase II.

[0053] In another preferred embodiment, the polypeptide is expressed from a
30 nucleic acid comprising sequences that encode a target peptide native to the host cell.

[0054] In another preferred embodiment, the polypeptide is expressed from a nucleic acid comprising sequences that encode a target peptide heterologous to the mannosidase catalytic domain.

[0055] In a preferred embodiment, the host cell is selected from the group consisting of *Pichia pastoris*, *Pichia finlandica*, *Pichia trehalophila*, *Pichia koclamae*, *Pichia membranaefaciens*, *Pichia opuntiae*, *Pichia thermotolerans*, *Pichia salictaria*, *Pichia guercuum*, *Pichia pijperi*, *Pichia stiptis*, *Pichia methanolica*, *Pichia sp.*, *Saccharomyces cerevisiae*, *Saccharomyces sp.*, *Hansenula polymorpha*, *Kluyveromyces sp.*, *Kluyveromyces lactis*, *Candida albicans*, *Aspergillus nidulans*, *Aspergillus niger*, *Aspergillus oryzae*, *Trichoderma reesei*, *Chrysosporium lucknowense*, *Fusarium sp.*, *Fusarium gramineum*, *Fusarium venenatum* and *Neurospora crassa*. In a more preferred embodiment, the host cell is *Pichia pastoris*.

[0056] The invention further provides glycoproteins and N-glycans produced by one of the above methods. In a preferred embodiment, the glycoprotein is a therapeutic protein. In a more preferred embodiment, the therapeutic protein is selected from the group consisting of erythropoietin, cytokines such as interferon- α , interferon- β , interferon- γ , interferon- ω , and granulocyte-CSF, coagulation factors such as factor VIII, factor IX, and human protein C, soluble IgE receptor α -chain, IgG, IgG fragments, IgM, interleukins, urokinase, chymase, and urea trypsin inhibitor, IGF-binding protein, epidermal growth factor, growth hormone-releasing factor, annexin V fusion protein, angiostatin, vascular endothelial growth factor-2, myeloid progenitor inhibitory factor-1, osteoprotegerin, α -1 antitrypsin, DNase II, α -feto proteins, AAT, rhTBP-1 (oncept, aka TNF Binding protein 1), TACI-Ig (transmembrane activator and calcium modulator and cyclophilin ligand interactor), FSH (follicle stimulating hormone), GM-CSF, GLP-1 w/ and w/o FC (glucagon like protein 1) IL-1 receptor agonist, sTNFr (enbrel, aka soluble TNF receptor Fc fusion) ATIII, rhThrombin, glucocerebrosidase and CTLA4-Ig (Cytotoxic T Lymphocyte associated Antigen 4 - Ig).

[0057] The invention further provides a nucleic acid library comprising at least two different genetic constructs, wherein at least one genetic construct comprises a

nucleic acid fragment encoding a mannosidase class 2, IIx or III catalytic domain ligated in-frame with a nucleic acid fragment encoding a cellular targeting signal peptide which it is not normally associated with.

[0058] In a preferred embodiment, the mannosidase catalytic domain is selected from the group consisting of: *Arabidopsis thaliana* Mannosidase II, *C. elegans* Mannosidase II, *Ciona intestinalis* mannosidase II, *Drosophila* mannosidase II, Human mannosidase II, Mouse mannosidase II, Rat mannosidase II, Human mannosidase IIx, Insect cell mannosidase III, Human lysosomal mannosidase II and Human cytoplasmic mannosidase II.

[0059] In another preferred embodiment, the nucleic acid fragment encoding a cellular targeting peptide is selected from the group consisting of: *Saccharomyces* GLS1, *Saccharomyces* MNS1, *Saccharomyces* SEC12, *Pichia* SEC, *Pichia* OCH1, *Saccharomyces* MNN9, *Saccharomyces* VAN1, *Saccharomyces* ANP1, *Saccharomyces* HOC1, *Saccharomyces* MNN10, *Saccharomyces* MNN11, *Saccharomyces* MNT1, *Pichia* D2, *Pichia* D9, *Pichia* J3, *Saccharomyces* KTR1, *Saccharomyces* KTR2, *Kluyveromyces* GnTI, *Saccharomyces* MNN2, *Saccharomyces* MNN5, *Saccharomyces* YUR1, *Saccharomyces* MNN1 and *Saccharomyces* MNN6.

[0060] Another embodiment of the invention provides a vector comprising a fusion construct derived from any one of the above libraries linked to an expression control sequence, wherein said cellular targeting signal peptide is targeted to at least one of the ER, Golgi or trans-Golgi network. In a more preferred embodiment, the expression control sequence is inducible or constitutive. In an even more preferred embodiment, the vector, upon expression in a host cell, encodes a mannosidase activity involved in producing GlcNAcMan₃GlcNAc₂ Man₃GlcNAc₂ or Man₄GlcNAc₂ *in vivo*.

[0061] Another embodiment of the invention provides a host cell comprising at least one of the above vectors. In more preferred embodiments, the vector is selected from the group of vectors designated pKD53, pKD1, pKD5, pKD6 and pKD16.

[0062] Another embodiment of the invention provides a chimeric polypeptide comprising a mannosidase catalytic domain fused in-frame to a targeting signal

peptide and, upon expression in a lower eukaryotic host cell, capable of hydrolyzing *in vivo* an oligosaccharide substrate comprising either or both a Man α 1,3 and Man α 1,6 glycosidic linkage to the extent that at least 10% of the Man α 1,3 and/or Man α 1,6 linkages of the substrate are hydrolyzed *in vivo*.

- 5 [0063] Another embodiment of the invention provides a chimeric polypeptide comprising a mannosidase catalytic domain fused in-frame to a targeting signal peptide and, upon expression in a lower eukaryotic host cell, capable of hydrolyzing *in vivo* an oligosaccharide substrate comprising a Man α 1,3, Man α 1,6, or Man α 1,2 glycosidic linkage to the extent that a detectable moiety of the
- 10 Man α 1,3, Man α 1,6 or Man α 1,2 linkage of the substrate is hydrolyzed *in vivo*.

[0064] Another embodiment of the invention provides a nucleic acid encoding the above chimeric polypeptide or a host cell comprising the above chimeric polypeptide.

- [0065] Another embodiment of the invention provides a host cell comprising the
- 15 above nucleic acid.

[0066] Another embodiment of the invention provides a glycoprotein produced in the above host cell. In a more preferred embodiment, an N-glycan produced in the host cell is provided. More preferably, the glycoprotein is characterized as uniform.

- 20 [0067] Another embodiment of the invention provides an isolated polynucleotide comprising or consisting of a nucleic acid sequence selected from the group consisting of the conserved regions SEQ ID NO: 5 – SEQ ID NO: 15

Brief Description of the Drawings

- 25 [0068] Figure 1A is a schematic diagram of a typical fungal N-glycosylation pathway.

[0069] Figure 1B is a schematic diagram of a typical human N-glycosylation pathway.

- [0070] Figure 2 depicts construction of a combinatorial DNA library of fusion
- 30 constructs. Figure 2A diagrams the insertion of a targeting peptide fragment into pCR2.1-TOPO (Invitrogen, Carlsbad, CA). Figure 2B shows the generated targeting peptide sub-library having restriction sites *NotI* - *AscI*. Figure 2C

diagrams the insertion of a catalytic domain region into pJN347, a modified pUC19 vector. **Figure 2D** shows the generated catalytic domain sub-library having restriction sites *NotI*, *AscI* and *PacI*. **Figure 2E** depicts one particular fusion construct generated from the targeting peptide sub-library and the catalytic domain sub-library.

[0071] **Figure 3** illustrates the *M.musculus* α -1,2-mannosidase IA open reading frame nucleic acid sequence (SEQ ID NO: 1) and encoded polypeptide sequence (SEQ ID NO: 2). The sequences of the PCR primers used to generate N-terminal truncations are underlined.

[0072] **Figures 4A – 4F** illustrate engineering of vectors with multiple auxotrophic markers and genetic integration of target proteins in the *P. pastoris* *OCH1* locus.

[0073] **Figures 5A – 5E** show MALDI-TOF analysis demonstrating production of kringle 3 domain of human plasminogen (K3) glycoproteins having $\text{Man}_5\text{GlcNAc}_2$ as the predominant N-glycan structure in *P. pastoris*. **Figure 5A** depicts the standard $\text{Man}_5\text{GlcNAc}_2$ [a] glycan (Glyko, Novato, CA) and $\text{Man}_5\text{GlcNAc}_2 + \text{Na}^+$ [b]. **Figure 5B** shows PNGase – released glycans from K3 wild type. The N-glycans shown are as follows: $\text{Man}_9\text{GlcNAc}_2$ [d]; $\text{Man}_{10}\text{GlcNAc}_2$ [e]; $\text{Man}_{11}\text{GlcNAc}_2$ [f]; $\text{Man}_{12}\text{GlcNAc}_2$ [g]. **Figure 5C** depicts the *och1* deletion resulting in the production of $\text{Man}_8\text{GlcNAc}_2$ [c] as the predominant N-glycan. **Figures 5D and 5E** show the production of $\text{Man}_5\text{GlcNAc}_2$ [b] after *in vivo* trimming of $\text{Man}_8\text{GlcNAc}_2$ with a chimeric α -1,2-mannosidase. The predominant N-glycan is indicated by a peak with a mass (m/z) of 1253 consistent with its identification as $\text{Man}_5\text{GlcNAc}_2$ [b].

[0074] **Figures 6A – 6F** show MALDI-TOF analysis demonstrating production of IFN- β glycoproteins having $\text{Man}_5\text{GlcNAc}_2$ as the predominant N-glycan structure in *P. pastoris*. **Figure 6A** shows the standard $\text{Man}_5\text{GlcNAc}_2$ [a] and $\text{Man}_5\text{GlcNAc}_2 + \text{Na}^+$ [b] as the standard (Glyko, Novato, CA). **Figure 6B** shows PNGase – released glycans from IFN- β wildtype. **Figure 6C** depicts the *och1* knock-out producing $\text{Man}_8\text{GlcNAc}_2$ [c]; $\text{Man}_9\text{GlcNAc}_2$ [d]; $\text{Man}_{10}\text{GlcNAc}_2$ [e]; $\text{Man}_{11}\text{GlcNAc}_2$ [f]; $\text{Man}_{12}\text{GlcNAc}_2$ [g]; and no production of $\text{Man}_5\text{GlcNAc}_2$ [b]. **Figure 6D** shows relatively small amount of $\text{Man}_5\text{GlcNAc}_2$ [b] among other

intermediate N-glycans Man₈GlcNAc₂ [c] to Man₁₂GlcNAc₂ [g]. Figure 6E shows a significant amount of Man₅GlcNAc₂ [b] relative to the other glycans Man₈GlcNAc₂ [c] and Man₉GlcNAc₂ [d] produced by pGC5 (*Saccharomyces* MNS1(m)/mouse mannosidase IB Δ99). Figure 6F shows predominant production of Man₅GlcNAc₂ [b] on the secreted glycoprotein IFN-β by pFB8 (*Saccharomyces* SEC12 (m)/mouse mannosidase IA Δ187). The N-glycan is indicated by a peak with a mass (m/z) of 1254 consistent with its identification as Man₅GlcNAc₂ [b].

[0075] Figure 7 shows a high performance liquid chromatogram for: (A) Man₉GlcNAc₂ standard labeled with 2-AB (negative control); (B) supernatant of growth medium from *P.pastoris*, Δ *och1* transformed with pFB8 mannosidase, which demonstrates a lack of extracellular mannosidase activity in the supernatant; and (C) Man₉GlcNAc₂ standard labeled with 2-AB after exposure to *T.reesei* mannosidase (positive control).

[0076] Figure 8 shows a high performance liquid chromatogram for: (A) Man₉GlcNAc₂ standard labeled with 2-AB (negative control); (B) supernatant of growth medium from *P.pastoris*, Δ *och1* transformed with pGC5 mannosidase, which demonstrates a lack of extracellular mannosidase activity in the supernatant; and (C) Man₉GlcNAc₂ standard labeled with 2-AB after exposure to *T.reesei* mannosidase (positive control).

[0077] Figure 9 shows a high performance liquid chromatogram for: (A) Man₉GlcNAc₂ standard labeled with 2-AB (negative control); (B) supernatant of growth medium from *P.pastoris*, Δ *och1* transformed with pBC18-5 mannosidase, which demonstrates lack of extracellular mannosidase activity in the supernatant; and (C) supernatant of medium *P.pastoris*, Δ *och1* transformed with pDD28-3, which demonstrates activity in the supernatant (positive control).

[0078] Figures 10A – 10B demonstrate the activity of an UDP-GlcNAc transporter in the production of GlcNAcMan₅GlcNAc₂ in *P. pastoris*. Figure 10A depicts a *P.pastoris* strain (YSH-3) transformed with a human GnTI but without the UDP-GlcNAc transporter resulting in some production of GlcNAcMan₅GlcNAc₂ [b] but a predominant production of Man₅GlcNAc₂ [a]. Figure 10B depicts the addition of UDP-GlcNAc transporter from *K.lactis* in a

strain (PBP-3) transformed with the human GnTI, which resulted in the predominant production of GlcNAcMan₅GlcNAc₂ [b]. The single prominent peak of mass (m/z) at 1457 is consistent with its identification as GlcNAcMan₅GlcNAc₂ [b] as shown in Figure 10B.

5 [0079] Figure 11 shows a pH optimum of a heterologous mannosidase enzyme encoded by pBB27-2 (*Saccharomyces* MNN10 (s)/*C. elegans* mannosidase IB Δ 31) expressed in *P.pastoris*.

[0080] Figures 12A – 12C show MALDI-TOF-MS analyses of N-glycans released from a cell free extract of *K.lactis*. Figure 12A shows the N-glycans released from wild-type cells, which includes high-mannose type N-glycans. Figure 12B shows the N-glycans released from *och1 mnn1* deleted cells, revealing a distinct peak of mass (m/z) at 1908 consistent with its identification as Man₉GlcNAc₂ [d]. Figure 12C shows the N-glycans released from *och1 mnn1* deleted cells after *in vitro* α -1,2-mannosidase digest corresponding to a peak consistent with Man₅GlcNAc₂.

[0081] Figure 13 shows a MALDI-TOF-MS analysis of N-glycans isolated from a kringle 3 glycoprotein produced in a *P.pastoris* YSH-1 (*och1* deletion mutant transformed with α -mannosidase and GnT I) showing a predominant peak at 1465 m/z corresponding to the mass of GlcNAcMan₅GlcNAc₂ [d].

[0082] Figure 14 shows a MALDI-TOF-MS analysis of N-glycans isolated from a kringle 3 glycoprotein produced in a *P.pastoris* YSH-1 transformed with *D. melanogaster* mannosidase II Δ 74/*S. cerevisiae* MNN2(s) showing a predominant peak at 1140 m/z corresponding to the mass of GlcNAcMan₃GlcNAc₂ [b] and other peaks corresponding to GlcNAcMan₄GlcNAc₂ [c] at 1303 m/z and GlcNAcMan₅GlcNAc₂ [d] at 1465 m/z. This strain was designated YSH-37.

[0083] Figure 15 shows a MALDI-TOF-MS analysis of N-glycans isolated from a kringle 3 glycoprotein produced in a *P.pastoris* YSH-37 transformed with rat GnT II/MNN2 (s) leader showing a predominant peak at 1356 m/z corresponding to the mass of GlcNAc₂Man₃GlcNAc₂ [x]. This strain was designated YSH-44.

[0084] Figure 16 shows a MALDI-TOF-MS analysis of N-glycans isolated from a kringle 3 glycoprotein produced in a *P.pastoris* YSH-44 (GlcNAc₂Man₃GlcNAc₂

[b] produced as shown in Figure 15) showing a predominant peak at 933 m/z corresponding to the mass of $\text{Man}_3\text{GlcNAc}_2$ [a] after β -N-acetylhexosaminidase digest.

5 [0085] Figure 17 shows a MALDI-TOF-MS analysis of N-glycans isolated from a kringle 3 glycoprotein produced in a *P.pastoris* YSH-44 ($\text{GlcNAc}_2\text{Man}_3\text{GlcNAc}_2$ [b] produced as shown in Figure 15) showing a predominant peak at 1665 m/z corresponding to the mass of $\text{Gal}_2\text{GlcNAc}_2\text{Man}_3\text{GlcNAc}_2$ after addition of β 1,4-galactosyltransferase *in vitro*.

10 [0086] Figure 18 shows a MALDI-TOF-MS analysis of N-glycans isolated from a kringle 3 glycoprotein produced in a *P.pastoris* YSH-1 transformed with *D. melanogaster* mannosidase II Δ 74/*S. cerevisiae* MNN9(m) showing a predominant peak at 1464 m/z corresponding to the mass of $\text{Man}_5\text{GlcNAc}_2$ [d].

15 [0087] Figure 19 shows a MALDI-TOF-MS analysis of N-glycans isolated from a kringle 3 glycoprotein produced in a *P.pastoris* YSH-1 transformed with *D. melanogaster* mannosidase II Δ 74/*S. cerevisiae* MNS1(l) showing a predominant peak at 1464 m/z corresponding to the mass of $\text{Man}_5\text{GlcNAc}_2$ [d] and other peaks corresponding to $\text{GlcNAcMan}_3\text{GlcNAc}_2$ [b] at 1139 m/z and $\text{GlcNAcMan}_4\text{GlcNAc}_2$ [c] at 1302 m/z.

20 [0088] Figure 20 shows a MALDI-TOF-MS analysis of N-glycans isolated from a kringle 3 glycoprotein produced in a *P.pastoris* YSH-1 transformed with *D. melanogaster* mannosidase II Δ 74/*S. cerevisiae* GLS1(s) showing a predominant peak at 1139 m/z corresponding to the mass of $\text{GlcNAcMan}_3\text{GlcNAc}_2$ [b]. This strain was designated YSH-27.

25 [0089] Figure 21 shows a MALDI-TOF-MS analysis of N-glycans isolated from a kringle 3 glycoprotein produced in a *P.pastoris* YSH-1 transformed with *D. melanogaster* mannosidase II Δ 74/*S. cerevisiae* MNS1(m) showing a predominant peak at 1140 m/z corresponding to the mass of $\text{GlcNAcMan}_3\text{GlcNAc}_2$ [b] and other peaks corresponding to $\text{GlcNAcMan}_4\text{GlcNAc}_2$ [c] at 1302 m/z and $\text{GlcNAcMan}_5\text{GlcNAc}_2$ [d] at 1464 m/z. This strain was designated YSH-74.

30 [0090] Figure 22 shows a MALDI-TOF-MS analysis of N-glycans isolated from a kringle 3 glycoprotein produced in a *P.pastoris* YSH-74 digested with a *T.*

reesei/A. saitoi α -1,2 mannosidase showing a predominant peak at 1141 m/z corresponding to the mass of GlcNAcMan₃GlcNAc₂ [b].

[0091] Figure 23 shows a BLAST Sequence Comparison of known and hypothetical mannosidase II, mannosidase IIx and Class III mannosidases (SEQ ID NOS 96, 92, 93, 99, 98, 97, 94, 95, and 100-102, respectively in order of appearance).

[0092] Figure 24 shows a phylogenetic tree of the classes of mannosidase.

[0093] Figure 25 shows an *Arabidopsis thaliana* Mannosidase II (NM_121499) nucleotide sequence (SEQ ID NO: 49) and encoded protein (SEQ ID NO: 95).

10 [0094] Figure 26 shows a *C. elegans* Mannosidase II (NM_073594) nucleotide sequence (SEQ ID NO: 50) and encoded protein (SEQ ID NO: 92).

[0095] Figure 27 shows a *Ciona intestinalis* mannosidase II (AK116684) nucleotide sequence (SEQ ID NO: 51) and encoded protein (SEQ ID NO: 94).

[0096] Figure 28 shows a *D. melanogaster* mannosidase II (X77652) nucleotide sequence (SEQ ID NO: 52) and encoded protein (SEQ ID NO: 96).

[0097] Figure 29 shows a human mannosidase II (U31520) nucleotide sequence (SEQ ID NO: 53) and encoded protein (SEQ ID NO: 97).

[0098] Figure 30 shows a mouse mannosidase II (X61172) nucleotide sequence (SEQ ID NO: 54) and encoded protein (SEQ ID NO: 98).

20 [0099] Figure 31 shows a rat mannosidase II (XM_218816) nucleotide sequence (SEQ ID NO: 55) and encoded protein (SEQ ID NO: 93).

[0100] Figure 32 shows a human mannosidase IIx (D55649) nucleotide sequence (SEQ ID NO: 56) and encoded protein (SEQ ID NO: 99).

[0101] Figure 33 shows an insect cell mannosidase III (AF005034) nucleotide sequence (SEQ ID NO: 57) and encoded protein (SEQ ID NO: 100).

[0102] Figure 34 shows a human lysosomal mannosidase II (NM_000528) nucleotide sequence (SEQ ID NO: 58) and encoded protein (SEQ ID NO: 101).

[0103] Figure 35 shows a human cytoplasmic mannosidase II (NM_006715) nucleotide sequence (SEQ ID NO: 59) and encoded protein (SEQ ID NO: 102).

30 [0104] Figure 36 illustrates oligosaccharide intermediates produced using mannosidase II, mannosidase IIx and mannosidase III activities.

Detailed Description of the Invention

[0105] Unless otherwise defined herein, scientific and technical terms used in connection with the present invention shall have the meanings that are commonly understood by those of ordinary skill in the art. Further, unless otherwise required
5 by context, singular terms shall include pluralities and plural terms shall include the singular. The methods and techniques of the present invention are generally performed according to conventional methods well known in the art. Generally, nomenclatures used in connection with, and techniques of biochemistry,
enzymology, molecular and cellular biology, microbiology, genetics and protein
10 and nucleic acid chemistry and hybridization described herein are those well-known and commonly used in the art.

[0106] The methods and techniques of the present invention are generally performed according to conventional methods well-known in the art and as described in various general and more specific references that are cited and
15 discussed throughout the present specification unless otherwise indicated. See, e.g., Sambrook *et al.* Molecular Cloning: A Laboratory Manual, 2d ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989); Ausubel *et al.*, Current Protocols in Molecular Biology, Greene Publishing Associates (1992, and Supplements to 2002); Harlow and Lane Antibodies: A Laboratory Manual Cold
20 Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1990); Introduction to Glycobiology, Maureen E. Taylor, Kurt Drickamer, Oxford Univ. Press (2003); Worthington Enzyme Manual, Worthington Biochemical Corp. Freehold, NJ; Handbook of Biochemistry: Section A Proteins Vol I 1976 CRC Press; Handbook
of Biochemistry: Section A Proteins Vol II 1976 CRC Press; Essentials of
25 Glycobiology, Cold Spring Harbor Laboratory Press (1999). The nomenclatures used in connection with, and the laboratory procedures and techniques of, molecular and cellular biology, protein biochemistry, enzymology and medicinal and pharmaceutical chemistry described herein are those well known and
commonly used in the art.

30 [0107] All publications, patents and other references mentioned herein are incorporated by reference.

[0108] The following terms, unless otherwise indicated, shall be understood to have the following meanings:

[0109] As used herein, the term "N-glycan" refers to an N-linked oligosaccharide, e.g., one that is attached by an asparagine-N-acetylglucosamine linkage to an asparagine residue of a polypeptide. N-glycans have a common pentasaccharide core of $\text{Man}_3\text{GlcNAc}_2$ ("Man" refers to mannose; "Glc" refers to glucose; and "NAc" refers to N-acetyl; GlcNAc refers to N-acetylglucosamine). The term "trimannose core" used with respect to the N-glycan also refers to the structure $\text{Man}_3\text{GlcNAc}_2$ (" Man_3 "). N-glycans differ with respect to the number of branches (antennae) comprising peripheral sugars (e.g., fucose and sialic acid) that are added to the Man_3 core structure. N-glycans are classified according to their branched constituents (e.g., high mannose, complex or hybrid).

[0110] A "high mannose" type N-glycan has five or more mannose residues. A "complex" type N-glycan typically has at least one GlcNAc attached to the 1,3 mannose arm and at least one GlcNAc attached to the 1,6 mannose arm of the trimannose core. Complex N-glycans may also have galactose ("Gal") residues that are optionally modified with sialic acid or derivatives ("NeuAc", where "Neu" refers to neuraminic acid and "Ac" refers to acetyl). A complex N-glycan typically has at least one branch that terminates in an oligosaccharide such as, for example: NeuNAc-; NeuAca2-6GalNAca1-; NeuAca2-3Galb1-3GalNAca1-; NeuAca2-3/6Galb1-4GlcNAcb1-; GlcNAca1-4Galb1-(mucins only); Fuca1-2Galb1-(blood group H). Sulfate esters can occur on galactose, GalNAc, and GlcNAc residues, and phosphate esters can occur on mannose residues. NeuAc (Neu: neuraminic acid; Ac:acetyl) can be O-acetylated or replaced by NeuGl (N-glycolylneuraminic acid). Complex N-glycans may also have intrachain substitutions comprising "bisecting" GlcNAc and core fucose ("Fuc"). A "hybrid" N-glycan has at least one GlcNAc on the terminal of the 1,3 mannose arm of the trimannose core and zero or more mannoses on the 1,6 mannose arm of the trimannose core.

[0111] The term "predominant" or "predominantly" used with respect to the production of N-glycans refers to a structure which represents the major peak detected by matrix assisted laser desorption ionization time of flight mass spectrometry (MALDI-TOF) analysis.

[0112] Abbreviations used herein are of common usage in the art, see, e.g., abbreviations of sugars, above. Other common abbreviations include "PNGase", which refers to peptide N-glycosidase F (EC 3.2.2.18); "GlcNAc Tr" or "GnT," which refers to *N*-acetylglucosaminyl Transferase enzymes; "NANA" refers to *N*-acetylneuraminic acid.

[0113] As used herein, a "humanized glycoprotein" or a "human-like glycoprotein" refers alternatively to a protein having attached thereto N-glycans having three or less mannose residues, and synthetic glycoprotein intermediates (which are also useful and can be manipulated further *in vitro* or *in vivo*).

Preferably, glycoproteins produced according to the invention contain at least 20 mole %, preferably 20–30 mole %, more preferably 30–40 mole %, even more preferably 40–50 mole % and even more preferably 50–100 mole % of the GlcNAcMan₃GlcNAc₂ intermediate, at least transiently. This may be achieved, e.g., by engineering a host cell of the invention to express a "better", i.e., a more efficient glycosylation enzyme. For example, a mannosidase II is selected such that it will have optimal activity under the conditions present at the site in the host cell where proteins are glycosylated and is introduced into the host cell preferably by targeting the enzyme to a host cell organelle where activity is desired.

[0114] The term "enzyme", when used herein in connection with altering host cell glycosylation, refers to a molecule having at least one enzymatic activity, and includes full-length enzymes, catalytically active fragments, chimerics, complexes, and the like. A "catalytically active fragment" of an enzyme refers to a polypeptide having a detectable level of functional (enzymatic) activity. Enzyme activity is "substantially intracellular" when subsequent processing enzymes have the ability to produce about 51% of the desired glycoforms *in vivo*.

[0115] A lower eukaryotic host cell, when used herein in connection with glycosylation profiles, refers to any eukaryotic cell which ordinarily produces high mannose containing N-glycans, and thus is meant to include some animal or plant cells and most typical lower eukaryotic cells, including uni- and multicellular fungal and algal cells.

[0116] As used herein, the term "secretion pathway" refers to the assembly line of various glycosylation enzymes to which a lipid-linked oligosaccharide precursor

and an N-glycan substrate are sequentially exposed, following the molecular flow of a nascent polypeptide chain from the cytoplasm to the endoplasmic reticulum (ER) and the compartments of the Golgi apparatus. Enzymes are said to be localized along this pathway. An enzyme X that acts on a lipid-linked glycan or an N-glycan before enzyme Y is said to be or to act "upstream" to enzyme Y; similarly, enzyme Y is or acts "downstream" from enzyme X.

[0117] The term "targeting peptide" as used herein refers to nucleotide or amino acid sequences encoding a cellular targeting signal peptide which mediates the localization (or retention) of an associated sequence to sub-cellular locations, e.g., organelles.

[0118] The term "polynucleotide" or "nucleic acid molecule" refers to a polymeric form of nucleotides of at least 10 bases in length. The term includes DNA molecules (e.g., cDNA or genomic or synthetic DNA) and RNA molecules (e.g., mRNA or synthetic RNA), as well as analogs of DNA or RNA containing non-natural nucleotide analogs, non-native internucleoside bonds, or both. The nucleic acid can be in any topological conformation. For instance, the nucleic acid can be single-stranded, double-stranded, triple-stranded, quadruplexed, partially double-stranded, branched, hairpinned, circular, or in a padlocked conformation. The term includes single and double stranded forms of DNA. A nucleic acid molecule of this invention may include both sense and antisense strands of RNA, cDNA, genomic DNA, and synthetic forms and mixed polymers of the above. They may be modified chemically or biochemically or may contain non-natural or derivatized nucleotide bases, as will be readily appreciated by those of skill in the art. Such modifications include, for example, labels, methylation, substitution of one or more of the naturally occurring nucleotides with an analog, internucleotide modifications such as uncharged linkages (e.g., methyl phosphonates, phosphotriesters, phosphoramidates, carbamates, etc.), charged linkages (e.g., phosphorothioates, phosphorodithioates, etc.), pendent moieties (e.g., polypeptides), intercalators (e.g., acridine, psoralen, etc.), chelators, alkylators, and modified linkages (e.g., alpha anomeric nucleic acids, etc.) Also included are synthetic molecules that mimic polynucleotides in their ability to bind to a designated sequence via hydrogen bonding and other chemical interactions. Such

molecules are known in the art and include, for example, those in which peptide linkages substitute for phosphate linkages in the backbone of the molecule.

[0119] Unless otherwise indicated, a "nucleic acid comprising SEQ ID NO:X" refers to a nucleic acid, at least a portion of which has either (i) the sequence of
5 SEQ ID NO:X, or (ii) a sequence complementary to SEQ ID NO:X. The choice between the two is dictated by the context. For instance, if the nucleic acid is used as a probe, the choice between the two is dictated by the requirement that the probe be complementary to the desired target.

[0120] An "isolated" or "substantially pure" nucleic acid or polynucleotide (e.g.,
10 an RNA, DNA or a mixed polymer) is one which is substantially separated from other cellular components that naturally accompany the native polynucleotide in its natural host cell, e.g., ribosomes, polymerases, and genomic sequences with which it is naturally associated. The term embraces a nucleic acid or polynucleotide that (1) has been removed from its naturally occurring environment, (2) is not
15 associated with all or a portion of a polynucleotide in which the "isolated polynucleotide" is found in nature, (3) is operatively linked to a polynucleotide which it is not linked to in nature, or (4) does not occur in nature. The term "isolated" or "substantially pure" also can be used in reference to recombinant or cloned DNA isolates, chemically synthesized polynucleotide analogs, or
20 polynucleotide analogs that are biologically synthesized by heterologous systems.

[0121] However, "isolated" does not necessarily require that the nucleic acid or polynucleotide so described has itself been physically removed from its native environment. For instance, an endogenous nucleic acid sequence in the genome of an organism is deemed "isolated" herein if a heterologous sequence (i.e., a
25 sequence that is not naturally adjacent to this endogenous nucleic acid sequence) is placed adjacent to the endogenous nucleic acid sequence, such that the expression of this endogenous nucleic acid sequence is altered. By way of example, a non-native promoter sequence can be substituted (e.g., by homologous recombination) for the native promoter of a gene in the genome of a human cell, such that this
30 gene has an altered expression pattern. This gene would now become "isolated" because it is separated from at least some of the sequences that naturally flank it.

[0122] A nucleic acid is also considered "isolated" if it contains any modifications that do not naturally occur to the corresponding nucleic acid in a genome. For instance, an endogenous coding sequence is considered "isolated" if it contains an insertion, deletion or a point mutation introduced artificially, e.g., by human intervention. An "isolated nucleic acid" also includes a nucleic acid integrated into a host cell chromosome at a heterologous site, a nucleic acid construct present as an episome. Moreover, an "isolated nucleic acid" can be substantially free of other cellular material, or substantially free of culture medium when produced by recombinant techniques, or substantially free of chemical precursors or other chemicals when chemically synthesized.

[0123] As used herein, the phrase "degenerate variant" of a reference nucleic acid sequence encompasses nucleic acid sequences that can be translated, according to the standard genetic code, to provide an amino acid sequence identical to that translated from the reference nucleic acid sequence.

[0124] The term "percent sequence identity" or "identical" in the context of nucleic acid sequences refers to the residues in the two sequences which are the same when aligned for maximum correspondence. The length of sequence identity comparison may be over a stretch of at least about nine nucleotides, usually at least about 20 nucleotides, more usually at least about 24 nucleotides, typically at least about 28 nucleotides, more typically at least about 32 nucleotides, and preferably at least about 36 or more nucleotides. There are a number of different algorithms known in the art that can be used to measure nucleotide sequence identity. For instance, polynucleotide sequences can be compared using FASTA, Gap or Bestfit, which are programs in Wisconsin Package Version 10.0, Genetics Computer Group (GCG), Madison, Wisconsin. FASTA provides alignments and percent sequence identity of the regions of the best overlap between the query and search sequences (Pearson, 1990, herein incorporated by reference). For instance, percent sequence identity between nucleic acid sequences can be determined using FASTA with its default parameters (a word size of 6 and the NOPAM factor for the scoring matrix) or using Gap with its default parameters as provided in GCG Version 6.1, herein incorporated by reference.

[0125] The term "substantial homology" or "substantial similarity," when referring to a nucleic acid or fragment thereof, indicates that, when optimally aligned with appropriate nucleotide insertions or deletions with another nucleic acid (or its complementary strand), there is nucleotide sequence identity in at least about 50%, more preferably 60% of the nucleotide bases, usually at least about 70%, more usually at least about 80%, preferably at least about 90%, and more preferably at least about 95%, 96%, 97%, 98% or 99% of the nucleotide bases, as measured by any well-known algorithm of sequence identity, such as FASTA, BLAST or Gap, as discussed above.

[0126] Alternatively, substantial homology or similarity exists when a nucleic acid or fragment thereof hybridizes to another nucleic acid, to a strand of another nucleic acid, or to the complementary strand thereof, under stringent hybridization conditions. "Stringent hybridization conditions" and "stringent wash conditions" in the context of nucleic acid hybridization experiments depend upon a number of different physical parameters. Nucleic acid hybridization will be affected by such conditions as salt concentration, temperature, solvents, the base composition of the hybridizing species, length of the complementary regions, and the number of nucleotide base mismatches between the hybridizing nucleic acids, as will be readily appreciated by those skilled in the art. One having ordinary skill in the art knows how to vary these parameters to achieve a particular stringency of hybridization.

[0127] In general, "stringent hybridization" is performed at about 25°C below the thermal melting point (T_m) for the specific DNA hybrid under a particular set of conditions. "Stringent washing" is performed at temperatures about 5°C lower than the T_m for the specific DNA hybrid under a particular set of conditions. The T_m is the temperature at which 50% of the target sequence hybridizes to a perfectly matched probe. See Sambrook *et al.*, *supra*, page 9.51, hereby incorporated by reference. For purposes herein, "high stringency conditions" are defined for solution phase hybridization as aqueous hybridization (i.e., free of formamide) in 6X SSC (where 20X SSC contains 3.0 M NaCl and 0.3 M sodium citrate), 1% SDS at 65°C for 8-12 hours, followed by two washes in 0.2X SSC, 0.1% SDS at 65°C for 20 minutes. It will be appreciated by the skilled artisan that hybridization at

65°C will occur at different rates depending on a number of factors including the length and percent identity of the sequences which are hybridizing.

[0128] The term "mutated" when applied to nucleic acid sequences means that nucleotides in a nucleic acid sequence may be inserted, deleted or changed compared to a reference nucleic acid sequence. A single alteration may be made at a locus (a point mutation) or multiple nucleotides may be inserted, deleted or changed at a single locus. In addition, one or more alterations may be made at any number of loci within a nucleic acid sequence. A nucleic acid sequence may be mutated by any method known in the art including but not limited to mutagenesis techniques such as "error-prone PCR" (a process for performing PCR under conditions where the copying fidelity of the DNA polymerase is low, such that a high rate of point mutations is obtained along the entire length of the PCR product. See, e.g., Leung, D. W., *et al.*, *Technique*, 1, pp. 11-15 (1989) and Caldwell, R. C. & Joyce G. F., *PCR Methods Applic.*, 2, pp. 28-33 (1992)); and "oligonucleotide-directed mutagenesis" (a process which enables the generation of site-specific mutations in any cloned DNA segment of interest. See, e.g., Reidhaar-Olson, J. F. & Sauer, R. T., *et al.*, *Science*, 241, pp. 53-57 (1988)).

[0129] The term "vector" as used herein is intended to refer to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a "plasmid", which refers to a circular double stranded DNA loop into which additional DNA segments may be ligated. Other vectors include cosmids, bacterial artificial chromosomes (BAC) and yeast artificial chromosomes (YAC). Another type of vector is a viral vector, wherein additional DNA segments may be ligated into the viral genome (discussed in more detail below). Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., vectors having an origin of replication which functions in the host cell). Other vectors can be integrated into the genome of a host cell upon introduction into the host cell, and are thereby replicated along with the host genome. Moreover, certain preferred vectors are capable of directing the expression of genes to which they are operatively linked. Such vectors are referred to herein as "recombinant expression vectors" (or simply, "expression vectors").

[0130] "Operatively linked" expression control sequences refers to a linkage in which the expression control sequence is contiguous with the gene of interest to control the gene of interest, as well as expression control sequences that act in *trans* or at a distance to control the gene of interest.

5 [0131] The term "expression control sequence" as used herein refers to polynucleotide sequences which are necessary to affect the expression of coding sequences to which they are operatively linked. Expression control sequences are sequences which control the transcription, post-transcriptional events and translation of nucleic acid sequences. Expression control sequences include
10 appropriate transcription initiation, termination, promoter and enhancer sequences; efficient RNA processing signals such as splicing and polyadenylation signals; sequences that stabilize cytoplasmic mRNA; sequences that enhance translation efficiency (e.g., ribosome binding sites); sequences that enhance protein stability; and when desired, sequences that enhance protein secretion. The nature of such
15 control sequences differs depending upon the host organism; in prokaryotes, such control sequences generally include promoter, ribosomal binding site, and transcription termination sequence. The term "control sequences" is intended to include, at a minimum, all components whose presence is essential for expression, and can also include additional components whose presence is advantageous, for
20 example, leader sequences and fusion partner sequences.

[0132] The term "recombinant host cell" (or simply "host cell"), as used herein, is intended to refer to a cell into which a nucleic acid such as a recombinant vector has been introduced. It should be understood that such terms are intended to refer not only to the particular subject cell but to the progeny of such a cell. Because
25 certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term "host cell" as used herein. A recombinant host cell may be an isolated cell or cell line grown in culture or may be a cell which resides in a living tissue or organism.

30 [0133] The term "peptide" as used herein refers to a short polypeptide, e.g., one that is typically less than about 50 amino acids long and more typically less than

about 30 amino acids long. The term as used herein encompasses analogs and mimetics that mimic structural and thus biological function.

[0134] The term "polypeptide" as used herein encompasses both naturally-occurring and non-naturally-occurring proteins, and fragments, mutants, derivatives and analogs thereof. A polypeptide may be monomeric or polymeric. Further, a polypeptide may comprise a number of different domains each of which has one or more distinct activities.

[0135] The term "isolated protein" or "isolated polypeptide" is a protein or polypeptide that by virtue of its origin or source of derivation (1) is not associated with naturally associated components that accompany it in its native state, (2) when it exists in a purity not found in nature, where purity can be adjudged with respect to the presence of other cellular material (e.g., is free of other proteins from the same species) (3) is expressed by a cell from a different species, or (4) does not occur in nature (e.g., it is a fragment of a polypeptide found in nature or it includes amino acid analogs or derivatives not found in nature or linkages other than standard peptide bonds). Thus, a polypeptide that is chemically synthesized or synthesized in a cellular system different from the cell from which it naturally originates will be "isolated" from its naturally associated components. A polypeptide or protein may also be rendered substantially free of naturally associated components by isolation, using protein purification techniques well-known in the art. As thus defined, "isolated" does not necessarily require that the protein, polypeptide, peptide or oligopeptide so described has been physically removed from its native environment.

[0136] The term "polypeptide fragment" as used herein refers to a polypeptide that has an amino-terminal and/or carboxy-terminal deletion compared to a full-length polypeptide. In a preferred embodiment, the polypeptide fragment is a contiguous sequence in which the amino acid sequence of the fragment is identical to the corresponding positions in the naturally-occurring sequence. Fragments typically are at least 5, 6, 7, 8, 9 or 10 amino acids long, preferably at least 12, 14, 16 or 18 amino acids long, more preferably at least 20 amino acids long, more preferably at least 25, 30, 35, 40 or 45, amino acids, even more preferably at least 50 or 60 amino acids long, and even more preferably at least 70 amino acids long.

[0137] A "modified derivative" refers to polypeptides or fragments thereof that are substantially homologous in primary structural sequence but which include, e.g., *in vivo* or *in vitro* chemical and biochemical modifications or which incorporate amino acids that are not found in the native polypeptide. Such modifications include, for example, acetylation, carboxylation, phosphorylation, glycosylation, ubiquitination, labeling, e.g., with radionuclides, and various enzymatic modifications, as will be readily appreciated by those well skilled in the art. A variety of methods for labeling polypeptides and of substituents or labels useful for such purposes are well-known in the art, and include radioactive isotopes such as ^{125}I , ^{32}P , ^{35}S , and ^3H , ligands which bind to labeled antiligands (e.g., antibodies), fluorophores, chemiluminescent agents, enzymes, and antiligands which can serve as specific binding pair members for a labeled ligand. The choice of label depends on the sensitivity required, ease of conjugation with the primer, stability requirements, and available instrumentation. Methods for labeling polypeptides are well-known in the art. See Ausubel *et al.*, *Current Protocols in Molecular Biology*, Greene Publishing Associates (1992, and supplement to 2002) hereby incorporated by reference.

[0138] A "polypeptide mutant" or "mutein" refers to a polypeptide whose sequence contains an insertion, duplication, deletion, rearrangement or substitution of one or more amino acids compared to the amino acid sequence of a native or wild type protein. A mutein may have one or more amino acid point substitutions, in which a single amino acid at a position has been changed to another amino acid, one or more insertions and/or deletions, in which one or more amino acids are inserted or deleted, respectively, in the sequence of the naturally-occurring protein, and/or truncations of the amino acid sequence at either or both the amino or carboxy termini. A mutein may have the same but preferably has a different biological activity compared to the naturally-occurring protein.

[0139] A mutein has at least 70% overall sequence homology to its wild-type counterpart. Even more preferred are muteins having 80%, 85% or 90% overall sequence homology to the wild-type protein. In an even more preferred embodiment, a mutein exhibits 95% sequence identity, even more preferably 97%, even more preferably 98% and even more preferably 99% overall sequence

identity. Sequence homology may be measured by any common sequence analysis algorithm, such as Gap or Bestfit.

[0140] Preferred amino acid substitutions are those which: (1) reduce susceptibility to proteolysis, (2) reduce susceptibility to oxidation, (3) alter binding affinity for forming protein complexes, (4) alter binding affinity or enzymatic activity, and (5) confer or modify other physicochemical or functional properties of such analogs.

[0141] As used herein, the twenty conventional amino acids and their abbreviations follow conventional usage. See *Immunology - A Synthesis* (2nd Edition, E.S. Golub and D.R. Gren, Eds., Sinauer Associates, Sunderland, Mass. (1991)), which is incorporated herein by reference. Stereoisomers (e.g., D-amino acids) of the twenty conventional amino acids, unnatural amino acids such as α -, α -disubstituted amino acids, N-alkyl amino acids, and other unconventional amino acids may also be suitable components for polypeptides of the present invention. Examples of unconventional amino acids include: 4-hydroxyproline, γ -carboxyglutamate, ϵ -N,N,N-trimethyllysine, ϵ -N-acetyllysine, O-phosphoserine, N-acetylserine, N-formylmethionine, 3-methylhistidine, 5-hydroxylysine, s-N-methylarginine, and other similar amino acids and imino acids (e.g., 4-hydroxyproline). In the polypeptide notation used herein, the left-hand direction is the amino terminal direction and the right hand direction is the carboxy-terminal direction, in accordance with standard usage and convention.

[0142] A protein has "homology" or is "homologous" to a second protein if the nucleic acid sequence that encodes the protein has a similar sequence to the nucleic acid sequence that encodes the second protein. Alternatively, a protein has homology to a second protein if the two proteins have "similar" amino acid sequences. (Thus, the term "homologous proteins" is defined to mean that the two proteins have similar amino acid sequences). In a preferred embodiment, a homologous protein is one that exhibits 60% sequence homology to the wild type protein, more preferred is 70% sequence homology. Even more preferred are homologous proteins that exhibit 80%, 85% or 90% sequence homology to the wild type protein. In a yet more preferred embodiment, a homologous protein exhibits 95%, 97%, 98% or 99% sequence identity. As used herein, homology

between two regions of amino acid sequence (especially with respect to predicted structural similarities) is interpreted as implying similarity in function.

[0143] When "homologous" is used in reference to proteins or peptides, it is recognized that residue positions that are not identical often differ by conservative amino acid substitutions. A "conservative amino acid substitution" is one in which an amino acid residue is substituted by another amino acid residue having a side chain (R group) with similar chemical properties (e.g., charge or hydrophobicity). In general, a conservative amino acid substitution will not substantially change the functional properties of a protein. In cases where two or more amino acid sequences differ from each other by conservative substitutions, the percent sequence identity or degree of homology may be adjusted upwards to correct for the conservative nature of the substitution. Means for making this adjustment are well known to those of skill in the art (see, e.g., Pearson *et al.*, 1994, herein incorporated by reference).

[0144] The following six groups each contain amino acids that are conservative substitutions for one another: 1) Serine (S), Threonine (T); 2) Aspartic Acid (D), Glutamic Acid (E); 3) Asparagine (N), Glutamine (Q); 4) Arginine (R), Lysine (K); 5) Isoleucine (I), Leucine (L), Methionine (M), Alanine (A), Valine (V), and 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W).

[0145] Sequence homology for polypeptides, which is also referred to as percent sequence identity, is typically measured using sequence analysis software. See, e.g., the Sequence Analysis Software Package of the Genetics Computer Group (GCG), University of Wisconsin Biotechnology Center, 910 University Avenue, Madison, Wisconsin 53705. Protein analysis software matches similar sequences using measure of homology assigned to various substitutions, deletions and other modifications, including conservative amino acid substitutions. For instance, GCG contains programs such as "Gap" and "Bestfit" which can be used with default parameters to determine sequence homology or sequence identity between closely related polypeptides, such as homologous polypeptides from different species of organisms or between a wild type protein and a mutein thereof. See, e.g., GCG Version 6.1.

[0146] A preferred algorithm when comparing a inhibitory molecule sequence to a database containing a large number of sequences from different organisms is the computer program BLAST (Altschul, S.F. *et al.* (1990) *J. Mol. Biol.* 215:403-410; Gish and States (1993) *Nature Genet.* 3:266-272; Madden, T.L. *et al.* (1996) *Meth. Enzymol.* 266:131-141; Altschul, S.F. *et al.* (1997) *Nucleic Acids Res.* 25:3389-3402; Zhang, J. and Madden, T.L. (1997) *Genome Res.* 7:649-656), especially blastp or tblastn (Altschul *et al.*, 1997). Preferred parameters for BLASTp are: Expectation value: 10 (default); Filter: seg (default); Cost to open a gap: 11 (default); Cost to extend a gap: 1 (default); Max. alignments: 100 (default); Word size: 11 (default); No. of descriptions: 100 (default); Penalty Matrix: BLOWSUM62.

[0147] The length of polypeptide sequences compared for homology will generally be at least about 16 amino acid residues, usually at least about 20 residues, more usually at least about 24 residues, typically at least about 28 residues, and preferably more than about 35 residues. When searching a database containing sequences from a large number of different organisms, it is preferable to compare amino acid sequences. Database searching using amino acid sequences can be measured by algorithms other than blastp known in the art. For instance, polypeptide sequences can be compared using FASTA, a program in GCG Version 6.1. FASTA provides alignments and percent sequence identity of the regions of the best overlap between the query and search sequences (Pearson, 1990, herein incorporated by reference). For example, percent sequence identity between amino acid sequences can be determined using FASTA with its default parameters (a word size of 2 and the PAM250 scoring matrix), as provided in GCG Version 6.1, herein incorporated by reference.

[0148] The term "motif" in reference to the conserved regions denotes the amino acid residues usually found in proteins and conventionally known as alanine (Ala or A), valine (Val or V), leucine (Leu or L), isoleucine (Ile or I), proline (Pro or P), phenylalanine (Phe or F), tryptophan (Trp or W), methionine (Met or M), glycine (Gly or G), serine (Ser or S), threonine (Thr or T), cysteine (Cys or C), tyrosine (Tyr or Y), asparagine (Asn or N), glutamine (Gln or Q), aspartic acid (Asp or D),

glutamic acid (Glu or E), lysine (Lys or K), arginine (Arg or R), and histidine (His or H).

[0149] The term "fusion protein" refers to a polypeptide comprising a polypeptide or fragment coupled to heterologous amino acid sequences. Fusion proteins are useful because they can be constructed to contain two or more desired functional elements from two or more different proteins. A fusion protein comprises at least 10 contiguous amino acids from a polypeptide of interest, more preferably at least 20 or 30 amino acids, even more preferably at least 40, 50 or 60 amino acids, yet more preferably at least 75, 100 or 125 amino acids. Fusion proteins can be produced recombinantly by constructing a nucleic acid sequence which encodes the polypeptide or a fragment thereof in-frame with a nucleic acid sequence encoding a different protein or peptide and then expressing the fusion protein. Alternatively, a fusion protein can be produced chemically by crosslinking the polypeptide or a fragment thereof to another protein.

[0150] The term "region" as used herein refers to a physically contiguous portion of the primary structure of a biomolecule. In the case of proteins, a region is defined by a contiguous portion of the amino acid sequence of that protein.

[0151] The term "domain" as used herein refers to a structure of a biomolecule that contributes to a known or suspected function of the biomolecule. Domains may be co-extensive with regions or portions thereof; domains may also include distinct, non-contiguous regions of a biomolecule. Examples of protein domains include, but are not limited to, an Ig domain, an extracellular domain, a transmembrane domain, and a cytoplasmic domain.

[0152] As used herein, the term "molecule" means any compound, including, but not limited to, a small molecule, peptide, protein, sugar, nucleotide, nucleic acid, lipid, etc., and such a compound can be natural or synthetic.

[0153] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. Exemplary methods and materials are described below, although methods and materials similar or equivalent to those described herein can also be used in the practice of the present invention and will be apparent to those of skill in the art. All publications and other references mentioned herein

are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control. The materials, methods, and examples are illustrative only and not intended to be limiting.

[0154] Throughout this specification and claims, the word "comprise" or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated integer or group of integers but not the exclusion of any other integer or group of integers.

10 **Methods For Producing Human-Like Glycoproteins In Lower Eukaryotic Host Cells**

[0155] The invention provides methods for producing a glycoprotein having human-like glycosylation in a non-human eukaryotic host cell. As described in more detail below, a eukaryotic host cell that does not naturally express, or which is engineered not to express, one or more enzymes involved in production of high mannose structures is selected as a starting host cell. Such a selected host cell is engineered to express one or more enzymes or other factors required to produce human-like glycoproteins. A desired host strain can be engineered one enzyme or more than one enzyme at a time. In addition, a nucleic acid molecule encoding one or more enzymes or activities may be used to engineer a host strain of the invention. Preferably, a library of nucleic acid molecules encoding potentially useful enzymes (e.g., chimeric enzymes comprising a catalytically active enzyme fragment ligated in-frame to a heterologous subcellular targeting sequence) is created (e.g., by ligation of sub-libraries comprising enzymatic fragments and subcellular targeting sequences), and a strain having one or more enzymes with optimal activities or producing the most "human-like" glycoproteins may be selected by transforming target host cells with one or more members of the library.

[0156] In particular, the methods described herein enable one to obtain, *in vivo*, Man₅GlcNAc₂ structures in high yield, at least transiently, for the purpose of further modifying it to yield complex N-glycans. A successful scheme to obtain suitable Man₅GlcNAc₂ structures in appropriate yields in a host cell, such as a lower eukaryotic organism, generally involves two parallel approaches: (1) reducing high mannose structures made by endogenous mannosyltransferase

activities, if any, and (2) removing 1,2- α -mannose by mannosidases to yield high levels of suitable $\text{Man}_5\text{GlcNAc}_2$ structures which may be further reacted inside the host cell to form complex, human-like glycoforms.

[0157] Accordingly, a first step involves the selection or creation of a eukaryotic host cell, e.g., a lower eukaryote, capable of producing a specific precursor structure of $\text{Man}_5\text{GlcNAc}_2$ that is able to accept *in vivo* GlcNAc by the action of a GlcNAc transferase I ("GnT1"). In one embodiment, the method involves making or using a non-human eukaryotic host cell depleted in a 1,6 mannosyltransferase activity with respect to the N-glycan on a glycoprotein. Preferably, the host cell is depleted in an initiating 1,6 mannosyltransferase activity (see below). Such a host cell will lack one or more enzymes involved in the production of high mannose structures which are undesirable for producing human-like glycoproteins.

[0158] One or more enzyme activities are then introduced into such a host cell to produce N-glycans within the host cell characterized by having at least 30 mol % of the $\text{Man}_5\text{GlcNAc}_2$ ("Man₅") carbohydrate structures. $\text{Man}_5\text{GlcNAc}_2$ structures are necessary for complex N-glycan formation: $\text{Man}_5\text{GlcNAc}_2$ must be formed *in vivo* in a high yield (e.g., in excess of 30%), at least transiently, as subsequent mammalian- and human-like glycosylation reactions require $\text{Man}_5\text{GlcNAc}_2$ or a derivative thereof.

[0159] This step also requires the formation of a particular isomeric structure of $\text{Man}_5\text{GlcNAc}_2$ within the cell at a high yield. While $\text{Man}_5\text{GlcNAc}_2$ structures are necessary for complex N-glycan formation, their presence is by no means sufficient. That is because $\text{Man}_5\text{GlcNAc}_2$ may occur in different isomeric forms, which may or may not serve as a substrate for GlcNAc transferase I. As most glycosylation reactions are not complete, a particular glycosylated protein generally contains a range of different carbohydrate structures (i.e. glycoforms) on its surface. Thus, the mere presence of trace amounts (i.e., less than 5%) of a particular structure like $\text{Man}_5\text{GlcNAc}_2$ is of little practical relevance for producing mammalian- or human-like glycoproteins. It is the formation of a GlcNAc transferase I-accepting $\text{Man}_5\text{GlcNAc}_2$ intermediate (Figure 1B) in high yield (i.e., above 30%), which is required. The formation of this intermediate is necessary to

enable subsequent *in vivo* synthesis of complex N-glycans on glycosylated proteins of interest (target proteins).

[0160] Accordingly, some or all of the $\text{Man}_5\text{GlcNAc}_2$ produced by the selected host cell must be a productive substrate for enzyme activities along a mammalian glycosylation pathway, e.g., can serve as a substrate for a GlcNAc transferase I activity *in vivo*, thereby forming the human-like N-glycan intermediate $\text{GlcNAcMan}_5\text{GlcNAc}_2$ in the host cell. In a preferred embodiment, at least 10%, more preferably at least 30% and most preferably 50% or more of the $\text{Man}_5\text{GlcNAc}_2$ intermediate produced in the host cell of the invention is a productive substrate for GnTI *in vivo*. It is understood that if, for example, $\text{GlcNAcMan}_5\text{GlcNAc}_2$ is produced at 10% and $\text{Man}_5\text{GlcNAc}_2$ is produced at 25% on a target protein, that the total amount of transiently produced $\text{Man}_5\text{GlcNAc}_2$ is 35% because $\text{GlcNAcMan}_5\text{GlcNAc}_2$ is a product of $\text{Man}_5\text{GlcNAc}_2$.

[0161] One of ordinary skill in the art can select host cells from nature, e.g., existing fungi or other lower eukaryotes that produce significant levels of $\text{Man}_5\text{GlcNAc}_2$ *in vivo*. As yet, however, no lower eukaryote has been shown to provide such structures *in vivo* in excess of 1.8% of the total N-glycans (see e.g. Maras et al., 1997, *Eur. J. Biochem.* 249, 701-707). Alternatively, such host cells may be genetically engineered to produce the $\text{Man}_5\text{GlcNAc}_2$ structure *in vivo*. Methods such as those described in U.S. Patent No. 5,595,900 may be used to identify the absence or presence of particular glycosyltransferases, mannosidases and sugar nucleotide transporters in a target host cell or organism of interest.

Inactivation of Undesirable Host Cell Glycosylation Enzymes

[0162] The methods of the invention are directed to making host cells which produce glycoproteins having altered, and preferably human-like, N-glycan structures. In a preferred embodiment, the methods are directed to making host cells in which oligosaccharide precursors are enriched in $\text{Man}_5\text{GlcNAc}_2$. Preferably, a eukaryotic host cell is used that does not express one or more enzymes involved in the production of high mannose structures. Such a host cell may be found in nature or may be engineered, e.g., starting with or derived from one of many such mutants already described in yeasts. Thus, depending on the

selected host cell, one or a number of genes that encode enzymes known to be characteristic of non-human glycosylation reactions will have to be deleted. Such genes and their corresponding proteins have been extensively characterized in a number of lower eukaryotes (e.g., *S.cerevisiae*, *T. reesei*, *A. nidulans* etc.), thereby providing a list of known glycosyltransferases in lower eukaryotes, their activities and their respective genetic sequence. These genes are likely to be selected from the group of mannosyltransferases e.g. 1,3 mannosyltransferases (e.g. *MNN1* in *S.cerevisiae*) (Graham, 1991), 1,2 mannosyltransferases (e.g. *KTR/KRE* family from *S.cerevisiae*), 1,6 mannosyltransferases (*OCH1* from *S.cerevisiae*), mannosylphosphate transferases and their regulators (*MNN4* and *MNN6* from *S.cerevisiae*) and additional enzymes that are involved in aberrant, i.e. non human, glycosylation reactions. Many of these genes have in fact been deleted individually giving rise to viable phenotypes with altered glycosylation profiles. Examples are shown in Table 1 (above).

[0163] Preferred lower eukaryotic host cells of the invention, as described herein to exemplify the required manipulation steps, are hypermannosylation-minus (*och1*) mutants of *Pichia pastoris* or *K.lactis*. Like other lower eukaryotes, *P.pastoris* processes $\text{Man}_9\text{GlcNAc}_2$ structures in the ER with an α -1,2-mannosidase to yield $\text{Man}_8\text{GlcNAc}_2$ (Figure 1A). Through the action of several mannosyltransferases, this structure is then converted to hypermannosylated structures ($\text{Man}_{>9}\text{GlcNAc}_2$), also known as mannans. In addition, it has been found that *P.pastoris* is able to add non-terminal phosphate groups, through the action of mannosylphosphate transferases, to the carbohydrate structure. This differs from the reactions performed in mammalian cells, which involve the removal rather than addition of mannose sugars. It is of particular importance to eliminate the ability of the eukaryotic host cell, e.g., fungus, to hypermannosylate an existing $\text{Man}_8\text{GlcNAc}_2$ structure. This can be achieved by either selecting for a host cell that does not hypermannosylate or by genetically engineering such a cell.

[0164] Genes that are involved in the hypermannosylation process have been identified, e.g., in *Pichia pastoris*, and by creating mutations in these genes, one can reduce the production of "undesirable" glycoforms. Such genes can be identified by homology to existing mannosyltransferases or their regulators (e.g.,

OCH1, *MNN4*, *MNN6*, *MNN1*) found in other lower eukaryotes such as *C. albicans*, *Pichia angusta* or *S.cerevisiae* or by mutagenizing the host strain and selecting for a glycosylation phenotype with reduced mannosylation. Based on homologies amongst known mannosyltransferases and mannosylphosphate transferases, one may either design PCR primers (examples of which are shown in Table 2, SEQ ID Nos: 60-91 are additional examples of primers), or use genes or gene fragments encoding such enzymes as probes to identify homologs in DNA libraries of the target or a related organism. Alternatively, one may identify a functional homolog having mannosyltransferase activity by its ability to complement particular glycosylation phenotypes in related organisms.

Table 2. PCR Primers

PCR primer A	PCR primer B	Target Gene(s) in <i>P.pastoris</i>	Homologs
ATGGCGAAGGC AGATGGCAGT (SEQ ID NO: 18)	TTAGTCCTTC CAACTTCCTT C (SEQ ID NO: 19)	1,6-mannosyltransferase	<i>OCH1</i> <i>S.cerevisiae</i> , <i>Pichia albicans</i>
TAYTGGMGNGT NGARCYNGAY ATHAA (SEQ ID NO: 103)	GCRTCNCCCC ANCKYTCRTA (SEQ ID NO: 104)	1,2-mannosyltransferases	KTR/KRE family, <i>S.cerevisiae</i>

Legend: M = A or C, R = A or G, W = A or T, S = C or G, Y = C or T, K = G or T, V = A or C or G, H = A or C or T, D = A or G or T, B = C or G or T, N = G or A or T or C.

[0165] To obtain the gene or genes encoding 1,6-mannosyltransferase activity in *P. pastoris*, for example, one would carry out the following steps: *OCH1* mutants of *S.cerevisiae* are temperature sensitive and are slow growers at elevated temperatures. One can thus identify functional homologs of *OCH1* in *P.pastoris* by complementing an *OCH1* mutant of *S.cerevisiae* with a *P.pastoris* DNA or cDNA library. Mutants of *S.cerevisiae* are available, e.g., from Stanford University and are commercially available from ResGen, an Invitrogen Corp. (Carlsbad, CA). Mutants that display a normal growth phenotype at elevated temperature, after having been transformed with a *P.pastoris* DNA library, are

likely to carry an *OCH1* homolog of *P. pastoris*. Such a library can be created by partially digesting chromosomal DNA of *P. pastoris* with a suitable restriction enzyme and, after inactivating the restriction enzyme, ligating the digested DNA into a suitable vector, which has been digested with a compatible restriction enzyme.

[0166] Suitable vectors include, e.g., pRS314, a low copy (CEN6/ARS4) plasmid based on pBluescript containing the Trp1 marker (Sikorski, R. S., and Hieter, P., 1989, *Genetics* 122, pg 19-27) and pFL44S, a high copy (2 μ) plasmid based on a modified pUC19 containing the URA3 marker (Bonneaud, N., et al., 1991, *Yeast* 7, pg. 609-615). Such vectors are commonly used by academic researchers and similar vectors are available from a number of different vendors (e.g., Invitrogen (Carlsbad, CA); Pharmacia (Piscataway, NJ); New England Biolabs (Beverly, MA)). Further examples include pYES/GS, 2 μ origin of replication based yeast expression plasmid from Invitrogen, or Yep24 cloning vehicle from New England Biolabs.

[0167] After ligation of the chromosomal DNA and the vector, one may transform the DNA library into a strain of *S. cerevisiae* with a specific mutation and select for the correction of the corresponding phenotype. After sub-cloning and sequencing the DNA fragment that is able to restore the wild-type phenotype, one may use this fragment to eliminate the activity of the gene product encoded by *OCH1* in *P. pastoris* using *in vivo* mutagenesis and/or recombination techniques well-known to those skilled in the art.

[0168] Alternatively, if the entire genomic sequence of a particular host cell, e.g., fungus, of interest is known, one may identify such genes simply by searching publicly available DNA databases, which are available from several sources, such as NCBI, Swissprot. For example, by searching a given genomic sequence or database with sequences from a known 1,6 mannosyltransferase gene (e.g., *OCH1* from *S. cerevisiae*), one can identify genes of high homology in such a host cell genome which may (but do not necessarily) encode proteins that have 1,6-mannosyltransferase activity. Nucleic acid sequence homology alone is not enough to prove, however, that one has identified and isolated a homolog encoding an enzyme having the same activity. To date, for example, no data exist to show

that an *OCH1* deletion in *P.pastoris* eliminates the crucial initiating 1,6-mannosyltransferase activity. (Martinet et al. *Biotech. Letters* 20(12) (Dec. 1998): 1171-1177; Contreras et al. WO 02/00856 A2). Thus, no data prove that the *P.pastoris OCH1* gene homolog actually encodes that function. That demonstration is provided for the first time herein.

[0169] Homologs to several *S.cerevisiae* mannosyltransferases have been identified in *P.pastoris* using these approaches. Homologous genes often have similar functions to genes involved in the mannosylation of proteins in *S.cerevisiae* and thus their deletion may be used to manipulate the glycosylation pattern in *P.pastoris* or, by analogy, in any other host cell, e.g., fungus, plant, insect or animal cells, with similar glycosylation pathways.

[0170] The creation of gene knock-outs, once a given target gene sequence has been determined, is a well-established technique in the art and can be carried out by one of ordinary skill in the art (see, e.g., R. Rothstein, (1991) *Methods in Enzymology*, vol. 194, p. 281). The choice of a host organism may be influenced by the availability of good transformation and gene disruption techniques.

[0171] If several mannosyltransferases are to be knocked out, the method developed by Alani and Kleckner, (*Genetics* 116:541-545 (1987)), for example, enables the repeated use of a selectable marker, e.g., the *URA3* marker in yeast, to sequentially eliminate all undesirable endogenous mannosyltransferase activity. This technique has been refined by others but basically involves the use of two repeated DNA sequences, flanking a counter selectable marker. For example: *URA3* may be used as a marker to ensure the selection of a transformants that have integrated a construct. By flanking the *URA3* marker with direct repeats one may first select for transformants that have integrated the construct and have thus disrupted the target gene. After isolation of the transformants, and their characterization, one may counter select in a second round for those that are resistant to 5-fluoroorotic acid (5-FOA). Colonies that are able to survive on plates containing 5-FOA have lost the *URA3* marker again through a crossover event involving the repeats mentioned earlier. This approach thus allows for the repeated use of the same marker and facilitates the disruption of multiple genes without requiring additional markers. Similar techniques for sequential elimination of

genes adapted for use in another eukaryotic host cells with other selectable and counter-selectable markers may also be used.

[0172] Eliminating specific mannosyltransferases, such as 1,6 mannosyltransferase (*OCH1*) or mannosylphosphate transferases (*MNN6*, or genes complementing *lbd* mutants) or regulators (*MNN4*) in *P.pastoris* enables one to create engineered strains of this organism which synthesize primarily $\text{Man}_8\text{GlcNAc}_2$ and which can be used to further modify the glycosylation pattern to resemble more complex glycoform structures, e.g., those produced in mammalian, e.g., human cells. A preferred embodiment of this method utilizes DNA sequences encoding biochemical glycosylation activities to eliminate similar or identical biochemical functions in *P. pastoris* to modify the glycosylation structure of glycoproteins produced in the genetically altered *P.pastoris* strain.

[0173] Methods used to engineer the glycosylation pathway in yeasts as exemplified herein can be used in filamentous fungi to produce a preferred substrate for subsequent modification. Strategies for modifying glycosylation pathways in *A.niger* and other filamentous fungi, for example, can be developed using protocols analogous to those described herein for engineering strains to produce human-like glycoproteins in yeast. Undesired gene activities involved in 1,2 mannosyltransferase activity, e.g., *KTR/KRE* homologs, are modified or eliminated. A filamentous fungus, such as *Aspergillus*, is a preferred host because it lacks the 1,6 mannosyltransferase activity and as such, one would not expect a hypermannosylating gene activity, e.g. *OCH1*, in this host. By contrast, other desired activities (e.g., α -1,2-mannosidase, UDP-GlcNAc transporter, glycosyltransferase (GnT), galactosyltransferase (GalT) and sialyltransferase (ST)) involved in glycosylation are introduced into the host using the targeting methods of the invention.

Engineering or Selecting Hosts Having Diminished Initiating α -1,6 Mannosyltransferase Activity

[0174] In a preferred embodiment, the method of the invention involves making or using a host cell which is diminished or depleted in the activity of an initiating α -1,6-mannosyltransferase, i.e., an initiation specific enzyme that initiates outer chain mannosylation on the α -1,3 arm of the $\text{Man}_3\text{GlcNAc}_2$ core structure. In

S.cerevisiae, this enzyme is encoded by the *OCH1* gene. Disruption of the *OCH1* gene in *S.cerevisiae* results in a phenotype in which N-linked sugars completely lack the poly-mannose outer chain. Previous approaches for obtaining mammalian-type glycosylation in fungal strains have required inactivation of *OCH1* (see, e.g., Chiba et al. (1998) *J. Biol. Chem.* 273:26298-304). Disruption of the initiating α -1,6-mannosyltransferase activity in a host cell of the invention may be optional, however (depending on the selected host cell), as the Och1p enzyme requires an intact Man₈GlcNAc₂ for efficient mannose outer chain initiation. Thus, host cells selected or produced according to this invention which accumulate oligosaccharides having seven or fewer mannose residues may produce hypoglycosylated N-glycans that will likely be poor substrates for Och1p (see, e.g., Nakayama et al. (1997) *FEBS Lett.* 412(3):547-50).

[0175] The *OCH1* gene was cloned from *P.pastoris* (Example 1) and *K.lactis* (Example 9), as described. The nucleic acid and amino acid sequences of the *OCH1* gene from *K.lactis* are set forth in SEQ ID NOS: 3 and 4. Using gene-specific primers, a construct was made from each clone to delete the *OCH1* gene from the genome of *P.pastoris* and *K.lactis* (Examples 1 and 9, respectively). Host cells depleted in initiating α -1,6-mannosyltransferase activity and engineered to produce N-glycans having a Man₅GlcNAc₂ carbohydrate structure were thereby obtained (see, e.g., Examples 4 and 9).

[0176] Thus, in another embodiment, the invention provides an isolated nucleic acid molecule having a nucleic acid sequence comprising or consisting of at least forty-five, preferably at least 50, more preferably at least 60 and most preferably 75 or more nucleotide residues of the *K.lactis* *OCH1* gene (SEQ ID NO: 3), and homologs, variants and derivatives thereof. The invention also provides nucleic acid molecules that hybridize under stringent conditions to the above-described nucleic acid molecules. Similarly, isolated polypeptides (including muteins, allelic variants, fragments, derivatives, and analogs) encoded by the nucleic acid molecules of the invention are provided. Also provided are vectors, including expression vectors, which comprise the above nucleic acid molecules of the invention, as described further herein. Similarly, host cells transformed with the nucleic acid molecules or vectors of the invention are provided.

[0177] The invention further provides methods of making or using a non-human eukaryotic host cell diminished or depleted in an *alg* gene activity (i.e., *alg* activities, including equivalent enzymatic activities in non-fungal host cells) and introducing into the host cell at least one glycosidase activity. In a preferred embodiment, the glycosidase activity is introduced by causing expression of one or more mannosidase activities within the host cell, for example, by activation of a mannosidase activity, or by expression from a nucleic acid molecule of a mannosidase activity, in the host cell.

[0178] In yet another embodiment, the invention provides a method for producing a human-like glycoprotein in a non-human host, wherein the glycoprotein comprises an N-glycan having at least two GlcNAcs attached to a trimannose core structure.

Expression of Class 2 Mannosidases in Lower Eukaryotes

[0179] The present invention additionally provides a method for making more human-like glycoproteins in lower eukaryotic host cells by expressing a gene encoding a catalytically active Class 2 mannosidases (EC. 3.2.1.114) (homologs, variants, derivatives and catalytically active fragment thereof).

[0180] Using known techniques in the art, gene-specific primers are designed to complement the homologous regions of the Class 2 mannosidase genes (e.g. *D.melanogaster* α -mannosidase II) in order to PCR amplify the mannosidase gene.

[0181] Through the expression of an active Class 2 mannosidase in a cell from a nucleic acid encoding the Class 2 mannosidase a host cell (e.g. *P. pastoris*) is engineered to produce more human-like glycoproteins (see, e.g., Examples 17 - 25).

[0182] In one aspect of the invention, a method is provided for producing a human-like glycoprotein in a lower eukaryote (e.g. *P. pastoris*) by constructing a library of α -mannosidase II enzymes. In a preferred embodiment, a sub-library of *D.melanogaster* α -mannosidase II sequences (e.g. Genbank Accession No. X77652) is fused to a sub-library of *S.cerevisiae* MNN2 targeting peptide sequences. In a more preferred embodiment of the invention, a fusion construct comprising *D. melanogaster* Mannosidase II $\Delta 74$ /MNN2(s) is transformed into a *P.*

pastoris host producing GlcNAcMan₅GlcNAc₂. See Choi et al. *Proc Natl Acad Sci U S A*. 2003 Apr 29;100(9):5022-7 and WO 02/00879, which disclose methods for making human-like glycoproteins in lower eukaryotes having the above N-glycan structure, which is now designated *P. pastoris* YSH-1.

5 [0183] In another embodiment, a Golgi α -mannosidase II sequence is selected from, rat, mouse, human, worms, plants and insects. Such sequences are available in databases such as Swissprot and Genbank. For example, sequences for the following genes were found in Genbank: *Arabidopsis thaliana* Mannosidase II (NM_121499); *C. elegans* Mannosidase II (NM_073594); *Ciona intestinalis*
 10 mannosidase II (AK116684); *Drosophila melanogaster* mannosidase II (X77652); human mannosidase II (U31520); mouse mannosidase II (X61172); rat mannosidase II (XM_218816); human mannosidase IIx (D55649); insect cell mannosidase III (AF005034); human lysosomal mannosidase II (NM_000528); and human cytosolic mannosidase II (NM_006715) (Figures 25-35, SEQ ID NOs:
 15 49-59, respectively). Because of the high sequence similarity and the presence of the Man α 1,3 and Man α 1,6 activity, cytoplasmic mannosidase II and lysosomal mannosidase II will be collectively referred to herein as Class 2 mannosidases.

[0184] Other mannosidases that exhibit the Golgi α -mannosidase II activity include, *inter alia*, insect mannosidase III (AF005034) and human mannosidase IIx
 20 (D55649). As such, these mannosidases may also be used to generate a combinatorial DNA library of catalytically active enzymes.

[0185] In another aspect of the invention, a sub-library of targeting peptide sequences (leaders) selected from the group consisting of *Saccharomyces* GLS1, *Saccharomyces* MNS1, *Saccharomyces* SEC12, *Pichia* SEC, *Pichia* OCH1,
 25 *Saccharomyces* MNN9, *Saccharomyces* VAN1, *Saccharomyces* ANP1, *Saccharomyces* HOC1, *Saccharomyces* MNN10, *Saccharomyces* MNN11, *Saccharomyces* MNT1, *Pichia* D2, *Pichia* D9, *Pichia* J3, *Saccharomyces* KTR1, *Saccharomyces* KTR2, *Kluyveromyces* GnTI, *Saccharomyces* MNN2, *Saccharomyces* MNN5, *Saccharomyces* YUR1, *Saccharomyces* MNN1, and
 30 *Saccharomyces* MNN6 are fused to sequences encoding catalytically active mannosidase II domains. The combination of the leader/catalytic domain library is illustrated in Table 11 (Example 14).

[0186] The Golgi α -mannosidase II fusion constructs generated according to the present invention display the α 1,3 and α 1,6 mannosidase trimming activity. For example, the catalytically active mannosidase II fusion construct cleaves the Man α 1,3 and Man α 1,6 glycosidic linkages present on GlcNAcMan₅GlcNAc₂ to
5 GlcNAcMan₃GlcNAc₂ in *P. pastoris* YSH-1. In another example, a catalytically active mannosidase IIx fusion construct cleaves the Man α 1,3 and Man α 1,6 glycosidic linkages present on Man₆GlcNAc₂ to Man₄GlcNAc₂.

Class 2 Mannosidase Hydrolysis of Glycosidic Linkage

[0187] The present invention also encompasses the mechanism in which the catalytically active domain of Class 2 enzymes hydrolyze the Man α 1,3 and/or Man α 1,6 glycosidic linkages on an oligosaccharide e.g. GlcNAcMan₅GlcNAc₂ structure to produce GlcNAcMan₃GlcNAc₂, a desired intermediate for further N-glycan processing in a lower eukaryote. In a first embodiment, the hydrolysis of
15 the glycosidic linkages occurs sequentially. The enzyme hydrolyzes at least one glycosidic linkage and conformationally rotates to hydrolyze the other glycosidic linkage. In a second embodiment, the hydrolysis of the glycosidic linkages occurs simultaneously. The intermediate produced is a substrate for further Golgi processing wherein other glycosylation enzymes such as N-
20 acetylglucosaminyltransferases (GnTs), galactosyltransferases (GalTs) and sialyltransferases (STs) can subsequently modify it to produce a desired glycoform. Fig. 36A illustrates the oligosaccharide intermediates (e.g. GlcNAcMan₃GlcNAc₂, GlcNAcMan₄GlcNAc₂) produced via the mannosidase II pathway and Fig. 36B illustrates the oligosaccharide intermediates (e.g. Man₄GlcNAc₂, Man₅GlcNAc₂)
25 produced via the mannosidase IIx pathway.

Conserved Regions of the Mannosidase II Enzymes

[0188] It is a feature of the present invention to express sequences encoding conserved regions of the mannosidase II enzyme. The present invention provides
30 isolated nucleic acid molecules that comprise the conserved regions of the

mannosidase II gene from various sources including insect, mammals, plants and worms.

[0189] Several full-length nucleic acid sequences encoding the mannosidase II enzyme have been identified and sequenced. The mannosidase II enzyme sequences are set forth in SEQ ID NO: 49 through SEQ ID NO: 59. An alignment of known mannosidase II sequences (*i.e.*, *Drosophila melanogaster* aligned to other insect, animal and plant sequences) shows a highly conserved motif between amino acids 144-166 and amino acids 222-285 (Figure 23). Accordingly, in another aspect, the invention relates to a method for providing to a host cell a nucleic acid encoding a Class 2 mannosidase enzyme activity wherein the nucleic acid is characterized by having the above conserved mannosidase II regions.

[0190] Moreover, the sequence alignment further reveals several highly conserved cystine-cystine disulfide bridges between amino acids 338-345 and amino acids 346-360 as shown in Fig. 23. These disulfide bridges may play an integral part in substrate binding and recognition, e.g., by maintaining protein architecture.

[0191] The present invention also provides catalytically active fragments of Class 2 mannosidases comprising conserved amino acid sequence regions, especially a first amino acid sequence consisting of 23 amino acid residues having the following sequence:

144

Leu Lys Val Phe Val Val Pro His Ser His Asn Asp Pro Gly Trp Ile Gln Thr Phe
Glu Glu Tyr Try (SEQ ID NO: 5).

[0192] In another preferred embodiment, the amino acid residue at position 145 of the first sequence is selected from the group consisting of K E Q N and Y.

[0193] In another preferred embodiment, the amino acid residue at position 146 of the first sequence is selected from the group consisting of V and I.

[0194] In another preferred embodiment, the amino acid residue at position 147 of the first sequence is selected from the group consisting of F I H and L.

[0195] In another preferred embodiment, the amino acid residue at position 148 of the first sequence is selected from the group consisting of V I L and T.

[0196] In another preferred embodiment, the amino acid residue at position 149 of the first sequence is selected from the group consisting of V I L and D.

[0197] In another preferred embodiment, the amino acid residue at position 150 of the first sequence is selected from the group consisting of P and R.

5 [0198] In another preferred embodiment, the amino acid residue at position 151 of the first sequence is selected from the group consisting of H and L.

[0199] In another preferred embodiment, the amino acid residue at position 152 of the first sequence is selected from the group consisting of S T and G.

10 [0200] In another preferred embodiment, the amino acid residue at position 153 of the first sequence is selected from the group consisting of H and E.

[0201] In another preferred embodiment, the amino acid residue at position 154 of the first sequence is selected from the group consisting of N C D and R.

[0202] In another preferred embodiment, the amino acid residue at position 156 of the first sequence is selected from the group consisting of P and V.

15 [0203] In another preferred embodiment, the amino acid residue at position 157 of the first sequence is selected from the group consisting of G and R

[0204] In another preferred embodiment, the amino acid residue at position 158 of the first sequence is selected from the group consisting of W and L

20 [0205] In another preferred embodiment, the amino acid residue at position 159 of the first sequence is selected from the group consisting of I L K and T.

[0206] In another preferred embodiment, the amino acid residue at position 160 of the first sequence is selected from the group consisting of Q M K and L.

[0207] In another preferred embodiment, the amino acid residue at position 161 of the first sequence is selected from the group consisting of T and Y.

25 [0208] In another preferred embodiment, the amino acid residue at position 162 of the first sequence is selected from the group consisting of F and V.

[0209] In another preferred embodiment, the amino acid residue at position 163 of the first sequence is selected from the group consisting of E D and N.

30 [0210] In another preferred embodiment, the amino acid residue at position 164 of the first sequence is selected from the group consisting of E K D R Q and V.

[0211] In another preferred embodiment, the amino acid residue at position 165 of the first sequence is selected from the group consisting of Y and A.

[0212] In another preferred embodiment, the amino acid residue at position 166 of the first sequence is selected from the group consisting of Y F and C.

[0213] The present invention further provides a catalytically active fragment of a Class 2 mannosidase comprising conserved amino acid sequence regions,
5 especially a second amino acid sequence consisting of 57 amino acid residues having the following sequence:

222

Glu Phe Val Thr Gly Gly Trp Val Met Pro Asp Glu Ala Asn Ser Trp Arg Asn Val
Leu Leu Gln Leu Thr Glu Gly Gln Thr Trp Leu Lys Gln Phe Met Asn Val Thr Pro
10 Thr Ala Ser Trp Ala Ile Asp Pro Phe Gly His Ser Pro Thr Met Pro Tyr Ile Leu
(SEQ ID NO: 6).

[0214] In another preferred embodiment, the amino acid residue at position 222 of the first sequence is selected from the group consisting of E and R.

[0215] In another preferred embodiment, the amino acid residue at position 223
15 of the first sequence is selected from the group consisting of F I and S.

[0216] In another preferred embodiment, the amino acid residue at position 224 of the first sequence is selected from the group consisting of V A T and F

[0217] In another preferred embodiment, the amino acid residue at position 225 of the first sequence is selected from the group consisting of T G N and Q.

20 [0218] In another preferred embodiment, the amino acid residue at position 226 of the first sequence is selected from the group consisting of G and A.

[0219] In another preferred embodiment, the amino acid residue at position 227 of the first sequence is selected from the group consisting of G and L.

[0220] In another preferred embodiment, the amino acid residue at position 228
25 of the first sequence is selected from the group consisting of W and Y.

[0221] In another preferred embodiment, the amino acid residue at position 229 of the first sequence is selected from the group consisting of V and T.

[0222] In another preferred embodiment, the amino acid residue at position 230 of the first sequence is selected from the group consisting of M and A.

30 [0223] In another preferred embodiment, the amino acid residue at position 231 of the first sequence is selected from the group consisting of P T and N.

- [0224] In another preferred embodiment, the amino acid residue at position 232 of the first sequence is selected from the group consisting of D and Q.
- [0225] In another preferred embodiment, the amino acid residue at position 233 of the first sequence is selected from the group consisting of E and M.
- 5 [0226] In another preferred embodiment, the amino acid residue at position 234 of the first sequence is selected from the group consisting of A and V.
- [0227] In another preferred embodiment, the amino acid residue at position 235 of the first sequence is selected from the group consisting of N T C and A.
- [0228] In another preferred embodiment, the amino acid residue at position 236 of the first sequence is selected from the group consisting of S A P T and V.
- 10 [0229] In another preferred embodiment, the amino acid residue at position 237 of the first sequence is selected from the group consisting of H and C.
- [0230] In another preferred embodiment, the amino acid residue at position 238 of the first sequence is selected from the group consisting of W Y I and D.
- 15 [0231] In another preferred embodiment, the amino acid residue at position 239 of the first sequence is selected from the group consisting of R H F Y G and P.
- [0232] In another preferred embodiment, the amino acid residue at position 240 of the first sequence is selected from the group consisting of N S and A.
- [0233] In another preferred embodiment, the amino acid residue at position 241 of the first sequence is selected from the group consisting of V M L I and Q.
- 20 [0234] In another preferred embodiment, the amino acid residue at position 242 of the first sequence is selected from the group consisting of L I V and P.
- [0235] In another preferred embodiment, the amino acid residue at position 243 of the first sequence is selected from the group consisting of L T G D and E.
- 25 [0236] In another preferred embodiment, the amino acid residue at position 244 of the first sequence is selected from the group consisting of Q E and T.
- [0237] In another preferred embodiment, the amino acid residue at position 245 of the first sequence is selected from the group consisting of L M and F.
- [0238] In another preferred embodiment, the amino acid residue at position 246 of the first sequence is selected from the group consisting of T F I A and P.
- 30 [0239] In another preferred embodiment, the amino acid residue at position 247 of the first sequence is selected from the group consisting of E L and V.

- [0240] In another preferred embodiment, the amino acid residue at position 248 of the first sequence is selected from the group consisting of G and A.
- [0241] In another preferred embodiment, the amino acid residue at position 249 of the first sequence is selected from the group consisting of Q H P M N and L.
- 5 [0242] In another preferred embodiment, the amino acid residue at position 250 of the first sequence is selected from the group consisting of T E P Q M H R and A.
- [0243] In another preferred embodiment, the amino acid residue at position 251 of the first sequence is selected from the group consisting of W P F and L.
- 10 [0244] In another preferred embodiment, the amino acid residue at position 252 of the first sequence is selected from the group consisting of L I V and A.
- [0245] In another preferred embodiment, the amino acid residue at position 253 of the first sequence is selected from the group consisting of K Q R E N and S.
- [0246] In another preferred embodiment, the amino acid residue at position 254 of the first sequence is selected from the group consisting of Q N R K D and T.
- 15 [0247] In another preferred embodiment, the amino acid residue at position 255 of the first sequence is selected from the group consisting of F H N and T.
- [0248] In another preferred embodiment, the amino acid residue at position 256 of the first sequence is selected from the group consisting of M I L and F.
- 20 [0249] In another preferred embodiment, the amino acid residue at position 257 of the first sequence is selected from the group consisting of N and G.
- [0250] In another preferred embodiment, the amino acid residue at position 258 of the first sequence is selected from the group consisting of V A G and H.
- [0251] In another preferred embodiment, the amino acid residue at position 259 of the first sequence is selected from the group consisting of T I K V R and G.
- 25 [0252] In another preferred embodiment, the amino acid residue at position 260 of the first sequence is selected from the group consisting of P and G.
- [0253] In another preferred embodiment, the amino acid residue at position 261 of the first sequence is selected from the group consisting of T Q R K and E.
- 30 [0254] In another preferred embodiment, the amino acid residue at position 262 of the first sequence is selected from the group consisting of A S N T and V.

- [0255] In another preferred embodiment, the amino acid residue at position 263 of the first sequence is selected from the group consisting of S H G A and Q.
- [0256] In another preferred embodiment, the amino acid residue at position 264 of the first sequence is selected from the group consisting of W and H.
- 5 [0257] In another preferred embodiment, the amino acid residue at position 265 of the first sequence is selected from the group consisting of A S H and T.
- [0258] In another preferred embodiment, the amino acid residue at position 266 of the first sequence is selected from the group consisting of I and V.
- [0259] In another preferred embodiment, the amino acid residue at position 267
10 of the first sequence is selected from the group consisting of D and H.
- [0260] In another preferred embodiment, the amino acid residue at position 268 of the first sequence is selected from the group consisting of P and A.
- [0261] In another preferred embodiment, the amino acid residue at position 269 of the first sequence is selected from the group consisting of F and T.
- 15 [0262] In another preferred embodiment, the amino acid residue at position 271 of the first sequence is selected from the group consisting of H L and Y.
- [0263] In another preferred embodiment, the amino acid residue at position 272 of the first sequence is selected from the group consisting of S T G and C.
- [0264] In another preferred embodiment, the amino acid residue at position 273
20 of the first sequence is selected from the group consisting of P S A R and H.
- [0265] In another preferred embodiment, the amino acid residue at position 274 of the first sequence is selected from the group consisting of T S E and L.
- [0266] In another preferred embodiment, the amino acid residue at position 275 of the first sequence is selected from the group consisting of M V Q and D.
- 25 [0267] In another preferred embodiment, the amino acid residue at position 276 of the first sequence is selected from the group consisting of P A and T.
- [0268] In another preferred embodiment, the amino acid residue at position 277 of the first sequence is selected from the group consisting of Y H S and A.
- [0269] In another preferred embodiment, the amino acid residue at position 278
30 of the first sequence is selected from the group consisting of I L and W.
- [0270] In another preferred embodiment, the amino acid residue at position 279 of the first sequence is selected from the group consisting of L and F.

[0271] In another preferred embodiment, the amino acid residue at position 280 of the first sequence is selected from the group consisting of Q T R K N D A and W.

5 [0272] In another preferred embodiment, the amino acid residue at position 281 of the first sequence is selected from the group consisting of K S R Q and P.

[0273] In another preferred embodiment, the amino acid residue at position 282 of the first sequence is selected from the group consisting of S A and M.

[0274] In another preferred embodiment, the amino acid residue at position 283 of the first sequence is selected from the group consisting of G N and K.

10 [0275] In another preferred embodiment, the amino acid residue at position 284 of the first sequence is selected from the group consisting of F I and L.

[0276] In another preferred embodiment, the amino acid residue at position 285 of the first sequence is selected from the group consisting of K T S E and D.

15 [0277] The present invention also provides a catalytically active fragment of a Class 2 mannosidase comprising conserved amino acid sequence regions, especially a third amino acid sequence consisting of 33 amino acid residues having the following sequence:

325

His Met Met Pro Phe Tyr Ser Tyr Asp Ile Pro His Thr Cys Gly Pro Asp Pro Arg Ile
20 Cys Cys Gln Phe Asp Phe Arg Arg Met Pro Gly Gly Arg (SEQ ID NO: 7).

[0278] In another preferred embodiment, the amino acid residue at position 325 of the first sequence is selected from the group consisting of H P and S.

25 [0279] In another preferred embodiment, the amino acid residue at position 326 of the first sequence is selected from the group consisting of M I L N T and R.

[0280] In another preferred embodiment, the amino acid residue at position 327 of the first sequence is selected from the group consisting of M Q A and Y.

[0281] In another preferred embodiment, the amino acid residue at position 328 of the first sequence is selected from the group consisting of P and D.

30 [0282] In another preferred embodiment, the amino acid residue at position 329 of the first sequence is selected from the group consisting of F L and G.

- [0283] In another preferred embodiment, the amino acid residue at position 330 of the first sequence is selected from the group consisting of Y D F and L.
- [0284] In another preferred embodiment, the amino acid residue at position 331 of the first sequence is selected from the group consisting of S I T and Y.
- 5 [0285] In another preferred embodiment, the amino acid residue at position 332 of the first sequence is selected from the group consisting of Y G and S.
- [0286] In another preferred embodiment, the amino acid residue at position 333 of the first sequence is selected from the group consisting of D S V and R.
- [0287] In another preferred embodiment, the amino acid residue at position 334
- 10 of the first sequence is selected from the group consisting of I V and L.
- [0288] In another preferred embodiment, the amino acid residue at position 335 of the first sequence is selected from the group consisting of P K and Q.
- [0289] In another preferred embodiment, the amino acid residue at position 336 of the first sequence is selected from the group consisting of H S N and E.
- 15 [0290] In another preferred embodiment, the amino acid residue at position 337 of the first sequence is selected from the group consisting of T G and F.
- [0291] In another preferred embodiment, the amino acid residue at position 338 of the first sequence is selected from the group consisting of C Y and A.
- [0292] In another preferred embodiment, the amino acid residue at position 339
- 20 of the first sequence is selected from the group consisting of G N and C.
- [0293] In another preferred embodiment, the amino acid residue at position 340 of the first sequence is selected from the group consisting of P and R.
- [0294] In another preferred embodiment, the amino acid residue at position 341 of the first sequence is selected from the group consisting of D E H P and G.
- 25 [0295] In another preferred embodiment, the amino acid residue at position 342 of the first sequence is selected from the group consisting of P R and Q.
- [0296] In another preferred embodiment, the amino acid residue at position 343 of the first sequence is selected from the group consisting of K S A N and F.
- [0297] In another preferred embodiment, the amino acid residue at position 344
- 30 of the first sequence is selected from the group consisting of V I and L.
- [0298] In another preferred embodiment, the amino acid residue at position 345 of the first sequence is selected from the group consisting of C and P.

[0299] In another preferred embodiment, the amino acid residue at position 346 of the first sequence is selected from the group consisting of C L W and V.

[0300] In another preferred embodiment, the amino acid residue at position 347 of the first sequence is selected from the group consisting of Q S D and G.

5 [0301] In another preferred embodiment, the amino acid residue at position 348 of the first sequence is selected from the group consisting of F V and G.

[0302] In another preferred embodiment, the amino acid residue at position 349 of the first sequence is selected from the group consisting of D L and T.

10 [0303] In another preferred embodiment, the amino acid residue at position 350 of the first sequence is selected from the group consisting of F C and W.

[0304] In another preferred embodiment, the amino acid residue at position 351 of the first sequence is selected from the group consisting of R K A and V.

[0305] In another preferred embodiment, the amino acid residue at position 352 of the first sequence is selected from the group consisting of R K D and E.

15 [0306] In another preferred embodiment, the amino acid residue at position 353 of the first sequence is selected from the group consisting of M L I and Q.

[0307] In another preferred embodiment, the amino acid residue at position 354 of the first sequence is selected from the group consisting of G P R and D.

20 [0308] In another preferred embodiment, the amino acid residue at position 355 of the first sequence is selected from the group consisting of S E G

[0309] In another preferred embodiment, the amino acid residue at position 356 of the first sequence is selected from the group consisting of F G and N.

[0310] In another preferred embodiment, the amino acid residue at position 357 of the first sequence is selected from the group consisting of G R K and L.

25 [0311] The present invention further provides a catalytically active fragment of a Class 2 mannosidase comprising conserved amino acid sequence regions, especially a fourth amino acid sequence consisting of 28 amino acid residues having the following sequence:

380

30 Leu Leu Leu Asp Gln Tyr Arg Lys Lys Ser Glu Leu Phe Arg Thr Asn Val Leu Leu Ile Pro Leu Gly Asp Asp Phe Arg Tyr (SEQ ID NO: 8).

- [0312] In another preferred embodiment, the amino acid residue at position 380 of the first sequence is selected from the group consisting of L M I K T and Y.
- [0313] In another preferred embodiment, the amino acid residue at position 381 of the first sequence is selected from the group consisting of L I F and C.
- 5 [0314] In another preferred embodiment, the amino acid residue at position 382 of the first sequence is selected from the group consisting of V Y L I and S.
- [0315] In another preferred embodiment, the amino acid residue at position 383 of the first sequence is selected from the group consisting of D E N and K.
- [0316] In another preferred embodiment, the amino acid residue at position 384 of the first sequence is selected from the group consisting of Q E V and F.
- 10 [0317] In another preferred embodiment, the amino acid residue at position 385 of the first sequence is selected from the group consisting of W Y and A.
- [0318] In another preferred embodiment, the amino acid residue at position 386 of the first sequence is selected from the group consisting of R D T and L.
- 15 [0319] In another preferred embodiment, the amino acid residue at position 387 of the first sequence is selected from the group consisting of K R A and P.
- [0320] In another preferred embodiment, the amino acid residue at position 388 of the first sequence is selected from the group consisting of K I Q and D.
- [0321] In another preferred embodiment, the amino acid residue at position 389 of the first sequence is selected from the group consisting of A S G and T.
- 20 [0322] In another preferred embodiment, the amino acid residue at position 390 of the first sequence is selected from the group consisting of E Q R K T S and F.
- [0323] In another preferred embodiment, the amino acid residue at position 391 of the first sequence is selected from the group consisting of L Y and G.
- 25 [0324] In another preferred embodiment, the amino acid residue at position 392 of the first sequence is selected from the group consisting of Y F and T.
- [0325] In another preferred embodiment, the amino acid residue at position 393 of the first sequence is selected from the group consisting of R P and S.
- [0326] In another preferred embodiment, the amino acid residue at position 394 of the first sequence is selected from the group consisting of T N S H and A.
- 30 [0327] In another preferred embodiment, the amino acid residue at position 395 of the first sequence is selected from the group consisting of N S K D and Q.

[0328] In another preferred embodiment, the amino acid residue at position 396 of the first sequence is selected from the group consisting of V T H and L.

[0329] In another preferred embodiment, the amino acid residue at position 397 of the first sequence is selected from the group consisting of L I V T and P.

5 [0330] In another preferred embodiment, the amino acid residue at position 398 of the first sequence is selected from the group consisting of L F V and Q.

[0331] In another preferred embodiment, the amino acid residue at position 399 of the first sequence is selected from the group consisting of I Q V A and M.

10 [0332] In another preferred embodiment, the amino acid residue at position 400 of the first sequence is selected from the group consisting of P I T and M.

[0333] In another preferred embodiment, the amino acid residue at position 401 of the first sequence is selected from the group consisting of L M and H.

[0334] In another preferred embodiment, the amino acid residue at position 403 of the first sequence is selected from the group consisting of D S and C.

15 [0335] In another preferred embodiment, the amino acid residue at position 404 of the first sequence is selected from the group consisting of D and G.

[0336] In another preferred embodiment, the amino acid residue at position 405 of the first sequence is selected from the group consisting of F and L.

20 [0337] In another preferred embodiment, the amino acid residue at position 406 of the first sequence is selected from the group consisting of R and Q.

[0338] In another preferred embodiment, the amino acid residue at position 407 of the first sequence is selected from the group consisting of F Y and R.

[0339] The present invention also provides a catalytically active fragment of a Class 2 mannosidase comprising conserved amino acid sequence regions,
25 especially a fifth amino acid sequence consisting of 12 amino acid residues having the following sequence:

438

Gln Phe Gly Thr Leu Ser Asp Tyr Phe Asp Ala Leu (SEQ ID NO: 9).

30 [0340] In another preferred embodiment, the amino acid residue at position 438 of the first sequence is selected from the group consisting of Q K L and H.

[0341] In another preferred embodiment, the amino acid residue at position 439 of the first sequence is selected from the group consisting of F and Y.

[0342] In another preferred embodiment, the amino acid residue at position 440 of the first sequence is selected from the group consisting of G S and P.

5 [0343] In another preferred embodiment, the amino acid residue at position 441 of the first sequence is selected from the group consisting of T and P.

[0344] In another preferred embodiment, the amino acid residue at position 442 of the first sequence is selected from the group consisting of L P and G.

10 [0345] In another preferred embodiment, the amino acid residue at position 443 of the first sequence is selected from the group consisting of Q S E L A and D.

[0346] In another preferred embodiment, the amino acid residue at position 444 of the first sequence is selected from the group consisting of E D C and S.

[0347] In another preferred embodiment, the amino acid residue at position 445 of the first sequence is selected from the group consisting of Y and F.

15 [0348] In another preferred embodiment, the amino acid residue at position 446 of the first sequence is selected from the group consisting of F L and G.

[0349] In another preferred embodiment, the amino acid residue at position 447 of the first sequence is selected from the group consisting of D K R N W and M.

20 [0350] In another preferred embodiment, the amino acid residue at position 448 of the first sequence is selected from the group consisting of A K T E and Q.

[0351] In another preferred embodiment, the amino acid residue at position 449 of the first sequence is selected from the group consisting of V L M and G.

[0352] The present invention also provides a catalytically active fragment of a Class 2 mannosidase comprising conserved amino acid sequence regions,
25 especially a sixth amino acid sequence consisting of 14 amino acid residues having the following sequence:

463

Leu Ser Gly Asp Phe Phe Thr Tyr Ala Asp Arg Ser Asp His (SEQ ID NO: 10).

30 [0353] In another preferred embodiment, the amino acid residue at position 463 of the first sequence is selected from the group consisting of L F and K.

- [0354] In another preferred embodiment, the amino acid residue at position 464 of the first sequence is selected from the group consisting of S K H and D.
- [0355] In another preferred embodiment, the amino acid residue at position 465 of the first sequence is selected from the group consisting of G D and V.
- 5 [0356] In another preferred embodiment, the amino acid residue at position 466 of the first sequence is selected from the group consisting of D and A.
- [0357] In another preferred embodiment, the amino acid residue at position 467 of the first sequence is selected from the group consisting of F and N.
- [0358] In another preferred embodiment, the amino acid residue at position 468 of the first sequence is selected from the group consisting of F and N.
- 10 [0359] In another preferred embodiment, the amino acid residue at position 469 of the first sequence is selected from the group consisting of T S V P and R.
- [0360] In another preferred embodiment, the amino acid residue at position 470 of the first sequence is selected from the group consisting of Y and D.
- 15 [0361] In another preferred embodiment, the amino acid residue at position 471 of the first sequence is selected from the group consisting of A S and K.
- [0362] In another preferred embodiment, the amino acid residue at position 472 of the first sequence is selected from the group consisting of D and G.
- [0363] In another preferred embodiment, the amino acid residue at position 473 of the first sequence is selected from the group consisting of R I and G.
- 20 [0364] In another preferred embodiment, the amino acid residue at position 474 of the first sequence is selected from the group consisting of S D E Q F P and A.
- [0365] In another preferred embodiment, the amino acid residue at position 475 of the first sequence is selected from the group consisting of D Q S H and N.
- 25 [0366] In another preferred embodiment, the amino acid residue at position 476 of the first sequence is selected from the group consisting of N H D E and Q.
- [0367] The present invention further provides a catalytically active fragment of a Class 2 mannosidase comprising conserved amino acid sequence regions, especially a seventh amino acid sequence consisting of 20 amino acid residues
- 30 having the following sequence:

477

Tyr Trp Ser Gly Tyr Tyr Thr Ser Arg Pro Phe Tyr Arg Arg Met Asp Arg Val Leu
Glu (SEQ ID NO: 11).

- 5 [0368] In another preferred embodiment, the amino acid residue at position 477
of the first sequence is selected from the group consisting of Y and F.
- [0369] In another preferred embodiment, the amino acid residue at position 478
of the first sequence is selected from the group consisting of W and G.
- [0370] In another preferred embodiment, the amino acid residue at position 479
10 of the first sequence is selected from the group consisting of S T and F.
- [0371] In another preferred embodiment, the amino acid residue at position 481
of the first sequence is selected from the group consisting of Y and D.
- [0372] In another preferred embodiment, the amino acid residue at position 482
of the first sequence is selected from the group consisting of Y F and G.
- 15 [0373] In another preferred embodiment, the amino acid residue at position 483
of the first sequence is selected from the group consisting of T V S and G.
- [0374] In another preferred embodiment, the amino acid residue at position 484
of the first sequence is selected from the group consisting of S T and G.
- [0375] In another preferred embodiment, the amino acid residue at position 485
20 of the first sequence is selected from the group consisting of R and G.
- [0376] In another preferred embodiment, the amino acid residue at position 487
of the first sequence is selected from the group consisting of Y F A and T.
- [0377] In another preferred embodiment, the amino acid residue at position 488
of the first sequence is selected from the group consisting of H Y F L and Q.
- 25 [0378] In another preferred embodiment, the amino acid residue at position 489
of the first sequence is selected from the group consisting of K and T.
- [0379] In another preferred embodiment, the amino acid residue at position 490
of the first sequence is selected from the group consisting of R Q S M A and I.
- [0380] In another preferred embodiment, the amino acid residue at position 491
30 of the first sequence is selected from the group consisting of M L Q V and Y.
- [0381] In another preferred embodiment, the amino acid residue at position 492
of the first sequence is selected from the group consisting of D E and A.

[0382] In another preferred embodiment, the amino acid residue at position 494 of the first sequence is selected from the group consisting of V I Q and L.

[0383] In another preferred embodiment, the amino acid residue at position 495 of the first sequence is selected from the group consisting of L M F S and K.

5 [0384] In another preferred embodiment, the amino acid residue at position 496 of the first sequence is selected from the group consisting of M Q E Y and R.

[0385] The present invention also provides a catalytically active fragment of a Class 2 mannosidase comprising conserved amino acid sequence regions, especially a eighth amino acid sequence consisting of 27 amino acid residues
10 having the following sequence:

524

Ala Arg Arg Glu Leu Gly Leu Phe Gln His His Asp Ala Ile Thr Gly Thr Ala Arg
Asp His Val Val Val Asp Tyr Gly (SEQ ID NO: 12).

15 [0386] In another preferred embodiment, the amino acid residue at position 524 of the first sequence is selected from the group consisting of A L and W.

[0387] In another preferred embodiment, the amino acid residue at position 525 of the first sequence is selected from the group consisting of R N and V.

[0388] In another preferred embodiment, the amino acid residue at position 526
20 of the first sequence is selected from the group consisting of R Q E and G.

[0389] In another preferred embodiment, the amino acid residue at position 527 of the first sequence is selected from the group consisting of E A T and N.

[0390] In another preferred embodiment, the amino acid residue at position 528 of the first sequence is selected from the group consisting of L and M.

25 [0391] In another preferred embodiment, the amino acid residue at position 529 of the first sequence is selected from the group consisting of S G A and F.

[0392] In another preferred embodiment, the amino acid residue at position 530 of the first sequence is selected from the group consisting of L and V.

[0393] In another preferred embodiment, the amino acid residue at position 531
30 of the first sequence is selected from the group consisting of F L and E.

[0394] In another preferred embodiment, the amino acid residue at position 532 of the first sequence is selected from the group consisting of Q and L.

- [0395] In another preferred embodiment, the amino acid residue at position 534 of the first sequence is selected from the group consisting of H and N.
- [0396] In another preferred embodiment, the amino acid residue at position 535 of the first sequence is selected from the group consisting of D and G.
- 5 [0397] In another preferred embodiment, the amino acid residue at position 536 of the first sequence is selected from the group consisting of G A and T.
- [0398] In another preferred embodiment, the amino acid residue at position 537 of the first sequence is selected from the group consisting of I V and Y.
- [0399] In another preferred embodiment, the amino acid residue at position 538
10 of the first sequence is selected from the group consisting of T and S.
- [0400] In another preferred embodiment, the amino acid residue at position 539 of the first sequence is selected from the group consisting of G and T.
- [0401] In another preferred embodiment, the amino acid residue at position 540 of the first sequence is selected from the group consisting of T and H.
- 15 [0402] In another preferred embodiment, the amino acid residue at position 541 of the first sequence is selected from the group consisting of A and S.
- [0403] In another preferred embodiment, the amino acid residue at position 542 of the first sequence is selected from the group consisting of K R and Q.
- [0404] In another preferred embodiment, the amino acid residue at position 543
20 of the first sequence is selected from the group consisting of T D E S Q and I.
- [0405] In another preferred embodiment, the amino acid residue at position 544 of the first sequence is selected from the group consisting of H A W Y S and K.
- [0406] In another preferred embodiment, the amino acid residue at position 545 of the first sequence is selected from the group consisting of V and K.
- 25 [0407] In another preferred embodiment, the amino acid residue at position 546 of the first sequence is selected from the group consisting of V M A and G.
- [0408] In another preferred embodiment, the amino acid residue at position 547 of the first sequence is selected from the group consisting of V L Q and N.
- [0409] In another preferred embodiment, the amino acid residue at position 548
30 of the first sequence is selected from the group consisting of D and R.
- [0410] In another preferred embodiment, the amino acid residue at position 549 of the first sequence is selected from the group consisting of Y and E.

[0411] In another preferred embodiment, the amino acid residue at position 550 of the first sequence is selected from the group consisting of E G A and C.

[0412] The present invention also provides a catalytically active fragment of a Class 2 mannosidase comprising conserved amino acid sequence regions,
5 especially a ninth amino acid sequence consisting of 11 amino acid residues having the following sequence:

788

Gly Ala Tyr Leu Phe Leu Pro Asp Gly Glu Ala (SEQ ID NO: 13).

10 [0413] In another preferred embodiment, the amino acid residue at position 789 of the first sequence is selected from the group consisting of A and W.

[0414] In another preferred embodiment, the amino acid residue at position 790 of the first sequence is selected from the group consisting of Y and D.

[0415] In another preferred embodiment, the amino acid residue at position 791
15 of the first sequence is selected from the group consisting of L I and V.

[0416] In another preferred embodiment, the amino acid residue at position 792 of the first sequence is selected from the group consisting of F and M.

[0417] In another preferred embodiment, the amino acid residue at position 793 of the first sequence is selected from the group consisting of L K M R and D.

20 [0418] In another preferred embodiment, the amino acid residue at position 794 of the first sequence is selected from the group consisting of P and Y.

[0419] In another preferred embodiment, the amino acid residue at position 795 of the first sequence is selected from the group consisting of N D A and H.

[0420] In another preferred embodiment, the amino acid residue at position 796
25 of the first sequence is selected from the group consisting of G N Y Q and L.

[0421] In another preferred embodiment, the amino acid residue at position 797 of the first sequence is selected from the group consisting of P E Q N and D.

[0422] In another preferred embodiment, the amino acid residue at position 798 of the first sequence is selected from the group consisting of A G S K and T.

30 [0423] The present invention further provides a catalytically active fragment of a Class 2 mannosidase comprising conserved amino acid sequence regions,

especially a tenth amino acid sequence consisting of 14 amino acid residues having the following sequence:

867

Phe Tyr Thr Asp Leu Asn Gly Phe Gln Met Gln Lys Arg Arg (SEQ ID NO: 14).

5

[0424] In another preferred embodiment, the amino acid residue at position 867 of the first sequence is selected from the group consisting of F T and Y.

[0425] In another preferred embodiment, the amino acid residue at position 868 of the first sequence is selected from the group consisting of Y F S and E.

10 [0426] In another preferred embodiment, the amino acid residue at position 869 of the first sequence is selected from the group consisting of T I and S.

[0427] In another preferred embodiment, the amino acid residue at position 870 of the first sequence is selected from the group consisting of D and Q.

15 [0428] In another preferred embodiment, the amino acid residue at position 871 of the first sequence is selected from the group consisting of L T Q S and F.

[0429] In another preferred embodiment, the amino acid residue at position 872 of the first sequence is selected from the group consisting of N S and G.

[0430] In another preferred embodiment, the amino acid residue at position 873 of the first sequence is selected from the group consisting of G T and H.

20 [0431] In another preferred embodiment, the amino acid residue at position 874 of the first sequence is selected from the group consisting of L M F AY and R.

[0432] In another preferred embodiment, the amino acid residue at position 875 of the first sequence is selected from the group consisting of Q R and E.

25 [0433] In another preferred embodiment, the amino acid residue at position 876 of the first sequence is selected from the group consisting of F M V I Y and R.

[0434] In another preferred embodiment, the amino acid residue at position 877 of the first sequence is selected from the group consisting of I Q S L and P.

[0435] In another preferred embodiment, the amino acid residue at position 878 of the first sequence is selected from the group consisting of K P R E and T.

30 [0436] In another preferred embodiment, the amino acid residue at position 879 of the first sequence is selected from the group consisting of R and H.

[0437] In another preferred embodiment, the amino acid residue at position 880 of the first sequence is selected from the group consisting of R M T E V and Y.

[0438] The present invention further provides a catalytically active fragment of a Class 2 mannosidase comprising conserved amino acid sequence regions,
5 especially a eleventh amino acid sequence consisting of 66 amino acid residues having the following sequence:

904

Lys Leu Pro Leu Gln Ala Asn Tyr Tyr Pro Met Pro Ser Met Ala Tyr Ile Gln Asp
Ala Asn Thr Arg Leu Thr Leu Leu Thr Gly Gln Pro Leu Gly Val Ser Ser Leu Ala
10 Ser Gly Gln Leu Glu Val Met Leu Asp Arg Arg Leu Met Ser Asp Asp Asn Arg
Gly Leu Gly Gln Gly Val Leu Asp Asn Lys (SEQ ID NO: 15).

[0439] In another preferred embodiment, the amino acid residue at position 904 of the first sequence is selected from the group consisting of N T Q E and K.

15 [0440] In another preferred embodiment, the amino acid residue at position 905 of the first sequence is selected from the group consisting of T R K H S Q M and F.

[0441] In another preferred embodiment, the amino acid residue at position 906 of the first sequence is selected from the group consisting of R Q and G.

20 [0442] In another preferred embodiment, the amino acid residue at position 907 of the first sequence is selected from the group consisting of L M and F.

[0443] In another preferred embodiment, the amino acid residue at position 908 of the first sequence is selected from the group consisting of T S and A.

[0444] In another preferred embodiment, the amino acid residue at position 909
25 of the first sequence is selected from the group consisting of L I and V.

[0445] In another preferred embodiment, the amino acid residue at position 910 of the first sequence is selected from the group consisting of L H and M.

[0446] In another preferred embodiment, the amino acid residue at position 911 of the first sequence is selected from the group consisting of T S and N.

30 [0447] In another preferred embodiment, the amino acid residue at position 912 of the first sequence is selected from the group consisting of G A R N and D.

- [0448] In another preferred embodiment, the amino acid residue at position 913 of the first sequence is selected from the group consisting of Q H R and C.
- [0449] In another preferred embodiment, the amino acid residue at position 914 of the first sequence is selected from the group consisting of P A S and K.
- 5 [0450] In another preferred embodiment, the amino acid residue at position 915 of the first sequence is selected from the group consisting of L Q and Y.
- [0451] In another preferred embodiment, the amino acid residue at position 917 of the first sequence is selected from the group consisting of G V and A.
- [0452] In another preferred embodiment, the amino acid residue at position 918
10 of the first sequence is selected from the group consisting of S and A.
- [0453] In another preferred embodiment, the amino acid residue at position 919 of the first sequence is selected from the group consisting of S and A.
- [0454] In another preferred embodiment, the amino acid residue at position 920 of the first sequence is selected from the group consisting of L M and Y.
- 15 [0455] In another preferred embodiment, the amino acid residue at position 921 of the first sequence is selected from the group consisting of A S G K E R and V.
- [0456] In another preferred embodiment, the amino acid residue at position 922 of the first sequence is selected from the group consisting of S N D E P and R.
- [0457] In another preferred embodiment, the amino acid residue at position 924
20 of the first sequence is selected from the group consisting of E Q W R and S.
- [0458] In another preferred embodiment, the amino acid residue at position 925 of the first sequence is selected from the group consisting of L and I.
- [0459] In another preferred embodiment, the amino acid residue at position 926 of the first sequence is selected from the group consisting of E and L.
- 25 [0460] In another preferred embodiment, the amino acid residue at position 927 of the first sequence is selected from the group consisting of I V L and S.
- [0461] In another preferred embodiment, the amino acid residue at position 928 of the first sequence is selected from the group consisting of M I F V and L.
- [0462] In another preferred embodiment, the amino acid residue at position 929
30 of the first sequence is selected from the group consisting of Q L M V and S.
- [0463] In another preferred embodiment, the amino acid residue at position 930 of the first sequence is selected from the group consisting of D H and L.

- [0464] In another preferred embodiment, the amino acid residue at position 931 of the first sequence is selected from the group consisting of R and L.
- [0465] In another preferred embodiment, the amino acid residue at position 933 of the first sequence is selected from the group consisting of L T and A.
- 5 [0466] In another preferred embodiment, the amino acid residue at position 934 of the first sequence is selected from the group consisting of A S M V L and P.
- [0467] In another preferred embodiment, the amino acid residue at position 935 of the first sequence is selected from the group consisting of S Q R Y and K.
- [0468] In another preferred embodiment, the amino acid residue at position 936 of the first sequence is selected from the group consisting of D and A.
- 10 [0469] In another preferred embodiment, the amino acid residue at position 937 of the first sequence is selected from the group consisting of D and P.
- [0470] In another preferred embodiment, the amino acid residue at position 938 of the first sequence is selected from the group consisting of E N G F and D.
- 15 [0471] In another preferred embodiment, the amino acid residue at position 939 of the first sequence is selected from the group consisting of R and A.
- [0472] In another preferred embodiment, the amino acid residue at position 940 of the first sequence is selected from the group consisting of G and T.
- [0473] In another preferred embodiment, the amino acid residue at position 941 of the first sequence is selected from the group consisting of L V I and A.
- 20 [0474] In another preferred embodiment, the amino acid residue at position 942 of the first sequence is selected from the group consisting of G Q E S and D.
- [0475] In another preferred embodiment, the amino acid residue at position 943 of the first sequence is selected from the group consisting of Q E and T.
- 25 [0476] In another preferred embodiment, the amino acid residue at position 944 of the first sequence is selected from the group consisting of G and P.
- [0477] In another preferred embodiment, the amino acid residue at position 945 of the first sequence is selected from the group consisting of V L I and R.
- [0478] In another preferred embodiment, the amino acid residue at position 946 of the first sequence is selected from the group consisting of L R K H Q M and V.
- 30 [0479] In another preferred embodiment, the amino acid residue at position 947 of the first sequence is selected from the group consisting of D and E.

- [0480] In another preferred embodiment, the amino acid residue at position 948 of the first sequence is selected from the group consisting of N and F.
- [0481] In another preferred embodiment, the amino acid residue at position 949 of the first sequence is selected from the group consisting of K L R G and T.
- 5 [0482] In another preferred embodiment, the amino acid residue at position 950 of the first sequence is selected from the group consisting of P R I A S and Y.
- [0483] In another preferred embodiment, the amino acid residue at position 951 of the first sequence is selected from the group consisting of V T M G and A.
- [0484] In another preferred embodiment, the amino acid residue at position 952 of the first sequence is selected from the group consisting of L V C A P T.
- 10 [0485] In another preferred embodiment, the amino acid residue at position 953 of the first sequence is selected from the group consisting of H A N E V F W and M.
- [0486] In another preferred embodiment, the amino acid residue at position 954 of the first sequence is selected from the group consisting of I H R L S V Q and P.
- 15 [0487] In another preferred embodiment, the amino acid residue at position 955 of the first sequence is selected from the group consisting of Y F N R and H.
- [0488] In another preferred embodiment, the amino acid residue at position 956 of the first sequence is selected from the group consisting of R V H W G and K.
- 20 [0489] In another preferred embodiment, the amino acid residue at position 957 of the first sequence is selected from the group consisting of L I R and G.
- [0490] In another preferred embodiment, the amino acid residue at position 958 of the first sequence is selected from the group consisting of V L M H and S.
- [0491] In another preferred embodiment, the amino acid residue at position 959 of the first sequence is selected from the group consisting of L I A F.
- 25 [0492] In another preferred embodiment, the amino acid residue at position 960 of the first sequence is selected from the group consisting of E V and Q.
- [0493] In another preferred embodiment, the amino acid residue at position 961 of the first sequence is selected from the group consisting of K P R S L and D.
- 30 [0494] In another preferred embodiment, the amino acid residue at position 962 of the first sequence is selected from the group consisting of V M R W N L and A.

- [0495] In another preferred embodiment, the amino acid residue at position 963 of the first sequence is selected from the group consisting of N S T I P D and G.
- [0496] In another preferred embodiment, the amino acid residue at position 964 of the first sequence is selected from the group consisting of N S L V A G and T.
- 5 [0497] In another preferred embodiment, the amino acid residue at position 965 of the first sequence is selected from the group consisting of C S M G V I Q and A.
- [0498] In another preferred embodiment, the amino acid residue at position 966 of the first sequence is selected from the group consisting of V S N A T and Q.
- [0499] In another preferred embodiment, the amino acid residue at position 967 of the first sequence is selected from the group consisting of R G P M T A and D.
- 10 [0500] In another preferred embodiment, the amino acid residue at position 968 of the first sequence is selected from the group consisting of P N E K and A.
- [0501] In another preferred embodiment, the amino acid residue at position 969 of the first sequence is selected from the group consisting of S K V E A K and Y.
- 15 [0502] In another preferred embodiment, the amino acid residue at position 970 of the first sequence is selected from the group consisting of K Q E S R and A.
- [0503] In another preferred embodiment, the amino acid residue at position 971 of the first sequence is selected from the group consisting of L E Q D K N and G.
- [0504] In another preferred embodiment, the amino acid residue at position 972 of the first sequence is selected from the group consisting of H E S K T and N.
- 20 [0505] In another preferred embodiment, the amino acid residue at position 973 of the first sequence is selected from the group consisting of P R S K and N.
- [0506] In another preferred embodiment, the amino acid residue at position 974 of the first sequence is selected from the group consisting of A V T L P and Y.
- 25 [0507] In another preferred embodiment, the amino acid residue at position 975 of the first sequence is selected from the group consisting of G S A R and Q.
- [0508] In another preferred embodiment, the amino acid residue at position 976 of the first sequence is selected from the group consisting of Y F N and V.
- [0509] In another preferred embodiment, the amino acid residue at position 977 of the first sequence is selected from the group consisting of L H and P.
- 30 [0510] In another preferred embodiment, the amino acid residue at position 978 of the first sequence is selected from the group consisting of T S and L.

- [0511] In another preferred embodiment, the amino acid residue at position 979 of the first sequence is selected from the group consisting of S H L M and Q.
- [0512] In another preferred embodiment, the amino acid residue at position 980 of the first sequence is selected from the group consisting of A V L and T.
- 5 [0513] In another preferred embodiment, the amino acid residue at position 981 of the first sequence is selected from the group consisting of A G S V and L.
- [0514] In another preferred embodiment, the amino acid residue at position 982 of the first sequence is selected from the group consisting of H Y D L and P.
- [0515] In another preferred embodiment, the amino acid residue at position 983 of the first sequence is selected from the group consisting of K L M I Q Y and A.
- 10 [0516] In another preferred embodiment, the amino acid residue at position 984 of the first sequence is selected from the group consisting of A T S I L and P.
- [0517] In another preferred embodiment, the amino acid residue at position 985 of the first sequence is selected from the group consisting of S T G and E.
- 15 [0518] In another preferred embodiment, the amino acid residue at position 986 of the first sequence is selected from the group consisting of Q W M S A R and P.
- [0519] In another preferred embodiment, the amino acid residue at position 987 of the first sequence is selected from the group consisting of S Y F L E H M and A.
- 20 [0520] In another preferred embodiment, the amino acid residue at position 988 of the first sequence is selected from the group consisting of L M F V and P.
- [0521] In another preferred embodiment, the amino acid residue at position 989 of the first sequence is selected from the group consisting of L H N and A.
- [0522] In another preferred embodiment, the amino acid residue at position 990 of the first sequence is selected from the group consisting of D Y T A and H.
- 25 [0523] In another preferred embodiment, the amino acid residue at position 991 of the first sequence is selected from the group consisting of P and S.
- [0524] In another preferred embodiment, the amino acid residue at position 992 of the first sequence is selected from the group consisting of L P A F V I Q and W.
- 30 [0525] In another preferred embodiment, the amino acid residue at position 993 of the first sequence is selected from the group consisting of D V L I R N and S.

[0526] In another preferred embodiment, the amino acid residue at position 994 of the first sequence is selected from the group consisting of K V A P and T.

[0527] In another preferred embodiment, the amino acid residue at position 995 of the first sequence is selected from the group consisting of F M L and Y.

5 [0528] In another preferred embodiment, the amino acid residue at position 996 of the first sequence is selected from the group consisting of I P V A S and L.

[0529] In another preferred embodiment, the amino acid residue at position 997 of the first sequence is selected from the group consisting of F G V L N A and P.

10 [0530] In another preferred embodiment, the amino acid residue at position 998 of the first sequence is selected from the group consisting of A D A S N K and G.

[0531] In another preferred embodiment, the amino acid residue at position 999 of the first sequence is selected from the group consisting of E A K R G T and S.

Expression of Class III Mannosidases in Lower Eukaryotes

15 [0532] The present invention also provides that a mannosidase having substrate specificity to Man α 1,2/Man α 1,3/Man α 1,6 be introduced into a lower eukaryote host.

[0533] In one embodiment, a class III mannosidase capable of hydrolyzing Man α 1,2/Man α 1,3/Man α 1,6 glycosidic linkages is expressed in a lower eukaryotic
20 host. By expressing Class III mannosidases *in vivo*, either alone or in conjunction with other N-glycan modifying enzymes, efficient trimming of high mannose structures to Man₃GlcNAc₂ is obtained on host glycoproteins.

[0534] In a preferred embodiment, the Sf9 mannosidase III (Genbank gi:2245567 (D. Jarvis, *et al. Glycobiology* 1997 7:113-127)) is cloned into a yeast integration
25 plasmid under the control of a constitutive or inducible promoter (see **Example 26**). The amount of Class III mannosidase activity is optimized while restricting adverse effects on the cell. This involves altering promoter strength and may include using an inducible or otherwise regulatable promoter to better control the expression of these proteins.

30 [0535] In addition to expressing the wild-type Class III mannosidase, modified forms of the Class III mannosidase can be expressed to enhance cellular localization and activity. This is achieved through the combinatorial DNA library

approach of the invention by fusing varying lengths of the catalytic domain of Class III mannosidase(s) to endogenous yeast targeting regions, as described herein.

5 **Class III Mannosidase Hydrolysis of Glycosidic Linkages**

[0536] The method of the present invention also encompasses the mechanism in which the catalytically active domain of Class III enzymes hydrolyzes the Man α 1,3 and/or Man α 1,6 and/or Man α 1,2 glycosidic linkages on an oligosaccharide e.g. Man₅GlcNAc₂ or Man₈GlcNAc₂ structures to produce Man₃GlcNAc₂, a desired
10 intermediate for further N-glycan processing in a lower eukaryote.

[0537] In a first embodiment, the hydrolysis of the glycosidic linkages occurs sequentially. The enzyme hydrolyzes at least one glycosidic linkage and conformationally rotates to hydrolyze the other glycosidic linkages.

[0538] In a second embodiment, the hydrolysis of the Man α 1,6 and Man α 1,3
15 glycosidic linkages occurs simultaneously. In another embodiment, the enzyme specifically hydrolyzes Man α 1,2 glycosidic linkages. The intermediate produced is a substrate for further Golgi processing wherein other glycosylation enzymes such as N-acetylglucosaminyltransferases (GnTs), galactosyltransferases (GalTs) and sialyltransferases (STs) can subsequently modify it to produce a desired
20 glycoform. Fig. 36C illustrates the oligosaccharide intermediates (e.g. Man₄GlcNAc₂, Man₃GlcNAc₂) produced via the mannosidase III pathway.

Host Cells of the Invention

[0539] A preferred host cell of the invention is a lower eukaryotic cell, e.g.,
25 yeast, a unicellular and multicellular or filamentous fungus. However, a wide variety of host cells are envisioned as being useful in the methods of the invention. Plant cells or insect cells, for instance, may be engineered to express a human-like glycoprotein according to the invention. Likewise, a variety of non-human, mammalian host cells may be altered to express more human-like or otherwise
30 altered glycoproteins using the methods of the invention. As one of skill in the art will appreciate, any eukaryotic host cell (including a human cell) may be used in conjunction with a library of the invention to express one or more chimeric

proteins which is targeted to a subcellular location, e.g., organelle, in the host cell where the activity of the protein is modified, and preferably is enhanced. Such a protein is preferably -- but need not necessarily be -- an enzyme involved in protein glycosylation, as exemplified herein. It is envisioned that any protein coding sequence may be targeted and selected for modified activity in a eukaryotic host cell using the methods described herein.

[0540] Lower eukaryotes that are able to produce glycoproteins having the attached *N*-glycan $\text{Man}_5\text{GlcNAc}_2$ are particularly useful because (a) lacking a high degree of mannosylation (e.g. greater than 8 mannoses per *N*-glycan, or especially 30-40 mannoses), they show reduced immunogenicity in humans; and (b) the *N*-glycan is a substrate for further glycosylation reactions to form an even more human-like glycoform, e.g., by the action of GlcNAc transferase I (Figure 1B; $\beta 1,2$ GnTI) to form $\text{GlcNAcMan}_5\text{GlcNAc}_2$. A yield is obtained of greater than 30 mole %, more preferably a yield of 50-100 mole %, glycoproteins with *N*-glycans having a $\text{Man}_5\text{GlcNAc}_2$ structure. In a preferred embodiment, more than 50% of the $\text{Man}_5\text{GlcNAc}_2$ structure is shown to be a substrate for a GnTI activity and can serve as such a substrate *in vivo*.

[0541] Preferred lower eukaryotes of the invention include but are not limited to: *Pichia pastoris*, *Pichia finlandica*, *Pichia trehalophila*, *Pichia koclamae*, *Pichia membranaefaciens*, *Pichia opuntiae*, *Pichia thermotolerans*, *Pichia salictaria*, *Pichia guercuum*, *Pichia pipperi*, *Pichia stiptis*, *Pichia methanolica*, *Pichia sp.*, *Saccharomyces cerevisiae*, *Saccharomyces sp.*, *Hansenula polymorpha*, *Kluyveromyces sp.*, *Kluyveromyces lactis*, *Candida albicans*, *Aspergillus nidulans*, *Aspergillus niger*, *Aspergillus oryzae*, *Trichoderma reseei*, *Chrysosporium lucknowense*, *Fusarium sp.* *Fusarium gramineum*, *Fusarium venenatum* and *Neurospora crassa*.

[0542] In each above embodiment, the method is directed to making a host cell in which the oligosaccharide precursors are enriched in $\text{Man}_5\text{GlcNAc}_2$. These structures are desirable because they may then be processed by treatment *in vitro*, for example, using the method of Maras and Contreras, U.S. Patent No. 5,834,251. In a preferred embodiment, however, precursors enriched in $\text{Man}_5\text{GlcNAc}_2$ are processed by at least one further glycosylation reaction *in vivo* -- with glycosidases

(e.g., α -mannosidases) and glycosyltransferases (e.g., GnTI) -- to produce human-like N-glycans. Oligosaccharide precursors enriched in $\text{Man}_5\text{GlcNAc}_2$, for example, are preferably processed to those having $\text{GlcNAcMan}_X\text{GlcNAc}_2$ core structures, wherein X is 3, 4 or 5, and is preferably 3. N-glycans having a
5 $\text{GlcNAcMan}_X\text{GlcNAc}_2$ core structure where X is greater than 3 may be converted to $\text{GlcNAcMan}_3\text{GlcNAc}_2$, e.g., by treatment with an α -1,3 and/or α -1,6 mannosidase activity, where applicable. Additional processing of $\text{GlcNAcMan}_3\text{GlcNAc}_2$ by treatment with glycosyltransferases (e.g., GnTII) produces $\text{GlcNAc}_2\text{Man}_3\text{GlcNAc}_2$ core structures which may then be modified, as
10 desired, e.g., by *ex vivo* treatment or by heterologous expression in the host cell of additional glycosylation enzymes, including glycosyltransferases, sugar transporters and mannosidases (see below), to become human-like N-glycans.
[0543] Preferred human-like glycoproteins which may be produced according to the invention include those which comprise N-glycans having seven or fewer, or
15 three or fewer, mannose residues; and which comprise one or more sugars selected from the group consisting of galactose, GlcNAc, sialic acid, and fucose.
[0544] While lower eukaryotic host cells are preferred, a wide variety of host cells having the aforementioned properties are envisioned as being useful in the methods of the invention. Plant cells, for instance, may be engineered to express a
20 human-like glycoprotein according to the invention. Likewise, a variety of non-human, mammalian host cells may be altered to express more human-like glycoproteins using the methods of the invention. An appropriate host cell can be engineered, or one of the many such mutants already described in yeasts may be used. A preferred host cell of the invention, as exemplified herein, is a
25 hypermannosylation-minus (*OCHI*) mutant in *Pichia pastoris*.

Formation of complex N-glycans

[0545] Formation of complex N-glycan synthesis is a sequential process by which specific sugar residues are removed and attached to the core oligosaccharide
30 structure. In higher eukaryotes, this is achieved by having the substrate sequentially exposed to various processing enzymes. These enzymes carry out specific reactions depending on their particular location within the entire

processing cascade. This "assembly line" consists of ER, early, medial and late Golgi, and the trans Golgi network all with their specific processing environment. To re-create the processing of human glycoproteins in the Golgi and ER of lower eukaryotes, numerous enzymes (e.g. glycosyltransferases, glycosidases, phosphatases and transporters) have to be expressed and specifically targeted to these organelles, and preferably, in a location so that they function most efficiently in relation to their environment as well as to other enzymes in the pathway.

[0546] Because one goal of the methods described herein is to achieve a robust protein production strain that is able to perform well in an industrial fermentation process, the integration of multiple genes into the host cell chromosome involves careful planning. As described above, one or more genes which encode enzymes known to be characteristic of non-human glycosylation reactions are preferably deleted. The engineered cell strain is transformed with a range of different genes encoding desired activities, and these genes are transformed in a stable fashion, thereby ensuring that the desired activity is maintained throughout the fermentation process.

[0547] Any combination of the following enzyme activities may be engineered singly or multiply into the host using methods of the invention: sialyltransferases, mannosidases, fucosyltransferases, galactosyltransferases, GlcNAc transferases, ER and Golgi specific transporters (e.g. syn- and antiport transporters for UDP-galactose and other precursors), other enzymes involved in the processing of oligosaccharides, and enzymes involved in the synthesis of activated oligosaccharide precursors such as UDP-galactose and CMP-N-acetylneuraminic acid. Preferably, enzyme activities are introduced on one or more nucleic acid molecules (see also below). Nucleic acid molecules may be introduced singly or multiply, e.g., in the context of a nucleic acid library such as a combinatorial library of the invention. It is to be understood, however, that single or multiple enzymatic activities may be introduced into a host cell in any fashion, including but not limited to protein delivery methods and/or by use of one or more nucleic acid molecules without necessarily using a nucleic acid library or combinatorial library of the invention.

Expression Of Glycosyltransferases To Produce Complex N-glycans:

[0548] With DNA sequence information, the skilled artisan can clone DNA molecules encoding GnT activities (e.g., **Example 3**). Using standard techniques well-known to those of skill in the art, nucleic acid molecules encoding GnTI, II, 5 III, IV or V (or encoding catalytically active fragments thereof) may be inserted into appropriate expression vectors under the transcriptional control of promoters and other expression control sequences capable of driving transcription in a selected host cell of the invention, e.g., a fungal host such as *Pichia sp.*, *Kluyveromyces sp.* and *Aspergillus sp.*, as described herein, such that one or more 10 of these mammalian GnT enzymes may be actively expressed in a host cell of choice for production of a human-like complex glycoprotein (e.g., **Examples 8, 15, 17, 19**).

[0549] Several individual glycosyltransferases have been cloned and expressed in *S.cerevisiae* (GalT, GnTI), *Aspergillus nidulans* (GnTI) and other fungi, without 15 however demonstrating the desired outcome of "humanization" on the glycosylation pattern of the organisms (Yoshida et al. (1999) *Glycobiology* 9(1):53-8; Kalsner et al. (1995) *Glycoconj. J.* 12(3):360-370). It was speculated that the carbohydrate structure required to accept sugars by the action of such glycosyltransferases was not present in sufficient amounts, which most likely 20 contributed to the lack of complex N-glycan formation.

[0550] A preferred method of the invention provides the functional expression of a glycosyltransferase, such as GnTI, GnTII and GnTIII (or other GnTs such as GnTIV and GnTVI and combinations of any of the above) in the early, medial or late Golgi apparatus, as well as ensuring a sufficient supply of UDP-GlcNAc (e.g., 25 by expression of a UDP-GlcNAc transporter; see below).

Methods for Providing Sugar Nucleotide Precursors to the Golgi Apparatus:

[0551] For a glycosyltransferase to function satisfactorily in the Golgi, the enzyme requires a sufficient concentration of an appropriate nucleotide sugar, 30 which is the high-energy donor of the sugar moiety added to a nascent glycoprotein. In humans, the full range of nucleotide sugar precursors (e.g. UDP-N-acetylglucosamine, UDP-N-acetylgalactosamine, CMP-N-acetylneuraminic

acid, UDP-galactose, etc.) are generally synthesized in the cytosol and transported into the Golgi, where they are attached to the core oligosaccharide by glycosyltransferases.

[0552] To replicate this process in non-human host cells such as lower eukaryotes, sugar nucleoside specific transporters have to be expressed in the Golgi to ensure adequate levels of nucleoside sugar precursors (Sommers and Hirschberg (1981) *J. Cell Biol.* 91(2):A406-A406; Sommers and Hirschberg (1982) *J. Biol. Chem.* 257(18):811-817; Perez and Hirschberg (1987) *Methods in Enzymology* 138:709-715). Nucleotide sugars may be provided to the appropriate compartments, e.g., by expressing in the host microorganism an exogenous gene encoding a sugar nucleotide transporter. The choice of transporter enzyme is influenced by the nature of the exogenous glycosyltransferase being used. For example, a GlcNAc transferase may require a UDP-GlcNAc transporter, a fucosyltransferase may require a GDP-fucose transporter, a galactosyltransferase may require a UDP-galactose transporter, and a sialyltransferase may require a CMP-sialic acid transporter.

[0553] The added transporter protein conveys a nucleotide sugar from the cytosol into the Golgi apparatus, where the nucleotide sugar may be reacted by the glycosyltransferase, e.g. to elongate an *N*-glycan. The reaction liberates a nucleoside diphosphate or monophosphate, e.g. UDP, GDP, or CMP. Nucleoside monophosphates can be directly exported from the Golgi in exchange for nucleoside triphosphate sugars by an antiport mechanism. Accumulation of a nucleoside diphosphate, however, inhibits the further activity of a glycosyltransferase. As this reaction appears to be important for efficient glycosylation, it is frequently desirable to provide an expressed copy of a gene encoding a nucleotide diphosphatase. The diphosphatase (specific for UDP or GDP as appropriate) hydrolyzes the diphosphonucleoside to yield a nucleoside monophosphate and inorganic phosphate.

[0554] Suitable transporter enzymes, which are typically of mammalian origin, are described below. Such enzymes may be engineered into a selected host cell using the methods of the invention.

[0555] In another example, α 2,3- or α 2,6-sialyltransferase caps galactose residues with sialic acid in the trans-Golgi and TGN of humans leading to a mature form of the glycoprotein (Figure 1B). To reengineer this processing step into a metabolically engineered yeast or fungus will require (1) α 2,3- or α 2,6-

5 sialyltransferase activity and (2) a sufficient supply of CMP-N-acetyl neuraminic acid, in the late Golgi of yeast. To obtain sufficient α 2,3-sialyltransferase activity in the late Golgi, for example, the catalytic domain of a known sialyltransferase (e.g. from humans) has to be directed to the late Golgi in fungi (see above).

Likewise, transporters have to be engineered to allow the transport of CMP-N-

10 acetyl neuraminic acid into the late Golgi. There is currently no indication that fungi synthesize or can even transport sufficient amounts of CMP-N-acetyl neuraminic acid into the Golgi. Consequently, to ensure the adequate supply of substrate for the corresponding glycosyltransferases, one has to metabolically engineer the production of CMP-sialic acid into the fungus.

15

UDP-N-acetylglucosamine

[0556] The cDNA of human UDP-N-acetylglucosamine transporter, which was recognized through a homology search in the expressed sequence tags database (dbEST), has been cloned (Ishida, 1999 *J. Biochem.* 126(1): 68-77). The

20 mammalian Golgi membrane transporter for UDP-N-acetylglucosamine was cloned by phenotypic correction with cDNA from canine kidney cells (MDCK) of a recently characterized *Kluyveromyces lactis* mutant deficient in Golgi transport of the above nucleotide sugar (Guillen et al. (1998) *Proc. Natl. Acad. Sci. USA* 95(14):7888-7892). Results demonstrate that the mammalian Golgi UDP-GlcNAc

25 transporter gene has all of the necessary information for the protein to be expressed and targeted functionally to the Golgi apparatus of yeast and that two proteins with very different amino acid sequences may transport the same solute within the same Golgi membrane (Guillen et al. (1998) *Proc. Natl. Acad. Sci. USA* 95(14):7888-7892).

30 [0557] Accordingly, one may incorporate the expression of a UDP-GlcNAc transporter in a host cell by means of a nucleic acid construct which may contain, for example: (1) a region by which the transformed construct is maintained in the

cell (e.g. origin of replication or a region that mediates chromosomal integration), (2) a marker gene that allows for the selection of cells that have been transformed, including counterselectable and recyclable markers such as *ura3* or *T-urf13* (Soderholm et al. (2001) *Biotechniques* 31(2):306-10) or other well characterized selection-markers (e.g., *his4*, *bla*, *Sh ble* etc.), (3) a gene or fragment thereof encoding a functional UDP-GlcNAc transporter (e.g. from *K.lactis*, (Abeijon, (1996) *Proc. Natl. Acad. Sci. U.S.A.* 93:5963-5968), or from *H.sapiens* (Ishida et al. (1996) *J. Biochem. (Tokyo)* 120(6):1074-8), and (4) a promoter activating the expression of the above mentioned localization/catalytic domain fusion construct library. **Example 8** shows the addition of a *Kluyveromyces lactis* *MNN2-2* gene (Genbank AN AF106080) encoding the UDP-GlcNAc transporter in a *P. pastoris* PBP-3. **Figure 10A and 10B** compares the MALDI-TOF N-glycan profiles of a *P. pastoris* strain without the UDP-GlcNAc transporter and a *P. pastoris* strain with the UDP-GlcNAc transporter (PBP-3), respectively. The *P. pastoris* PBP-3 exhibits a single prominent peak at 1457 (m/z) consistent with its identification as GlcNAcMan₅GlcNAc₂ [b].

GDP-Fucose

[0558] The rat liver Golgi membrane GDP-fucose transporter has been identified and purified by Puglielli, L. and C. B. Hirschberg (Puglielli, 1999 *J. Biol. Chem.* 274(50):35596-35600). The corresponding gene has not been identified, however, N-terminal sequencing can be used for the design of oligonucleotide probes specific for the corresponding gene. These oligonucleotides can be used as probes to clone the gene encoding for GDP-fucose transporter.

UDP-Galactose

[0559] Two heterologous genes, *gal2(+)* encoding alpha 1,2-galactosyltransferase (alpha 1,2 GalT) from *Schizosaccharomyces pombe* and (*hUGT2*) encoding human UDP-galactose (UDP-Gal) transporter, have been functionally expressed in *S.cerevisiae* to examine the intracellular conditions required for galactosylation. Correlation between protein galactosylation and UDP-galactose transport activity indicated that an exogenous supply of UDP-Gal

transporter, rather than alpha 1,2 GalT played a key role for efficient galactosylation in *S.cerevisiae* (Kainuma, 1999 *Glycobiology* 9(2): 133-141). Likewise, an UDP-galactose transporter from *S. pombe* was cloned (Segawa, 1999 *Febs Letters* 451(3): 295-298).

5

CMP-N-acetylneuraminic acid (CMP-Sialic acid).

[0560] Human CMP-sialic acid transporter (hCST) has been cloned and expressed in Lec 8 CHO cells (Aoki et al. (1999) *J. Biochem. (Tokyo)* 126(5):940-50; Eckhardt et al. (1997) *Eur. J. Biochem.* 248(1):187-92). The functional
10 expression of the murine CMP-sialic acid transporter was achieved in *Saccharomyces cerevisiae* (Berninsone et al. (1997) *J. Biol. Chem.* 272(19):12616-9). Sialic acid has been found in some fungi, however it is not clear whether the chosen host system will be able to supply sufficient levels of CMP-Sialic acid. Sialic acid can be either supplied in the medium or alternatively fungal pathways
15 involved in sialic acid synthesis can also be integrated into the host genome.

Expression of Diphosphatases:

[0561] When sugars are transferred onto a glycoprotein, either a nucleoside diphosphate or monophosphate is released from the sugar nucleotide precursors.
20 While monophosphates can be directly exported in exchange for nucleoside triphosphate sugars by an antiport mechanism, diphosphonucleosides (e.g. GDP) have to be cleaved by phosphatases (e.g. GDPase) to yield nucleoside monophosphates and inorganic phosphate prior to being exported. This reaction appears to be important for efficient glycosylation, as GDPase from *S.cerevisiae*
25 has been found to be necessary for mannosylation. However, the enzyme only has 10% of the activity towards UDP (Berninsone et al. (1994) *J. Biol. Chem.* 269(1):207-211). Lower eukaryotes often do not have UDP-specific diphosphatase activity in the Golgi as they do not utilize UDP-sugar precursors for glycoprotein synthesis in the Golgi. *Schizosaccharomyces pombe*, a yeast which adds galactose
30 residues to cell wall polysaccharides (from UDP-galactose), was found to have specific UDPase activity, further suggesting the requirement for such an enzyme (Berninsone et al. (1994) *J. Biol. Chem.* 269(1):207-211). UDP is known to be a

potent inhibitor of glycosyltransferases and the removal of this glycosylation side product is important to prevent glycosyltransferase inhibition in the lumen of the Golgi.

5 **Recombinant Vectors**

[0562] A variety of expression vectors may be used to express the nucleotide sequences of the present invention (see, e.g., **Example 13**). The sequences may be operatively linked to an expression control sequence in a suitable vector for transformation of a host cell. In one embodiment, a sequence of the present
10 invention is operably linked to a vector designated pJN348, which comprises a GAPDH promoter, a *NotI* *AscI* *PacI* restriction site cassette, CycII transcriptional terminator, the *ura3* selection cassette for expression in a *P. pastoris* YSH-1 (Amp^r).

[0563] In a preferred embodiment, the vector comprises a catalytically active
15 fragment of a mannosidase II enzyme as set forth in the above description. Other suitable expression vectors for use in yeast and filamentous fungi are well-known in the art.

20 **Methods For Altering N-Glycans in a Host By Expressing A Targeted Enzymatic Activity From a Nucleic Acid Molecule**

[0564] The present invention further provides a method for producing a human-like glycoprotein in a non-human host cell comprising the step of introducing into the cell one or more nucleic acid molecules which encode an enzyme or enzymes
25 for production of the Man₅GlcNAc₂ carbohydrate structure. In one preferred embodiment, a nucleic acid molecule encoding one or more mannosidase activities involved in the production of Man₅GlcNAc₂ from Man₈GlcNAc₂ or Man₉GlcNAc₂ is introduced into the host. The invention additionally relates to methods for making altered glycoproteins in a host cell comprising the step of introducing into
30 the host cell a nucleic acid molecule which encodes one or more glycosylation enzymes or activities. Preferred enzyme activities are selected from the group consisting of UDP-GlcNAc transferase, UDP-galactosyltransferase, GDP-fucosyltransferase, CMP-sialyltransferase, UDP-GlcNAc transporter, UDP-galactose transporter, GDP-fucose transporter, CMP-sialic acid transporter, and

nucleotide diphosphatases. In a particularly preferred embodiment, the host is selected or engineered to express two or more enzymatic activities in which the product of one activity increases substrate levels of another activity, e.g., a glycosyltransferase and a corresponding sugar transporter, e.g., GnTI and UDP-
5 GlcNAc transporter activities. In another preferred embodiment, the host is selected or engineered to express an activity to remove products which may inhibit subsequent glycosylation reactions, e.g. a UDP- or GDP-specific diphosphatase activity.

[0565] Preferred methods of the invention involve expressing one or more
10 enzymatic activities from a nucleic acid molecule in a host cell and comprise the step of targeting at least one enzymatic activity to a desired subcellular location (e.g., an organelle) by forming a fusion protein comprising a catalytic domain of the enzyme and a cellular targeting signal peptide, e.g., a heterologous signal peptide which is not normally ligated to or associated with the catalytic domain.
15 The fusion protein is encoded by at least one genetic construct ("fusion construct") comprising a nucleic acid fragment encoding a cellular targeting signal peptide ligated in the same translational reading frame ("in-frame") to a nucleic acid fragment encoding an enzyme (e.g., glycosylation enzyme), or catalytically active fragment thereof.

20 [0566] The targeting signal peptide component of the fusion construct or protein is preferably derived from a member of the group consisting of: membrane-bound proteins of the ER or Golgi, retrieval signals, Type II membrane proteins, Type I membrane proteins, membrane spanning nucleotide sugar transporters, mannosidases, sialyltransferases, glucosidases, mannosyltransferases and
25 phosphomannosyltransferases.

[0567] The catalytic domain component of the fusion construct or protein is preferably derived from a glycosidase, mannosidase or a glycosyltransferase activity derived from a member of the group consisting of GnTI, GnTII, GnTIII, GnTIV, GnTV, GnTVI, GalT, Fucosyltransferase and Sialyltransferase. The
30 catalytic domain preferably has a pH optimum within 1.4 pH units of the average pH optimum of other representative enzymes in the organelle in which the enzyme is localized, or has optimal activity at a pH between 5.1 and 8.0. In a preferred

embodiment, the catalytic domain encodes a mannosidase selected from the group consisting of *C. elegans* mannosidase IA, *C. elegans* mannosidase IB, *D. melanogaster* mannosidase IA, *H. sapiens* mannosidase IB, *P. citrinum* mannosidase I, mouse mannosidase IA, mouse mannosidase IB, *A. nidulans* mannosidase IA, *A. nidulans* mannosidase IB, *A. nidulans* mannosidase IC, mouse mannosidase II, *C. elegans* mannosidase II, *H. sapiens* mannosidase II, and mannosidase III.

Selecting a Glycosylation Enzyme: pH Optima and Subcellular Localization

[0568] In one embodiment of the invention, a human-like glycoprotein is made efficiently in a non-human eukaryotic host cell by introducing into a subcellular compartment of the cell a glycosylation enzyme selected to have a pH optimum similar to the pH optima of other enzymes in the targeted subcellular compartment. For example, most enzymes that are active in the ER and Golgi apparatus of *S. cerevisiae* have pH optima that are between about 6.5 and 7.5 (see Table 3). Because the glycosylation of proteins is a highly evolved and efficient process, the internal pH of the ER and the Golgi is likely also in the range of about 6-8. All previous approaches to reduce mannosylation by the action of recombinant mannosidases in fungal hosts, however, have introduced enzymes that have a pH optimum of around pH 5.0 (Martinet et al. (1998) *Biotech. Letters* 20(12): 1171-1177, and Chiba et al. (1998) *J. Biol. Chem.* 273(41): 26298-26304). At pH 7.0, the *in vitro* determined activity of those mannosidases is reduced to less than 10%, which is likely insufficient activity at their point of use, namely, the ER and early Golgi, for the efficient *in vivo* production of Man₅GlcNAc₂ on N-glycans.

[0569] Accordingly, a preferred embodiment of this invention targets a selected glycosylation enzyme (or catalytic domain thereof), e.g., an α -mannosidase, to a subcellular location in the host cell (e.g., an organelle) where the pH optimum of the enzyme or domain is within 1.4 pH units of the average pH optimum of other representative marker enzymes localized in the same organelle(s). The pH optimum of the enzyme to be targeted to a specific organelle should be matched with the pH optimum of other enzymes found in the same organelle to maximize the activity per unit enzyme obtained. Table 3 summarizes the activity of

mannosidases from various sources and their respective pH optima. Table 4 summarizes their typical subcellular locations.

Table 3. Mannosidases and their pH optimum.

Source	Enzyme	pH optimum	Reference
<i>Aspergillus saitoi</i>	α -1,2-mannosidase	5.0	Ichishima et al., 1999 Biochem. J. 339(Pt 3):589-597
<i>Trichoderma reesei</i>	α -1,2-mannosidase	5.0	Maras et al., 2000 J. Biotechnol. 77(2-3):255-263
<i>Penicillium citrinum</i>	α -D-1,2-mannosidase	5.0	Yoshida et al., 1993 Biochem. J. 290(Pt 2):349-354
<i>C. elegans</i>	α -1,2-mannosidase	5.5	Figure 11 herein
<i>Aspergillus nidulans</i>	α -1,2-mannosidase	6.0	Eades and Hintz, 2000 Gene 255(1):25-34
<i>Homo sapiens</i> IA(Golgi)	α -1,2-mannosidase	6.0	
<i>Homo sapiens</i> IB (Golgi)	α -1,2-mannosidase	6.0	
<i>Lepidopteran</i> insect cells	Type I α -1,2-Man α - mannosidase	6.0	Ren et al., 1995 Biochem. 34(8):2489-2495
<i>Homo sapiens</i>	α -D-mannosidase	6.0	Chandrasekaran et al., 1984 Cancer Res. 44(9):4059-68
<i>Xanthomonas</i> <i>manihotis</i>	α -1,2,3-mannosidase	6.0	U.S. Pat. No. 6,300,113
<i>Drosophila</i> <i>melanogaster</i>	α -1,2-mannosidase	6.2	Reported herein
<i>Mouse</i> IB (Golgi)	α -1,2-mannosidase	6.5	Schneikert and Herscovics, 1994 Glycobiology. 4(4):445- 50
<i>Bacillus</i> sp. (secreted)	α -D-1,2-mannosidase	7.0	Maruyama et al., 1994 Carbohydrate Res. 251:89-98

5

[0570] In a preferred embodiment, a particular enzyme or catalytic domain is targeted to a subcellular location in the host cell by means of a chimeric fusion construct encoding a protein comprising a cellular targeting signal peptide not normally associated with the enzymatic domain. Preferably, an enzyme or domain is targeted to the ER, the early, medial or late Golgi, or the trans Golgi apparatus of the host cell.

[0571] In a more preferred embodiment, the targeted glycosylation enzyme is a mannosidase, glycosyltransferase or a glycosidase. In an especially preferred embodiment, mannosidase activity is targeted to the ER or cis Golgi, where the early reactions of glycosylation occur. While this method is useful for producing a human-like glycoprotein in a non-human host cell, it will be appreciated that the

15

method is also useful more generally for modifying carbohydrate profiles of a glycoprotein in any eukaryotic host cell, including human host cells.

[0572] Targeting sequences which mediate retention of proteins in certain organelles of the host cell secretory pathway are well-known and described in the scientific literature and public databases, as discussed in more detail below with respect to libraries for selection of targeting sequences and targeted enzymes. Such subcellular targeting sequences may be used alone or in combination to target a selected glycosylation enzyme (or catalytic domain thereof) to a particular subcellular location in a host cell, i.e., especially to one where the enzyme will have enhanced or optimal activity based on pH optima or the presence of other stimulatory factors.

[0573] When one attempts to trim high mannose structures to yield $\text{Man}_5\text{GlcNAc}_2$ in the ER or the Golgi apparatus of a host cell such as *S.cerevisiae*, for example, one may choose any enzyme or combination of enzymes that (1) has a sufficiently close pH optimum (i.e. between pH 5.2 and pH 7.8), and (2) is known to generate, alone or in concert, the specific isomeric $\text{Man}_5\text{GlcNAc}_2$ structure required to accept subsequent addition of GlcNAc by GnTI. Any enzyme or combination of enzymes that is shown to generate a structure that can be converted to $\text{GlcNAcMan}_5\text{GlcNAc}_2$ by GnTI *in vitro* would constitute an appropriate choice. This knowledge may be obtained from the scientific literature or experimentally.

[0574] For example, one may determine whether a potential mannosidase can convert $\text{Man}_8\text{GlcNAc}_2\text{-2AB}$ (2-aminobenzamide) to $\text{Man}_5\text{GlcNAc}_2\text{-AB}$ and then verify that the obtained $\text{Man}_5\text{GlcNAc}_2\text{-2AB}$ structure can serve a substrate for GnTI and UDP-GlcNAc to give $\text{GlcNAcMan}_5\text{GlcNAc}_2$ *in vitro*. Mannosidase IA from a human or murine source, for example, would be an appropriate choice (see, e.g., Example 4). Examples described herein utilize 2-aminobenzamide labeled N-linked oligomannose followed by HPLC analysis to make this determination.

Table 4. Cellular location and pH optima of various glycosylation-related enzymes of *S.cerevisiae*.

Gene	Activity	Location	pH optimum	Reference(s)
<i>KTR1</i>	α -1,2 mannosyltransferase	Golgi	7.0	Romero et al. (1997) <i>Biochem. J.</i> 321(Pt 2):289-295
<i>MNS1</i>	α -1,2- mannosidase	ER	6.5	

<i>CWH41</i>	glucosidase I mannosyltransferase	ER Golgi	6.8 7-8	Lehele and Tanner (1974) <i>Biochim. Biophys. Acta</i> 350(1):225-235 Romero et al. (1997) <i>Biochem. J.</i> 321(Pt 2):289-295
<i>KRE2</i>	α -1,2 mannosyltransferase	Golgi	6.5-9.0	

[0575] Accordingly, a glycosylation enzyme such as an α -1,2-mannosidase enzyme used according to the invention has an optimal activity at a pH of between 5.1 and 8.0. In a preferred embodiment, the enzyme has an optimal activity at a pH of between 5.5 and 7.5. The *C. elegans* mannosidase enzyme, for example, works well in the methods of the invention and has an apparent pH optimum of about 5.5). Preferred mannosidases include those listed in Table 3 having appropriate pH optima, e.g. *Aspergillus nidulans*, *Homo sapiens* IA (Golgi), *Homo sapiens* IB (Golgi), *Lepidopteran* insect cells (IPLB-SF21AE), *Homo sapiens*, mouse IB (Golgi), *Xanthomonas manihotis*, *Drosophila melanogaster* and *C. elegans*.

[0576] The experiment which illustrates the pH optimum for an α -1,2-mannosidase enzyme is described in Example 7. A chimeric fusion protein BB27-2 (*Saccharomyces MNN10* (s)/*C. elegans* mannosidase IB Δ 31), which leaks into the medium was subjected to various pH ranges to determine the optimal activity of the enzyme. The results of the experiment show that the α -1,2-mannosidase has an optimal pH of about 5.5 for its function (Figure 11).

[0577] In a preferred embodiment, a single cloned mannosidase gene is expressed in the host organism. However, in some cases it may be desirable to express several different mannosidase genes, or several copies of one particular gene, in order to achieve adequate production of Man₅GlcNAc₂. In cases where multiple genes are used, the encoded mannosidases preferably all have pH optima within the preferred range of about 5.1 to about 8.0, or especially between about 5.5 and about 7.5. Preferred mannosidase activities include α -1,2-mannosidases derived from mouse, human, *Lepidoptera*, *Aspergillus nidulans*, or *Bacillus* sp., *C. elegans*, *D. melanogaster*, *P. citrinum*, *X. laevis* or *A. nidulans*.

***In Vivo* Alteration of Host Cell Glycosylation Using a Combinatorial DNA Library**

[0578] Certain methods of the invention are preferably (but need not necessarily be) carried out using one or more nucleic acid libraries. An exemplary feature of a combinatorial nucleic acid library of the invention is that it comprises sequences encoding cellular targeting signal peptides and sequences encoding proteins to be targeted (e.g., enzymes or catalytic domains thereof, including but not limited to those which mediate glycosylation).

[0579] In one embodiment, a combinatorial nucleic acid library comprises: (a) at least two nucleic acid sequences encoding different cellular targeting signal peptides; and (b) at least one nucleic acid sequence encoding a polypeptide to be targeted. In another embodiment, a combinatorial nucleic acid library comprises: (a) at least one nucleic acid sequence encoding a cellular targeting signal peptide; and (b) at least two nucleic acid sequences encoding a polypeptide to be targeted into a host cell. As described further below, a nucleic acid sequence derived from (a) and a nucleic acid sequence derived from (b) are ligated to produce one or more fusion constructs encoding a cellular targeting signal peptide functionally linked to a polypeptide domain of interest. One example of a functional linkage is when the cellular targeting signal peptide is ligated to the polypeptide domain of interest in the same translational reading frame ("in-frame").

[0580] In a preferred embodiment, a combinatorial DNA library expresses one or more fusion proteins comprising cellular targeting signal peptides ligated in-frame to catalytic enzyme domains. The encoded fusion protein preferably comprises a catalytic domain of an enzyme involved in mammalian- or human-like modification of *N*-glycans. In a more preferred embodiment, the catalytic domain is derived from an enzyme selected from the group consisting of mannosidases, glycosyltransferases and other glycosidases which is ligated in-frame to one or more targeting signal peptides. The enzyme domain may be exogenous and/or endogenous to the host cell. A particularly preferred signal peptide is one normally associated with a protein that undergoes ER to Golgi transport.

[0581] The combinatorial DNA library of the present invention may be used for producing and localizing *in vivo* enzymes involved in mammalian- or human-like *N*-glycan modification. The fusion constructs of the combinatorial DNA library

are engineered so that the encoded enzymes are localized in the ER, Golgi or the trans-Golgi network of the host cell where they are involved in producing particular *N*-glycans on a glycoprotein of interest. Localization of *N*-glycan modifying enzymes of the present invention is achieved through an anchoring mechanism or through protein-protein interaction where the localization peptide constructed from the combinatorial DNA library localizes to a desired organelle of the secretory pathway such as the ER, Golgi or the trans Golgi network.

5 [0582] An example of a useful *N*-glycan, which is produced efficiently and in sufficient quantities for further modification by human-like (complex) glycosylation reactions is $\text{Man}_5\text{GlcNAc}_2$. A sufficient amount of $\text{Man}_5\text{GlcNAc}_2$ is needed on a glycoprotein of interest for further human-like processing *in vivo* (e.g., more than 30 mole %). The $\text{Man}_5\text{GlcNAc}_2$ intermediate may be used as a substrate for further *N*-glycan modification to produce $\text{GlcNAcMan}_5\text{GlcNAc}_2$ (Figure 1B; see above). Accordingly, the combinatorial DNA library of the present invention
15 may be used to produce enzymes which subsequently produce $\text{GlcNAcMan}_5\text{GlcNAc}_2$, or other desired complex *N*-glycans, in a useful quantity.

[0583] A further aspect of the fusion constructs produced using the combinatorial DNA library of the present invention is that they enable sufficient and often near complete intracellular *N*-glycan trimming activity in the engineered host cell.
20 Preferred fusion constructs produced by the combinatorial DNA library of the invention encode a glycosylation enzyme, e.g., a mannosidase, which is effectively localized to an intracellular host cell compartment and thereby exhibits very little and preferably no extracellular activity. The preferred fusion constructs of the present invention that encode a mannosidase enzyme are shown to localize where
25 the *N*-glycans are modified, namely, the ER and the Golgi. The fusion enzymes of the present invention are targeted to such particular organelles in the secretory pathway where they localize and act upon *N*-glycans such as $\text{Man}_8\text{GlcNAc}_2$ to produce $\text{Man}_5\text{GlcNAc}_2$ on a glycoprotein of interest.

[0584] Enzymes produced by the combinatorial DNA library of the present
30 invention can modify *N*-glycans on a glycoprotein of interest as shown for K3 or IFN- β proteins expressed in *P.pastoris*, as shown in Figures 5 and 6, respectively (see also Examples 2 and 4). It is, however, appreciated that other types of

glycoproteins, without limitation, including erythropoietin, cytokines such as interferon- α , interferon- β , interferon- γ , interferon- ω , and granulocyte-CSF, coagulation factors such as factor VIII, factor IX, and human protein C, soluble IgE receptor α -chain, IgG, IgG fragments, IgM, interleukins, urokinase, chymase, and urea trypsin inhibitor, IGF-binding protein, epidermal growth factor, growth hormone-releasing factor, annexin V fusion protein, angiostatin, vascular endothelial growth factor-2, myeloid progenitor inhibitory factor-1, osteoprotegerin, α -1 antitrypsin, DNase II, α -feto proteins, AAT, rhTBP-1 (oncept, aka TNF Binding protein 1), TACI-Ig (transmembrane activator and calcium modulator and cyclophilin ligand interactor), FSH (follicle stimulating hormone), GM-CSF, GLP-1 w/ and w/o FC (glucagon like protein 1) IL-1 receptor agonist, sTNFr (enbrel, aka soluble TNF receptor Fc fusion) ATIII, rhThrombin, glucocerebrosidase and CTLA4-Ig (Cytotoxic T Lymphocyte associated Antigen 4 - Ig) may be glycosylated in this way.

15

Constructing a Combinatorial DNA Library of Fusion Constructs:

[0585] A combinatorial DNA library of fusion constructs features one or more cellular targeting signal peptides ("targeting peptides") generally derived from N-terminal domains of native proteins (e.g., by making C-terminal deletions). Some targeting peptides, however, are derived from the C-terminus of native proteins (e.g. *SEC12*). Membrane-bound proteins of the ER or the Golgi are preferably used as a source for targeting peptide sequences. These proteins have sequences encoding a cytosolic tail (ct), a transmembrane domain (tmd) and a stem region (sr) which are varied in length. These regions are recognizable by protein sequence alignments and comparisons with known homologs and/or other localized proteins (e.g., comparing hydrophobicity plots).

[0586] The targeting peptides are indicated herein as short (s), medium (m) and long (l) relative to the parts of a type II membrane. The targeting peptide sequence indicated as short (s) corresponds to the transmembrane domain (tmd) of the membrane-bound protein. The targeting peptide sequence indicated as long (l) corresponds to the length of the transmembrane domain (tmd) and the stem region (sr). The targeting peptide sequence indicated as medium (m) corresponds to the

transmembrane domain (tmd) and approximately half the length of the stem region (sr). The catalytic domain regions are indicated herein by the number of nucleotide deletion with respect to its wild-type glycosylation enzyme.

5 *Sub-libraries*

[0587] In some cases a combinatorial nucleic acid library of the invention may be assembled directly from existing or wild-type genes. In a preferred embodiment, the DNA library is assembled from the fusion of two or more sub-libraries. By the in-frame ligation of the sub-libraries, it is possible to create a
10 large number of novel genetic constructs encoding useful targeted protein domains such as those which have glycosylation activities.

Catalytic Domain Sub-Libraries Encoding Glycosylation Activities

[0588] One useful sub-library includes DNA sequences encoding enzymes such
15 as glycosidases (e.g., mannosidases), glycosyltransferases (e.g., fucosyltransferases, galactosyltransferases, glucosyltransferases), GlcNAc transferases and sialyltransferases. Catalytic domains may be selected from the host to be engineered, as well as from other related or unrelated organisms. Mammalian, plant, insect, reptile, algal or fungal enzymes are all useful and should be chosen to
20 represent a broad spectrum of biochemical properties with respect to temperature and pH optima. In a preferred embodiment, genes are truncated to give fragments some of which encode the catalytic domains of the enzymes. By removing endogenous targeting sequences, the enzymes may then be redirected and expressed in other cellular loci.

25 [0589] The choice of such catalytic domains may be guided by the knowledge of the particular environment in which the catalytic domain is subsequently to be active. For example, if a particular glycosylation enzyme is to be active in the late Golgi, and all known enzymes of the host organism in the late Golgi have a certain pH optimum, or the late Golgi is known to have a particular pH, then a catalytic
30 domain is chosen which exhibits adequate, and preferably maximum, activity at that pH, as discussed above.

Targeting Peptide Sequence Sub-Libraries

[0590] Another useful sub-library includes nucleic acid sequences encoding targeting signal peptides that result in localization of a protein to a particular location within the ER, Golgi, or trans Golgi network. These targeting peptides may be selected from the host organism to be engineered as well as from other related or unrelated organisms. Generally such sequences fall into three categories: (1) N-terminal sequences encoding a cytosolic tail (ct), a transmembrane domain (tmd) and part or all of a stem region (sr), which together or individually anchor proteins to the inner (luminal) membrane of the Golgi; (2) retrieval signals which are generally found at the C-terminus such as the HDEL (SEQ ID NO: 105) or KDEL tetrapeptide (SEQ ID NO: 106); and (3) membrane spanning regions from various proteins, e.g., nucleotide sugar transporters, which are known to localize in the Golgi.

[0591] In the first case, where the targeting peptide consists of various elements (ct, tmd and sr), the library is designed such that the ct, the tmd and various parts of the stem region are represented. Accordingly, a preferred embodiment of the sub-library of targeting peptide sequences includes ct, tmd, and/or sr sequences from membrane-bound proteins of the ER or Golgi. In some cases it may be desirable to provide the sub-library with varying lengths of sr sequence. This may be accomplished by PCR using primers that bind to the 5' end of the DNA encoding the cytosolic region and employing a series of opposing primers that bind to various parts of the stem region.

[0592] Still other useful sources of targeting peptide sequences include retrieval signal peptides, e.g. the tetrapeptides HDEL (SEQ ID NO: 105) or KDEL (SEQ ID NO: 106), which are typically found at the C-terminus of proteins that are transported retrograde into the ER or Golgi. Still other sources of targeting peptide sequences include (a) type II membrane proteins, (b) the enzymes listed in Table 3, (c) membrane spanning nucleotide sugar transporters that are localized in the Golgi, and (d) sequences referenced in Table 5.

Table 5. Sources of useful compartmental targeting sequences

<i>Gene or Sequence</i>	<i>Organism</i>	<i>Function</i>	<i>Location of Gene Product</i>
-------------------------	-----------------	-----------------	---------------------------------

<i>Gene or Sequence</i>	<i>Organism</i>	<i>Function</i>	<i>Location of Gene Product</i>
<i>MNSI</i>	<i>A.nidulans</i>	α -1,2-mannosidase	ER
<i>MNSI</i>	<i>A.niger</i>	α -1,2-mannosidase	ER
<i>MNSI</i>	<i>S.cerevisiae</i>	α -1,2-mannosidase	ER
<i>GLSI</i>	<i>S.cerevisiae</i>	glucosidase	ER
<i>GLSI</i>	<i>A.niger</i>	glucosidase	ER
<i>GLSI</i>	<i>A.nidulans</i>	glucosidase	ER
HDEL (SEQ ID NO: 105) at C-terminus	<i>Universal in fungi</i>	retrieval signal	ER
<i>SEC12</i>	<i>S.cerevisiae</i>	COPII vesicle protein	ER/Golgi
<i>SEC12</i>	<i>A.niger</i>	COPII vesicle protein	ER/Golgi
<i>OCH1</i>	<i>S.cerevisiae</i>	1,6-mannosyltransferase	Golgi (cis)
<i>OCH1</i>	<i>P.pastoris</i>	1,6-mannosyltransferase	Golgi (cis)
<i>MNN9</i>	<i>S.cerevisiae</i>	1,6-mannosyltransferase complex	Golgi
<i>MNN9</i>	<i>A.niger</i>	undetermined	Golgi
<i>VAN1</i>	<i>S.cerevisiae</i>	undetermined	Golgi
<i>VAN1</i>	<i>A.niger</i>	undetermined	Golgi
<i>ANP1</i>	<i>S.cerevisiae</i>	undetermined	Golgi
<i>HOC1</i>	<i>S.cerevisiae</i>	undetermined	Golgi
<i>MNN10</i>	<i>S.cerevisiae</i>	undetermined	Golgi
<i>MNN10</i>	<i>A.niger</i>	undetermined	Golgi
<i>MNN11</i>	<i>S.cerevisiae</i>	undetermined	Golgi (cis)
<i>MNN11</i>	<i>A.niger</i>	undetermined	Golgi (cis)
<i>MNT1</i>	<i>S.cerevisiae</i>	1,2-mannosyltransferase	Golgi (cis, medial)
<i>KTR1</i>	<i>P.pastoris</i>	undetermined	Golgi (medial)
<i>KRE2</i>	<i>P.pastoris</i>	undetermined	Golgi (medial)
<i>KTR3</i>	<i>P.pastoris</i>	undetermined	Golgi (medial)
<i>MNN2</i>	<i>S.cerevisiae</i>	1,2-mannosyltransferase	Golgi (medial)
<i>KTR1</i>	<i>S.cerevisiae</i>	undetermined	Golgi (medial)

<i>Gene or Sequence</i>	<i>Organism</i>	<i>Function</i>	<i>Location of Gene Product</i>
<i>KTR2</i>	<i>S.cerevisiae</i>	undetermined	Golgi (medial)
<i>MNN1</i>	<i>S.cerevisiae</i>	1,3-mannosyltransferase	Golgi (trans)
<i>MNN6</i>	<i>S.cerevisiae</i>	Phosphomannosyltransferase	Golgi (trans)
2,6 ST	<i>H. sapiens</i>	2,6-sialyltransferase	trans Golgi network
UDP-Gal T	<i>S. pombe</i>	UDP-Gal transporter	Golgi

[0593] In any case, it is highly preferred that targeting peptide sequences are selected which are appropriate for the particular enzymatic activity or activities to function optimally within the sequence of desired glycosylation reactions. For example, in developing a modified host microorganism capable of terminal sialylation of nascent *N*-glycans, a process which occurs in the late Golgi in humans, it is desirable to utilize a sub-library of targeting peptide sequences derived from late Golgi proteins. Similarly, the trimming of $\text{Man}_8\text{GlcNAc}_2$ by an α -1,2-mannosidase to give $\text{Man}_5\text{GlcNAc}_2$ is an early step in complex *N*-glycan formation in humans (Figure 1B). It is therefore desirable to have this reaction occur in the ER or early Golgi of an engineered host microorganism. A sub-library encoding ER and early Golgi retention signals is used.

[0594] A series of fusion protein constructs (i.e., a combinatorial DNA library) is then constructed by functionally linking one or a series of targeting peptide sequences to one or a series of sequences encoding catalytic domains. In a preferred embodiment, this is accomplished by the in-frame ligation of a sub-library comprising DNA encoding targeting peptide sequences (above) with a sub-library comprising DNA encoding glycosylation enzymes or catalytically active fragments thereof (see below).

[0595] The resulting library comprises synthetic genes encoding targeting peptide sequence-containing fusion proteins. In some cases it is desirable to provide a targeting peptide sequence at the N-terminus of a fusion protein, or in other cases at the C-terminus. In some cases, targeting peptide sequences may be inserted within the open reading frame of an enzyme, provided the protein structure of individual folded domains is not disrupted. Each type of fusion protein

is constructed (in a step-wise directed or semi-random fashion) and optimal constructs may be selected upon transformation of host cells and characterization of glycosylation patterns in transformed cells using methods of the invention.

5 *Generating Additional Sequence Diversity*

[0596] The method of this embodiment is most effective when a nucleic acid, e.g., a DNA library transformed into the host contains a large diversity of sequences, thereby increasing the probability that at least one transformant will exhibit the desired phenotype. Single amino acid mutations, for example, may drastically alter the activity of glycoprotein processing enzymes (Romero et al. 10 (2000) *J. Biol. Chem.* 275(15):11071-4). Accordingly, prior to transformation, a DNA library or a constituent sub-library may be subjected to one or more techniques to generate additional sequence diversity. For example, one or more rounds of gene shuffling, error prone PCR, *in vitro* mutagenesis or other methods for generating sequence diversity, may be performed to obtain a larger diversity of 15 sequences within the pool of fusion constructs.

Expression Control Sequences

[0597] In addition to the open reading frame sequences described above, it is 20 generally preferable to provide each library construct with expression control sequences, such as promoters, transcription terminators, enhancers, ribosome binding sites, and other functional sequences as may be necessary to ensure effective transcription and translation of the fusion proteins upon transformation of fusion constructs into the host organism.

25 [0598] Suitable vector components, e.g., selectable markers, expression control sequences (e.g., promoter, enhancers, terminators and the like) and, optionally, sequences required for autonomous replication in a host cell, are selected as a function of which particular host cell is chosen. Selection criteria for suitable vector components for use in a particular mammalian or a lower eukaryotic host 30 cell are routine. Preferred lower eukaryotic host cells of the invention include *Pichia pastoris*, *Pichia finlandica*, *Pichia trehalophila*, *Pichia koclamae*, *Pichia membranaefaciens*, *Pichia opuntiae*, *Pichia thermotolerans*, *Pichia salictaria*,

Pichia guercuum, *Pichia pijperi*, *Pichia stiptis*, *Pichia methanolica*, *Pichia* sp., *Saccharomyces cerevisiae*, *Saccharomyces* sp., *Hansenula polymorpha*, *Khuyveromyces* sp., *Khuyveromyces lactis*, *Candida albicans*, *Aspergillus nidulans*, *Aspergillus niger*, *Aspergillus oryzae*, *Trichoderma reesei*, *Chrysosporium*
5 *lucknowense*, *Fusarium* sp. *Fusarium gramineum*, *Fusarium venenatum* and *Neurospora crassa*. Where the host is *Pichia pastoris*, suitable promoters include, for example, the *AOX1*, *AOX2*, *GAPDH* and *P40* promoters.

Selectable Markers

10 [0599] It is also preferable to provide each construct with at least one selectable marker, such as a gene to impart drug resistance or to complement a host metabolic lesion. The presence of the marker is useful in the subsequent selection of transformants; for example, in yeast the *URA3*, *HIS4*, *SUC2*, *G418*, *BLA*, or *SH*
15 *BLE* genes may be used. A multitude of selectable markers are known and available for use in yeast, fungi, plant, insect, mammalian and other eukaryotic host cells.

Transformation

[0600] The nucleic acid library is then transformed into the host organism. In
20 yeast, any convenient method of DNA transfer may be used, such as electroporation, the lithium chloride method, or the spheroplast method. In filamentous fungi and plant cells, conventional methods include particle bombardment, electroporation and agrobacterium mediated transformation. To produce a stable strain suitable for high-density culture (e.g., fermentation in
25 yeast), it is desirable to integrate the DNA library constructs into the host chromosome. In a preferred embodiment, integration occurs via homologous recombination, using techniques well-known in the art. For example, DNA library elements are provided with flanking sequences homologous to sequences of the host organism. In this manner, integration occurs at a defined site in the host
30 genome, without disruption of desirable or essential genes.

[0601] In an especially preferred embodiment, library DNA is integrated into the site of an undesired gene in a host chromosome, effecting the disruption or deletion

of the gene. For example, integration into the sites of the *OCH1*, *MNN1*, or *MNN4* genes allows the expression of the desired library DNA while preventing the expression of enzymes involved in yeast hypermannosylation of glycoproteins. In other embodiments, library DNA may be introduced into the host via a nucleic acid molecule, plasmid, vector (e.g., viral or retroviral vector), chromosome, and may be introduced as an autonomous nucleic acid molecule or by homologous or random integration into the host genome. In any case, it is generally desirable to include with each library DNA construct at least one selectable marker gene to allow ready selection of host organisms that have been stably transformed. Recyclable marker genes such as *URA3*, which can be selected for or against, are especially suitable.

Screening and Selection Processes

[0602] After transformation of the host strain with the DNA library, transformants displaying a desired glycosylation phenotype are selected. Selection may be performed in a single step or by a series of phenotypic enrichment and/or depletion steps using any of a variety of assays or detection methods. Phenotypic characterization may be carried out manually or using automated high-throughput screening equipment. Commonly, a host microorganism displays protein N-glycans on the cell surface, where various glycoproteins are localized.

[0603] One may screen for those cells that have the highest concentration of terminal GlcNAc on the cell surface, for example, or for those cells which secrete the protein with the highest terminal GlcNAc content. Such a screen may be based on a visual method, like a staining procedure, the ability to bind specific terminal GlcNAc binding antibodies or lectins conjugated to a marker (such lectins are available from E.Y. Laboratories Inc., San Mateo, CA), the reduced ability of specific lectins to bind to terminal mannose residues, the ability to incorporate a radioactively labeled sugar *in vitro*, altered binding to dyes or charged surfaces, or may be accomplished by using a Fluorescence Assisted Cell Sorting (FACS) device in conjunction with a fluorophore labeled lectin or antibody (Guillen et al. (1998) *Proc. Natl. Acad. Sci. USA* 95(14):7888-7892).

- [0604] Accordingly, intact cells may be screened for a desired glycosylation phenotype by exposing the cells to a lectin or antibody that binds specifically to the desired *N*-glycan. A wide variety of oligosaccharide-specific lectins are available commercially (e.g., from EY Laboratories, San Mateo, CA). Alternatively, antibodies to specific human or animal *N*-glycans are available commercially or may be produced using standard techniques. An appropriate lectin or antibody may be conjugated to a reporter molecule, such as a chromophore, fluorophore, radioisotope, or an enzyme having a chromogenic substrate (Guillen et al., 1998. *Proc. Natl. Acad. Sci. USA* 95(14): 7888-7892).
- 10 [0605] Screening may then be performed using analytical methods such as spectrophotometry, fluorimetry, fluorescence activated cell sorting, or scintillation counting. In other cases, it may be necessary to analyze isolated glycoproteins or *N*-glycans from transformed cells. Protein isolation may be carried out by techniques known in the art. In a preferred embodiment, a reporter protein is
- 15 secreted into the medium and purified by affinity chromatography (e.g. Ni-affinity or glutathione-S-transferase affinity chromatography). In cases where an isolated *N*-glycan is preferred, an enzyme such as endo- β -*N*-acetylglucosaminidase (Genzyme Co., Boston, MA; New England Biolabs, Beverly, MA) may be used to cleave the *N*-glycans from glycoproteins. Isolated proteins or *N*-glycans may then
- 20 be analyzed by liquid chromatography (e.g. HPLC), mass spectroscopy, or other suitable means. U.S. Patent No. 5,595,900 teaches several methods by which cells with desired extracellular carbohydrate structures may be identified. In a preferred embodiment, MALDI-TOF mass spectrometry is used to analyze the cleaved *N*-glycans.
- 25 [0606] Prior to selection of a desired transformant, it may be desirable to deplete the transformed population of cells having undesired phenotypes. For example, when the method is used to engineer a functional mannosidase activity into cells, the desired transformants will have lower levels of mannose in cellular glycoprotein. Exposing the transformed population to a lethal radioisotope of
- 30 mannose in the medium depletes the population of transformants having the undesired phenotype, i.e. high levels of incorporated mannose (Huffaker TC and Robbins PW., *Proc Natl Acad Sci U S A*. 1983 Dec;80(24):7466-70).

Alternatively, a cytotoxic lectin or antibody, directed against an undesirable *N*-glycan, may be used to deplete a transformed population of undesired phenotypes (e.g., Stanley P and Siminovitch L. *Somatic Cell Genet* 1977 Jul;3(4):391-405). U.S. Patent No. 5,595,900 teaches several methods by which
5 cells with a desired extracellular carbohydrate structures may be identified. Repeatedly carrying out this strategy allows for the sequential engineering of more and more complex glycans in lower eukaryotes.

[0607] To detect host cells having on their surface a high degree of the human-like *N*-glycan intermediate GlcNAcMan₃GlcNAc₂, for example, one may select for
10 transformants that allow for the most efficient transfer of GlcNAc by GlcNAc Transferase from UDP-GlcNAc in an *in vitro* cell assay. This screen may be carried out by growing cells harboring the transformed library under selective pressure on an agar plate and transferring individual colonies into a 96-well microtiter plate. After growing the cells, the cells are centrifuged, the cells
15 resuspended in buffer, and after addition of UDP-GlcNAc and GnTII, the release of UDP is determined either by HPLC or an enzyme linked assay for UDP. Alternatively, one may use radioactively labeled UDP-GlcNAc and GnTII, wash the cells and then look for the release of radioactive GlcNAc by *N*-actylglucosaminidase. All this may be carried out manually or may be automated
20 through the use of high throughput screening equipment. Transformants that release more UDP in the first assay, or more radioactively labeled GlcNAc in the second assay, are expected to have a higher degree of GlcNAcMan₃GlcNAc₂ on their surface and thus constitute the desired phenotype. Similar assays may be adapted to look at the *N*-glycans on secreted proteins as well.

[0608] Alternatively, one may use any other suitable screen such as a lectin
25 binding assay that is able to reveal altered glycosylation patterns on the surface of transformed cells. In this case the reduced binding of lectins specific to terminal mannoses may be a suitable selection tool. *Galantus nivalis* lectin binds specifically to terminal α -1,3 mannose, which is expected to be reduced if
30 sufficient mannosidase II activity is present in the Golgi. One may also enrich for desired transformants by carrying out a chromatographic separation step that allows for the removal of cells containing a high terminal mannose content. This

separation step would be carried out with a lectin column that specifically binds cells with a high terminal mannose content (e.g., *Galantus nivalis* lectin bound to agarose, Sigma, St. Louis, MO) over those that have a low terminal mannose content.

- 5 [0609] In addition, one may directly create such fusion protein constructs, as additional information on the localization of active carbohydrate modifying enzymes in different lower eukaryotic hosts becomes available in the scientific literature. For example, it is known that human β 1,4-GalTr can be fused to the membrane domain of *MNT*, a mannosyltransferase from *S.cerevisiae*, and localized
10 to the Golgi apparatus while retaining its catalytic activity (Schwientek et al. (1995) *J. Biol. Chem.* 270(10):5483-9). If *S.cerevisiae* or a related organism is the host to be engineered one may directly incorporate such findings into the overall strategy to obtain complex N-glycans from such a host. Several such gene fragments in *P.pastoris* have been identified that are related to glycosyltransferases
15 in *S.cerevisiae* and thus could be used for that purpose.

Alteration of Host Cell Glycosylation Using Fusion Constructs From Combinatorial Libraries

- [0610] The construction of a preferred combinatorial DNA library is illustrated
20 schematically in Figure 2 and described in Example 4. The fusion construct may be operably linked to a multitude of vectors, such as expression vectors well-known in the art. A wide variety of such fusion constructs were assembled using representative activities as shown in Table 6. Combinations of targeting peptide/catalytic domains may be assembled for use in targeting mannosidase,
25 glycosyltransferase and glycosidase activities in the ER, Golgi and the trans Golgi network according to the invention. Surprisingly, the same catalytic domain may have no effect to a very profound effect on N-glycosylation patterns, depending on the type of targeting peptide used (see, e.g., Table 7, Example 4).

30 *Mannosidase I Fusion Constructs*

- [0611] A representative example of a mannosidase fusion construct derived from a combinatorial DNA library of the invention is pFB8, which has a truncated *Saccharomyces SEC12*(m) targeting peptide (988-1296 nucleotides of *SEC12* from

SwissProt P11655) ligated in-frame to a 187 N-terminal amino acid deletion of a mouse α -mannosidase IA (Genbank AN 6678787). The nomenclature used herein, thus, refers to the targeting peptide/catalytic domain region of a glycosylation enzyme as *Saccharomyces SEC12* (m)/mouse mannosidase IA Δ 187. The encoded fusion protein localizes in the ER by means of the *SEC12* targeting peptide sequence while retaining its mannosidase catalytic domain activity and is capable of producing *in vivo* N-glycans having a Man₅GlcNAc₂ structure (**Example 4; Figures 6F and 7B**).

[0612] The fusion construct pGC5, *Saccharomyces MNS1* (m)/mouse

mannosidase IB Δ 99, is another example of a fusion construct having intracellular mannosidase trimming activity (**Example 4; Figures 5D and 8B**). Fusion construct pBC18-5 (*Saccharomyces VANI* (s)/*C. elegans* mannosidase IB Δ 80) is yet another example of an efficient fusion construct capable of producing *in vivo* N-glycans having a Man₅GlcNAc₂ structure. By creating a combinatorial DNA library of these and other such mannosidase fusion constructs according to the invention, a skilled artisan may distinguish and select those constructs having optimal intracellular trimming activity from those having relatively low or no activity. Methods using combinatorial DNA libraries of the invention are advantageous because only a select few mannosidase fusion constructs may produce a particularly desired N-glycan *in vivo*.

[0613] In addition, mannosidase trimming activity may be specific to a particular protein of interest. Thus, it is to be further understood that not all targeting peptide/mannosidase catalytic domain fusion constructs may function equally well to produce the proper glycosylation on a glycoprotein of interest. Accordingly, a protein of interest may be introduced into a host cell transfected with a combinatorial DNA library to identify one or more fusion constructs which express a mannosidase activity optimal for the protein of interest. One skilled in the art will be able to produce and select optimal fusion construct(s) using the combinatorial DNA library approach described herein.

[0614] It is apparent, moreover, that other such fusion constructs exhibiting localized active mannosidase catalytic domains (or more generally, domains of any enzyme) may be made using techniques such as those exemplified in **Example 4**

and described herein. It will be a matter of routine experimentation for one skilled in the art to make and use the combinatorial DNA library of the present invention to optimize, for example, Man₅GlcNAc₂ production from a library of fusion constructs in a particular expression vector introduced into a particular host cell.

5

Glycosyltransferase Fusion Constructs

[0615] Similarly, a glycosyltransferase combinatorial DNA library was made using the methods of the invention. A combinatorial DNA library of sequences derived from glycosyltransferase I (GnTI) activities were assembled with targeting peptides and screened for efficient production in a lower eukaryotic host cell of a GlcNAcMan₅GlcNAc₂ N-glycan structure on a marker glycoprotein. A fusion construct shown to produce GlcNAcMan₅GlcNAc₂ (pPB104), *Saccharomyces MN9*(s)/human GnTI Δ38 was identified (Example 8). A wide variety of such GnTI fusion constructs were assembled (Example 8, Table 10). Other combinations of targeting peptide/GnTI catalytic domains can readily be assembled by making a combinatorial DNA library. It is also apparent to one skilled in the art that other such fusion constructs exhibiting glycosyltransferase activity may be made as demonstrated in Example 8. It will be a matter of routine experimentation for one skilled in the art to use the combinatorial DNA library method described herein to optimize GlcNAcMan₅GlcNAc₂ production using a selected fusion construct in a particular expression vector and host cell line.

[0616] As stated above for mannosidase fusion constructs, not all targeting peptide/GnTI catalytic domain fusion constructs will function equally well to produce the proper glycosylation on a glycoprotein of interest as described herein. However, one skilled in the art will be able to produce and select optimal fusion construct(s) using a DNA library approach as described herein. Example 8 illustrates a preferred embodiment of a combinatorial DNA library comprising targeting peptides and GnTI catalytic domain fusion constructs involved in producing glycoproteins with predominantly GlcNAcMan₅GlcNAc₂ structure.

30

Using Multiple Fusion Constructs to Alter Host Cell Glycosylation

[0617] In another example of using the methods and libraries of the invention to alter host cell glycosylation, a *P.pastoris* strain with an *OCH1* deletion that expresses a reporter protein (K3) was transformed with multiple fusion constructs isolated from combinatorial libraries of the invention to convert high mannose N-glycans to human-like N-glycans (**Example 8**). First, the mannosidase fusion construct **pFB8** (*Saccharomyces SEC12* (m)/mouse mannosidase IA Δ 187) was transformed into a *P.pastoris* strain lacking 1,6 initiating mannosyltransferases activity (i.e. *och1* deletion; **Example 1**). Second, **pPB103** comprising a *K.lactis* *MNN2-2* gene (Genbank AN AF106080) encoding an UDP-GlcNAc transporter was constructed to increase further production of GlcNAcMan₅GlcNAc₂. The addition of the UDP-GlcNAc transporter increased production of GlcNAcMan₅GlcNAc₂ significantly in the *P.pastoris* strain as illustrated in **Figure 10B**. Third, **pPB104** comprising *Saccharomyces MNN9* (s)/human GnTI Δ 38 was introduced into the strain. This *P.pastoris* strain is referred to as “**PBP-3**.”

[0240] It is understood by one skilled in the art that host cells such as the above-described yeast strains can be sequentially transformed and/or co-transformed with one or more expression vectors. It is also understood that the order of transformation is not particularly relevant in producing the glycoprotein of interest. The skilled artisan recognizes the routine modifications of the procedures disclosed herein may provide improved results in the production of the glycoprotein of interest.

[0618] The importance of using a particular targeting peptide sequence with a particular catalytic domain sequence becomes readily apparent from the experiments described herein. The combinatorial DNA library provides a tool for constructing enzyme fusions that are involved in modifying *N*-glycans on a glycoprotein of interest, which is especially useful in producing human-like glycoproteins. (Any enzyme fusion, however, may be selected using libraries and methods of the invention.) Desired transformants expressing appropriately targeted, active α -1,2-mannosidase produce K3 with *N*-glycans of the structure Man₅GlcNAc₂ as shown in **Figures 5D** and **5E**. This confers a reduced molecular mass to the cleaved glycan compared to the K3 of the parent *OCH1* deletion strain, as was detected by MALDI-TOF mass spectrometry in **Figure 5C**.

[0619] Similarly, the same approach was used to produce another secreted glycoprotein: IFN- β comprising predominantly Man₅GlcNAc₂. The Man₅GlcNAc₂ was removed by PNGase digestion (Papac et al. 1998 *Glycobiology* 8, 445-454) and subjected to MALDI-TOF as shown in **Figures 6A – 6F**. A single prominent peak at 1254 (m/z) confirms Man₅GlcNAc₂ production on IFN- β in **Figures 6E (pGC5)** (*Saccharomyces MNS1*(m)/mouse mannosidase IB Δ 99) and **6F (pFB8)** (*Saccharomyces SEC12* (m)/mouse mannosidase IA Δ 187). Furthermore, in the *P.pastoris* strain PBP-3 comprising **pFB8** (*Saccharomyces SEC12* (m)/mouse mannosidase IA Δ 187), **pPB104** (*Saccharomyces MNN9* (s)/human GnTI Δ 38) and **pPB103** (*K.lactis MNN2-2* gene), the hybrid N-glycan GlcNAcMan₅GlcNAc₂ [b] was detected by MALDI-TOF (**Figure 10**). [0243] After identifying transformants with a high degree of mannose trimming, additional experiments were performed to confirm that mannosidase (trimming) activity occurred *in vivo* and was not predominantly the result of extracellular activity in the growth medium (**Example 6; Figures 7-9**).

Golgi α -Mannosidase II Fusion Constructs

[0620] As provided by the methods of the invention, a combinatorial DNA library of Golgi α -mannosidase II was made by fusing the catalytic domain of several mannosidase II enzymes to an array of cellular targeting peptide signals (**Example 14**). The resulting more than 500 combinatorial fusion constructs were introduced into a *P. pastoris* strain capable of producing the human precursor of complex glycosylation, GlcNAcMan₅GlcNAc₂ YSH-1 (**Example 17**) on the reporter K3. Only a small subset of strains about (<5%) were capable of quantitatively converting GlcNAcMan₅GlcNAc₂ to GlcNAcMan₃GlcNAc₂. These strains were isolated and subsequently transformed with a combinatorial library of several hundred GnTII/leader peptide fusions. Screening for the presence of GlcNAc₂Man₃GlcNAc₂ allowed for the isolation of strains that were able to secrete homogeneous complex glycan, as exemplified by strain YSH-44 (**Example 19**). [0621] A representative example of a Golgi α -mannosidase II fusion construct derived from a combinatorial DNA library of the invention is **pKD53**, which a truncated *S.cerevisiae MNN2*(s) targeting peptide (1-108 nucleotides of *MNN2*

from SwissProt P38069) ligated in-frame to a 74 N-terminal amino acid deletion of a *D.melanogaster* golgi α -mannosidase II (Genbank AN X77652). The nomenclature used herein, thus, refers to the targeting peptide/catalytic domain region of a glycosylation enzyme as *S. cerevisiae* MNN2(s)/*D.melanogaster* mannosidase II Δ 74. The encoded fusion protein localizes in the Golgi by means of the MNN2(s) targeting peptide sequence while retaining its mannosidase catalytic domain activity and is capable of producing *in vivo* N-glycans having a predominant GlcNAcMan₃GlcNAc₂ structure (Example 18).

[0622] Another example of a Golgi α -mannosidase II fusion construct derived from a combinatorial DNA library of the invention is pKD1, which a truncated *Saccharomyces GLS1*(s) targeting peptide (1-102 nucleotides of *GLS1* from SwissProt P53008) ligated in-frame to a 74 N-terminal amino acid deletion of a *D.melanogaster* golgi α -mannosidase II (Genbank AN X77652). The nomenclature used herein, thus, refers to the targeting peptide/catalytic domain region of a glycosylation enzyme as *Saccharomyces GLS1* (s)/*D.melanogaster* mannosidase II Δ 74. The encoded fusion protein localizes in the Golgi by means of the *GLS1*(s) targeting peptide sequence while retaining its mannosidase catalytic domain activity and is capable of producing *in vivo* N-glycans having a predominant GlcNAcMan₃GlcNAc₂ structure (Example 22).

[0623] Another example of a Golgi α -mannosidase II fusion construct derived from a combinatorial DNA library of the invention is pKD5, which a truncated *Saccharomyces MNS1*(m) targeting peptide (1-246 nucleotides of *MNS1* from SwissProt P32906) ligated in-frame to a 74 N-terminal amino acid deletion of a *D.melanogaster* golgi α -mannosidase II (Genbank AN X77652). The nomenclature used herein, thus, refers to the targeting peptide/catalytic domain region of a glycosylation enzyme as *Saccharomyces MNS1*(m)/*D.melanogaster* mannosidase II Δ 74. The encoded fusion protein localizes in the Golgi by means of the *MNS1*(m) targeting peptide sequence while retaining its mannosidase catalytic domain activity and is capable of producing *in vivo* N-glycans having a GlcNAcMan₃GlcNAc₂ structure (Example 23). Unlike the uniformity of N-glycans present in YSH-27, Fig. 21 shows heterogenous mixture of N-glycans produced YSH-74. The apparent mediocre trimming activity of this mannosidase

II enzyme, however, indicates the heterogeneity as Man α 1,2 additions as suggested in Fig. 23, where the GlcNAcMan₃GlcNAc₂ peak appears after digestion of YSH-74 with *A. saitoi* α -1,2-mannosidase. By creating a combinatorial DNA library of these and other such mannosidase fusion constructs according to the invention, a skilled artisan may distinguish and select those constructs having optimal intracellular trimming activity from those having relatively low or no activity. Methods using combinatorial DNA libraries of the invention are advantageous because only a select few mannosidase fusion constructs may produce a particularly desired *N*-glycan *in vivo*.

[0624] In addition, mannosidase trimming activity may be specific to a particular protein of interest. Thus, it is to be further understood that not all targeting peptide/mannosidase catalytic domain fusion constructs may function equally well to produce the proper glycosylation on a glycoprotein of interest. Figure 18 shows no apparent activity in a *P. pastoris* YSH-1 transformed a Golgi α -mannosidase II fusion construct derived from a combinatorial DNA library of the invention pKD16, which a truncated *Saccharomyces MNN9*(m) targeting peptide (1-273 nucleotides of *MNN9* from SwissProt P39107) ligated in-frame to a 74 N-terminal amino acid deletion of a *D.melanogaster* golgi α -mannosidase II (Genbank AN X77652). Accordingly, a protein of interest may be introduced into a host cell transformed with a combinatorial DNA library to identify one or more fusion constructs which express a mannosidase activity optimal for the protein of interest. One skilled in the art will be able to produce and select optimal fusion construct(s) using the combinatorial DNA library approach described herein.

Host Cells

[0625] Although the present invention is exemplified using a *P.pastoris* host organism, it is to be understood by those skilled in the art that other eukaryotic host cells, including other species of yeast and fungal hosts, may be altered as described herein to produce human-like glycoproteins. The techniques described herein for identification and disruption of undesirable host cell glycosylation genes, e.g. *OCH1*, is understood to be applicable for these and/or other homologous or functionally related genes in other eukaryotic host cells such as other yeast and

fungal strains. As described in **Example 9**, *och1 mnn1* genes were deleted from *K.lactis* to engineer a host cell leading to N-glycans that are completely converted to Man₅GlcNAc₂ by 1,2-mannosidase (**Figure 12C**).

[0626] The *MNN1* gene was cloned from *K.lactis* as described in **Example 9**.

5 The nucleic acid and deduced amino acid sequences of the *K.lactis MNN1* gene are shown in SEQ ID NOS: 16 and 17, respectively. Using gene-specific primers, a construct was made to delete the *MNN1* gene from the genome of *K.lactis* (**Example 9**). Host cells depleted in *och1* and *mnn1* activities produce N-glycans having a Man₉GlcNAc₂ carbohydrate structure (see, e.g., **Figure 10**). Such host
10 cells may be engineered further using, e.g., methods and libraries of the invention, to produce mammalian- or human-like glycoproteins.

[0627] Thus, in another embodiment, the invention provides an isolated nucleic acid molecule having a nucleic acid sequence comprising or consisting of at least forty-five, preferably at least 50, more preferably at least 60 and most preferably
15 75 or more nucleotide residues of the *K.lactis MNN1* gene (SEQ ID NO: 16), and homologs, variants and derivatives thereof. The invention also provides nucleic acid molecules that hybridize under stringent conditions to the above-described nucleic acid molecules. Similarly, isolated polypeptides (including muteins, allelic variants, fragments, derivatives, and analogs) encoded by the nucleic acid
20 molecules of the invention are provided. In addition, also provided are vectors, including expression vectors, which comprise a nucleic acid molecule of the invention, as described further herein. Similarly host cells transformed with the nucleic acid molecules or vectors of the invention are provided.

[0628] Another aspect of the present invention thus relates to a non-human
25 eukaryotic host strain expressing glycoproteins comprising modified N-glycans that resemble those made by human-cells. Performing the methods of the invention in species other than yeast and fungal cells is thus contemplated and encompassed by this invention. It is contemplated that a combinatorial nucleic acid library of the present invention may be used to select constructs that modify
30 the glycosylation pathway in any eukaryotic host cell system. For example, the combinatorial libraries of the invention may also be used in plants, algae and insects, and in other eukaryotic host cells, including mammalian and human cells,

to localize proteins, including glycosylation enzymes or catalytic domains thereof, in a desired location along a host cell secretory pathway. Preferably, glycosylation enzymes or catalytic domains and the like are targeted to a subcellular location along the host cell secretory pathway where they are capable of functioning, and preferably, where they are designed or selected to function most efficiently.

[0629] Preferred host cells of the present invention include *Pichia pastoris*, *Pichia finlandica*, *Pichia trehalophila*, *Pichia koclamae*, *Pichia membranaefaciens*, *Pichia opuntiae*, *Pichia thermotolerans*, *Pichia salictaria*, *Pichia guercuum*, *Pichia pijperi*, *Pichia stiptis*, *Pichia methanolica*, *Pichia sp.*, *Saccharomyces cerevisiae*, *Saccharomyces sp.*, *Hansenula polymorpha*, *Khuyveromyces sp.*, *Khuyveromyces lactis*, *Candida albicans*, *Aspergillus nidulans*, *Aspergillus niger*, *Aspergillus oryzae*, *Trichoderma reesei*, *Chrysosporium lucknowense*, *Fusarium sp.*, *Fusarium gramineum*, *Fusarium venenatum* and *Neurospora crassa*.

[0630] Plant and insect cells may also be engineered to alter the glycosylation of expressed proteins using the combinatorial library and methods of the invention. Furthermore, glycosylation in mammalian cells, including human cells, may also be modified using the combinatorial library and methods of the invention. It may be possible, for example, to optimize a particular enzymatic activity or to otherwise modify the relative proportions of various N-glycans made in a mammalian host cell using the combinatorial library and methods of the invention.

[0631] Examples of modifications to glycosylation which can be affected using a method according to this embodiment of the invention are: (1) engineering a eukaryotic host cell to trim mannose residues from $\text{Man}_8\text{GlcNAc}_2$ to yield a $\text{Man}_5\text{GlcNAc}_2$ N-glycan; (2) engineering eukaryotic host cell to add an N-acetylglucosamine (GlcNAc) residue to $\text{Man}_5\text{GlcNAc}_2$ by action of GlcNAc transferase I; (3) engineering a eukaryotic host cell to functionally express an enzyme such as an N-acetylglucosaminyl Transferase (GnTI, GnTII, GnTIII, GnTIV, GnTV, GnTVI), mannosidase II, fucosyltransferase (FT), galactosyl transferase (GalT) or a sialyltransferase (ST).

[0632] By repeating the method, increasingly complex glycosylation pathways can be engineered into a target host, such as a lower eukaryotic microorganism. In

one preferred embodiment, the host organism is transformed two or more times with DNA libraries including sequences encoding glycosylation activities.

Selection of desired phenotypes may be performed after each round of transformation or alternatively after several transformations have occurred.

- 5 Complex glycosylation pathways can be rapidly engineered in this manner.

Sequential Glycosylation Reactions

- [0633] In a preferred embodiment, such targeting peptide/catalytic domain libraries are designed to incorporate existing information on the sequential nature
10 of glycosylation reactions in higher eukaryotes. Reactions known to occur early in the course of glycoprotein processing require the targeting of enzymes that catalyze such reactions to an early part of the Golgi or the ER. For example, the trimming of $\text{Man}_8\text{GlcNAc}_2$ to $\text{Man}_5\text{GlcNAc}_2$ by mannosidases is an early step in complex N-glycan formation. Because protein processing is initiated in the ER
15 and then proceeds through the early, medial and late Golgi, it is desirable to have this reaction occur in the ER or early Golgi. When designing a library for mannosidase I localization, for example, one thus attempts to match ER and early Golgi targeting signals with the catalytic domain of mannosidase I.

20 *Integration Sites*

- [0634] As one ultimate goal of this genetic engineering effort is a robust protein production strain that is able to perform well in an industrial fermentation process, the integration of multiple genes into the host (e.g., fungal) chromosome preferably involves careful planning. The engineered strain may likely have to be
25 transformed with a range of different genes, and these genes will have to be transformed in a stable fashion to ensure that the desired activity is maintained throughout the fermentation process. As described herein, any combination of various desired enzyme activities may be engineered into the fungal protein expression host, e.g., sialyltransferases, mannosidases, fucosyltransferases,
30 galactosyltransferases, glucosyltransferases, GlcNAc transferases, ER and Golgi specific transporters (e.g. sym and antiport transporters for UDP-galactose and other precursors), other enzymes involved in the processing of oligosaccharides,

and enzymes involved in the synthesis of activated oligosaccharide precursors such as UDP-galactose, CMP-N-acetylneuraminic acid. Examples of preferred methods for modifying glycosylation in a lower eukaryotic host cell, such as *Pichia pastoris*, are shown in Table 6.

5

Table 6. Some preferred embodiments for modifying glycosylation in a lower eukaryotic microorganism

<i>Desired Structure</i>	<i>Suitable Catalytic Activities</i>	<i>Suitable Sources of Localization Sequences</i>	<i>Suitable Gene Deletions</i>	<i>Suitable Transporters and/or Phosphatases</i>
Man ₅ GlcNAc ₂	α-1,2-mannosidase (murine, human, <i>Bacillus</i> sp., <i>A.nidulans</i>)	Mns1 (N-terminus, <i>S.cerevisiae</i>) Och1 (N-terminus, <i>S.cerevisiae</i> , <i>P.pastoris</i>) Ktr1 Mnn9 Mnt1 (<i>S.cerevisiae</i>) KDEL, HDEL (C-terminus)	<i>OCH1</i> <i>MNN4</i> <i>MNN6</i>	none
GlcNAcMan ₅ GlcNAc ₂	GlcNAc Transferase I, (human, murine, rat etc.)	Och1 (N-terminus, <i>S.cerevisiae</i> , <i>P.pastoris</i>) KTR1 (N-terminus) Mnn1 (N-terminus, <i>S.cerevisiae</i>) Mnt1 (N-terminus, <i>S.cerevisiae</i>) GDPase (N-terminus, <i>S.cerevisiae</i>)	<i>OCH1</i> <i>MNN4</i> <i>MNN6</i>	UDP-GlcNAc transporter (human, murine, <i>K.lactis</i>) UDPase (human)
GlcNAcMan ₃ GlcNAc ₂	mannosidase II	Ktr1 Mnn1 (N-terminus, <i>S.cerevisiae</i>) Mnt1 (N-terminus, <i>S.cerevisiae</i>) Kre2/Mnt1 (<i>S.cerevisiae</i>) Kre2 (<i>P.pastoris</i>) Ktr1 (<i>S.cerevisiae</i>) Ktr1 (<i>P.pastoris</i>) Mnn1 (<i>S.cerevisiae</i>)	<i>OCH1</i> <i>MNN4</i> <i>MNN6</i>	UDP-GlcNAc transporter (human, murine, <i>K.lactis</i>) UDPase (human)
GlcNAc ₍₂₋₄₎ Man ₃ GlcNAc ₂	GlcNAc Transferase II, III, IV, V (human, murine)	Mnn1 (N-terminus, <i>S.cerevisiae</i>) Mnt1 (N-terminus, <i>S.cerevisiae</i>) Kre2/Mnt1 (<i>S.cerevisiae</i>) Kre2 (<i>P.pastoris</i>) Ktr1 (<i>S.cerevisiae</i>) Ktr1 (<i>P.pastoris</i>) Mnn1 (<i>S.cerevisiae</i>)	<i>OCH1</i> <i>MNN4</i> <i>MNN6</i>	UDP-GlcNAc transporter (human, murine, <i>K.lactis</i>) UDPase (human)

Desired Structure	Suitable Catalytic Activities	Suitable Sources of Localization Sequences	Suitable Gene Deletions	Suitable Transporters and/or Phosphatases
Gal ₍₁₋₄₎ GlcNAc ₍₂₋₄₎ - Man ₃ GlcNAc ₂	β -1,4-Galactosyl transferase (human)	Mnn1 (N-terminus, <i>S.cerevisiae</i>) Mnt1 (N-terminus, <i>S.cerevisiae</i>) Kre2/Mnt1 (<i>S.cerevisiae</i>) Kre2 (<i>P.pastoris</i>) Ktr1 (<i>S.cerevisiae</i>) Ktr1 (<i>P.pastoris</i>) Mnn1 (<i>S.cerevisiae</i>)	<i>OCH1</i> <i>MNN4</i> <i>MNN6</i>	UDP-Galactose transporter (human, <i>S.pombe</i>)
NANA ₍₁₋₄₎ - Gal ₍₁₋₄₎ GlcNAc ₍₂₋₄₎ - Man ₃ GlcNAc ₂	α -2,6-Sialyltransferase (human) α -2,3-Sialyltransferase	KTR1 MNN1 (N-terminus, <i>S.cerevisiae</i>) MNT1 (N-terminus, <i>S.cerevisiae</i>) Kre2/Mnt1 (<i>S.cerevisiae</i>) Kre2 (<i>P.pastoris</i>) Ktr1 (<i>S.cerevisiae</i>) Ktr1 (<i>P.pastoris</i>) MNN1 (<i>S.cerevisiae</i>)	<i>OCH1</i> <i>MNN4</i> <i>MNN6</i>	CMP-Sialic acid transporter (human)

[0635] As any strategy to engineer the formation of complex N-glycans into a host cell such as a lower eukaryote involves both the elimination as well as the addition of particular glycosyltransferase activities, a comprehensive scheme will attempt to coordinate both requirements. Genes that encode enzymes that are undesirable serve as potential integration sites for genes that are desirable. For example, 1,6 mannosyltransferase activity is a hallmark of glycosylation in many known lower eukaryotes. The gene encoding alpha-1,6 mannosyltransferase (*OCH1*) has been cloned from *S.cerevisiae* and mutations in the gene give rise to a viable phenotype with reduced mannosylation. The gene locus encoding alpha-1,6 mannosyltransferase activity therefore is a prime target for the integration of genes encoding glycosyltransferase activity. In a similar manner, one can choose a range of other chromosomal integration sites that, based on a gene disruption event in that locus, are expected to: (1) improve the cell's ability to glycosylate in a more human-like fashion, (2) improve the cell's ability to secrete proteins, (3) reduce proteolysis of foreign proteins and (4) improve other characteristics of the process that facilitate purification or the fermentation process itself.

Target Glycoproteins

- [0636] The methods described herein are useful for producing glycoproteins, especially glycoproteins used therapeutically in humans. Glycoproteins having specific glycoforms may be especially useful, for example, in the targeting of therapeutic proteins. For example, mannose-6-phosphate has been shown to direct proteins to the lysosome, which may be essential for the proper function of several enzymes related to lysosomal storage disorders such as Gaucher's, Hunter's, Hurler's, Scheie's, Fabry's and Tay-Sachs disease, to mention just a few. Likewise, the addition of one or more sialic acid residues to a glycan side chain may increase the lifetime of a therapeutic glycoprotein *in vivo* after administration. Accordingly, host cells (e.g., lower eukaryotic or mammalian) may be genetically engineered to increase the extent of terminal sialic acid in glycoproteins expressed in the cells. Alternatively, sialic acid may be conjugated to the protein of interest *in vitro* prior to administration using a sialic acid transferase and an appropriate substrate. Changes in growth medium composition may be employed in addition to the expression of enzyme activities involved in human-like glycosylation to produce glycoproteins more closely resembling human forms (Weikert et al. (1999) *Nature Biotechnology* 17, 1116-1121; Werner et al. (1998) *Arzneimittelforschung* 48(8):870-880; Andersen and Goochee (1994) *Cur. Opin. Biotechnol.* 5:546-549; Yang and Butler (2000) *Biotechnol. Bioengin.* 68(4):370-380). Specific glycan modifications to monoclonal antibodies (e.g. the addition of a bisecting GlcNAc) have been shown to improve antibody dependent cell cytotoxicity (Umana et al. (1999) *Nat. Biotechnol.* 17(2):176-80), which may be desirable for the production of antibodies or other therapeutic proteins.
- [0637] Therapeutic proteins are typically administered by injection, orally, or by pulmonary or other means. Examples of suitable target glycoproteins which may be produced according to the invention include, without limitation: erythropoietin, cytokines such as interferon- α , interferon- β , interferon- γ , interferon- ω , and granulocyte-CSF, coagulation factors such as factor VIII, factor IX, and human protein C, soluble IgE receptor α -chain, IgG, IgG fragments, IgM, interleukins, urokinase, chymase, and urea trypsin inhibitor, IGF-binding protein, epidermal growth factor, growth hormone-releasing factor, annexin V fusion protein,

angiostatin, vascular endothelial growth factor-2, myeloid progenitor inhibitory factor-1, osteoprotegerin, α -1 antitrypsin, DNase II, α -feto proteins, AAT, rhTBP-1 (oncept, aka TNF Binding protein 1), TACI-Ig (transmembrane activator and calcium modulator and cyclophilin ligand interactor), FSH (follicle stimulating hormone), GM-CSF, GLP-1 w/ and w/o FC (glucagon like protein 1) IL-1 receptor agonist, sTNFr (enbrel, aka soluble TNF receptor Fc fusion) ATIII, rhThrombin, glucocerebrosidase and CTLA4-Ig (Cytotoxic T Lymphocyte associated Antigen 4 - Ig)

10 **Subsequent Glycosyltransferase Activities: N-acetylglucosaminyltransferase II, Galactosyltransferase and Sialyltransferase**

[0638] In a further aspect of the invention, the newly formed glycans produced by the Golgi α -mannosidase II enzyme are substrates for subsequent glycosylation reactions. In one embodiment, GnT II, UDP-GlcNAc and optionally the UDP-GlcNAc transporter cap the newly formed Man α 1,6 branch of the oligosaccharide produced in *P. pastoris* YSH-37 with a GlcNAc to form GlcNAc₂Man₃GlcNAc₂ (Example 19) In another embodiment, other GnTs (e.g. GnT III, GnT IV, GnT V) react upon the transient GlcNAc₂Man₃GlcNAc₂ substrate. This substrate in turn becomes a substrate for galactosyltransferases (Example 25) and further processing occurs with sialyltransferases.

[0639] The following are examples which illustrate the compositions and methods of this invention. These examples should not be construed as limiting: the examples are included for the purposes of illustration only.

25

EXAMPLE 1

Cloning and Disruption of the *OCH1* gene in *P.pastoris*

[0640] A 1215 bp ORF of the *P.pastoris* *OCH1* gene encoding a putative α -1,6 mannosyltransferase was amplified from *P.pastoris* genomic DNA (strain X-33, Invitrogen, Carlsbad, CA) using the oligonucleotides 5'-ATGGCGAAGGCAGATGGCAGT-3' (SEQ ID NO: 18) and 5'-TTAGTCCTTCCAACCTTCCTTC-3' (SEQ ID NO: 19) which were designed

based on the *P.pastoris* *OCH1* sequence (Japanese Patent Application Publication No. 8-336387). Subsequently, 2685 bp upstream and 1175 bp downstream of the ORF of the *OCH1* gene were amplified from a *P.pastoris* genomic DNA library (Boehm, T. et al. Yeast 1999 May;15(7):563-72) using the internal
5 oligonucleotides 5'-ACTGCCATCTGCCTTCGCCAT-3' (SEQ ID NO: 20) in the *OCH1* gene, and 5'-GTAATACGACTCACTATAGGGC-3' T7 (SEQ ID NO: 21) and 5'-AATTAACCCTCACTAAAGGG-3' T3 (SEQ ID NO: 22) oligonucleotides in the backbone of the library bearing plasmid lambda ZAP II (Stratagene, La Jolla, CA). The resulting 5075 bp fragment was cloned into the pCR2.1-TOPO
10 vector (Invitrogen, Carlsbad, CA) and designated pBK9.

[0641] After assembling a gene knockout construct that substituted the *OCH1* reading frame with a *HIS4* resistance gene, *P.pastoris* was transformed and colonies were screened for temperature sensitivity at 37°C. *OCH1* mutants of *S.cerevisiae* are temperature sensitive and are slow growers at elevated
15 temperatures. One can thus identify functional homologs of *OCH1* in *P.pastoris* by complementing an *OCH1* mutant of *S.cerevisiae* with a *P.pastoris* DNA or cDNA library. About 20 temperature sensitive strains were further subjected to a colony PCR screen to identify colonies with a deleted *och1* gene. Several *och1* deletions were obtained.

20 [0642] The linearized pBK9.1, which has 2.1 kb upstream sequence and 1.5 kb down stream sequence of *OCH1* gene cassette carrying *Pichia* *HIS4* gene, was transformed into *P.pastoris* BK1 [GS115 (*his4* Invitrogen Corp., San Diego, CA) carrying the human IFN- β gene in the *AOX1* locus] to knock out the wild-type *OCH1* gene. The initial screening of transformants was performed using histidine
25 drop-out medium followed by replica plating to select the temperature sensitive colonies. Twenty out of two hundred histidine-positive colonies showed a temperature sensitive phenotype at 37°C. To exclude random integration of pBK9.1 into the *Pichia* genome, the 20 temperature-sensitive isolates were subjected to colony PCR using primers specific to the upstream sequence of the
30 integration site and to *HIS4* ORF. Two out of twenty colonies were *och1* defective and further analyzed using a Southern blot and a Western blot indicating the functional *och1* disruption by the *och1* knock-out construct. Genomic DNA were

digested using two separate restriction enzymes *BglII* and *ClaI* to confirm the *och1* knock-out and to confirm integration at the open reading frame. The Western Blot showed *och1* mutants lacking a discrete band produced in the GS115 wild type at 46.2 kDa.

5

EXAMPLE 2

Engineering of *P.pastoris* with α -1,2-Mannosidase to Produce Man₅GlcNAc₂-Containing IFN- β Precursors

- 10 [0643] An α -1,2-mannosidase is required for the trimming of Man₈GlcNAc₂ to yield Man₅GlcNAc₂, an essential intermediate for complex *N*-glycan formation. While the production of a Man₅GlcNAc₂ precursor is essential, it is not necessarily sufficient for the production of hybrid and complex glycans because the specific isomer of Man₅GlcNAc₂ may or may not be a substrate for GnTI. An *och1* mutant
- 15 of *P.pastoris* is engineered to express secreted human interferon- β under the control of an *aox* promoter. A DNA library is constructed by the in-frame ligation of the catalytic domain of human mannosidase IB (an α -1,2-mannosidase) with a sub-library including sequences encoding early Golgi and ER localization peptides. The DNA library is then transformed into the host organism, resulting in a
- 20 genetically mixed population wherein individual transformants each express interferon- β as well as a synthetic mannosidase gene from the library. Individual transformant colonies are cultured and the production of interferon is induced by addition of methanol. Under these conditions, over 90% of the secreted protein is glycosylated interferon- β .
- 25 [0644] Supernatants are purified to remove salts and low-molecular weight contaminants by C₁₈ silica reversed-phase chromatography. Desired transformants expressing appropriately targeted, active α -1,2-mannosidase produce interferon- β including *N*-glycans of the structure Man₅GlcNAc₂, which has a reduced molecular mass compared to the interferon- β of the parent strain. The purified interferon- β is
- 30 analyzed by MALDI-TOF mass spectroscopy and colonies expressing the desired form of interferon- β are identified.

EXAMPLE 3

Generation of an *och1* Mutant Strain Expressing an α -1,2-Mannosidase, GnTI for Production of a Human-Like Glycoprotein.

[0645] The 1215 bp open reading frame of the *P.pastoris* *OCH1* gene as well as 2685 bp upstream and 1175 bp downstream was amplified by PCR (see also WO 02/00879), cloned into the pCR2.1-TOPO vector (Invitrogen) and designated pBK9. To create an *och1* knockout strain containing multiple auxotrophic markers, 100 μ g of pJN329, a plasmid containing an *och1::URA3* mutant allele flanked with *SfiI* restriction sites was digested with *SfiI* and used to transform *P.pastoris* strain JC308 (Cereghino et al. *Gene* 263 (2001) 159-169) by electroporation. Following incubation on defined medium lacking uracil for 10 days at room temperature, 1000 colonies were picked and re-streaked. URA^+ clones that were unable to grow at 37°C, but grew at room temperature, were subjected to colony PCR to test for the correct integration of the *och1::URA3* mutant allele. One clone that exhibited the expected PCR pattern was designated YJN153. The Kringle 3 domain of human plasminogen (K3) was used as a model protein. A Neo^R marked plasmid containing the K3 gene was transformed into strain YJN153 and a resulting strain, expressing K3, was named BK64-1.

[0646] Plasmid pPB103, containing the *Kluyveromyces lactis* *MNN2-2* gene which encodes a Golgi UDP-N-acetylglucosamine transporter was constructed by cloning a blunt *BglII-HindIII* fragment from vector pDL02 (Abeijon et al. (1996) *Proc. Natl. Acad. Sci. U.S.A.* 93:5963-5968) into *BglII* and *BamHI* digested and blunt ended pBLADE-SX containing the *P.pastoris* *ADE1* gene (Cereghino et al. (2001) *Gene* 263:159-169). This plasmid was linearized with *EcoNI* and transformed into strain BK64-1 by electroporation and one strain confirmed to contain the *MNN2-2* by PCR analysis was named PBP1.

[0647] A library of mannosidase constructs was generated, comprising in-frame fusions of the leader domains of several type I or type II membrane proteins from *S.cerevisiae* and *P.pastoris* fused with the catalytic domains of several α -1,2-mannosidase genes from human, mouse, fly, worm and yeast sources (see, e.g., WO02/00879, incorporated herein by reference). This library was created in a *P.pastoris* *HIS4* integration vector and screened by linearizing with *SaII*, transforming by electroporation into strain PBP1, and analyzing the glycans released from the K3 reporter protein. One active construct chosen was a chimera

of the 988-1296 nucleotides (C-terminus) of the yeast *SEC12* gene fused with a N-terminal deletion of the mouse α -1,2-mannosidase IA gene (Figure 3), which was missing the 187 nucleotides. A *P.pastoris* strain expressing this construct was named PBP2.

- 5 [0648] A library of GnTI constructs was generated, comprising in-frame fusions of the same leader library with the catalytic domains of GnTI genes from human, worm, frog and fly sources (WO 02/00879). This library was created in a *P.pastoris* ARG4 integration vector and screened by linearizing with *AatII*, transforming by electroporation into strain PBP2, and analyzing the glycans released from K3. One active construct chosen was a chimera of the first 120 bp of
10 the *S.cerevisiae* MNN9 gene fused to a deletion of the human GnTI gene, which was missing the first 154 bp. A *P.pastoris* strain expressing this construct was named PBP3.

15

EXAMPLE 4

Engineering of *P.pastoris* to Produce Man₅GlcNAc₂ as the Predominant N-Glycan Structure Using a Combinatorial DNA Library

- [0649] An *och1* mutant of *P.pastoris* (see Examples 1 and 3) was engineered to express and secrete proteins such as the kringle 3 domain of human plasminogen
20 (K3) under the control of the inducible *AOXI* promoter. The Kringle 3 domain of human plasminogen (K3) was used as a model protein. A DNA fragment encoding the K3 was amplified using Pfu turbo polymerase (Stratagene, La Jolla, CA) and cloned into *EcoRI* and *XbaI* sites of pPICZ α A (Invitrogen, Carlsbad, CA), resulting in a C-terminal 6- His tag. In order to improve the N-linked glycosylation
25 efficiency of K3 (Hayes et al. 1975 *J. Arch. Biochem. Biophys.* 171, 651-655), Pro₄₆ was replaced with Ser₄₆ using site-directed mutagenesis. The resulting plasmid was designated pBK64. The correct sequence of the PCR construct was confirmed by DNA sequencing.
- [0650] A combinatorial DNA library was constructed by the in-frame ligation of
30 murine α -1,2-mannosidase IB (Genbank AN 6678787) and IA (Genbank AN 6754619) catalytic domains with a sub-library including sequences encoding Cop II vesicle, ER, and early Golgi localization peptides according to Table 6. The combined DNA library was used to generate individual fusion constructs, which

were then transformed into the K3 expressing host organism, resulting in a genetically mixed population wherein individual transformants each express K3 as well as a localization signal/mannosidase fusion gene from the library. Individual transformants were cultured and the production of K3 was induced by transfer to a methanol containing medium. Under these conditions, after 24 hours of induction, over 90% of the protein in the medium was K3. The K3 reporter protein was purified from the supernatant to remove salts and low-molecular weight contaminants by Ni-affinity chromatography. Following affinity purification, the protein was desalted by size exclusion chromatography on a Sephadex G10 resin (Sigma, St. Louis, MO) and either directly subjected to MALDI-TOF analysis described below or the *N*-glycans were removed by PNGase digestion as described below (Release of *N*-glycans) and subjected to MALDI-TOF analysis Miele et al. 1997 *Biotechnol. Appl. Biochem.* 25, 151-157.

[0651] Following this approach, a diverse set of transformants were obtained; some showed no modification of the *N*-glycans compared to the *och1* knockout strain; and others showed a high degree of mannose trimming (Figures 5D and 5E). Desired transformants expressing appropriately targeted, active α -1,2-mannosidase produced K3 with *N*-glycans of the structure $\text{Man}_5\text{GlcNAc}_2$. This confers a reduced molecular mass to the glycoprotein compared to the K3 of the parent *och1* deletion strain, a difference which was readily detected by MALDI-TOF mass spectrometry (Figure 5). Table 7 indicates the relative $\text{Man}_5\text{GlcNAc}_2$ production levels.

Table 7. A representative combinatorial DNA library of localization sequences/catalytic domains exhibiting relative levels of $\text{Man}_5\text{GlcNAc}_2$ production.

		Targeting peptide sequences				
		<i>MNS1</i> (s)	<i>MNS1</i> (m)	<i>MNS1</i> (l)	<i>SEC12</i> (s)	<i>SEC12</i> (m)
Catalytic Domains	Mouse mannosidase 1A Δ 187	FB4 ++	FB5 +	FB6 -	FB7 ++	FB8 ++++
	Mouse mannosidase 1B Δ 58	GB4 ++	GB5 +	GB6 +	GB7 ++	GB8 +
	Mouse mannosidase 1B Δ 99	GC4 -	GC5 +++	GC6 +	GC7 +	GC8 +
	Mouse mannosidase 1B Δ 170	GD4 -	GD5 -	GD6 -	GD7 +	GD8 +

Table 8. Another combinatorial DNA library of localization sequences/catalytic domains exhibiting relative levels of Man₅GlcNAc₂ production.

		Targeting peptide sequences					
		VANI(s)	VANI(m)	VANI(l)	MNN10(s)	MNN10(m)	MNN10(l)
Catalytic Domains	<i>C. elegans</i> mannosidase 1B Δ80	BC18-5 +++++	BC19 ++++	BC20 +++	BC27 +++++	BC28 +++++	BC29 +++
	<i>C. elegans</i> mannosidase 1B Δ31	BB18 +++++	BB19 +++++	BB20 ++++	BB18 +++++	BB19 +++++	BB20 ++++

5

[0652] Targeting peptides were selected from MNS I (SwissProt P32906) in *S.cerevisiae* (long, medium and short) (see *supra*, Nucleic Acid Libraries; Combinatorial DNA Library of Fusion Constructs) and SEC12 (SwissProt P11655) in *S.cerevisiae* (988-1140 nucleotides: short) and (988-1296: medium). Although the majority of targeting peptide sequences were N-terminal deletions, some targeting peptide sequences, such as SEC12, were C-terminal deletions. Catalytic domains used in this experiment were selected from mouse mannosidase 1A with a 187 amino acid N-terminal deletion; and mouse mannosidase 1B with a 58, 99 and 170 amino acid deletion. The number of (+)s, as used herein, indicates the relative levels of Man₅GlcNAc₂ production. The notation (-) indicates no apparent production of Man₅GlcNAc₂. The notation (+) indicates less than 10% production of Man₅GlcNAc₂. The notation (++) indicates about 10-20% production of Man₅GlcNAc₂. The notation with (+++) indicates about 20-40% production of Man₅GlcNAc₂. The notation with (+++++) indicates about 50% production of Man₅GlcNAc₂. The notation with (+++++) indicates greater than 50% production of Man₅GlcNAc₂.

[0653] Table 9 shows the relative amounts of Man₅GlcNAc₂ detected on a secreted K3 reporter glycoprotein. Six hundred and eight (608) different strains of *P.pastoris* (Δoch1) were generated by transforming each with a single construct from a combinatorial genetic library that was generated by fusing nineteen (19) α-1,2 mannosidase catalytic domains to thirty-two (32) fungal ER, and cis-Golgi leaders.

25

Table 9

Amount of Man ₅ GlcNAc ₂ on secreted K3 protein (% of total glycans)	Number of constructs (%)
N.D.*	19 (3.1)
0-10%	341 (56.1)
10-20%	50 (8.2)
20-40%	75 (12.3)
40-60%	72 (11.8)
More than 60%	51 (8.4) [†]
Total	608 (100)

* Several fusion constructs were not tested because the corresponding plasmids could not be propagated in *E.coli* prior to transformation into *P.pastoris*.

[†] Clones with the highest degree of Man₅GlcNAc₂ trimming (30/51) were further analyzed for mannosidase activity in the supernatant of the medium. The majority (28/30) displayed detectable mannosidase activity in the supernatant (e.g. Figure 4B). Only two constructs displayed high Man₅GlcNAc₂ levels, while lacking mannosidase activity in the medium (e.g. Figure 4C).

[0654] Table 7 shows two constructs pFB8 and pGC5, among others, which enable a transformed host cell to make K3 glycoprotein displaying Man₅GlcNAc₂. Table 8 shows a more preferred construct, pBC18-5, a *S.cerevisiae* VAN1(s) targeting peptide sequence (from SwissProt 23642) ligated in-frame to a *C. elegans* mannosidase IB (Genbank AN CAA98114) with an 80 amino acid N-terminal deletion (*Saccharomyces* Van1(s)/ *C.elegans* mannosidase IB Δ80). This fusion construct also produces a predominant Man₅GlcNAc₂ structure, as shown in Figure 5E. This mannosidase fusion construct was shown to produce greater than 50% Man₅GlcNAc₂ (++++).

Generation of a combinatorial localization/mannosidase library:

[0655] Generating a combinatorial DNA library of α-1,2-mannosidase catalytic domains fused to targeting peptides required the amplification of mannosidase domains with varying lengths of N-terminal deletions from a number of organisms. To approach this goal, the full length open reading frames (ORFs) of α-1,2-mannosidases were PCR amplified from either cDNA or genomic DNA obtained from the following sources: *Homo sapiens*, *Mus musculus*, *Drosophila melanogaster*, *Caenorhabditis elegans*, *Aspergillus nidulans* and *Penicillium*

citrinum. In each case, DNA was incubated in the presence of oligonucleotide primers specific for the desired mannosidase sequence in addition to reagents required to perform the PCR reaction. For example, to amplify the ORF of the *M. musculus* α -1,2-mannosidase IA, the 5'-primer

- 5 ATGCCCGTGGGGGGCCTGTTGCCGCTCTTCAGTAGC (SEQ ID NO: 23) and the 3'-primer TCATTTCTCTTTGCCATCAATTTCCTTCTTCTGTTACGG (SEQ ID NO: 24) were incubated in the presence of Pfu DNA polymerase (Stratagene, La Jolla, CA) and amplified under the conditions recommended by Stratagene using the cycling parameters: 94°C for 1min (1 cycle); 94°C for 30 sec, 68°C for 30 sec, 72°C for 3min (30 cycles). Following amplification the DNA sequence encoding the ORF was incubated at 72 °C for 5 min with 1U Taq DNA polymerase (Promega, Madison, WI) prior to ligation into pCR2.1-TOPO (Invitrogen, Carlsbad, CA) and transformed into TOP10 chemically competent *E. coli*, as recommended by Invitrogen. The cloned PCR product was confirmed by
- 10 ABI sequencing using primers specific for the mannosidase ORF.

[0656] To generate the desired N-terminal truncations of each mannosidase, the complete ORF of each mannosidase was used as the template in a subsequent round of PCR reactions wherein the annealing position of the 5'-primer was specific to the 5'-terminus of the desired truncation and the 3'-primer remained specific for the original 3'-terminus of the ORF. To facilitate subcloning of the truncated mannosidase fragment into the yeast expression vector, pJN347 (Figure 2C) *AscI* and *PacI* restriction sites were engineered onto each truncation product, at the 5'- and 3'-termini respectively. The number and position of the N-terminal truncations generated for each mannosidase ORF depended on the position of the transmembrane (TM) region in relation to the catalytic domain (CD). For instance,

20 if the stem region located between the TM and CD was less than 150bp, then only one truncation for that protein was generated. If, however, the stem region was longer than 150bp then either one or two more truncations were generated depending on the length of the stem region.

25 [0657] An example of how truncations for the *M. musculus* mannosidase IA (Genbank AN 6678787) were generated is described herein, with a similar approach being used for the other mannosidases. Figure 3 illustrates the ORF of

the *M. musculus* α -1,2-mannosidase 1A with the predicted transmembrane and catalytic domains being highlighted in bold. Based on this structure, three 5'-primers were designed (annealing positions underlined in **Figure 3**) to generate the Δ 65-, Δ 105- and Δ 187-N-terminal deletions. Using the Δ 65 N-terminal deletion as an example the 5'-primer used was 5'-

5 **GGCGCGCCGACTCCTCCAAGCTGCTCAGCGGGGTCCTGTTCCAC**-3' (SEQ ID NO: 25) (with the *AscI* restriction site highlighted in bold) in conjunction with the 3'-primer 5'-

10 **CCTTAATTAATCATTCTCTTTGCCATCAATTCCTTCTTCTGTTACGG**-3' (SEQ ID NO: 26) (with the *PacI* restriction site highlighted in bold). Both of these primers were used to amplify a 1561 bp fragment under the conditions outlined above for amplifying the full length *M. musculus* mannosidase 1A ORF. Furthermore, like the product obtained for the full length ORF, the truncated product was also incubated with Taq DNA polymerase, ligated into pCR2.1-TOPO (Invitrogen, Carlsbad, CA), transformed into TOP10 and ABI sequenced. After

15 having amplified and confirmed the sequence of the truncated mannosidase fragment, the resulting plasmid, pCR2.1- Δ 65mMannIA, was digested with *AscI* and *PacI* in New England Biolabs buffer #4 (Beverly, MA) for 16h at 37°C. In parallel, the pJN347 (**Figure 2C**) was digested with the same enzymes and

20 incubated as described above. Post-digestion, both the pJN347 (**Figure 2C**) backbone and the truncated catalytic domain were gel extracted and ligated using the Quick Ligation Kit (New England Biolabs, Beverly, MA), as recommended by the manufacturers, and transformed into chemically competent DH5 α cells (Invitrogen, Carlsbad, CA). Colony PCR was used to confirm the generation of the pJN347-

25 mouse Mannosidase IA Δ 65 construct.

[0658] Having generated a library of truncated α -1,2-mannosidase catalytic domains in the yeast expression vector pJN347 (**Figure 2C**) the remaining step in generating the targeting peptide/catalytic domain library was to clone in-frame the targeting peptide sequences (**Figure 2**). Both the pJN347-mannosidase constructs

30 (**Figure 2D**) and the pCR2.1TOPO-targeting peptide constructs (**Figure 2B**) such as were incubated overnight at 37°C in New England Biolabs buffer #4 in the presence of the restriction enzymes *NotI* and *AscI*. Following digestion, both the

pJN347-mannosidase back-bone and the targeting peptide regions were gel-extracted and ligated using the Quick Ligation Kit (New England Biolabs, Beverly, MA), as recommended by the manufacturers, and transformed into chemically competent DH5 α cells (Invitrogen, Carlsbad, CA). Subsequently, the pJN347-
5 targeting peptide/mannosidase constructs were ABI sequenced to confirm that the generated fusions were in-frame. The estimated size of the final targeting peptide/alpha-1,2-mannosidase library contains over 1300 constructs generated by the approach described above. Figure 2 illustrates construction of the combinatorial DNA library.

10

Engineering a *P.pastoris* *OCH1* knock-out strain with multiple auxotrophic markers.

[0659] The first step in plasmid construction involved creating a set of universal plasmids containing DNA regions of the *KEX1* gene of *P.pastoris* (Boehm *et al.*
15 Yeast 1999 May;15(7):563-72) as space holders for the 5' and 3' regions of the genes to be knocked out. The plasmids also contained the *S.cerevisiae* Ura-blaster (Alani *et al.*, *Genetics* 116, 541-545. 1987) as a space holder for the auxotrophic markers, and an expression cassette with a multiple cloning site for insertion of a foreign gene. A 0.9-kb fragment of the *P.pastoris* *KEX1*-5' region was amplified
20 by PCR using primers
GGCGAGCTCGGCCTACCCGGCCAAGGCTGAGATCATTTGTCCAGCTTCA
GA (SEQ ID NO: 27) and
GCCACGTCGACGGATCCGTTTAAACATCGATTGGAGAGGCTGACACC
GCTACTA (SEQ ID NO: 28) and *P.pastoris* genomic DNA as a template and
25 cloned into the *SacI*, *Sall* sites of pUC19 (New England Biolabs, Beverly, MA). The resulting plasmid was cut with *BamHI* and *Sall*, and a 0.8-kb fragment of the *KEX1*-3' region that had been amplified using primers
CGGGATCCACTAGTATTTAAATCATATGTGCGAGTGTACAACTCTTCCC
ACATGG (SEQ ID NO: 29) and
30 GGACGCGTCGACGGCCTACCCGGCCGTACGAGGAATTTCTCGG
ATGACTCTTTTC (SEQ ID NO: 30) was cloned into the open sites creating pJN262. This plasmid was cut with *BamHI* and the 3.8-kb *BamHI*, *BglII* fragment of pNKY51 (Alani *et al.*, *Genetics* 116, 541-545. 1987) was inserted in both

possible orientations resulting in plasmids pJN263 (Figure 4A) and pJN284 (Figure 4B).

[0660] An expression cassette was created with *NotI* and *PacI* as cloning sites. The GAPDH promoter of *P.pastoris* was amplified using primers

5 CGGGATCCCTCGAGAGATCTTTTTTGTAGAAATGTCTTGGTGCCT (SEQ ID NO: 31) and

GGACATGCATGCACTAGTGCGGCCGCCACGTGATAGTTGTTCA

ATTGATTGAAATAGGGACAA (SEQ ID NO: 32) and plasmid pGAPZ-A

(Invitrogen) as template and cloned into the *BamHI*, *SphI* sites of pUC19 (New England Biolabs, Beverly, MA) (Figure 4B). The resulting plasmid was cut with *SpeI* and *SphI* and the CYC1 transcriptional terminator region ("TT") that had been amplified using primers

CCTTGCTAGCTTAATTAACCGCGGCACGTCCGACGGCGGCCCA

CGGGTCCCA (SEQ ID NO: 33) and

15 GGACATGCATGCGGATCCCTTAAGAGCCGGCAGCTTGCAAATT

AAAGCCTTCGAGCGTCCC (SEQ ID NO: 34) and plasmid pPICZ-A

(Invitrogen) as a template was cloned into the open sites creating pJN261 (Figure 4B).

[0661] A knockout plasmid for the *P.pastoris* *OCH1* gene was created by digesting pJN263 with *Sall* and *SpeI* and a 2.9-kb DNA fragment of the *OCH1*-5' region, which had been amplified using the primers

GAACCACGTCGACGGCCATTGCGGCCAAAACCTTTTTTCCTATT

CAACACAAGGCATTGC (SEQ ID NO: 35) and

CTCCAATACTAGTCGAAGATTATCTTCTACGGTGCCTGGACTC (SEQ ID

25 NO: 36) and *P.pastoris* genomic DNA as a template, was cloned into the open sites (Figure 4C). The resulting plasmid was cut with *EcoRI* and *PmeI* and a 1.0-kb

DNA fragment of the *OCH1*-3' region that had been generated using the primers

TGGAAGGTTTAAACAAAGCTAGAGTAAAATAGATATAGCGAG

ATTAGAGAATG (SEQ ID NO: 37) and

30 AAGAATTCGGCTGGAAGGCCTTGTACCTTGATGTAGTTCCCGTT

TTCATC (SEQ ID NO: 38) was inserted to generate pJN298 (Figure 4C). To

allow for the possibility to simultaneously use the plasmid to introduce a new gene,

the *Bam*HI expression cassette of pJN261 (Figure 4B) was cloned into the unique *Bam*HI site of pJN298 (Figure 4C) to create pJN299 (Figure 4E).

[0662] The *P.pastoris* Ura3-blaster cassette was constructed using a similar strategy as described in Lu *et al.* (1998) *Appl. Microbiol. Biotechnol.* 49:141-146.

5 A 2.0-kb *Pst*I, *Spe*I fragment of *P.pastoris* *URA3* was inserted into the *Pst*I, *Xba*I sites of pUC19 (New England Biolabs, Beverly, MA) to create pJN306 (Figure 4D). Then a 0.7-kb *Sac*I, *Pvu*II DNA fragment of the *lacZ* open reading frame was cloned into the *Sac*I, *Sma*I sites to yield pJN308 (Figure 4D). Following digestion of pJN308 (Figure 4D) with *Pst*I, and treatment with T4 DNA polymerase, the
10 *Sac*I - *Pvu*II fragment from *lacZ* that had been blunt-ended with T4 DNA polymerase was inserted generating pJN315 (Figure 4D). The *lacZ*/*URA3* cassette was released by digestion with *Sac*I and *Sph*I, blunt ended with T4 DNA polymerase and cloned into the backbone of pJN299 that had been digested with *Pme*I and *Afl*III and blunt ended with T4 DNA polymerase. The resulting plasmid
15 was named pJN329 (Figure 4E).

[0663] A *HIS4* marked expression plasmid was created by cutting pJN261 (Figure 4F) with *Eco*ICRI (Figure 4F). A 2.7kb fragment of the *Pichia pastoris* *HIS4* gene that had been amplified using the primers

GCCCAAGCCGCGCCTTAAGGGATCTCCTGATGACTGACTCACTGATAATA

20 AAAATACGG (SEQ ID NO: 39) and

GGGCGCGTATTAAATACTAGTGGATCTATCGAATCTAAATGTAAGTTA

AAATCTCTAA (SEQ ID NO: 40) cut with *Ngo*MIV and *Swa*I and then blunt-

ended using T4 DNA polymerase, was then ligated into the open site. This

plasmid was named pJN337 (Figure 4F). To construct a plasmid with a multiple

25 cloning site suitable for fusion library construction, pJN337 was cut with *Not*I and *Pac*I and the two oligonucleotides

GGCCGCCTGCAGATTTAAATGAATTCGGCGCGCCTTAAT (SEQ ID NO:

41) and TAAGGCGCGCCGAATTCATTTAAATCTGCAGGGC (SEQ ID NO:

42), that had been annealed *in vitro* were ligated into the open sites, creating

30 pJN347 (Figure 4F).

[0664] To create an *och1* knockout strain containing multiple auxotrophic markers, 100 µg of pJN329 was digested with *Sfi*I and used to transform *P.pastoris*

strain JC308 (Cereghino et al. *Gene* 263 (2001) 159-169) by electroporation. Following transformation, the URA dropout plates were incubated at room temperature for 10 days. One thousand (1000) colonies were picked and restreaked. All 1000 clones were then streaked onto 2 sets of URA dropout plates. One set was incubated at room temperature, whereas the second set was incubated at 37°C. The clones that were unable to grow at 37°C, but grew at room temperature, were subjected to colony PCR to test for the correct *OCH1* knockout. One clone that showed the expected PCR signal (about 4.5 kb) was designated YJN153.

EXAMPLE 5

Characterization of the Combinatorial Localization/Mannosidase Library

[0665] Positive transformants (Example 4) screened by colony PCR to confirm integration of the mannosidase construct into the *P.pastoris* genome were subsequently grown at room temperature in 50ml BMGY buffered methanol-complex medium consisting of 1% yeast extract, 2% peptone, 100 mM potassium phosphate buffer, pH 6.0, 1.34% yeast nitrogen base, $4 \times 10^{-5}\%$ biotin, and 1% glycerol as a growth medium) until OD_{600nm} 2-6 at which point they were washed with 10ml BMMY (buffered methanol-complex medium consisting of 1% yeast extract, 2% peptone, 100 mM potassium phosphate buffer, pH 6.0, 1.34% yeast nitrogen base, $4 \times 10^{-5}\%$ biotin, and 1.5% methanol as a growth medium) media prior to induction of the reporter protein for 24 hours at room temperature in 5ml BMMY. Consequently, the reporter protein was isolated and analyzed as described in Example 3 to characterize its glycan structure. Using the targeting peptides in Table 6, mannosidase catalytic domains localized to either the ER or the Golgi showed significant level of trimming of a glycan predominantly containing Man₈GlcNAc₂ to a glycan predominantly containing Man₅GlcNAc₂. This is evident when the glycan structure of the reporter glycoprotein is compared between that of *P.pastoris och1* knock-out in Figures 5C and 6C and the same strain transformed with *M. musculus* mannosidase constructs as shown in Figures 5D, 5E, 6D – 6F. Figures 5 and 6 show expression of constructs generated from the combinatorial DNA library which show significant mannosidase activity in *P.pastoris*. Expression of pGC5 (*Saccharomyces MNS1*(m)/mouse mannosidase

IB Δ99) (Figures 5D and 6E) produced a protein which has approximately 30% of all glycans trimmed to Man₅GlcNAc₂, while expression of pFB8 (*Saccharomyces SEC12*(m)/mouse mannosidase IA Δ187) (Figure 6F) produced approximately 50% Man₅GlcNAc₂ and expression of pBC18-5 (*Saccharomyces VANI*(s)/ *C. elegans* mannosidase IB Δ80) (Figure 5E) produced 70% Man₅GlcNAc₂.

EXAMPLE 6

Trimming *in vivo* by alpha-1,2-mannosidase

[0666] To ensure that the novel engineered strains of Example 4 in fact produced the desired Man₅GlcNAc₂ structure *in vivo*, cell supernatants were tested for mannosidase activity (see Figures 7 – 9). For each construct/host strain described below, HPLC was performed at 30°C with a 4.0mm x 250 mm column of Altech (Avondale, PA, USA) Econosil-NH₂ resin (5μm) at a flow rate of 1.0 ml/min for 40 min. In Figures 7 and 8, degradation of the standard Man₉GlcNAc₂ [b] was shown to occur resulting in a peak which correlates to Man₈GlcNAc₂. In Figure 7, the Man₉GlcNAc₂ [b] standard eluted at 24.61 min and Man₅GlcNAc₂ [a] eluted at 18.59 min. In Figure 8, Man₉GlcNAc₂ eluted at 21.37 min and Man₅GlcNAc₂ at 15.67 min. In Figure 9, the standard Man₈GlcNAc₂ [b] was shown to elute at 20.88 min.

[0667] *P.pastoris* cells comprising plasmid pFB8 (*Saccharomyces SEC12* (m)/mouse mannosidase IA Δ187) were grown at 30°C in BMGY to an OD600 of about 10. Cells were harvested by centrifugation and transferred to BMMY to induce the production of K3 (kringle 3 from human plasminogen) under control of an *AOX1* promoter. After 24 hours of induction, cells were removed by centrifugation to yield an essentially clear supernatant. An aliquot of the supernatant was removed for mannosidase assays and the remainder was used for the recovery of secreted soluble K3. A single purification step using CM-sepharose chromatography and an elution gradient of 25mM NaAc, pH5.0 to 25mM NaAc, pH5.0, 1M NaCl, resulted in a 95% pure K3 eluting between 300-500mM NaCl. N-glycan analysis of the K3 derived glycans is shown in Figure 6F. The earlier removed aliquot of the supernatant was further tested for the presence of secreted mannosidase activity. A commercially available standard of

2-aminobenzamide-labeled N-linked-type oligomannose 9 (Man9-2-AB) (Glyko, Novato, CA) was added to: BMMY (Figure 7A), the supernatant from the above aliquot (Figure 7B), and BMMY containing 10ng of 75mU/mL of α -1,2-mannosidase from *Trichoderma reesei* (obtained from Contreras et al., WO 02/00856 A2) (Figure 7C). After incubation for 24 hours at room temperature, samples were analyzed by amino silica HPLC to determine the extent of mannosidase trimming.

[0668] *P.pastoris* cells comprising plasmid pGC5 (*Saccharomyces MNS1(m)*/mouse mannosidase IB Δ 99) were similarly grown and assayed. Cells were grown at room temperature in BMGY to an OD600 of about 10. Cells were harvested by centrifugation and transferred to BMMY to induce the production of K3 under control of an *AOX1* promoter. After 24 hours of induction, cells were removed by centrifugation to yield an essentially clear supernatant. An aliquot of the supernatant was removed for mannosidase assays and the remainder was used for the recovery of secreted soluble K3. A single purification step using CM-sepharose chromatography and an elution gradient of 25mM NaAc, pH5.0 to 25mM NaAc, pH5.0, 1M NaCl, resulted in a 95% pure K3 eluting between 300-500mM NaCl. N-glycan analysis of the K3 derived glycans is shown in Figure 5D. The earlier removed aliquot of the supernatant was further tested for the presence of secreted mannosidase activity as shown in Figure 8B. A commercially available standard of Man9-2-AB (Glyko, Novato, CA) were added to: BMMY (Figure 8A), supernatant from the above aliquot (Figure 8B), and BMMY containing 10ng of 75mU/mL of α -1,2-mannosidase from *Trichoderma reesei* (obtained from Contreras et al., WO 02/00856 A2) (Figure 8C). After incubation for 24 hours at room temperature, samples were analyzed by amino silica HPLC to determine the extent of mannosidase trimming.

[0669] Man9-2-AB was used as a substrate and it is evident that after 24 hours of incubation, mannosidase activity was virtually absent in the supernatant of the pFB8 (*Saccharomyces SEC12(m)*/mouse mannosidase IA Δ 187) strain digest (Figure 7B) and pGC5 (*Saccharomyces MNS1(m)*/mouse mannosidase IB Δ 99) strain digest (Figure 8B) whereas the positive control (purified α -1,2-mannosidase from *T. reesei* obtained from Contreras) leads to complete conversion of

Man₉GlcNAc₂ to Man₅GlcNAc₂ under the same conditions, as shown in Figures 7C and 8C. This is conclusive data showing *in vivo* mannosidase trimming in *P.pastoris* pGC5 strain; and pFB8 strain, which is distinctly different from what has been reported to date (Contreras et al., WO 02/00856 A2).

5 [0670] Figure 9 further substantiates localization and activity of the mannosidase enzyme. *P.pastoris* comprising pBC18-5 (*Saccharomyces VANI(s)/ C.elegans* mannosidase IB Δ80) was grown at room temperature in BMGY to an OD600 of about 10. Cells were harvested by centrifugation and transferred to BMMY to induce the production of K3 under control of an *AOX1* promoter. After 24 hours of
10 induction, cells were removed by centrifugation to yield an essentially clear supernatant. An aliquot of the supernatant was removed for mannosidase assays and the remainder was used for the recovery of secreted soluble K3. A single purification step using CM-sepharose chromatography and an elution gradient 25mM NaAc, pH5.0 to 25mM NaAc, pH5.0, 1M NaCl, resulted in a 95% pure K3
15 eluting between 300-500mM NaCl. *N*-glycan analysis of the K3 derived glycans is shown in Figure 5E. The earlier removed aliquot of the supernatant was further tested for the presence of secreted mannosidase activity as shown in Figure 9B. A commercially available standard of Man8-2-AB (Glyko, Novato, CA) was added to: BMMY (Figure 9A), supernatant from the above aliquot pBC18-5
20 (*Saccharomyces VANI(s)/ C. elegans* mannosidase IB Δ80) (Figure 9B), and BMMY containing media from a different fusion construct pDD28-3 (*Saccharomyces MNN10(m)* (from SwissProt 50108)/*H. sapiens* mannosidase IB Δ99) (Figure 9C). After incubation for 24 hours at room temperature, samples were analyzed by amino silica HPLC to determine the extent of mannosidase
25 trimming. Figure 9B demonstrates intracellular mannosidase activity in comparison to a fusion construct pDD28-3 (*Saccharomyces MNN10(m) H. sapiens* mannosidase IB Δ99) exhibiting a negative result (Figure 9C).

EXAMPLE 7

30 pH Optimum Assay of an Engineered α-1,2-mannosidase

[0671] *P.pastoris* cells comprising plasmid pBB27-2 (*Saccharomyces MNN10* (s) (from SwissProt 50108)/*C. elegans* mannosidase IB Δ31) were grown at room

temperature in BMGY to an OD600 of about 17. About 80 μ L of these cells were inoculated into 600 μ L BMGY and were grown overnight. Subsequently, cells were harvested by centrifugation and transferred to BMMY to induce the production of K3 (kringle 3 from human plasminogen) under control of an *AOXI* promoter. After 24 hours of induction, cells were removed by centrifugation to yield an essentially clear supernatant (pH 6.43). The supernatant was removed for mannosidase pH optimum assays. Fluorescence-labeled Man₈GlcNAc₂ (0.5 μ g) was added to 20 μ L of supernatant adjusted to various pH (Figure 11) and incubated for 8 hours at room temperature. Following incubation the sample was analyzed by HPLC using an Econosil NH2 4.6 X 250 mm, 5 micron bead, amino-bound silica column (Altech, Avondale, PA). The flow rate was 1.0 ml/min for 40 min and the column was maintained to 30°C. After eluting isocratically (68% A:32% B) for 3 min, a linear solvent gradient (68% A:32% B to 40% A:60% B) was employed over 27 min to elute the glycans (18). Solvent A (acetonitrile) and solvent B (ammonium formate, 50 mM, pH 4.5). The column was equilibrated with solvent (68% A:32% B) for 20 min between runs.

EXAMPLE 8

Engineering of *P.pastoris* to Produce *N*-glycans with the Structure
GlcNAcMan₅GlcNAc₂

[0672] GlcNAc Transferase I activity is required for the maturation of complex and hybrid *N*-glycans (U.S. Pat. No. 5,834,251). Man₅GlcNAc₂ may only be trimmed by mannosidase II, a necessary step in the formation of human glycoforms, after the addition of *N*-acetylglucosamine to the terminal α -1,3 mannose residue of the trimannose stem by GlcNAc Transferase I (Schachter, 1991 Glycobiology 1(5):453-461). Accordingly, a combinatorial DNA library was prepared including DNA fragments encoding suitably targeted catalytic domains of GlcNAc Transferase I genes from *C. elegans* and *Homo sapiens*; and localization sequences from *GLS*, *MNS*, *SEC*, *MNN9*, *VAN1*, *ANP1*, *HOC1*, *MNN10*, *MNN11*, *MNT1*, *KTR1*, *KTR2*, *MNN2*, *MNN5*, *YUR1*, *MNN1*, and *MNN6* from *S.cerevisiae* and *P.pastoris* putative α -1,2-mannosyltransferases based on the homology from *S.cerevisiae*: D2, D9 and J3, which are *KTR* homologs. Table 10 includes but does not limit targeting peptide sequences such as *SEC* and *OCH1*, from *P.pastoris* and *K.lactis* GnTI, (See Table 6 and Table 10)

Table 10. A representative combinatorial library of targeting peptide sequences/ catalytic domain for UDP-*N*-Acetylglucosaminyl Transferase I (GnTI)

		Targeting peptide				
		<i>OCHI</i> (s)	<i>OCHI</i> (m)	<i>OCHI</i> (l)	<i>MNN9</i> (s)	<i>MNN9</i> (m)
Catalytic Domain	Human, GnTI, Δ 38	PB105	PB106	PB107	PB104	N/A
	Human, GnTI, Δ 86	NB12	NB13	NB14	NB15	NB
	<i>C.elegans</i> , GnTI, Δ 88	OA12	OA13	OA14	OA15	OA16
	<i>C.elegans</i> , GnTI, Δ 35	PA12	PA13	PA14	PA15	PA16
	<i>C.elegans</i> , GnTI, Δ 63	PB12	PB13	PB14	PB15	PB16
	<i>X.leavis</i> , GnTI, Δ 33	QA12	QA13	QA14	QA15	QA16
	<i>X.leavis</i> , GnTI, Δ 103	QB12	QB13	QB14	QB15	QB 16

[0673] Targeting peptide sequences were selected from *OCHI* in *P.pastoris* (long, medium and short) (see Example 4) and *MNN9* (SwissProt P39107) in *S.cerevisiae* short, and medium. Catalytic domains were selected from human GnTI with a 38 and 86 amino acid *N*-terminal deletion, *C. elegans* (gly-12) GnTI with a 35 and 63 amino acid deletion as well as *C. elegans* (gly-14) GnTI with a 88

amino acid *N*-terminal deletion and *X. leavis* GnTI with a 33 and 103 amino acid *N*-terminal deletion, respectively.

[0674] A portion of the gene encoding human *N*-acetylglucosaminyl Transferase I (MGATI, Accession# NM002406), lacking the first 154 bp, was amplified by
5 PCR using oligonucleotides 5'-TGGCAGGCGCGCCTCAGTCAGCGCTCTCG-3' (SEQ ID NO: 43) and 5'-AGGTTAATTA AGTGCTAATTCCAGCTAGG-3' (SEQ ID NO: 44) and vector pHG4.5 (ATCC# 79003) as template. The resulting PCR product was cloned into pCR2.1-TOPO and the correct sequence was confirmed. Following digestion with *AscI* and *PacI* the truncated GnTI was
10 inserted into plasmid pJN346 to create pNA. After digestion of pJN271 with *NotI* and *AscI*, the 120 bp insert was ligated into pNA to generate an in-frame fusion of the *MNN9* transmembrane domain with the GnTI, creating pNA15.

[0675] The host organism is a strain of *P.pastoris* that is deficient in hypermannosylation (e.g. an *och1* mutant), provides the substrate UDP-GlcNAc in
15 the Golgi and/or ER (i.e. contains a functional UDP-GlcNAc transporter), and provides *N*-glycans of the structure Man₅GlcNAc₂ in the Golgi and/or ER (e.g. *P.pastoris* pFB8 (*Saccharomyces SEC12* (m)/mouse mannosidase IA Δ187) from above). First, *P.pastoris* pFB8 was transformed with pPB103 containing the *Kluyveromyces lactis* *MNN2-2* gene (Genbank AN AF106080) (encoding UDP-
20 GlcNAc transporter) cloned into *BamHI* and *BglII* site of pBLADE-SX plasmid (Cereghino et al. Gene 263 (2001) 159-169). Then the aforementioned combinatorial DNA library encoding a combination of exogenous or endogenous GnTI/localization genes was transformed and colonies were selected and analyzed for the presence of the GnTI construct by colony PCR. Our transformation and
25 integration efficiency was generally above 80% and PCR screening can be omitted once robust transformation parameters have been established.

[0676] In summary, the methods of the invention yield strains of *P.pastoris* that produce GlcNAcMan₅GlcNAc₂ in high yield, as shown in Figure 10B. At least 60% of the *N*-glycans are GlcNAcMan₅GlcNAc₂. To date, no report exists that
30 describes the formation of GlcNAcMan₅GlcNAc₂ on secreted soluble glycoproteins in any yeast. Results presented herein show that addition of the UDP-GlcNAc transporter along with GnTI activity produces a predominant

GlcNAcMan₅GlcNAc₂ structure, which is confirmed by the peak at 1457 (m/z) (Figure 10B).

Construction of strain PBP-3:

[0677] The *P.pastoris* strain expressing K3, ($\Delta och1$, arg-, ade-, his-) was
5 transformed successively with the following vectors. First, pFB8 (*Saccharomyces*
SEC12 (m)/mouse mannosidase IA $\Delta 187$) was transformed in the *P.pastoris* strain
by electroporation. Second, pPB103 containing *Kluyveromyces lactis* MNN2-2
gene (Genbank AN AF106080) (encoding UDP-GlcNAc transporter) cloned into
pBLADE-SX plasmid (Cereghino et al. Gene 263 (2001) 159-169) digested with
10 *Bam*HI and *Bgl*II enzymes was transformed in the *P.pastoris* strain. Third,
pPB104 containing *Saccharomyces* MNN9(s)/human GnTI $\Delta 38$ encoding gene
cloned as *Not*I-*Pac*I fragment into pJN336 was transformed into the *P.pastoris*
strain.

15

EXAMPLE 9

**Engineering *K.lactis* Cells to Produce *N*-glycans with the Structure
Man₅GlcNAc₂**

Identification and Disruption of the *K.lactis* *OCH1* gene

[0678] The *OCH1* gene of the budding yeast *S.cerevisiae* encodes a 1,6-
20 mannosyltransferase that is responsible for the first Golgi localized mannose
addition to the Man₈GlcNAc₂ *N*-glycan structure on secreted proteins (Nakanishi-
Shindo et al. (1993), *J. Biol. Chem.*; 268(35):26338-45). This mannose transfer is
generally recognized as the key initial step in the fungal specific
polymannosylation of *N*-glycan structures (Nakanishi-Shindo et al. (1993) *J. Biol.*
25 *Chem.* 268(35):26338-26345; Nakayama et al. (1992) *EMBO J.* 11(7):2511-19;
Morin-Ganet et al, *Traffic* 1(1):56-68. (Jan 2000)). Deletion of this gene in
S.cerevisiae results in a significantly shorter *N*-glycan structure that does not
include this typical polymannosylation or a growth defect at elevated temperatures
(Nakayama et al. (1992) *EMBO J.* 11(7):2511-19).

30 [0679] The *Och1p* sequence from *S.cerevisiae* was aligned with known
homologs from *Candida albicans* (Genbank accession # AAL49987), and
P.pastoris along with the *Hoc1* proteins of *S.cerevisiae* (Neiman et al, *Genetics*,
145(3):637-45 (Mar 1997) and *K.lactis* (PENDANT EST database) which are

related but distinct mannosyltransferases. Regions of high homology that were in common among *Och1p* homologs but distinct from the *Hoc1p* homologs were used to design pairs of degenerate primers that were directed against genomic DNA from the *K.lactis* strain MG1/2 (Bianchi et al, *Current Genetics* 12, 185-192 (1987)). PCR amplification with primers RCD33 (CCAGAAGAATTCAATTYTGYCARTGG) (SEQ ID NO: 45) and RCD34 (CAGTGAAAATACCTGGNCCNGTCCA) (SEQ ID NO: 46) resulted in a 302 bp product that was cloned and sequenced and the predicted translation was shown to have a high degree of homology to *Och1* proteins (>55% to *S.cerevisiae Och1p*).

10 [0680] The 302 bp PCR product was used to probe a Southern blot of genomic DNA from *K.lactis* strain (MG1/2) with high stringency (Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 2nd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989). Hybridization was observed in a pattern consistent with a single gene indicating that this 302 bp segment

15 corresponds to a portion of the *K.lactis* genome and *K.lactis* (*KIOCH1*) contains a single copy of the gene. To clone the entire *KIOCH1* gene, the Southern blot was used to map the genomic locus. Accordingly, a 5.2 kb *Bam*HI/*Pst*I fragment was cloned by digesting genomic DNA and ligating those fragments in the range of 5.2 kb into pUC19 (New England Biolabs, Beverly, MA) to create a *K.lactis*

20 subgenomic library. This subgenomic library was transformed into *E. coli* and several hundred clones were tested by colony PCR using RCD 33/34. The 5.2 kb clone containing the predicted *KIOCH1* gene was sequenced and an open reading frame of 1362 bp encoding a predicted protein that is 46.5% identical to the *S.cerevisiae OCH1* gene. The 5.2 kb sequence was used to make primers for

25 construction of an *och1::KAN^R* deletion allele using a PCR overlap method (Davidson et al. (2002) *Microbiol.* 148(Pt 8):2607-15). This deletion allele was transformed into two *K.lactis* strains and G418 resistant colonies selected. These colonies were screened by both PCR and for temperature sensitivity to obtain a strain deleted for the *OCH1* ORF. The results of the experiment show strains

30 which reveal a mutant PCR pattern, which were characterized by analysis of growth at various temperatures and N-glycan carbohydrate analysis of secreted and cell wall proteins following PNGase digestion. The *och1* mutation conferred a

temperature sensitivity which allowed strains to grow at 30°C but not at 35°C.

Figure 12A shows a MALDI-TOF analysis of a wild type *K.lactis* strain producing N-glycans of Man₈GlcNAc₂ [c] and higher.

Identification, Cloning, and Disruption of the *K.lactis* *MNN1* gene

- 5 [0681] *S.cerevisiae* *MNN1* is the structural gene for the Golgi α -1,3-mannosyltransferase. The product of *MNN1* is a 762-amino acid type II membrane protein (Yip et al., *Proc Natl Acad Sci U S A.* 91(7):2723-7. (1994)). Both N-linked and O-linked oligosaccharides isolated from *mnn1* mutants lack α -1,3-mannose linkages (Raschke et al., *J Biol Chem.*, 248(13):4660-6. (Jul 10, 1973).
- 10 [0682] The *Mnn1p* sequence from *S.cerevisiae* was used to search the *K.lactis* translated genomic sequences (PEDANT). One 405 bp DNA sequence encoding a putative protein fragment of significant similarity to *Mnn1p* was identified. An internal segment of this sequence was subsequently PCR amplified with primers KMN1 (TGCCATCTTTTAGGTCCAGGCCCGTTC) (SEQ ID NO: 47) and
- 15 KMN2 (GATCCCACGACGCATCGTATTCTTTC), (SEQ ID NO: 48) and used to probe a Southern blot of genomic DNA from *K.lactis* strain (MG1/2). Based on the Southern hybridization data a 4.2 Kb *Bam*HI-*Pst*I fragment was cloned by generating a size-selected library as described herein. A single clone containing the *K.lactis* *MNN1* gene was identified by whole colony PCR using primers KMN1
- 20 (SEQ ID NO: 47) and KMN2 (SEQ ID NO: 48) and sequenced. Within this clone a 2241 bp ORF was identified encoding a predicted protein that was 34% identical to the *S.cerevisiae* *MNN1* gene. Primers were designed for construction of a *mnn1::NAT^R* deletion allele using the PCR overlap method (Davidson et al. (2002) *Microbiol.* 148(Pt 8):2607-15).
- 25 [0683] This disruption allele was transformed into a strain of *K.lactis* by electroporation and nourseothricin resistant transformants were selected and PCR amplified for homologous insertion of the disruption allele. Strains that reveal a mutant PCR pattern may be subjected to N-glycan carbohydrate analysis of a known reporter gene.
- 30 [0684] Figure 12B depicts the N-glycans from the *K.lactis* *och1 mnn1* deletion strain observed following PNGase digestion the MALDI-TOF as described herein.

The predominant peak at 1908 (m/z) indicated as [d] is consistent with the mass of $\text{Man}_9\text{GlcNAc}_2$.

[0685] Additional methods and reagents which can be used in the methods for modifying the glycosylation are described in the literature, such as U.S. Patent No. 5,955,422, U.S. Patent No. 4,775,622, U.S. Patent No. 6,017,743, U.S. Patent No. 4,925,796, U.S. Patent No. 5,766,910, U.S. Patent No. 5,834,251, U.S. Patent No. 5,910,570, U.S. Patent No. 5,849,904, U.S. Patent No. 5,955,347, U.S. Patent No. 5,962,294, U.S. Patent No. 5,135,854, U.S. Patent No. 4,935,349, U.S. Patent No. 5,707,828, and U.S. Patent No. 5,047,335. Appropriate yeast expression systems can be obtained from sources such as the American Type Culture Collection, Rockville, MD. Vectors are commercially available from a variety of sources.

EXAMPLE 10

Strains, Culture Conditions and Reagents

[0686] For the examples below, the following strains, culture conditions and reagents were used. *Escherichia coli* strains TOP10 or DH5 α were used for recombinant DNA work.

[0687] Protein expression was carried out at room temperature in a 96-well plate format with buffered glycerol-complex medium (BMGY) consisting 1% yeast extract, 2% peptone, 100 mM potassium phosphate buffer, pH 6.0, 1.34% yeast nitrogen base, 4 X 10⁻⁵% biotin, and 1% glycerol as a growth medium. The induction medium was buffered methanol-complex medium (BMMY) consisting of 1.5% methanol instead of glycerol in BMGY.

[0688] Restriction and modification enzymes were from New England BioLabs (Beverly, MA).

[0689] Oligonucleotides were obtained from the Dartmouth College Core facility (Hanover, NH) or Integrated DNA Technologies (Coralville, IA).

EXAMPLE 11

Cloning And Generation Of Expression Vectors To Produce $\text{Man}_3\text{GlcNAc}_2$

[0690] Restriction and modification enzymes were from New England BioLabs (Beverly, MA). The shuttle vector pVM2 was generated from pUC19 by inverse

PCR (Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989) In: Molecular Cloning, a Laboratory Manual 2nd Edition, Cold Spring Harbor N.Y.: Cold Spring Harbor Laboratory Press.) using the primers VJM104 and VJM106 (5'-

GCGGCCGCGGATCCCCGGGTACCGAGCTCGAATTCAC-3' (SEQ ID NO: 107) and 5'- GGGGCGCGCC

TTAATTAACGACCTGCAGGCATGCAAGCTTGGCGTAATCATGGTCAT-3' (SEQ ID NO: 108) respectively, introduced restriction sites *NotI*, *AscI* and *PacI* are underlined).

[0691] The roll-in plasmid pJN285 is a derivative of the knock-in plasmid pJN266 that was constructed in the following way. A 0.9-kb fragment of the

PpKEX1-5' region was amplified by PCR using primers Kex55 (5'-

GGCGAGCTCGGCCTACCCGGCCAAGGCTGAGATCATTTGTCCAG CTTCAGA-3', SEQ ID NO: 27) and Kex53 (5'-

GCCACGTCGACGGATCCGTTTAAACATCGATTGGAG

AGGCTGACACCGCTACTA-3', SEQ ID NO: 28) from *Pichia pastoris* genomic DNA and cloned into pUC19 digested with *SacI* and *SalI*. The resulting plasmid was cut with *BamHI* and *SalI*, and a 0.8-kb fragment of the *KEX1*-3' region that had been amplified using primers Kex35 (5'-

CGGGATCCACTAGTATTTAAATCATATGTGCGAGTGTACAACTCTTCCC

ACATGG-3', SEQ ID NO: 29) and Kex33 (5'-

GGACGCGTCGACGGCCTACCCGGCCGTACGAGGAATTTCTCGGATGA CTCTTTTC-3', SEQ ID NO: 30) was cloned into pJN262 digested with the

same enzymes. This plasmid was cut with *BamHI* and the 3.8-kb *BamHI*-*BglII* fragment of pNKY51 (1) was inserted in each of the two possible orientations

resulting in plasmids pJN263 and pJN264. To create an expression cassette with *NotI* and *PacI* cloning sites, the *GAPDH* promoter of *P. pastoris* was amplified using primers Gap5 (5'-

CGGGATCCCTCGAGAGATCTTTTTGTAGAAATGTCTTGGTGCCT-3', SEQ ID NO: 31) and Gap3 (5'-

GGACATGCATGCACTAGTGCGGCCGACGTGATAGTTGTTC

ATTGATTGAAATAGGGACAA-3', SEQ ID NO: 32) and plasmid pGAPZ-A (Invitrogen) as template and cloned into the *BamHI*-*SphI* sites of pUC19. The

resulting plasmid was cut with *SpeI* and *SphI* and the *S. cerevisiae CYC1* transcriptional terminator region, that had been amplified from pPICZ-A (Invitrogen) using primers Cyc5 (5'- CCTTGCTAGCTTAATTAACC GCGGCACGTCCGACGGCGGCCACGGGTCCCA -3', SEQ ID NO: 33) and
5 Cyc3 (5'- GGACATGCATG CGGATCCCTTAAGAGCCGGCAGCTTGCAAATTAAAGCCTTCGAGCGTCC -3', SEQ ID NO: 34), was cloned into the open sites creating pJN261. The *GAPDH/CYC1* expression cassette was released by *BamHI* digestion and cloned either into pJN263 resulting in plasmid pJN265, or into pJN264 resulting in
10 plasmids pJN266 and pJN267 (depending on orientation of the insert). Subsequently the plasmid pJN266 was cut with *NgoMIV* and *SwaI* to release the URA-blaster cassette, and a *NgoMIV-SwaI* fragment containing the *PpHIS4* gene, that had been amplified from pPIC3.5 (Invitrogen) using primers JNHIS1 (5'- GCCCAAGCCGGCCTTAAGGGATCTCCTGATGACTGACTCACTGATAATA
15 AAAATACGG-3', SEQ ID NO: 39) and JNHIS2 (5'-GGGCGCGTATTTAAATACTAGTGGATCTATCGAATCTAAATGTAAGTTAAATCTCTAA-3', SEQ ID NO: 40), was cloned into the open sites to create pJN285.

[0692] The pJN348 expression vector is based on plasmid pBLURA-SX (2). First a *BamHI* fragment containing the *GAPDH/CYC1* expression cassette from
20 vector pJN261 was cloned into pBLURA-SX that had been cut with *BamHI* and *BglII* to create plasmid pJN338. Subsequently the latter plasmid was cut with *NotI* and *PacI* and the two oligonucleotides Expr1 (5'- GGCCGCCTGCAGATTTAAATGAATTCGGCGCGCCTTAAT-3', SEQ ID NO: 41) and Expr2 (5'-TAAGGCGCGCCGAATTCATTTAAATCTGCAGGGC-
25 3' (SEQ ID NO: 42), the restriction site *AscI* is underlined) that had been annealed *in vitro*, were ligated into the open sites, to create pJN348.

[0693] The pPB124 expression vector was constructed in several steps based on pBLADE-SX vector described by Cereghino et al. *Gene* 263 (2001) 159-169. First, *BamHI* fragment containing *GAPDH/CYC1* expression cassette from vector
30 pJN261 (described in Choi et al. *Proc Natl Acad Sci U S A.* 2003 Apr 29;100(9):5022-7) was cloned into pBLADE-SX vector after *BamHI-BglII* digest. Next, the *XhoI-NotI* fragment containing *P. pastoris* *GAPDH* promoter was

replaced with the promoter of *P. pastoris* *PMA1* gene that was amplified with PMA1 (5'-TTCCTCGAGATTCAAGCGAATGAGAATAATG-3', SEQ ID NO: 109) and PMA2 (5'-TTGCGGCCGCGAAG TTTTAAAGGAAAGAGATA-3', SEQ ID NO: 110) primers. The resulting vector was then digested with *XbaI*-
 5 *BamHI* enzymes to remove *ADE1* marker, and after fill-in reaction ligated with blunt-ended *BglIII-SacI* fragment containing nourseothricin resistance marker from vector pAG25 (Goldstein and McCusker, Yeast. 1999 Oct;15(14):1541-53).

EXAMPLE 12

10 **Generation of Localization Signal/Mannosidase I Catalytic Domain Fusions**
 [0694] *Amplification of mouse mannosidase IA.* The gene sequence encoding the catalytic domain of mouse mannosidase IA (Genbank: NM_008548, Lal & Moremen 1994) was amplified from mouse liver cDNA (Clontech). Briefly, the forward primer mMIAΔ187-*AscI* and reverse primer mMIA-*PacI* (5'-
 15 GGCGCGCCGAGCCCGCTGACGCCACCATCCGTGAGAAGAGG GC-3', (SEQ ID NO: 111) and 5'-
CCTTAATTAATCATTCTCTTTGCCATCAATTCCTTCTTCTGTTCACGG-
 3' (SEQ ID NO: 26), respectively, introduced *AscI* and *PacI* restriction sites are underlined) where used to amplify amino acids 188-655 of the mouse mannosidase
 20 IA ORF from mouse liver cDNA (Clontech) with Pfu DNA polymerase (Stratagene). The conditions used for thermo cycling were: 94°C for 1min, 1 cycle; 94°C for 30 sec, 68°C for 30sec, 72°C for 3min, 30 cycles. Subsequently, 1μl *Taq* DNA polymerase (Promega) was added and the reaction further incubated at 72°C for 10min with the 1.4Kb product being ligated into pCR2.1, giving the plasmid
 25 pSH9. Following confirmation of the PCR product by *Taq* DyeDeoxy terminal sequencing the mouse mannosidase IA was digested with the restriction enzymes *AscI* and *PacI* prior to subcloning into the vector pVM2, digested with the same restriction enzymes, generating the plasmid pSH21.
 [0695] To facilitate the subsequent localization of the truncated mouse
 30 mannosidase IA to the yeast Golgi a region of the *S.cerevisiae* Sec12 protein (amino acids 331-432, encoding the transmembrane domain) was amplified with the primers SC125 and SC122 (5'-

ATGTGGCGGCGGCCGCCACCATGAACACTATCCACATAATAAAATTAC
CGCTTAACCTACGCC-3', (SEQ ID NO: 112) and 5'-
GGCGCGCCCCACGCCTAGCACTTTTATGGAATCTACGCTAGGTAC-3'
(SEQ ID NO: 113), respectively, introduced NotI and AscI restriction sites are
5 underlined) in the presence of *Taq* DNA polymerase and *S.cerevisiae* genomic
DNA, producing the plasmid pJN305. Following confirmation of the PCR product
by *Taq* DyeDeoxy terminal sequencing the *Sec12* fragment, digested with the
restriction enzymes *NotI* and *AscI*, was subcloned into pSH21 digested with the
same enzymes, generating the plasmid pSH29. Subsequently the NotI/PacI
10 fragment of pSH29, encoding the *Sec12* fragment in-frame with the truncated
mouse mannosidase IA, was subcloned into pJN285 digested with the same
enzymes, generating the plasmid pFB8.

EXAMPLE 13

Generation of Mannosidase II construct

15 [0696] The catalytic domain of a *Drosophila* mannosidase II (GenBank: X77652,
Foster and Roberts 1995), encoding amino acids 75-1108, was amplified from
Drosophila ovary cDNA using *ExTaq* DNA polymerase under the thermocycling
conditions outlined above, by annealing at 55°C and extending for 5 minutes. The
forward primer dMannIIΔ74_AscI and the reverse primer dMannII_PacI (5'-
20 GGCGCGCCCGCGACGATCCAATAAGACCTCCAC-3' (SEQ ID NO: 69) and
5'- CCTTAATTAATCAGCTTG AGTGACTGCTCACATAAGCGGCGG-3'
(SEQ ID NO: 71), respectively, introduced *AscI* and *PacI* restriction sites are
underlined) were used. Following confirmation of the PCR product by *Taq*
DyeDeoxy terminal sequencing, the plasmid was named pSH214. Subsequently,
25 the *Drosophila* mannosidase II fragment was removed from this plasmid by
digestion with the restriction enzymes *AscI* and *PacI*, and subcloned into pJN348
digested with the same enzymes, generating the plasmid pSH220.
[0697] To facilitate the subsequent localization of the truncated *Drosophila*
mannosidase II domain to the Golgi, a region of the *S.cerevisiae* Mnn2 protein
30 (amino acids 1-36, encoding the transmembrane domain) was amplified with the
primers Mnn25 and Mnn21 (5'-
AGTAAAATGCGGCCGCCACCATGCTGCTTACCAAAGGTTTTCAAAGC

- TGTTC-3' (SEQ ID NO: 114) and 5'-
GGCGCGCCCCGACGTGTTCTCATCCATGTATTTGTTTGTAATGAC-3'
 (SEQ ID NO: 115), respectively, introduced NotI and AscI restriction sites are
 underlined) in the presence of *Taq* DNA polymerase and *S.cerevisiae* genomic
 5 DNA, producing the plasmid pJN281. Following confirmation of the PCR product
 by *Taq* DyeDeoxy terminal sequencing, the *Mnn2* fragment was digested with the
 restriction enzymes NotI and AscI and subcloned into pSH220 digested with the
 same enzymes, producing an in-frame fusion of the *Mnn2* localization signal with
 the *Drosophila* mannosidase II catalytic domain, generating the plasmid pKD53.
 10 The pH optimum of this engineered *Drosophila* mannosidase II catalytic domain
 was determined to be pH 6.2 using a pH assay essentially as described in Example
 7.

EXAMPLE 14

15 Mannosidase II Catalytic Domain Library

- [0698] The library of mannosidase II catalytic domains and leaders showing
 activity are shown below in Table 11. The number of (+)s, as used herein,
 indicates the relative levels of GlcNAcMan₃GlcNA₂ production of % neutral
 glycans. The notation (-) indicates no apparent production of
 20 GlcNAcMan₃GlcNA₂. The notation (+) indicates less than 20% production of
 GlcNAcMan₃GlcNA₂. The notation (++) indicates about 20-30% production of
 GlcNAcMan₃GlcNA₂. The notation (+++) indicates about 30-40% production
 of GlcNAcMan₃GlcNA₂. The notation with (+++++) indicates about 40-50%
 production of GlcNAcMan₃GlcNA₂. The notation with (+++++) indicates greater
 25 than 50% production of GlcNAcMan₃GlcNA₂. The notation (NG) indicates that no
 apparent glycans detected from any colonies transformed with the fusion construct.

Table 11. Catalytic Domains

Leaders	D.melanogaster mannosidase II Δ48	D.melanogaster mannosidase II Δ99	human mannosidase II Δ48	D.melanogaster mannosidase II Δ74	C.elegans mannosidase II Δ108
Gls1-s	++		+	+++++	+++++
Gls1-m	+				++

Leaders	D.melanogaster mannosidase II Δ48	D.melanogaster mannosidase II Δ99	human mannosidase II Δ48	D.melanogaster mannosidase II Δ74	C.elegans mannosidase II Δ108
Gls1-l				++	++
Mns1-s	++			++++	++++
Mns1-m	++			++++	++++
Mns1-l				++	
S.Sec-s	++			++++	++++
S.Sec-m	++			++++	++++
S.Sec-l				++++	++++
P.Sec-s	++			++++	++++
P.Sec-m				++++	++
P.Och-s				++	++
P.Och-m				++++	++++
P.Och-l				++	++
Mnn9-s	++			++++	++++
Mnn9-m				++++	++++
Mnn9-l				++	++
Van1-s				++++	++++
Van1-m				++++	++++
Van1-l				++++	++++
Anp1-s				++++	++++
Anp1-m				++++	++
Anp1-l				++++	+++
Hoc1-s	-	-	-	++++	+++
Hoc1-m	-	-	-	++++	++++
Hoc1-l	+	-	-	++++	++
Mnn10-s	-	-	-	+	++++
Mnn10-m	-	-	-	++++	++++

Leaders	D.melanogaster mannosidase II $\Delta 48$	D.melanogaster mannosidase II $\Delta 99$	human mannosidase II $\Delta 48$	D.melanogaster mannosidase II $\Delta 74$	C.elegans mannosidase II $\Delta 108$
Mnn10-l					++++
Mnn11-s				++++	++++
Mnn11-m					++++
Mnn11-l				++	++
Mnt1-s				++	++++
Mnt1-m					++++
Mnt1-l					++++
D2-s				++	++++
D2-m					++++
D2-l					++
D9-s					
D9-m					++++
D9-l					++
J3-s					++
J3-m				++++	
J3-l				++	
Ktr1-s				++++	++
Ktr1-l				++	++
Ktr2-s				++++	++++
Ktr2-m				++	++
Ktr2-l				++	++
Gnt1-s	+	+			++++
Gnt1-m			+	++++	++++
Gnt1-l		+			++
Mnn2-s	+	+	+		++++
Mnn2-m	+	+		++++	++++

Leaders	D.melanogaster mannosidase II Δ48	D.melanogaster mannosidase II Δ99	human mannosidase II Δ48	D.melanogaster mannosidase II Δ74	C.elegans mannosidase II Δ108
Mnn2-l				+++	+++
Mnn5-s				+++	+++
Mnn5-m				+++++	+++++
Mnn5-l				++	+++
Yur1-s				++	+++
Yur1-m				+++	+++
Yur1-l				+++	+++
Mnn1-s				+++++	+++++
Mnn1-m				+++++	+++++
Mnn1-l				+++++	+++
Mnn6-s				+++	+++
Mnn6-m				+++++	+++
Mnn6-l				++	+++

EXAMPLE 15

Generation of GnTII expression constructs

- 5 [0699] The construction of a GnTI expression vector (pNA15) containing a human GnTI gene fused with the N-terminal part of *S. cerevisiae* MNN9 gene was described previously (Choi et al. *Proc Natl Acad Sci U S A.* 2003 Apr 29;100(9):5022-7). In a similar fashion, the rat GnTII gene was cloned. The rat GnTII gene (GenBank accession number U21662) was PCR amplified using
- 10 Takara *EX Taq*TM polymerase (Panvera) from rat liver cDNA library (Clontech) with RAT1 (5'-TTCCTCACTGCAGTCTTCTATAACT-3', SEQ ID NO: 116) and RAT2 (5'-TGGAGACCATGAGGTTCCGCATCTAC-3', SEQ ID NO: 117) primers. The PCR product was then cloned into pCR2.1-TOPO vector (Invitrogen) and sequenced. Using this vector as a template, the *AscI*-*PacI* fragment of GnTII,
- 15 encoding amino-acids 88-443, was amplified with *Pfu Turbo* polymerase

(Stratagene) and primers, RAT44 and RAT11 (5'-TTGGCGCGCCTCCCT
AGTGTACCAGTTGAACTTTG-3' (SEQ ID NO: 118) and 5'-
GATTAATTAACTCACTGCAGTCTTCTATAACT-3' (SEQ ID NO: 119)
respectively, introduced *Asc*I and *Pac*I restriction sites are underlined). Following
5 confirmation by sequencing, the catalytic domain of rat GnTII was then cloned
downstream of the *PMA1* promoter as a *Asc*I-*Pac*I fragment in pBP124. In the
final step, the gene fragment encoding the *S. cerevisiae Mnn2* localization signal
was cloned from pJN281 as a *Not*I-*Asc*I fragment to generate an in-frame fusion
with the catalytic domain of GnTII, to generate plasmid pTC53.

10

EXAMPLE 16

Reporter protein expression, purification and release of N-linked glycans

[0700] The K3 domain, under the control of the alcohol oxidase 1 (AOX1)
promoter, was used as a model glycoprotein and was purified using the hexa-
15 histidine tag as reported in Choi et al. *Proc Natl Acad Sci U S A.* 2003 Apr
29;100(9):5022-7). The glycans were released and separated from the
glycoproteins by a modification of a previously reported method (Papac et al. A. J.
S. (1998) *Glycobiology* 8, 445-454). After the proteins were reduced and
carboxymethylated, and the membranes blocked, the wells were washed three
20 times with water. The protein was deglycosylated by the addition of 30 μ l of 10
mM NH_4HCO_3 pH 8.3 containing one milliunit of N-glycanase (Glyko). After
incubation for 16 hr at 37°C, the solution containing the glycans was removed by
centrifugation and evaporated to dryness.

Protein Purification

25 [0701] Kringle 3 was purified using a 96-well format on a Beckman BioMek
2000 sample-handling robot (Beckman/Coulter Ranch Cucamonga, CA). Kringle
3 was purified from expression media using a C-terminal hexa-histidine tag. The
robotic purification was an adaptation of the protocol provided by Novagen for
their HisBind resin. Briefly, a 150 μ L (μ L) settled volume of resin was poured into
30 the wells of a 96-well lysate-binding plate, washed with 3 volumes of water and
charged with 5 volumes of 50mM NiSO_4 and washed with 3 volumes of binding
buffer (5mM imidazole, 0.5M NaCl, 20mM Tris-HCL pH7.9). The protein

expression media was diluted 3:2, media/PBS (60mM PO₄, 16mM KCl, 822mM NaCl pH7.4) and loaded onto the columns. After draining, the columns were washed with 10 volumes of binding buffer and 6 volumes of wash buffer (30mM imidazole, 0.5M NaCl, 20mM Tris-HCl pH7.9) and the protein was eluted with 6
5 volumes of elution buffer (1M imidazole, 0.5M NaCl, 20mM Tris-HCl pH7.9). The eluted glycoproteins were evaporated to dryness by lyophilization.

Release of N-linked Glycans

[0702] The glycans were released and separated from the glycoproteins by a modification of a previously reported method (Papac, et al. A. J. S. (1998)
10 Glycobiology 8, 445-454). The wells of a 96-well MultiScreen IP (Immobilon-P membrane) plate (Millipore) were wetted with 100uL of methanol, washed with 3X150uL of water and 50uL of RCM buffer (8M urea, 360mM Tris, 3.2mM EDTA pH8.6), draining with gentle vacuum after each addition. The dried protein samples were dissolved in 30uL of RCM buffer and transferred to the wells
15 containing 10uL of RCM buffer. The wells were drained and washed twice with RCM buffer. The proteins were reduced by addition of 60uL of 0.1M DTT in RCM buffer for 1hr at 37°C. The wells were washed three times with 300uL of water and carboxymethylated by addition of 60uL of 0.1M iodoacetic acid for 30min in the dark at room temperature. The wells were again washed three times
20 with water and the membranes blocked by the addition of 100uL of 1% PVP 360 in water for 1hr at room temperature. The wells were drained and washed three times with 300uL of water and deglycosylated by the addition of 30uL of 10mM NH₄HCO₃ pH 8.3 containing one milliunit of N-glycanase (Glyko). After 16 hours at 37°C, the solution containing the glycans was removed by centrifugation and
25 evaporated to dryness.

MALDI/Time-of-Flight (TOF) Mass Spectrometry.

[0703] Molecular weights of the glycans were determined using a Voyager DE PRO linear MALDI-TOF (Applied Biosciences) mass spectrometer using delayed extraction. The dried glycans from each well were dissolved in 15 µl of water and
30 0.5 µl was spotted on stainless steel sample plates and mixed with 0.5 µl of S-DHB matrix (9 mg/ml of dihydroxybenzoic acid, 1 mg/ml of 5-methoxysalicylic acid in 1:1 water/acetonitrile 0.1% TFA) and allowed to dry. Ions were generated by

irradiation with a pulsed nitrogen laser (337 nm) with a 4 ns pulse time. The instrument was operated in the delayed extraction mode with a 125 ns delay and an accelerating voltage of 20 kV. The grid voltage was 93.00%, guide wire voltage was 0.1%, the internal pressure was less than 5×10^{-7} torr, and the low mass gate was 875 Da. Spectra were generated from the sum of 100-200 laser pulses and acquired with a 500 MHz digitizer. $\text{Man}_5\text{GlcNAc}_2$ oligosaccharide was used as an external molecular weight standard. All spectra were generated with the instrument in the positive ion mode.

Miscellaneous:

[0704] Proteins were separated by SDS/PAGE according to Laemmli (Laemmli 1970).

EXAMPLE 17

Generation of Yeast Strain YSH-1 ($\Delta och1$, $\alpha 1,2$ -mannosidase, GnTI)

[0705] The previously reported *P. pastoris* strain BK64 (Choi et al. *Proc Natl Acad Sci U S A.* 2003 Apr 29;100(9):5022-7), a triple auxotroph (*ADE*, *ARG*, *HIS*) possessing the *OCH1* knock-out and expressing the kringle 3 domain (K3) of human plasminogen, was used as the host strain. BK64 was transformed with the plasmid pPB103 linearized with the restriction enzyme *EcoNI* to introduce the *K.lactis* UDP-N-acetylglucosamine transporter into the host cell, thus creating the strain PBP-1. The mouse *MnsI* was introduced into this strain by transformation with the plasmid pFB8 linearized with the restriction enzyme *EcoNI*, generating strain PBP-2. K3 glycan analysis from proteins isolated from strain PBP-2 demonstrated that the primary glycoform present was $\text{Man}_5\text{GlcNAc}_2$.

[0706] PBP-2 was subsequently transformed with the human GnTI plasmid pNA15 linearized with the restriction enzyme *AatII*, generating the strain PBP-3. Analysis of the K3 glycoforms produced in strain PBP-3 demonstrated that the hybrid glycan $\text{GlcNAcMan}_5\text{GlcNAc}_2$ was the predominant structure. To recover the *URA3* marker from PBP-3, this strain was grown in YPD prior to selection on minimal media containing 5-Fluoroorotic (5-FOA, BioVectra) and uracil (Boeke et al., *Mol. Gen. Genet.* 197:345-346 (1984)). The recovered Ura-minus strain producing $\text{GlcNAcMan}_5\text{GlcNAc}_2$ glycoforms was designated YSH-1. The N-

glycan profile from strain YSH-1 is shown in Fig. 13 and displays a predominant peak at 1465 m/z corresponding to the mass of GlcNAcMan₅GlcNAc₂ [d].

EXAMPLE 18

5 **Generation of Yeast Strain YSH-37 (*P. pastoris* expressing mannosidase II)**
[0707] YSH-1 (Example 17) was transformed with the *D. melanogaster* mannosidase IIΔ74/*S. cerevisiae* MNN2(s) plasmid (pKD53) linearized with the restriction enzyme *ApaI*, generating strain YSH-37. Analysis of the K3 glycan structures produced in strain YSH-37 (Fig. 14) demonstrated that the predominant
10 glycoform at 1140 m/z corresponds to the mass of GlcNAcMan₃GlcNAc₂ [b] and other glycoforms GlcNAcMan₄GlcNAc₂ [c] at 1303 m/z and GlcNAcMan₅GlcNAc₂ [d] at 1465 m/z.

EXAMPLE 19

15 **Generation of Yeast Strain YSH-44**
[0708] Strain YSH-37 (Example 18) was transformed with a plasmid encoding a rat GnT II/MNN2 (s) leader, pTC53, linearized with the restriction enzyme *EcoRI*. The resulting strain, YSH-44, produced a K3 N-glycan having a single glycoform at 1356 m/z, corresponding to the mass of GlcNAc₂Man₃GlcNAc₂ [x], by positive
20 mode MALDI-TOF mass spectrometry (Fig. 15).

β-N-acetylhexosaminidase Digestion

[0709] The glycans from YSH-44 were released and separated from the glycoproteins by a modification of a previously reported method (Papac, et al. A. J. S. (1998) *Glycobiology* 8, 445-454). After the proteins were reduced and
25 carboxymethylated and the membranes blocked, the wells were washed three time with water. The protein was deglycosylated by the addition of 30 μl of 10 mM NH₄HCO₃ pH 8.3 containing one milliunit of N-glycanase (Glyko, Novato, CA). After a 16 hr digestion at 37°C, the solution containing the glycans was removed
30 by centrifugation and evaporated to dryness. The glycans were then dried in aSC210A speed vac (Thermo Savant, Halbrook, NY). The dried glycans were put in 50 mM NH₄Ac pH 5.0 at 37°C overnight and 1mU of hexos (Glyko, Novato,

CA) was added. The glycans were analyzed and shown to contain a single glycan shown in Fig. 16 at 933 m/z corresponding to the mass of Man₃GlcNAc₂ [a].

EXAMPLE 20

5 **Generation of a Yeast Strain with No Apparent Mannosidase II Activity**

[0710] YSH-1 was transformed with a plasmid encoding a *D. melanogaster* mannosidase IIΔ74/*S. cerevisiae* MNN9(m), plasmid pKD16, linearized with the restriction enzyme *EcoRI*. The resulting strain produced a single glycoform at 1464 m/z corresponding to the mass of Man₅GlcNAc₂ [d] by positive mode
10 MALDI-TOF mass spectrometry (Fig. 18). This strain thus expressed no apparent mannosidase II activity from the *D. melanogaster* mannosidase IIΔ74/*S. cerevisiae* MNSI(l) fusion construct, at least with respect to glycosylation of the K3 reporter glycoprotein.

15 **EXAMPLE 21**

Generation of a Yeast Strain Having Mannosidase II Activity

[0711] YSH-1 was transformed with a plasmid encoding a *D. melanogaster* mannosidase IIΔ74/*S. cerevisiae* MNSI(l), plasmid (pKD6), linearized with the restriction enzyme *EcoRI*. The N-glycan profile of K3 glycoprotein expressed in
20 the resulting strain (Fig. 19) exhibited a predominant peak at 1464 m/z corresponding to the mass of Man₅GlcNAc₂ [d] and other peaks corresponding to GlcNAcMan₃GlcNAc₂ [b] at 1139 m/z and GlcNAcMan₄GlcNAc₂ [c] at 1302 m/z. The resulting yeast strain thus expressed some detectable mannosidase II activity from the *D. melanogaster* mannosidase IIΔ74/*S. cerevisiae* MNSI(l) fusion
25 construct.

EXAMPLE 22

Generation of Yeast Strain YSH-27 Having Mannosidase II Activity

[0712] YSH-1 was transformed with *D. melanogaster* mannosidase IIΔ74/*S. cerevisiae* GLSI(s) plasmid (pKD1), linearized with the restriction enzyme *EcoRI*.
30 The N-glycan profile of K3 glycoprotein expressed in the resulting strain, YSH-27, exhibited a predominant peak at 1139 m/z corresponding to the mass of

GlcNAcMan₃GlcNAc₂ [b] (Fig. 20). The resulting strain YSH-27 thus expressed significant levels of mannosidase II activity from the *D. melanogaster* mannosidase IIΔ74/*S. cerevisiae* GLS1(s) fusion construct.

5

EXAMPLE 23

Generation of Yeast Strain YSH-74 (Low Mannosidase II Activity)

[0713] YSH-1 was transformed with *D. melanogaster* mannosidase IIΔ74/*S. cerevisiae* MNS1(m) plasmid (pKD5), linearized with the restriction enzyme *EcoRI*. The N-glycan profile of K3 glycoprotein expressed in the resulting strain, YSH-74, exhibited a predominant peak at 1140 m/z corresponding to the mass of GlcNAcMan₃GlcNAc₂ [b] and other peaks corresponding to GlcNAcMan₄GlcNAc₂ [c] at 1302 m/z and GlcNAcMan₅GlcNAc₂ [d] at 1464 m/z (Fig. 21). The resulting strain YSH-74 expressed mediocre levels of mannosidase II activity from the *D. melanogaster* mannosidase IIΔ74/*S. cerevisiae* MNS1(m) fusion construct, at least with respect to glycosylation of the K3 reporter glycoprotein. The glycans from YSH-74 were analyzed further by digestion with *A. saitoi* α-1,2 mannosidase (Glyko, Novato, CA), which resulted in glycans exhibiting a predominant peak at 1141 m/z corresponding to the mass of GlcNAcMan₃GlcNAc₂ [b] (Fig. 22).

20

EXAMPLE 24

Mannosidase Assays

[0714] Fluorescently-labeled Man₈GlcNAc₂ (0.5 μg) was added to 20 μL of supernatant and incubated for 30 hours at room temperature. After incubation, the sample was analyzed by HPLC with an Econosil NH₂ 4.6 X 250 mm, 5 micron bead, amino-bound silica column (Altech, Avondale, PA). The flow rate was 1.0 ml/min for 40 min and the column was maintained to 30°C. After eluting isocratically (68% A:32% B) for 3 min, a linear solvent gradient (68% A:32% B to 40% A:60% B) was employed over 27 min to elute the glycans (Turco, S. J. (1981) *Anal. Biochem.* 118, 278-283). Solvent A (acetonitrile) and solvent B was an

30

aqueous solution of ammonium formate, 50 mM, pH 4.5. The column was equilibrated with solvent (68% A:32% B) for 20 min between runs.

5

EXAMPLE 25 ***In vitro* Galactose Transfer**

[0715] N-linked glycan GlcNAc₂Man₃GlcNAc₂ obtained from strain YSH-44 was used as the substrate for galactose transfer. Twenty mg of this glycan were incubated with 75mg UDP-Gal and 10 to 50mU β -1,4-galactosyltransferase (Bovine milk, Calbiochem) in 50mM NH₄HCO₃, 1mM MnCl₂, pH7.5 at 37°C for 16-20hr. Fig. 17 shows a positive mode MALDI-TOF mass spectrometry displaying a uniform peak at 1665 m/z corresponding to the mass of Gal₂GlcNAc₂Man₃GlcNAc₂. The negative control, minus galactosyltransferase, was carried out as described above and showed no transfer of galactose to the substrate GlcNAc₂Man₃GlcNAc₂.

20

EXAMPLE 26 **Introduction of a Class III Mannosidase into Lower Eukaryotes**

[0716] A cDNA encoding a class III mannosidase (Jarvis et al. *Glycobiology* 1997 7:113-127) from insect Sf9 cells was amplified using primers specific for the 5' and 3' termini. Subsequently, the cDNA was subcloned into a yeast integration plasmid to investigate the effect of this protein on the N-glycosylation pattern of a secreted reporter protein. A number of truncated products of were produced to generate a library of class III mannosidase constructs with different targeting leader fragments, as described, e.g., in Example 14. In addition to being expressed alone in a desired host strain, resulting fusion proteins are expressed in combination with other glycosylation modifying enzymes to enhance the production of a desired N-glycan structure.

30

[0717] Although the Sf9 mannosidase is the only cloned member of this class III to date, genes and ESTs that show significant homology to this ORF, and in particular the catalytic domain (residues 273 to 2241 of the ORF). A library of class III mannosidases that possess a range of temperature and pH optima is

generated. In turn, this will enable the selection of one or more class III
mannosidase fusion constructs that perform optimally in modifying the
glycosylation pattern of a selected reporter protein to produce a desired N-glycan
structure when expressed in a desired host strain such as yeast and filamentous
5 fungi.

Sequence Listings

- SEQ ID NO: 1
M.musculus α -1,2-mannosidase IA nucleic acid sequence
- 5 SEQ ID NO: 2
M.musculus α -1,2-mannosidase IA encoded polypeptide sequence
- SEQ ID NO: 3
primer for *K.lactis* OCH1 gene: ccagaagaat tcaattytgy cartgg
- 10 SEQ ID NO: 4
primer for *K.lactis* OCH1 gene: cagtgaaaat acctggncn gtcca
- SEQ ID NO: 5
Class 2 mannosidase conserved amino acid sequence:
Leu Lys Val Phe Val Val Pro His Ser His Asn Asp Pro Gly Trp Ile Gln Thr Phe
Glu Glu Tyr Tyr
- 15 SEQ ID NO: 6
Class 2 mannosidase conserved amino acid sequence:
Glu Phe Val Thr Gly Gly Trp Val Met Pro Asp Glu Ala Asn Ser Trp Arg Asn Val
Leu Leu Gln Leu Thr Glu Gly Gln Thr Trp Leu Lys Gln Phe Met Asn Val Thr Pro
Thr Ala Ser Trp Ala Ile Asp Pro Phe Gly His Ser Pro Thr Met Pro Tyr Ile Leu
- 20 SEQ ID NO: 7
Class 2 mannosidase conserved amino acid sequence:
His Met Met Pro Phe Tyr Ser Tyr Asp Ile Pro His Thr Cys Gly Pro Asp Pro Arg Ile
Cys Cys Gln Phe Asp Phe Arg Arg Met Pro Gly Gly Arg
- SEQ ID NO: 8
- 25 Class 2 mannosidase conserved amino acid sequence:
Leu Leu Leu Asp Gln Tyr Arg Lys Lys Ser Glu Leu Phe Arg Thr Asn Val Leu Leu
Ile Pro Leu Gly Asp Asp Phe Arg Tyr
- SEQ ID NO: 9
- 30 Class 2 mannosidase conserved amino acid sequence:
Gln Phe Gly Thr Leu Ser Asp Tyr Phe Asp Ala Leu
- SEQ ID NO: 10
- Class 2 mannosidase conserved amino acid sequence:
Leu Ser Gly Asp Phe Phe Thr Tyr Ala Asp Arg Ser Asp His
- SEQ ID NO: 11
- 35 Class 2 mannosidase conserved amino acid sequence:
Tyr Trp Ser Gly Tyr Tyr Thr Ser Arg Pro Phe Tyr Arg Arg Met Asp Arg Val Leu
Glu

SEQ ID NO: 12

Class 2 mannosidase conserved amino acid sequence:

Ala Arg Arg Glu Leu Gly Leu Phe Gln His His Asp Ala Ile Thr Gly Thr Ala Arg
Asp His Val Val Val Asp Tyr Gly

5 SEQ ID NO: 13

Class 2 mannosidase conserved amino acid sequence:

Gly Ala Tyr Leu Phe Leu Pro Asp Gly Glu Ala

SEQ ID NO: 14

Class 2 mannosidase conserved amino acid sequence:

10 Phe Tyr Thr Asp Leu Asn Gly Phe Gln Met Gln Lys Arg Arg

SEQ ID NO: 15

Class 2 mannosidase conserved amino acid sequence:

Lys Leu Pro Leu Gln Ala Asn Tyr Tyr Pro Met Pro Ser Met Ala Tyr Ile Gln Asp
Ala Asn Thr Arg Leu Thr Leu Leu Thr Gly Gln Pro Leu Gly Val Ser Ser Leu Ala
15 Ser Gly Gln Leu Glu Val Met Leu Asp Arg Arg Leu Met Ser Asp Asp Asn Arg
Gly Leu Gly Gln Gly Val Leu Asp Asn Lys

SEQ ID NO: 16

primer for K.lactis MNN1 gene: tgccatcttt taggtccagg cccgttc

SEQ ID NO: 17

20 primer for K.lactis MNN1 gene: gatcccacga cgcacgtat ttctttc

SEQ ID NO: 18

Primer: ATGGCGAAGGCAGATGGCAGT

SEQ ID NO: 19

Primer: TTAGTCCTTCCAACCTTCCTTC

25 SEQ ID NO: 20

Primer: ACTGCCATCTGCCTTCGCCAT

SEQ ID NO: 21

Primer: GTAATACGACTCACTATAGGGC

SEQ ID NO: 22

30 Primer: AATTAACCCTCACTAAAGGG

SEQ ID NO: 23

Primer: ATGCCCGTGGGGGGCCTGTTGCCGCTCTTCAGTAGC

SEQ ID NO: 24

Primer: TCATTCTCTTTGCCATCAATTCCTTCTTCTGTTACGG

35 SEQ ID NO: 25

Primer: GGCGCGCCGACTCCTCCAAGCTGCTCAGCGGGGTCCTGTTCCAC

SEQ ID NO: 26

Primer:

CCTTAATTAATCATTCTCTTTGCCATCAATTCCTTCTTCTGTTACGG

SEQ ID NO: 27

5 Primer:

GGCGAGCTCGGCCTACCCGGCCAAGGCTGAGATCATTGTCCAGCTTCA
GA

SEQ ID NO: 28

Primer:

10 GCCCACGTCGACGGATCCGTTTAAACATCGATTGGAGAGGCTGACACC
GCTACTA

SEQ ID NO: 29

Primer:

15 CGGGATCCACTAGTATTTAAATCATATGTGCGACTGTACAACTCTTCCC
ACATGG

SEQ ID NO: 30

Primer: GGACGCGTCGACGGCCTACCCGGCCGTACGAGGAATTTCTCGG
ATGACTCTTTTC

SEQ ID NO: 31

20 Primer:

CGGGATCCCTCGAGAGATCTTTTTTGTAGAAATGTCTTGGTGCCT

SEQ ID NO: 32

Primer: GGACATGCATGCACTAGTGCGGCCGCCACGTGATAGTTGTTCA
ATTGATTGAAATAGGGACAA

25 SEQ ID NO: 33

Primer: CTTTGCTAGCTTAATTAACCGCGGCACGTCCGACGGCGGCCCA
CGGGTCCCA

SEQ ID NO: 34

30 Primer: GGACATGCATGCGGATCCCTTAAGAGCCGGCAGCTTGCAAATT
AAAGCCTTCGAGCGTCCC

SEQ ID NO: 35

Primer: GAACCACGTCGACGGCCATTGCGGCCAAAACCTTTTTTCCTATT
CAAACACAAGGCATTGC

SEQ ID NO: 36

35 Primer: CTCCAATACTAGTCGAAGATTATCTTCTACGGTGCCTGGACTC

SEQ ID NO: 37

Primer: TGGAAGGTTTAAACAAAGCTAGAGTAAAATAGATATAGCGAG
ATTAGAGAATG

- SEQ ID NO: 38
Primer: AAGAATTCGGCTGGAAGGCCTTGACCTTGATGTAGTTCCCGTT
TTCATC
- 5 SEQ ID NO: 39
Primer:
GCCCAAGCCGGCCTTAAGGGATCTCCTGATGACTGACTCACTGATAATA
AAAATACGG
- 10 SEQ ID NO: 40
Primer:
GGGCGCGTATTTAAATACTAGTGGATCTATCGAATCTAAATGTAAGTTA
AAATCTCTAA
- SEQ ID NO: 41
Primer: GGCCGCCTGCAGATTTAAATGAATTCGGCGCGCCTTAAT
- 15 SEQ ID NO: 42
Primer: TAAGGCGCGCCGAATTCATTTAAATCTGCAGGGC
- SEQ ID NO: 43
Primer: TGGCAGGCGCGCCTCAGTCAGCGCTCTCG
- SEQ ID NO: 44
Primer: AGGTTAATTA AGTGCTAATTCCAGCTAGG
- 20 SEQ ID NO: 45
Primer: CCAGAAGAATTCAATTYTGYCARTGG
- SEQ ID NO: 46
Primer: CAGTGAAAATACCTGGNCCNGTCCA
- 25 SEQ ID NO: 47
Primer: TGCCATCTTTTAGGTCCAGGCCCGTTC
- SEQ ID NO: 48
Primer: GATCCCACGACGCATCGTATTTCTTTC
- SEQ ID NO: 49
Arabidopsis thaliana Mannosidase II (NM_121499)
- 30 SEQ ID NO: 50
C. elegans Mannosidase II (NM_073594)
- SEQ ID NO: 51
Ciona intestinalis mannosidase II (AK116684)
- 35 SEQ ID NO: 52
Drosophila mannosidase II (X77652)

- SEQ ID NO: 53
Human mannosidase II (U31520)
- SEQ ID NO: 54
Mouse mannosidase II (X61172)
- 5 SEQ ID NO: 55
Rat mannosidase II (XM_218816)
- SEQ ID NO: 56
Human mannosidase IIx (D55649)
- 10 SEQ ID NO: 57
Insect cell mannosidase III (AF005034)
- SEQ ID NO: 58
Human lysosomal mannosidase II (NM_000528)
- SEQ ID NO: 59
Human cytoplasmic mannosidase II (NM_006715)
- 15 SEQ ID NO: 60
sense primer
5'-GGCGCGCCCTCACTCTCTTCCACTTCGGCGTACCAGGAC-3'
Arabidopsis MannII d69 AscI
- 20 SEQ ID NO: 61
antisense primer
5'-CCTTAATTAATCACTTGTGAGGTCGCAGTTCAAGCTTATAAGCTC-3'
Arabidopsis MannII PacI
- SEQ ID NO: 62
sense primer
- 25 5'-GGCGCGCCGCGCTCACCAAACGACAAGCAAATGATTTACGG-3'
C.elegans MannII d31 AscI
- SEQ ID NO: 63
sense primer
- 30 5'-GGCGCGCCGCTCATATTCATCAAGTAAAGCAACATATCAAGCC-3'
C.elegans MannII d108 AscI
- SEQ ID NO: 64
antisense primer
- 5'-CTTAATTAATTAATGATACAAGAATACTGGAAATATCGTTTGG-3'
C.elegans MannII PacI
- 35 SEQ ID NO: 65
sense primer
5'-GGCGCGCCACCCTTCAAGACAAACTTAGTCTGGTGG-3'
C.intestinalis MannII d47 AscI

- SEQ ID NO: 66
sense primer
5'-GGCGCGCCCTACCACTTATAATGCCCAAGCAATTTGCG
C.intestinalis MannII d100 AscI
- 5 SEQ ID NO: 67
antisense primer
5'-CCTTAATTAATTACGTCAGTACTATTTTGTAAAGCTTGTATCTC-3'
C. intestinalis ManII PacI
- 10 SEQ ID NO: 68
sense primer
5'-GGCGCGCCCATGAGCTGGAAAATGGTTTGCAGGAGCACG-3'
D.melanogaster MannII d48 AscI
- 15 SEQ ID NO: 69
sense primer
5'-GGCGCGCCCGCGACGATCCAATAAGACCTCCAC-3'
D.melanogaster MannII d74 AscI
- 20 SEQ ID NO: 70
sense primer
5'-GGCGCGCCGACGTGCCCAATGTGGATGTACAGATGCTG-3'
D.melanogaster MannII d99 AscI
- SEQ ID NO: 71
antisense primer
5'-CCTTAATTAATCAGCTTGAGTGACTGCTCACATAAGCGGCGG-3'
D.melanogaster MannII PacI
- 25 SEQ ID NO: 72
sense primer
5'-GGCGCGCCATAGACCATTTGGAGCGTTTGCTAGCTGAG-3'
human Mann2a d53 AscI
- 30 SEQ ID NO: 73
sense primer
5'-GGCGCGCCGCTTCACAAAGTGGAAGTCACAATTCAGATGTGC-3'
human Man2 d118 AscI
- SEQ ID NO: 74
antisense primer
35 5'-CCCTTAATTAATCACCTCAACTGGATTTCGGAATGTGCTGATTTC-3'
human Mann2A PacI
- SEQ ID NO: 75
sense primer
40 5'-GGCGCGCCGACCATTTGGAGCGTTTGCTCGCTGAGAAC-3'
mouse Man2 d54 AscI

- SEQ ID NO: 76
sense primer
5'-GGCGCGCCCTGCAGGCTGACCCCAGAGACTGT-3'
mouse Man2 d107 AscI
- 5 SEQ ID NO: 77
antisense primer
5'-
CCCTTAATTAATCAGGTCCAACGCAAGCGGATACGGAACGTGCTGATC
TC-
10 3'
mouse Man2 PacI
- SEQ ID NO: 78
sense primer
5'-GGCGCGCCGGTGGAACCTCCCCAGGAGCCAAATTTCTG-3'
15 rat MannII AscI d38
- SEQ ID NO: 79
sense primer
5'-GGCGCGCCGCGGAGGGCCCACCAGCCCTGCTGCCCTACCAC-3'
rat MannII AscI d81
- 20 SEQ ID NO: 80
antisense primer
5'-CCTTAATTAATAACCCAAGCGCAGGCGGAAGGTGCTG-3'
rat MannII PacI
- 25 SEQ ID NO: 81
sense primer
5'-GGCGCGCCCAACACGATCCCACCCGACACCAGAATG-3'
human MannIIx d29 AscI
- 30 SEQ ID NO: 82
sense primer
5'-GGCGCGCCGTGCTGGAGCTGACAGCCAACGCAGAGGG-3'
human MannIIx d74 AscI
- 35 SEQ ID NO: 83
sense primer
5'-GGCGCGCCGGTCAGAAGCCAGAGCTGCAGATGCTCACTG-3'
human MannIIx d123 AscI
- 40 SEQ ID NO: 84
antisense primer
5'-CCTTAATTAATAACCCAAGCGGAGGCGAAAGGTAGCAATC-3'
human MannIIx PacI
- SEQ ID NO: 85
sense primer

5'-GGCGCGCCCAGAACTATAACAAACCAAGAATCAGTTACCCAGCC-3'
SfMannIII d36 AscI

SEQ ID NO: 86

antisense primer

5 5'-CCTTAATTAATTAACCTGATCTTGTAAGTTTTACCTCCATAGCG-3'
SfMannIII PacI

SEQ ID NO: 87

sense primer

10 5'-GGCGCGCCATGGGCTACGCGCGGGCTTCGGGGGTCTGCG-3'
human lysosomal MannII AscI

SEQ ID NO: 88

sense primer

5'-GGCGCGCCCCGCCTCTCTGCTTTTTCCTTTTGTTGCTG-3'
human lysosomal MannII d31 AscI

15 SEQ ID NO:89

antisense primer

5'-CCTTAATTAATAACCATCCACCTCCTTCCATTGAACTGAG-3'
human lysosomal MannII PacI

SEQ ID NO: 90

20 sense primer

5'-GGCGCGCCATGGCGGCAGCGCCGTTCTTGAAGCACTGGCGC-3'
human cytosolic MannII AscI

SEQ ID NO: 91

antisense primer

25 5'-CCTTAATTAATTAGGCTGGGGAAGCAGAAATTAGGAGTCC-3'
human cytosolic MannII PacI

What is Claimed is:

1. A method for producing a human-like glycoprotein in a lower eukaryotic host cell comprising the step of expressing in the cell a mannosidase enzymatic activity that is capable of hydrolyzing an oligosaccharide substrate
5 comprising either or both a $\text{Man}\alpha 1,3$ and $\text{Man}\alpha 1,6$ glycosidic linkage to the extent that at least 10% of the $\text{Man}\alpha 1,3$ and/or $\text{Man}\alpha 1,6$ linkages of the substrate are hydrolyzed *in vivo*.
2. A method for producing a desired N-glycan in a lower eukaryotic host cell comprising the step of expressing in the cell a mannosidase
10 enzymatic activity that is capable of hydrolyzing *in vivo* an oligosaccharide substrate comprising either or both a $\text{Man}\alpha 1,3$ and $\text{Man}\alpha 1,6$ glycosidic linkage wherein the desired N-glycan is produced within the host cell at a yield of at least 10 mole percent. The method of claim 2, wherein the desired N-glycan produced is selected from the group consisting of $\text{Man}_3\text{GlcNAc}_2$, $\text{GlcNAcMan}_3\text{GlcNAc}_2$ and
15 $\text{Man}_4\text{GlcNAc}_2$.
3. The method of claim 2, wherein the desired N-glycan is characterized as having at least the oligosaccharide branch $\text{Man}\alpha 1,3$ ($\text{Man}\alpha 1,6$) $\text{Man}\beta 1,4\text{-GlcNAc } \beta 1,4\text{-GlcNAc-Asn}$.
4. The method of claim 1 or 2, wherein the mannosidase enzymatic
20 activity is capable of hydrolyzing *in vivo* both $\text{Man}\alpha 1,3$ and $\text{Man}\alpha 1,6$ linkages of an oligosaccharide substrate comprising a $\text{Man}\alpha 1,3$ and $\text{Man}\alpha 1,6$ glycosidic linkage.
5. The method of claim 1 or 2, wherein the oligosaccharide substrate is characterized as $\text{Man}\alpha 1,3$ ($\text{Man}\alpha 1,6$ $\text{Man}\alpha 1,6$) $\text{Man}\beta 1,4\text{-GlcNAc } \beta 1,4\text{-GlcNAc-Asn}$; $\text{Man}\alpha 1,3$ ($\text{Man}\alpha 1,3$ $\text{Man}\alpha 1,6$) $\text{Man}\beta 1,4\text{-GlcNAc } \beta 1,4\text{-GlcNAc-Asn}$; $\text{GlcNAc}\beta 1,2$ $\text{Man}\alpha 1,3$ ($\text{Man}\alpha 1,6$ $\text{Man}\alpha 1,6$) $\text{Man}\beta 1,4\text{-GlcNAc } \beta 1,4\text{-GlcNAc-Asn}$; $\text{GlcNAc}\beta 1,2$ $\text{Man}\alpha 1,3$ ($\text{Man}\alpha 1,3$ $\text{Man}\alpha 1,6$) $\text{Man}\beta 1,4\text{-GlcNAc } \beta 1,4\text{-GlcNAc-Asn}$; $\text{Man}\alpha 1,3$ ($\text{Man}\alpha 1,3$ $\text{Man}\alpha 1,6$ $\text{Man}\alpha 1,6$) $\text{Man}\beta 1,4\text{-GlcNAc } \beta 1,4\text{-GlcNAc-Asn}$; $\text{GlcNAc}\beta 1,2$ $\text{Man}\alpha 1,3$ ($\text{Man}\alpha 1,3$ $\text{Man}\alpha 1,6$ $\text{Man}\alpha 1,6$) $\text{Man}\beta 1,4\text{-GlcNAc } \beta 1,4\text{-GlcNAc-Asn}$; $\text{Man}\alpha 1,2$ $\text{Man}\alpha 1,3$ ($\text{Man}\alpha 1,3$ $\text{Man}\alpha 1,6$ $\text{Man}\alpha 1,6$) $\text{Man}\beta 1,4\text{-GlcNAc}$
25 GlcNAc-Asn ; $\text{Man}\alpha 1,2$ $\text{Man}\alpha 1,3$ ($\text{Man}\alpha 1,3$ $\text{Man}\alpha 1,6$ $\text{Man}\alpha 1,6$) $\text{Man}\beta 1,4\text{-GlcNAc}$
30 GlcNAc-Asn ; $\text{Man}\alpha 1,2$ $\text{Man}\alpha 1,3$ ($\text{Man}\alpha 1,3$ $\text{Man}\alpha 1,6$ $\text{Man}\alpha 1,6$) $\text{Man}\beta 1,4\text{-GlcNAc}$

β 1,4-GlcNAc-Asn; Man α 1,2 Man α 1,3 (Man α 1,3 Man α 1,6) Man β 1,4-GlcNAc
 β 1,4-GlcNAc-Asn; Man α 1,2 Man α 1,3 (Man α 1,6 Man α 1,6) Man β 1,4-GlcNAc
 β 1,4-GlcNAc-Asn or high mannan.

6. The method of claim 1 or 2, wherein the mannosidase activity is
35 characterized as a Class 2 mannosidase activity.

7. The method of claim 6, wherein the Class 2 mannosidase
activity has a substrate specificity for GlcNAc β 1,2 Man α 1,3 (Man α 1,6 Man α 1,6)
Man β 1,4-GlcNAc β 1,4-GlcNAc-Asn; GlcNAc β 1,2 Man α 1,3 (Man α 1,3 Man α 1,6)
Man β 1,4-GlcNAc β 1,4-GlcNAc-Asn; or GlcNAc β 1,2 Man α 1,3 (Man α 1,3
40 Man α 1,6 Man α 1,6) Man β 1,4-GlcNAc β 1,4-GlcNAc-Asn.

8. The method of claim 6, wherein the Class 2 mannosidase
activity is one which is normally found in the Golgi apparatus of a higher
eukaryotic host cell.

9. The method of claim 1 or 2, wherein the mannosidase activity is
45 characterized as a Class IIx mannosidase activity.

10. The method of claim 9, wherein the Class IIx mannosidase
activity has a substrate specificity for Man α 1,3 (Man α 1,6 Man α 1,6) Man β 1,4-
GlcNAc β 1,4-GlcNAc-Asn; Man α 1,3 (Man α 1,3 Man α 1,6) Man β 1,4-GlcNAc β 1,4-
GlcNAc-Asn; or Man α 1,2 Man α 1,3 (Man α 1,3 Man α 1,6 Man α 1,6) Man β 1,4-
50 GlcNAc β 1,4-GlcNAc-Asn.

11. The method of claim 1 or 2, wherein the mannosidase activity is
characterized as a Class III mannosidase activity.

12. The method of claim 11, wherein the Class III mannosidase
activity has a substrate specificity for (Man α 1,6 Man α 1,6) Man β 1,4-GlcNAc β 1,4-
55 GlcNAc-Asn; (Man α 1,3 Man α 1,6) Man β 1,4-GlcNAc β 1,4-GlcNAc-Asn; or high
mannans.

13. The method of claim 1 or 2, wherein the mannosidase activity is
overexpressed.

14. The method of claim 1 or 2, wherein the mannosidase is further
60 capable of hydrolyzing a Man α 1,2 linkage.

15. The method of claim 1 or 2, wherein the mannosidase activity
has a pH optimum of from about 5.0 to about 8.0.

16. The method of claim 1 or 2, wherein the mannosidase is further
capable of hydrolyzing a Man α 1,2 linkage.

65 17. The method of claim 1 or 2, wherein the mannosidase activity is
localized within the secretory pathway of the host cell.

18. The method of claim 1 or 2, wherein the mannosidase activity is
expressed from a polypeptide localized within at least one of the ER, Golgi
apparatus or the trans golgi network of the host cell.

70 19. The method of claim 1 or 2, wherein the mannosidase activity is
expressed from a nucleic acid encoding a polypeptide comprising a mannosidase
catalytic domain fused to a cellular targeting signal peptide.

20. The method of claim 19, wherein the mannosidase activity is
expressed from a nucleic acid comprising sequences that encode a mannosidase
75 catalytic domain native to the host cell

21. The method of claim 19, wherein the mannosidase activity is
expressed from a nucleic acid comprising sequences that encode a mannosidase
catalytic domain heterologous to the host cell.

22. The method of claim 1 or 2, wherein the mannosidase enzymatic
80 activity is selected from the group consisting of *Arabidopsis thaliana* Mannosidase
II, *C. elegans* Mannosidase II, *Ciona intestinalis* mannosidase II, *Drosophila*
mannosidase II, Human mannosidase II, Mouse mannosidase II, Rat mannosidase
II, Human mannosidase IIx, Insect cell mannosidase III, Human lysosomal
mannosidase II and Human cytoplasmic mannosidase II.

85 23. The method of claim 1 or 2, wherein the polypeptide is
expressed from a nucleic acid comprising sequences that encode a target peptide
native to the host cell.

 24. The method of claim 1 or 2, wherein the polypeptide is
expressed from a nucleic acid comprising sequences that encode a target peptide
90 heterologous to the mannosidase catalytic domain.

 25. The method of claim 1 or 2, further comprising the step of
isolating the glycoprotein from the host cell.

 26. The method of claim 1 or 2, wherein the host cell is selected
from the group consisting of *Pichia pastoris*, *Pichia finlandica*, *Pichia*
95 *trehalophila*, *Pichia koclamae*, *Pichia membranaefaciens*, *Pichia opuntiae*, *Pichia*
thermotolerans, *Pichia salictaria*, *Pichia guercuum*, *Pichia pijperi*, *Pichia stiptis*,
Pichia methanolica, *Pichia sp.*, *Saccharomyces cerevisiae*, *Saccharomyces sp.*,
Hansenula polymorpha, *Kluyveromyces sp.*, *Kluyveromyces lactis*, *Candida*
albicans, *Aspergillus nidulans*, *Aspergillus niger*, *Aspergillus oryzae*, *Trichoderma*
100 *reesei*, *Chrysosporium lucknowense*, *Fusarium sp.*, *Fusarium gramineum*,
Fusarium venenatum and *Neurospora crassa*.

 27. The method of claim 26, wherein the host cell is *Pichia pastoris*.

 28. The method of claim 1 or 2, wherein the glycoprotein is a
therapeutic protein.

105 The method of claim 28, wherein the therapeutic protein is selected from the group
consisting of erythropoietin, cytokines, coagulation factors, soluble IgE receptor α -
chain, IgG, IgG fragments, IgM, interleukins, urokinase, chymase, urea trypsin
inhibitor, IGF-binding protein, epidermal growth factor, growth hormone-releasing
factor, annexin V fusion protein, angiostatin, vascular endothelial growth factor-2,
110 myeloid progenitor inhibitory factor-1, osteoprotegerin, α -1-antitrypsin, α - feto
protein, AAT, rhTBP-1 (onerecept, aka TNF Binding protein 1), TACI-Ig
(transmembrane activator and calcium modulator and cyclophilin ligand
interactor), FSH (follicle stimulating hormone), GM-CSF, GLP-1 w/ and w/o FC

(glucagon like protein 1) IL-1 receptor agonist, sTNFr (enbrel, aka soluble TNF
115 receptor Fc fusion) ATIII, rhThrombin, glucocerebrosidase and CTLA4-Ig
(Cytotoxic T Lymphocyte associated Antigen 4 - Ig).

29. A nucleic acid library comprising at least two different genetic
constructs, wherein at least one genetic construct comprises a nucleic acid
fragment encoding a mannosidase class 2, IIx or III catalytic domain ligated in-
120 frame with a nucleic acid fragment encoding a cellular targeting signal peptide
which it is not normally associated with.

30. The library of claim 29, wherein the mannosidase catalytic
domain is selected from the group consisting of *Arabidopsis thaliana*
Mannosidase II, *C. elegans* Mannosidase II, *Ciona intestinalis* mannosidase II,
125 *Drosophila* mannosidase II, Human mannosidase II, Mouse mannosidase II, Rat
mannosidase II, Human mannosidase IIx, Insect cell mannosidase III, Human
lysosomal mannosidase II and Human cytoplasmic mannosidase II.

31. The library of claim 29, wherein the nucleic acid fragment
encoding a cellular targeting peptide is selected from the group consisting of:
130 *Saccharomyces* GLS1, *Saccharomyces* MNS1, *Saccharomyces* SEC12, *Pichia*
SEC, *Pichia* OCH1, *Saccharomyces* MNN9, *Saccharomyces* VAN1,
Saccharomyces ANP1, *Saccharomyces* HOC1, *Saccharomyces* MNN10,
Saccharomyces MNN11, *Saccharomyces* MNT1, *Pichia* D2, *Pichia* D9, *Pichia* J3,
Saccharomyces KTR1, *Saccharomyces* KTR2, *Kluyveromyces* GnTI,
135 *Saccharomyces* MNN2, *Saccharomyces* MNN5, *Saccharomyces* YUR1,
Saccharomyces MNN1, and *Saccharomyces* MNN6.

32. A vector comprising a fusion construct derived from a library of
any one of claims 29-31 operably linked to an expression control sequence,
wherein said cellular targeting signal peptide is targeted to at least one of the ER,
140 Golgi or trans-Golgi network.

33. The vector of claim 32, wherein the expression control sequence
is inducible or constitutive.

34. The vector of claim 32 which, upon expression in a host cell, encodes a mannosidase activity involved in producing GlcNAcMan₃GlcNAc₂
145 Man₃GlcNAc₂ or Man₄GlcNAc₂ *in vivo*.

35. A host cell comprising at least one vector of claim 34.

36. A host cell comprising at least one vector selected from the group of vectors designated pKD53, pKD1, pKD5, pKD6 and pKD16.

37. A chimeric polypeptide comprising a mannosidase catalytic
150 domain fused in-frame to a targeting signal peptide and, upon expression in a lower eukaryotic host cell, capable of hydrolyzing *in vivo* an oligosaccharide substrate comprising either or both a Man α 1,3 and Man α 1,6 glycosidic linkage to the extent that at least 10% of the Man α 1,3 and/or Man α 1,6 linkages of the substrate are hydrolyzed *in vivo*.

38. A chimeric polypeptide comprising a mannosidase catalytic
155 domain fused in-frame to a targeting signal peptide and, upon expression in a lower eukaryotic host cell, capable of hydrolyzing *in vivo* an oligosaccharide substrate comprising a Man α 1,3, Man α 1,6, or Man α 1,2 glycosidic linkage to the extent that a detectable moiety of the Man α 1,3, Man α 1,6 or Man α 1,2 linkage of
160 the substrate is hydrolyzed *in vivo*.

39. A nucleic acid encoding a chimeric polypeptide of claim 37.

40. A host cell comprising a chimeric polypeptide of claim 37.

41. A host cell comprising a nucleic acid of claim 39.

42. A glycoprotein produced in a host cell of claim 40 or claim 41.

43. An N-glycan produced in a host cell of claim 40 or claim 41.
165

44. The N-glycan of claim 43, wherein the N-glycan is characterized as uniform.

45. A glycoprotein produced by the method of claim 1 or claim 2.

46. An N-glycan produced by the method of claim 1 or claim 2.

170 47. The N-glycan of claim 46, wherein the N-glycan is characterized as uniform.

48. An isolated polynucleotide comprising or consisting of a nucleic acid sequence selected from the group consisting of:

- (a) SEQ ID NO: 92 (*C.elegans* **FROM FIG. 23**);
- 175 (b) at least about 90% similar to the amino acid residues of the donor nucleotide binding site of SEQ ID NO: 92;
- (c) a nucleic acid sequence at least 92%, at least 95%, at least 98%, at least 99% or at least 99.9% identical to SEQ ID NO: 93;
- (d) a nucleic acid sequence that encodes a conserved
- 180 polypeptide having the amino acid sequence of SEQ ID NO: 92;
- (e) a nucleic acid sequence that encodes a polypeptide at least 78%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99% or at least 99.9% identical to SEQ ID NO:92;
- (f) a nucleic acid sequence that hybridizes under stringent
- 185 conditions to SEQ ID NO:92; and
- (g) a nucleic acid sequence comprising a fragment of any one of (a) – (f) that is at least 60 contiguous nucleotides in length.

49. An isolated polynucleotide comprising or consisting of a nucleic acid sequence selected from the group consisting of:

- 190 (a) SEQ ID NO: 93(rat **FROM FIG. 23**);
- (b) at least about 95% similar to the amino acid residues of the donor nucleotide binding site of SEQ ID NO: 93;
- (c) a nucleic acid sequence at least 95%, at least 98%, at least 99% or at least 99.9% identical to SEQ ID NO: 93;
- 195 (d) a nucleic acid sequence that encodes a conserved polypeptide having the amino acid sequence of SEQ ID NO: 93;
- (e) a nucleic acid sequence that encodes a polypeptide at least 97%, at least 98%, at least 99% or at least 99.9% identical to SEQ ID NO: 93;
- (f) a nucleic acid sequence that hybridizes under stringent

200 conditions to SEQ ID NO: 93; and

(g) a nucleic acid sequence comprising a fragment of any one of (a) – (f) that is at least 60 contiguous nucleotides in length.

50. An isolated polynucleotide comprising or consisting of a nucleic acid sequence selected from the group consisting of:

205 (a) SEQ ID NO: 94(Ciona **FROM FIG. 23**);

(b) at least about 90% similar to the amino acid residues of the donor nucleotide binding site of SEQ ID NO: 94;

(c) a nucleic acid sequence at least 92%, at least 95%, at least 98%, at least 99% or at least 99.9% identical to SEQ ID NO: 94;

210 (d) a nucleic acid sequence that encodes a conserved polypeptide having the amino acid sequence of SEQ ID NO: 94;

(e) a nucleic acid sequence that encodes a polypeptide at least 73%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99% or at least 99.9% identical to SEQ ID NO: 94;

215 (f) a nucleic acid sequence that hybridizes under stringent conditions to SEQ ID NO: 94; and

(g) a nucleic acid sequence comprising a fragment of any one of (a) – (f) that is at least 60 contiguous nucleotides in length.

51. An isolated polynucleotide comprising or consisting of a nucleic acid sequence selected from the group consisting of:

220 (a) SEQ ID NO: 95(Arabidopsis **FROM FIG. 23**);

(b) at least about 95% similar to the amino acid residues of the donor nucleotide binding site of SEQ ID NO: 95;

225 (c) a nucleic acid sequence at least 96%, at least 98%, at least 99% or at least 99.9% identical to SEQ ID NO: 95;

(d) a nucleic acid sequence that encodes a conserved polypeptide having the amino acid sequence of SEQ ID NO: 95;

(e) a nucleic acid sequence that encodes a polypeptide at least 95%, at least 98%, at least 99% or at least 99.9% identical to SEQ ID NO: 95;

230 (f) a nucleic acid sequence that hybridizes under stringent

conditions to SEQ ID NO: 95; and

(g) a nucleic acid sequence comprising a fragment of any one of (a) – (f) that is at least 60 contiguous nucleotides in length.

235 52. A modified polynucleotide comprising or consisting of a nucleic acid sequence selected from the group consisting of the conserved regions SEQ ID NO: 5 – SEQ ID NO: 15 wherein the encoded polypeptide is involved in hydrolyzing a $\text{Man}\alpha 1,3$ and/or a $\text{Man}\alpha 1,6$ glycosidic linkage of an oligosaccharide.

240 53. A modified polynucleotide comprising or consisting of a nucleic acid sequence selected from the group consisting of the conserved regions of SEQ ID NO: 49 – SEQ ID NO: 59 wherein the encoded polypeptide is involved in hydrolyzing a $\text{Man}\alpha 1,3$ and/or a $\text{Man}\alpha 1,6$ glycosidic linkage of an oligosaccharide.

54. A vector selected from the group consisting of pKD53, pKD1, pKD5, pKD6 and pKD16.

1/47




FIG. 1A




FIG. 1B




FIG.2

M. musculus α -1,2-mannosidase IA open reading frame. The transmembrane and catalytic domains are highlighted in bold respectively. The sequence of the primers used to generate the N-terminal truncations are highlighted by underlining and the start of each respective protein fragment indicated by an arrow.

1 atgcccgtggggccctgttcgcgcctcttcagtacccctggggcgccgcccctgggcagctggccctggcgccggggcttggcgccggaggaagggg
1▶ M P V G G L L P L F S S P G G G L G S G L G G L G G L G G R K G
97 tctggcccgctgccttcgcgcctcaccgagaagtctgtctgtctgtggtgttcgaagcccttcctacgcctatcagctctgtctgggggcaata
33▶ S G P A A F R L T E K F V L L V F S A F I T L C F G A I
104 tcttcctgtgootgactctctccaagctctcagcgggtctctgttccactcaaccctgccttgcagccgcgcggcgagcacaagcccggcctc
62▶ F F L P D S S K L L S G V L F H S N P A L G I P P A E H K P G L
d65 primer
278 ggcgcgtcgcggaggatccgcgcgagggagtcgcgcgcaccgcgaggaaagcgcgcctgggaccctggagctggactggagacaacttaacca
93▶ G A R A E D A E G R V R H R E E G A P G D P G A G L E D N L A
d105 primer
374 ggatccgcgaaaccacgagcgggctctcagggaagcccaaggagaccctgcagaagctgccggagagatccaaagagacattctcctggagaagg
125▶ R I R E N H E R A L R E A K E T L Q K L P E E I Q R D I L L E K
470 aaaagtgcccccaggaccagctgcgtgacaaggatctgttttagggcttgcccaaggtggacttctgcctcccccctgcgggtgagagaacccgggggc
157▶ E K V A Q D Q L R D K D L F R G L P K V D F L P P V G V E N R E
d187 primer
566 ccgctgacgccaccatccctgtagaagaggccaagatcaaaagagatgatgaacccatgtgttggaataattataaacgctatgcgtgggggc
189▶ P A D A T I R E K R A K I K E M M T H A W N Y K R Y A W G

FIG. 3

5/47

655 ttgaacgaactgaacacotatatcaaaaagaaggccattcaagcagtttgtttggaaacatcaaaaggagactacaatagtagatg
 219▶ L N E L K P I S K E G H S S L F G N I K G A T I V D
 737 ccotggataccottttcaattatgggaatgaagactgaattcaagaagotaaatcggtgattaaaaaatatttagatttttaa
 246▶ A L D T L F I M G M K T E F Q E A K S W I K K Y L D F N
 819 tctgaatgctgaagtcttctgttttttgaagtcaacatacagcttctgtgtggactgctgtcaagtaatactatttctcoggagag
 273▶ V N A E V S V F E V N I R F V G G L L S A Y Y L S G E
 901 gagatatttcgaagaagaagcagtggaacttgggtgaacttggatadctgaatttcaatactccototggaaatacacttgggcac
 301▶ E I F R K K A V E L G V K L L P A F H T P S G I P W A
 983 tgotgaatatgaagaagtgggatacgggggaagaaotggccotctgtggagcagcagtagtactcctggcagatttggaaactct
 328▶ L L N M K S G I G R N W P W A S G G S I L A E F G T L
 1065 gaatttagagtttatgcaacttgtcccaacttatcaggagacccagctcttcccgaaagagtttatgaaattcgaacagtggttg
 355▶ H L E F M H L S H L S G D P V F A E K V M K I R T V L
 1147 aacaaactgggaacaaacagaggoctttatcctaactatctgaaccccaagtagtggacagtggtgggtcaacatcctgtgtgg
 383▶ N K L D K P E G L Y P N Y L N P S S G Q W G Q H H V S
 1229 ttggaggaaottggaagacagcttttatgaatatatttgccttaaggogtgggttaattgtctgaacaagacagatctcgaagacaaagaa
 410▶ V G G L G D S F Y E Y L L K A W L M S D K T D L E A K K
 1311 gatgtatttctgctgttccagccatcgagactcaacttgatacgcgaagtaagtggtgggactaaacgtaacatcgcagagtg
 437▶ M Y F D A V Q A I E T H L I R K S S G G L T Y I A E W
 1393 aagggtggccctcctggaaacacacagatgggocacctgaogtcttcttggaaggagcactgttttgcacttgggggaagatggagctc
 465▶ K G G L L E H K M G H L T C F A G G M F A L G A D G A
 1475 cggaaagocgggcccacaaactaacttgaactcggagctgaatggcccgacttgcctgaatcttataatcgtacatctgt
 492▶ P E A R A Q H Y L E L G A E I A R T C H E S Y N R T Y V
 1557 gaagtgggaacgggaagcgtttctgatttctgattggtgggtgtggaagctattggcagcagggacaaatgaaagtattacatotta
 519▶ K L G P E A F R F D G G V E A I A T R Q N E K Y I L
 1639 cggcccgaggtcactcgaacatacaatgtactgtggtgactgaactcagaccccaagtaagggccctgggocctgggaagcag
 547▶ R P E V I E T Y M Y M W R L T H D P K Y R T W A W E A
 1721 tggaggctctagaagaagtcactgcagagtggaagggaggtactactcaggttaccgggtgtttacatttgcctgagaggttatga
 574▶ V E A L E S H C R V N G G Y S G L R D V Y I A R E S Y D
 1803 cgaatgccagcaagttctctcctggcagagacactgaagtatttctgacttgatatttctcogagtgatgacotctctccaa
 601▶ D V Q Q S F F L A E T L K Y L Y L I F S D D L L P L
 1885 gaacactggtcttcaaaacccgaggtcctccttccctatactccgtgaacagaggaagaaattgctggcaagagaatga
 629▶ E H W I F N T E A H P F P I L R E Q K K E I D G K E K

FIG. 3 CONT

6/47




FIG. 4A

7/47




FIG. 4B

8/47




FIG. 4C

9/47




FIG. 4D

10/47




FIG. 4E




FIG. 4F

12/47








Fig. 5




Fig. 6






14/47





15/47



16/47



17/47



18/47







FIG. 11

19/47



20/47




FIG. 13

21/47




FIG. 14

22/47




FIG. 15

23/47





FIG. 16

24/47

FIG. 17

Applied Biosystems Voyager System 1246

Voyager S10c 51→BC→NR(200)BP = 1664.6, 6501



Mode of operation: Linear
 Extraction mode: Delayed
 Polarity: Positive
 Acquisition control: Manual

Accelerating voltage: 20000 V
 Grid voltage: 84%
 Guide wire Q: 0.05%
 Extraction delay time: 100 msec

Acquisition mass range: 850 - 2000 Da
 Number of laser shots: 100/spectrum
 Laser intensity: 2713
 Laser Rep Rate: 20.0 Hz
 Calibration type: Delayed
 Calibration method: 2,5-Dihydroxybenzoic acid
 Low mass gate: 800 Da

Dryer start time: 18.502
 Bin size: 2 msec
 Number of data points: 8878
 Vertical scale: 500 mV
 Vertical offset: 0%
 Input bandwidth: 150 kHz

Sample name: 47
 Plate ID: 100 WELL PLATE
 Serial number: 1246
 Instrument name: Voyager-DE
 Plate type/ID: C:\VOYAGER\100 well plate.pl
 Lab name: PE Biosystems

Absolute x-position: 31305.6
 Absolute y-position: 28093.3
 Relative x-position: -761.913
 Relative y-position: 1091.83
 Spot in spectrum: 100
 Source pressure: 4.39e-007
 Mirror pressure: 0
 TIC3 pressure: 0.004253
 TIS gate width: 30
 TIS flight length: 940

Printed: 06:41, June 19, 2003

Milestone IV gal

25/47




FIG. 18

26/47




FIG. 19

27/47




FIG. 20

28/47




FIG. 21

29/47






FIG. 22

30/47

**Selected Sequence(s)**

- Droso MannII (X77652),
C.elegans MannII,
rMannII (XM_218816.1),
hMannIIx D55649,
Mouse MannII (X61172),
human MannII (U31520),
CionaMannII (AK116684),
ArabMannII,
Insect ManIII,
hLyso MannII,
hCyto MannII (NM_006715)




FIG. 23

31/47

Fig. 23 (cont.)

Download a PostScript version of the output

```

Droso_MammII_[X] 1 -----
C.elegans_MammI 1 -----
rMammII_[X]_218 1 MACIGGAGGQGPDAVERKEPSEHQYPMXPMTGSGCSHALLKXTRMYCHQGCVRPPPTDVXN
hMammIIx_D55649 1 -----
Mouse_MammII_[X] 1 -----
hMammII 1 -----
CionaMammII_[AR] 1 -----
ArabMammII 1 -----
Insect_MammII 1 -----
hLyso_MammII 1 -----
hCyto_MammII_[N] 1 -----

Droso_MammII_[X] 1 -----
C.elegans_MammI 1 -----
rMammII_[X]_218 61 YKTTTDTQSVPGVATGKXGVTCCGAATPCAAVPSATMDRVOHDPAR-HQNGGHFPRS
hMammIIx_D55649 1 -----
Mouse_MammII_[X] 1 -----
hMammII 1 -----
CionaMammII_[AR] 1 -----
ArabMammII 1 -----
Insect_MammII 1 -----
hLyso_MammII 1 -----
hCyto_MammII_[N] 1 -----

Droso_MammII_[X] 40 YENEDRREELNGHCEBGEKERNARAKTNRD-----
C.elegans_MammI 37 CANDRRRGWASVVAEDNGRTIDRGEQERARARASVDFDEKXKTEKKEVEXERKHV
rMammII_[X]_218 120 ESVLONKEECASCLVEEMERISEREDSLEKANAEGPALLPY-----
hMammIIx_D55649 46 ESVLONKEECASCLVEEMERISEREDSLEKANAEGPALLPY-----
Mouse_MammII_[X] 47 ESILONKEEDRERLVAEMERISEREDSLEKANAEGPALLPY-----
hMammII 47 ESILONKEEDRERLVAEMERISEREDSLEKANAEGPALLPY-----
CionaMammII_[AR] 45 CHTTGDLSLSERENIERYARRKEDSDODKPMKHNVEVPMDGZIR-----
ArabMammII 37 AKKKRPRTTLVVFPAFFALAEVSLFFILTFHFGVPGPIS-----
Insect_MammII 28 YCYFYASPOYKXPRISYASEREPSSATRTVK-----
hLyso_MammII 1 -----
hCyto_MammII_[N] 34 RFFGASCPAVLSFPTPEPLPYQRAVQDFRPAQVG-----

Droso_MammII_[X] 77 -----
C.elegans_MammI 97 APVPVRGHRGEMAHIRQVQRIKPTPSMKDVSGIREHVSIAHSDQMSIDAEITWIFHPD
rMammII_[X]_218 166 BTANGSMVLPKPRPSFPSPSPDQFALGGRGQKPCMTISDEPFIHV-----
hMammIIx_D55649 92 YTVNGSMVLPKPRPSFPSPSPDQFALGGRGQKPCMTISDEPFIHV-----
Mouse_MammII_[X] 93 KASQGS-ILHLSPLA-LOADPRDCLFASQSGSGOPRQCHNDATLPEHPD
hMammII 93 KFSQAGCSHLLPSQLS-LSVDTADCLFASQSGSGHSDUCHNDASLISHPD
CionaMammII_[AR] 94 HNVKPVLPILMPKQFANDERMSTCPVLSYSGGXSQKGNHAGDEPFPDP
ArabMammII 83 SFLTSRSHRIVPRKNIWRPLNDHSGAVVDTTTDGDRREGLDTH
Insect_MammII 63 SDEPTPDQCPALKESEADIDTA YPTDFDQFSPMLRT
hLyso_MammII 13 GCLDSAGPWTMSRALRPPIPPCFILLIAAGAR
hCyto_MammII_[N] 71 DSGPTNWTCTMFRVELTIPAMGQVRLCWSDG

Droso_MammII_[X] 122 GGVWRCQNRPLIENARRK-DEFFVVPSEMDPG-----CT
C.elegans_MammI 157 GGVWRCQNRPLIENARRK-DEFFVVPSEMDPG-----MT
rMammII_[X]_218 219 GGVWRCQNRPLIENARRK-DEFFVVPSEMDPG-----KRT
hMammIIx_D55649 145 GGVWRCQNRPLIENARRK-DEFFVVPSEMDPG-----KRT
Mouse_MammII_[X] 144 GGVWRCQNRPLIENARRK-DEFFVVPSEMDPG-----KRT
hMammII 145 GGVWRCQNRPLIENARRK-DEFFVVPSEMDPG-----KRT
CionaMammII_[AR] 147 GGVWRCQNRPLIENARRK-DEFFVVPSEMDPG-----KRT
ArabMammII 132 GGPVRCQNRPLIENARRK-DEFFVVPSEMDPG-----KRT
Insect_MammII 101 KFFDKSEHDMRIRIRHTTRPRN-DEFFVVPSEMDPG-----KRT
hLyso_MammII 48 KGGITTCPTQPNM-DEFFVVPSEMDPG-----KRT
hCyto_MammII_[N] 107 SIMVDEGEPKGLTRCHITS--YLTDLRIGEDPES-----LTLY

Droso_MammII_[X] 162 EEEY-EDKHNTSWARRRNMFEEMFIMABISFAEDGRMLC
C.elegans_MammI 197 EEEY-EDKHNTSWARRRNMFEEMFIMABISFAEDGRMLC
rMammII_[X]_218 277 EEEY-EDKHNTSWARRRNMFEEMFIMABISFAEDGRMLC
hMammIIx_D55649 184 EEEY-EDKHNTSWARRRNMFEEMFIMABISFAEDGRMLC
Mouse_MammII_[X] 183 EEEY-EDKHNTSWARRRNMFEEMFIMABISFAEDGRMLC
hMammII 184 EEEY-EDKHNTSWARRRNMFEEMFIMABISFAEDGRMLC
CionaMammII_[AR] 186 EEEY-EDKHNTSWARRRNMFEEMFIMABISFAEDGRMLC
ArabMammII 171 EEEY-EDKHNTSWARRRNMFEEMFIMABISFAEDGRMLC
Insect_MammII 142 EEEY-EDKHNTSWARRRNMFEEMFIMABISFAEDGRMLC
hLyso_MammII 80 EEEY-EDKHNTSWARRRNMFEEMFIMABISFAEDGRMLC
hCyto_MammII_[N] 146 EEEY-EDKHNTSWARRRNMFEEMFIMABISFAEDGRMLC

```

214 S V K V G G C - L E F V T G G W V D E A T H E Y F A T A D O L I E G C R O L R R M G - V T F T A S A I D P F
Droso_MannII_[X 214 S V K V G G C - L E F V T G G W V D E A T H E Y F A T A D O L I E G C R O L R R M G - V T F T A S A I D P F
C.elegans_MannI 249 G Y T S A C K - F E V T G G W V D E A T H E Y F A T A D O L I E G C R O L R R M G - V T F T A S A I D P F
rMannII_[X_M_218 329 R I V G G G C - L E F V T G G W V D E A T H E Y F A T A D O L I E G C R O L R R M G - V T F T A S A I D P F
hMannIIa_D55649 236 R I V G G G C - L E F V T G G W V D E A T H E Y F A T A D O L I E G C R O L R R M G - V T F T A S A I D P F
Mouse_MannII_[X 235 S I T V G G C - L E F V T G G W V D E A T H E Y F A T A D O L I E G C R O L R R M G - V T F T A S A I D P F
hMannII 236 S I T V G G C - L E F V T G G W V D E A T H E Y F A T A D O L I E G C R O L R R M G - V T F T A S A I D P F
CionaMannII_[AX 238 T I V K G G C - L E F V T G G W V D E A T H E Y F A T A D O L I E G C R O L R R M G - V T F T A S A I D P F
ArabMannII 223 K I V K G G C - L E F V T G G W V D E A T H E Y F A T A D O L I E G C R O L R R M G - V T F T A S A I D P F
Insect_MannIII 194 K I K E C R - L E F V T G G W V D E A T H E Y F A T A D O L I E G C R O L R R M G - V T F T A S A I D P F
hLyso_MannII 140 D I V E C R - L E F V T G G W V D E A T H E Y F A T A D O L I E G C R O L R R M G - V T F T A S A I D P F
hCyto_MannII_[W 198 I A E G L K D E R S F C I T A T A M V V C D P A P T F P V G A L A C R F F S - Q R G G S Q E T H R A T

270 G S P T P P M T S A N I T A M O R V E S A R E L A L K N A S E Y F A T A D O L I E G C R O L R R M G - V T F T A S A I D P F
Droso_MannII_[X 270 G S P T P P M T S A N I T A M O R V E S A R E L A L K N A S E Y F A T A D O L I E G C R O L R R M G - V T F T A S A I D P F
C.elegans_MannI 307 G S P T P P M T S A N I T A M O R V E S A R E L A L K N A S E Y F A T A D O L I E G C R O L R R M G - V T F T A S A I D P F
rMannII_[X_M_218 375 G S P T P P M T S A N I T A M O R V E S A R E L A L K N A S E Y F A T A D O L I E G C R O L R R M G - V T F T A S A I D P F
hMannIIa_D55649 292 G S P T P P M T S A N I T A M O R V E S A R E L A L K N A S E Y F A T A D O L I E G C R O L R R M G - V T F T A S A I D P F
Mouse_MannII_[X 291 G S P T P P M T S A N I T A M O R V E S A R E L A L K N A S E Y F A T A D O L I E G C R O L R R M G - V T F T A S A I D P F
hMannII 292 G S P T P P M T S A N I T A M O R V E S A R E L A L K N A S E Y F A T A D O L I E G C R O L R R M G - V T F T A S A I D P F
CionaMannII_[AX 294 G S P T P P M T S A N I T A M O R V E S A R E L A L K N A S E Y F A T A D O L I E G C R O L R R M G - V T F T A S A I D P F
ArabMannII 279 G S P T P P M T S A N I T A M O R V E S A R E L A L K N A S E Y F A T A D O L I E G C R O L R R M G - V T F T A S A I D P F
Insect_MannIII 250 G E A C V F T A D Q S L E G T I O R E M A R Q M L A R Q I E B E L A S A T - K P S I V E M O P E
hLyso_MannII 198 G S P T P P M T S A N I T A M O R V E S A R E L A L K N A S E Y F A T A D O L I E G C R O L R R M G - V T F T A S A I D P F
hCyto_MannII_[W 257 G E C H I D T A M P - S E R T A C A R S A T A L Q M E W P E S A C S - Q A Q L W V I S R Y G

330 Y S O I P H T C G P P R C C O F D P P A P G G G S - C D G E P P O K I M D E V A R S A L D O Y R R R
Droso_MannII_[X 330 Y S O I P H T C G P P R C C O F D P P A P G G G S - C D G E P P O K I M D E V A R S A L D O Y R R R
C.elegans_MannI 367 Y S O I P H T C G P P R C C O F D P P A P G G G S - C D G E P P O K I M D E V A R S A L D O Y R R R
rMannII_[X_M_218 435 Y S O I P H T C G P P R C C O F D P P A P G G G S - C D G E P P O K I M D E V A R S A L D O Y R R R
hMannIIa_D55649 352 Y S O I P H T C G P P R C C O F D P P A P G G G S - C D G E P P O K I M D E V A R S A L D O Y R R R
Mouse_MannII_[X 351 Y S O I P H T C G P P R C C O F D P P A P G G G S - C D G E P P O K I M D E V A R S A L D O Y R R R
hMannII 352 Y S O I P H T C G P P R C C O F D P P A P G G G S - C D G E P P O K I M D E V A R S A L D O Y R R R
CionaMannII_[AX 354 Y S O I P H T C G P P R C C O F D P P A P G G G S - C D G E P P O K I M D E V A R S A L D O Y R R R
ArabMannII 339 Y S O I P H T C G P P R C C O F D P P A P G G G S - C D G E P P O K I M D E V A R S A L D O Y R R R
Insect_MannIII 309 D I S I S T S C G P P S I C L S D P P T E C - Y S E K A R K E D I B U R S E Y F A T A D O L I E G C R O L R R M G - V T F T A S A I D P F
hLyso_MannII 252 G V P S G G G P P R C C O F D P P A P G G G S - C D G E P P O K I M D E V A R S A L D O Y R R R
hCyto_MannII_[W 313 L Y S K C R F A C R G Q P P V G G T V E D S I P S G E A K V R Q Y L Q G Q F F Q R F I C S P L P D

389 A E T E V U L A M P L G D D F E K O N T E D V C V M E S L P R H S E - A R F E V C A O F G T L O Y F D
Droso_MannII_[X 389 A E T E V U L A M P L G D D F E K O N T E D V C V M E S L P R H S E - A R F E V C A O F G T L O Y F D
C.elegans_MannI 426 S O K T M V V E C P L G D D F E K O N T E D V C V M E S L P R H S E - A R F E V C A O F G T L O Y F D
rMannII_[X_M_218 494 S O K T M V V E C P L G D D F E K O N T E D V C V M E S L P R H S E - A R F E V C A O F G T L O Y F D
hMannIIa_D55649 411 S O K T M V V E C P L G D D F E K O N T E D V C V M E S L P R H S E - A R F E V C A O F G T L O Y F D
Mouse_MannII_[X 410 S O K T M V V E C P L G D D F E K O N T E D V C V M E S L P R H S E - A R F E V C A O F G T L O Y F D
hMannII 411 S O K T M V V E C P L G D D F E K O N T E D V C V M E S L P R H S E - A R F E V C A O F G T L O Y F D
CionaMannII_[AX 413 S O K T M V V E C P L G D D F E K O N T E D V C V M E S L P R H S E - A R F E V C A O F G T L O Y F D
ArabMannII 399 S O K T M V V E C P L G D D F E K O N T E D V C V M E S L P R H S E - A R F E V C A O F G T L O Y F D
Insect_MannIII 366 G S T P P B U V A M P L G D D F E K O N T E D V C V M E S L P R H S E - A R F E V C A O F G T L O Y F D
hLyso_MannII 303 G R Y T P P B U V A M P L G D D F E K O N T E D V C V M E S L P R H S E - A R F E V C A O F G T L O Y F D
hCyto_MannII_[W 373 F G S A C A P O M B G C G I R E P L T Q L S L V N S F P R H T F W E G L D G S R U L E P P P G D S G M

448 T B O A R R A G - G - A E F T L S G D P P T A D R S D - Y M S G Y T S R P F R R
Droso_MannII_[X 448 T B O A R R A G - G - A E F T L S G D P P T A D R S D - Y M S G Y T S R P F R R
C.elegans_MannI 485 E D D T A I S A S - G - I Q L T F S G D P P T A D R S D - Y M S G Y T S R P F R R
rMannII_[X_M_218 553 I Y K R T G V E - P G A R P C P P V L S G D P P T A D R S D - Y M S G Y T S R P F R R
hMannIIa_D55649 470 I Y K R T G V E - P G A R P C P P V L S G D P P T A D R S D - Y M S G Y T S R P F R R
Mouse_MannII_[X 469 I X S A V A A E - K I S S G V P A L S G D P P T A D R S D - Y M S G Y T S R P F R R
hMannII 470 I X S A V A A E - K I S S G V P A L S G D P P T A D R S D - Y M S G Y T S R P F R R
CionaMannII_[AX 472 I X S A V A A E - K I S S G V P A L S G D P P T A D R S D - Y M S G Y T S R P F R R
ArabMannII 458 T R R R A D R V N Y S R P G V G S G Q V V G S L S G D P P T A D R S D - Y M S G Y T S R P F R R
Insect_MannIII 426 A K R R R Q N - I S S K G D P P T A D R S D - Y M S G Y T S R P F R R
hLyso_MannII 361 E U K A F - L T S V X R D P P T A D R S D - Y M S G Y T S R P F R R
hCyto_MannII_[W 433 Q G S V E V L L - V A N N R D R G A N S A F I G P D G G G G P T Q M

492 D R V T M Y D R A E T A M S M D - M A R - I E R P V C A R R S L F O R B D
Droso_MannII_[X 492 D R V T M Y D R A E T A M S M D - M A R - I E R P V C A R R S L F O R B D
C.elegans_MannI 529 D R V T M Y D R A E T A M S M D - M A R - I E R P V C A R R S L F O R B D
rMannII_[X_M_218 601 D R V T M Y D R A E T A M S M D - M A R - I E R P V C A R R S L F O R B D
hMannIIa_D55649 518 D R V T M Y D R A E T A M S M D - M A R - I E R P V C A R R S L F O R B D
Mouse_MannII_[X 517 D R V T M Y D R A E T A M

rMannII_XM_218	715	GSOST	HPSAALVPAALAAAG	LPOR-AP	PV	NPPL	CERLS	V	LVSPR	RV	SEE
hMannIIz_D55649	630	LSBDA	P	-----	ERTV	OLDS-SP	PV	NPPL	CERFS	V	LVSPR
Mouse_MannII_X	629	SSQDS	P	-----	QZII	QLSAQEP	P	NPPL	CERRS	V	LVSPR
hMannII	630	XSQDS	P	-----	QZII	QLSAQEP	P	NPPL	CERRS	V	LVSPR
CionaMannII_[AK	626	QMOOPAP	-----	VVVK	PTINEEA	AV	NSL	YDSTG	VE	IVTSPD	VV
ArabMannII	627	YDARP	HPK	-----	AAAREG	SET	CT	SEE	V	VUNRAE	SV
Insect_ManIII	590	PXX	-----	QVSFID	KK	NP	PAKT	TR	V	REN	SH
hLyso_MannII	508	R	-----	FO	NP	GRV	W	VR	PUSIG	GV	VLDPN
hCyto_MannII_[N	583	-----	SCIQVAKRA	CR	ED	RSRGT	-----	AAAAAL	CAGE	PGPR	-----
Droso_MannII_[X	648	N-NP	URAC	SPV	WHRD	TLT	KTIR	PGSTT	R	IFAR	PP
C.elegans_MannI	674	P-PIK	QOP	SVI	AYD	ERTT	LVVNG	-----	I	CM	GP
rMannII_XM_218	774	G-OP	SV	ISV	CSATH	MVPD	-----	V	CSVPVR	PA	GLGVLC
hMannIIz_D55649	680	G-OP	SV	ISV	CSATH	MVPD	-----	V	CSVPVR	PA	GLGVLC
Mouse_MannII_[X	680	G-OP	SV	ISV	CSATH	MVPD	-----	V	CSVPVR	PA	GLGVLC
hMannII	680	G-OP	SV	ISV	CSATH	MVPD	-----	V	CSVPVR	PA	GLGVLC
CionaMannII_[AK	677	X-NV	PS	CTSH	EDST	IRTD	-----	C	SVLS	PA	GLAVR
ArabMannII	676	M-TC	VP	SO	SEV	CHDD	TLFTG	-----	RER	YKA	PA
Insect_ManIII	633	KRKE	LYL	PS	SI	IQD	GKSVS	-----	DTT	MEVA	SPITS
hLyso_MannII	541	G-RT	PSD	VIFP	SD	QARPP	-----	-----	-----	-----	-----
hCyto_MannII_[N	623	G-L	IV	TL	EW	XIE	VMA	LKPC	-----	GAB	LALV
Droso_MannII_[X	706	RTSY	ASH	LL	RA	NPT	SLP	IGC	PHD	KFG	DP
C.elegans_MannI	728	VEIT	TH	AA	RP	KETS	PS	SS	TSG	DFT	-----
rMannII_XM_218	824	LQSS	V	RY	LL	NG	V	L	VER	QTT	-----
hMannIIz_D55649	730	LPSS	V	RY	LL	NG	V	L	VER	QTT	-----
Mouse_MannII_[X	730	LADY	V	LY	NED	-----	GLA	ENG	IR	EL	VD
hMannII	730	LADY	V	LY	NED	-----	GLA	ENG	IR	EL	VD
CionaMannII_[AK	727	TRST	V	KP	IN	PR	V	G	F	K	TR
ArabMannII	727	ATPS	K	L	X	A	S	F	D	P	P
Insect_ManIII	688	CVIF	C	NH	-----	CR	Q	X	Q	S	N
hLyso_MannII	589	ARAP	Q	P	-----	PP	Q	ET	D	G	S
hCyto_MannII_[N	674	QD	-----	-----	-----	-----	-----	-----	-----	-----	-----
Droso_MannII_[X	763	TCH	SP	H	V	P	Y	K	E	L	K
C.elegans_MannI	785	NH	P	I	R	G	A	R	S	K	R
rMannII_XM_218	881	VH	Q	H	Q	O	O	V	-----	-----	-----
hMannIIz_D55649	787	VH	Q	H	Q	O	O	V	-----	-----	-----
Mouse_MannII_[X	782	RH	S	R	Q	H	E	E	-----	-----	-----
hMannII	781	KH	S	R	Q	H	E	E	-----	-----	-----
CionaMannII_[AK	782	VH	Q	H	Q	O	O	V	-----	-----	-----
ArabMannII	781	RH	S	R	Q	H	E	E	-----	-----	-----
Insect_ManIII	738	KH	S	R	Q	H	E	E	-----	-----	-----
hLyso_MannII	628	ME	Q	L	L	P	Y	O	T	E	F
hCyto_MannII_[N	714	RH	S	R	Q	H	E	E	-----	-----	-----
Droso_MannII_[X	808	LV	H	S	K	E	S	S	V	G	-----
C.elegans_MannI	830	W	I	V	C	H	E	S	S	V	G
rMannII_XM_218	927	LV	H	S	K	E	S	S	V	G	-----
hMannIIz_D55649	833	C	-----	-----	-----	-----	-----	-----	-----	-----	-----
Mouse_MannII_[X	828	LV	H	S	K	E	S	S	V	G	-----
hMannII	827	LV	H	S	K	E	S	S	V	G	-----
CionaMannII_[AK	829	LV	H	S	K	E	S	S	V	G	-----
ArabMannII	821	LV	H	S	K	E	S	S	V	G	-----
Insect_ManIII	792	LV	H	S	K	E	S	S	V	G	-----
hLyso_MannII	678	LV	H	S	K	E	S	S	V	G	-----
hCyto_MannII_[N	759	LV	H	S	K	E	S	S	V	G	-----
Droso_MannII_[X	852	LV	H	S	K	E	S	S	V	G	-----
C.elegans_MannI	879	LV	H	S	K	E	S	S	V	G	-----
rMannII_XM_218	977	LV	H	S	K	E	S	S	V	G	-----
hMannIIz_D55649	874	LV	H	S	K	E	S	S	V	G	-----
Mouse_MannII_[X	878	LV	H	S	K	E	S	S	V	G	-----
hMannII	877	LV	H	S	K	E	S	S	V	G	-----
CionaMannII_[AK	882	LV	H	S	K	E	S	S	V	G	-----
ArabMannII	880	LV	H	S	K	E	S	S	V	G	-----
Insect_ManIII	846	LV	H	S	K	E	S	S	V	G	-----
hLyso_MannII	727	LV	H	S	K	E	S	S	V	G	-----
hCyto_MannII_[N	814	LV	H	S	K	E	S	S	V	G	-----
Droso_MannII_[X	902	LV	H	S	K	E	S	S	V	G	-----
C.elegans_MannI	929	LV	H	S	K	E	S	S	V	G	-----
rMannII_XM_218	1027	LV	H	S	K	E	S	S	V	G	-----
hMannIIz_D55649	922	LV	H	S	K	E	S	S	V	G	-----
Mouse_MannII_[X	928	LV	H	S	K	E	S	S	V	G	-----
hMannII	927	LV	H	S	K	E	S	S	V	G	-----
CionaMannII_[AK	932	LV	H	S	K	E	S	S	V	G	-----
ArabMannII	930	LV	H	S	K	E	S	S	V	G	-----
Insect_ManIII	898	LV	H	S	K	E	S	S	V	G	-----
hLyso_MannII	785	LV	H	S	K	E	S	S	V	G	-----
hCyto_MannII_[N	858	LV	H	S	K	E	S	S	V	G	-----
Droso_MannII_[X	960	LV	H	S	K	E	S	S	V	G	-----
C.elegans_MannI	987	LV	H	S	K	E	S	S	V	G	-----
rMannII_XM_218	1085	LV	H	S	K	E	S	S	V	G	-----
hMannIIz_D55649	980	LV	H	S	K	E	S	S	V	G	-----

34/47

```

Mouse_MammII_[X] 986 E P A N M K E E X X ----- S P V S L P S L S R T S S P L A E F P P V L S G
hMammII 985 E P A N T E E E X X ----- S - V S L P S L S R T S S L A E F P P A N
CionaMammII_[AX] 990 E P A A A K E S I S S ----- A K L A P S S A V Y Q S S W E L E R P S S E G
ArabMammII 989 E S E T S Q A D P A S E T ----- H P R P S L S R S L G A R P T P E N T F I A K K
Insect_ManIII 956 E S M P G T R A R D T S R P G Y X P V N E R R P G P G Q R E S P Y Q V S O T A D Y I S R M P T P E N T F I A K K
hLyso_MammII 843 V L L D T A Q A A A A G H R ----- L A R O E L A E C V L A P G G
hCyto_MammII_[N] 916 Q D A G V Q A A Y S L N ----- P L L A L P A P S P A P A T E M S A F S S S S

Droso_MammII_[X] 1000 N E W I G A G G O ----- Y G G D E S S A R E D N D S V P R L T I S
C.elegans_MammI 1027 T P L S I S S I E ----- E C O R D E C D R E P T F R A S P T T Y
rMammII_[XM_218] 1126 R E S T S P T E ----- S E R P P A S P M P C O F E L A A L S M P A R V S V P V R A N P R Q A P C I L L G R H A A D
hMammIIx_D55649 1020 M Q L P G P G R ----- S E R P P A S S M P C O F E L A A L S M P A R V S V P V R A N P R Q A P C I L L G R H A A D
Mouse_MammII_[X] 1027 - Q L P S P A F N L L S E P P L O S S L P C D S E L Y D L A R O S K N G
hMammII 1023 - X F S S P T E L Q G E S P P O S S L P C D S E L Y D L A R O S K V G
CionaMammII_[AX] 1032 ----- P E L L E D R A S P P O P M P C O F E L A A L S M P A R V S V P V R A N P R Q A P C I L L G R H A A D
ArabMammII 1029 P Q D I S V R P Q Y G S P A P P A K P M P C O F E L A A L S M P A R V S V P V R A N P R Q A P C I L L G R H A A D
Insect_ManIII 1016 S E V G E I E X P ----- Q S F L O S F P P G E L L T L R E D D V L E
hLyso_MammII 875 G A A X H L G A P P T Q S G F R D D P S E L L T L A W G P E K V L L R
hCyto_MammII_[N] 953 P A V V L E T K ----- Q A E S S P Q R S H V A R L Y R A N

Droso_MammII_[X] 1032 ----- S A K T O R V Y H R T H L M C T P E R T Q X L D V C R I L P H V A R C H R T T T F L
C.elegans_MammI 1059 E A N E R S T A E I X A A M V M H R V P D C R - S E L L T P D T S C L A T G L I E P K I
rMammII_[XM_218] 1183 P P P L L S L T V P Q D T L P A A D A P Q A R R G P C E A H G F N C T O G K L A G S L F R G D L
hMammIIx_D55649 1054 D T L P A E T A G A R R G P C E A H G F N C T O G K L A G S L F R G D V
Mouse_MammII_[X] 1064 I G Y D E A L A R R G P C O F S S G G L P C T O G K M E V L L F N K P A X
hMammII 1060 E G E W E A L A R R G P C O F S S G G L P C T O G K L A G S L F R G D V
CionaMammII_[AX] 1064 ----- V A P D O S A M P E T V G R C S D A D K Y F P T C L M G V E R L A I T I S T P T N
ArabMammII 1068 Q Q L E R D P R F A T P E R A N S Y C H G R O V N C S M A N E P V H F S D M P K L A A
Insect_ManIII 1052 L P F E S Y S V A R P G S G A G H P A S P K F S T R F E G L N I C H T A V
hLyso_MammII 916 L E R O F A V E D S G E L S A P V T E L D Y S T P I E L Q R T L V A N Q L E R A A
hCyto_MammII_[N] 981 C E R V D C W E L S L P V O E L C D L E R P D P A G H L T S G P P E A N L F S P

Droso_MammII_[X] 1081 Q N D E R L D G M A P E V C P M E ----- T A A Y S R S S
C.elegans_MammI 1107 S T P L S A K I E S T N I X E G N ----- E A R O F R P O F E I S I L S V
rMammII_[XM_218] 1243 F - H O P S T A Y P L A S P S ----- N S T D E S P M E I S T P L G
hMammIIx_D55649 1103 F - H O P S T A Y P L A S P S ----- N S T D E S P M E I S T P L G
Mouse_MammII_[X] 1112 S - I V P S T A Y S P P D A Q ----- N M S E E S P M E I S T P L R W T
hMammII 1108 S - I T P S T A Y S P P G T O ----- N I S E E S P M E I S T P L R
CionaMammII_[AX] 1112 S G T R X S T A Y C H D G S L L D ----- F O G G E S P M E I S T P L R
ArabMammII 1119 S A K P E S T E S Q E D M E I L G Y D D Q E L P R D S S Q P R E G E S P M E I R A E D R P H X
Insect_ManIII 1100 S L T G L I S T E P T G ----- L E D E T W A E S L E S P
hLyso_MammII 965 S P T X W E S G P T P R Q T P Y ----- Q L D P A E E S P M E I R T L A S Q W K E V D G
hCyto_MammII_[N] 1027 S A P V A R A S A T L S P W G ----- W G F V C R E P W G I L S A S P A

```

Return Help Report Bugs

Citation

Algorithm Citation:

Not given, but presumably Kay Hofmann and Michael D. Baron.


Program Citation:

Boxshade version 3.3.1, by Kay Hofmann and Michael D. Baron.



35/47

FIG. 24



Arabidopsis thaliana Mannosidase II (NM 121499)

[illegible]

37/47

FIG. 26

C. elegans Mannosidase II (NM_073594)

```

1  ATGGGAAAACCGCAATTTCTATATTATCTTATCTTCTGGAGTCTTTCTCAGCTATCACTCTATTGTACAATGGAATTGAAACCGGAGCTGAAGCGCTCACCAGGACA
2  M G K R N F Y I I L C L G V F L T V S L Y L Y N G I E T G A E A L T K R Q
111 ACCAAATGATTACCGCGGAAATTCGAAATTTGGAGCATGTAGCAGACAGAAATGGAAGACGATAGACCGCTTGGAAACAGCAAGTTCAACGAGCAAAAGCTCAAAAAAT
37  A N D L R R K I G N L E N V A E E N G R T I D R L E Q E V Q R A K A E K
221 CGGTAGATTTTGTGAGCAAAAAGCAAAAAGCAAAAAGCAAAAAGCAAAAAGCAAAAAGCAAAAAGCAAAAAGCAAAAAGCAAAAAGCAAAAAGCAAAAAGCAAAAAGCA
74  S V D F D E E K E K T E E K E V E K E E K E V A P V P V R G N R G E M A H
331 ATTCATCAAGTAAAGCAACATATCAAGCCAATCCATCGATGAAAGATGTTTGTGGAATTAGAGAAAACGTCAGCATTGCTCAATCAGACCTGCAGATGCTCGATCTTA
133 I H Q V K Q H I K P T P S M K D V C G G I R E N V S I A H S D L Q M L D L Y
441 TGACACCTCGAAGTTCGAAATTCAGACCGGAGCTGTATGGAACAGAGATGCAAAATCAATACGATCCAGACAACTCAAAATCTCTCCAGCTTTCGAACTTATTGTGA
147  D T W K F E N P D G G V W K Q G W K I E Y D A E K V K S L P R L E V I V
551 TACCTCATCTCAATGTGATCCCGGATGATATGATCTTCCAGAGATATTACAACAGACAAACTCGCAATATTCTGATGGAATGGCTAAACATTTCCGACAAAAGAC
144  I P H S H C D P G W I M T F E E Y Y N R Q T R N I L D G M A K H L A E K D
661 GAAATCGCGTTTATATATGAGAAATATCATTTTTCGAACTTGGTGGACAGACCGGACATCAAAATTAAGAAAGTTAAAGCATATTTCGAAAGCAGGAAAGTTTGA
221  E M R F I Y A E I S F F E T W W R D Q A D E I K K K V K G Y L E A G K F E
771 AATGTACTGCGGATCGGTTATGACAGATGAAGTAAAGCAATATCACTCAATGATCACTCAATGTTTCCAAAGGACATGAATGCATTCAAAATCATTTCCGAAATTA
257  I V T G G W V M T D E A N A H Y H S M I T E L F E G H E W I O N H L G K
881 CCGCCATTCGCAATCTCAATGCTCAATGATCCATTCGCTTATCACCATCAATGCCACATCTTCAACTCTGCTAATATACCAATGCTGTAAATTCGAAAGCTTCF
294  S A I P Q S H W S I D P F G L S P S M P H L L T S A N I T N A V I O R V H
991 TATTCGGTCAAGCTGAGTCTGCTCAAAAAGAACTTCAATCTCACTGAGACAAATATTGGATCACTCGACATCTGATCTTCTTACATATATGCTCTTCTA
311  Y S V K R E L A L K K N L E F Y W R L F G S T G H P D L R S H I M P F Y
1301 CTCTACGATATACCTCATAGCTGTGCGCCAGAACTCTCTGTTGCTCAATTCGATTCGCTAGCAATGCCAGAGCTGCAAAATCATGTGATTCCGAAATCTCTCCAC
367  S Y D I P H T C G P E P S V C C Q F D F R R M P E G G K S C D W G I P P
1211 ACAAATATCAAGTACCAATGCTGCTCAGACAGCTCAAAATGATTTATGATCAATATAGAAAGAAAGTCAAACTTTCAAGAAATATGTGATTTTCAACCACTTCGAGAT
404  Q K I N D D N V A H R A E M I Y D Q Y R K K S Q L F K N M V I F O P L O D
1321 GATTCAGGTACCAATGATTTTCAATGCAATTCACAATATCAAACTATCAAACTATCAAACTATCAAACTATCAAACTATCAAACTATCAAACTATCAAACTATCAAACT
441  D F R Y D I D F E W N S Q Y E N Y K K L F E Y M N S K S E W N V H A Q F G
1431 AACTCTTCTGATTATTCAAGAGCTTGATGATGCAATTTCTGCGCTCTGCGGAGCACTTCAAACTTTTCTGAGATTTCTTCACTATGCGGACAGAGATGATCAT
477  T L S D Y F K K L D T A I S A S G E Q L P T F S G D F F T Y A D R D H
1541 ATTGGAGTGGATACTTCACTTCCCTCCATCTATATAACAGCTTCACTGCTTCTCAAACTATTTAAGATCAGCTGAAATCGCTTTACCTTTCAAAATATGCAAGAA
514  Y W S G Y F T S R P F Y K Q L D R V L O N Y L R S A E I A F T L A N I E E
1631 CAAGCAATGCTTCAAGCAAAATTTTCAGAACTTGTGACTGCTCAGCAGCTCTTCACTTTTCAACATCAGCATGCTGTAATGCTGACGCAAGAAAGTCAAGTCTG
551  E G M V E A K I F E K L Y T A R R A L S L F Q H H D G V T G T A K D H V V
1761 CTTCGATATGCTCAGAAATGATGATGCTTTGAAGCAATCTGAGGATATTTCTTGGAACTCTTGTGATTGCTGGAATGATTCAACCAATGAAGATGCAAGTGG
587  L D Y G Q K M I D A L N A C E D I L S E A L V L L G I D S T N K M Q M
1871 ATGACCATAGCTTATGCAAACTTCTACCCGAAAGCTGTCTATATAATTCGGCAAAAGCTGCTATTGTTCAATCTTTATCTAGAAATCGCAACGAGCAATTTGT
624  D E H R V N E N L L P E K R V Y K I G Q N V V L F N T L S R N R N E P I C
1981 ATTCAGTGTGATTCTTTCAGCTGCTGCTGCAAGCTCATCTTCCAATTAAGAAACAGCAAGTTTCCCGCTTATTGATATGATGAAGCAAGAAAGTTCGAAATGCAACAA
661  I Q V D S L D A G V E A D P P I K K Q Q V S P V I A Y D E E K K T L V V K
2091 AAACGCAATATTGCAACTTCTGCTTATCTTCACTTCCACCAATGGAGTCTGTCAGTTTCAAGATTTGCAAAATATCAACAACTCCAAGTTGAAATTAATCACCATA
697  N G I F E L C F M L S L G P M E S V S F R L V K N T T T S K V E I I T N
2201 ATCCGCGCAATTCAGAAAGCAAGTTTAAATCTTCACTCACTTCTGAGCACTTACTCTCAAAACGACAAAGTTCAAGCTGAAATTTGATGCAAGAAATGCAATGAT
724  N A A E F K E T S F K S S S T S G D P T V K N D K V E A E F D G E N G M I
2321 AAAGAGCTACCACTCTTGTGATGATATAACCAATGATTGAAATCTCACTTATTCAATTGAGGACGGAAGTCAAGAGAAAGTTCGAAATGCAATGCAACAA
773  K R A T S L V D D K P I O L N S H P I N Y G A R K S K R K F A N G H E D N
2421 CCGGCTGCGGATACCTGCTTCTTCCGATGCAAGCTAGACAACTCAAAACCAATCAAGTCAATGATTCGATATGCTGAAAGCAAGTTCGAAATGCAATGCAACAA
807  P A G A Y L F L P D G E A R E L K K Q S S D W I L V K G E V V Q K V F A
2531 CTCCAAACATGATCTCAAAATTTGCAACGTAACATTTATCAAGCGCTTCCATGCAATGATTGATTAATGAAGTTTCAATGCTTCCAAAGCAAAATTTCCAGTTG
844  P T P N N D L K I L O T Y T L Y Q G L P W I D L D N E V D V R S K E N F E L
2641 GCACATGATTCAGTTCTTCAATTAATAGTGTGATGATTTTCACTGATTTCACTGATTTCACTGATTTCACTGATTTCACTGATTTCACTGATTTCACTGATTTCACTGAT
881  A I R F S S S V N S G D E F F T O L N G M Q M I K R R R Q T K L P T Q A N
2751 TTTCTATCCATGCTCTGCTGCTTACATTCAGTACGATACGAGTCTCAGCAAGCACTTACAGCAAGCACTTACAGCAAGCACTTACAGCAAGCACTTACAGCAAGCACT
927  F Y P M S A G V Y I E D D T T R M S I N S A Q A L G V S S L S G Q I E
2861 TAATGCTTATGCAAGCACTTATGTCAGATGACAAAGCTCTCAGCAAGCACTTACAGCAAGCACTTACAGCAAGCACTTACAGCAAGCACTTACAGCAAGCACTTACAGCA
954  I M L D R R L S S D D N R O L O G V R D N K R T V A H F R I V I E P M S
2971 TCATCGAGTGTAAATAGAGCAAGCAAGCTTGGATTCGATTCAGTGTGATTCAGTGTGATTCAGTGTGATTCAGTGTGATTCAGTGTGATTCAGTGTGATTCAGTGTGAT
991  S S S G N K K E E R V G F H S H V G H L A T W S L H Y P L V K M I G D A T
3081 ACCAAATCTATTCTTTCGAAATGCTGCAACAGCAAGCTCAACTGACCTGACATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT
1027  P K S I S S K N V E Q E L N C D L H L V T F R T L A S P T T Y E A N E R
3191 CTACGCGCTGAGCAAGCAAGCAAGCTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT
1064  S T A A E K K A A M V M H R V T G C R S R L T L P D T S C L A T Q L E I
3301 GAGCGCTCAATGATCTGCAAGCAAGCTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT
3301  E P L K L I S T L K S A K K T S L T N L Y E G N K A E Q F R L O P N D I S
3411 CAGTATTCTGATCATTTTAA
3527  S I L V S F

```

Cjona intestinalis mannosidase II (AK116684)

1 ATGAAGCTCAAAAGCCAGCTTCTATTCTTGGTGGAAATCTGTTCTCGGAGATATCTGGTTATCATAGGTCACCTTGACACTCCTAATTCGCCACAGAAAGCTCAAT
120 1) M K L K R Q F L F F G G I L F F G S I M G Q L D T P N S P Q K V K
2) TCTCGGAAGGCACTGAATAATGACCAATTCACCACTTCACAGCAAACTAGTCTGGTGAAAAACAAATGTTACAAAATCTGAATAATGACCAAGCTCAAGAGATAG
37) F S E G S E N D Q V R T L O D K L S L V E K E L L E N R K I M H K V K D S
219 TCTACAGGATATGACACCCATCAAAAATGTTTCATGTGCTTATGCGCCGGAGAAATAAGAAACAACTCAATAAACTCTGTCTACCACTTATAATGCCAACAAATTT
73) L O D M T P M K N V N V P M O R G E I R N N V N K P V L P L I M P K Q F
328 GCGAATGACTCECCAACTGACGTGACGCTGCTCTGTCTCTGATCTCCGTCGGCAAGTCCGATGTTAAAGATTAACGTATGATCATCTCCATTTGATGATCCAG
110) A N D S R M S D T C P V L T S Y S G G K S D V N M I N V Y D H L P F D O P
437 ATGCTGCACTTTCGAAACAAGGTTGGCAGATTCGAGATCGGATCAGGAATGGGCTGGGAGAAATTCGAAAGTGTTCATGTCCCTCAGTCACATGATCATGCTCTGCTG
146) D G G V W K Q G W D I Q T S D Q E W A G R K L K V F I V P H S H N D P G W
546 TTTAAAGCAAGCTGCAAGATACCTTCAGAGCTCAAAACAACATATCTCAATATATTTGGATGCTTTGAGTCAAGACCTTCCAGCAAGCTTTATCTGGCCAGAGAT
682 L K T V E R Y F S D Q T Q H I L N N I V D A L S Q D P A R K F I W A E M
155 TCGTATCTCTCAATGTGGTGGCACTTGCCACACTCATCTGAAGCAAAATGCAACACTCGTCAAGAAAGTGCAACCTTGAGATATCTACGGCTGGTGGCTCATCA
719) S Y L S M W W D I A T P D R K Q K M Q T L V K A G G O L E I V Y T G G W V M
764 ATGATGAAGCAAACTCATTACTTGTATGCTATGCTCACTCACTGAAAGTATGGAAGTGTTCAGGCAACGTTCAATGTTGTTCAAAAAGTGGGTGGGCAATGA
255) N D E A N T Y F A M I D Q L I E G M E W L R R T L R N V V P K S G W A I D
873 TCCCTTTGGTCACACCCCAAGCTGCTTATATGCTCAAAACAGATCAAGTTCAAAAACATCTGGATCAAGAGAGTCCATATGCACTCAAGCAAGTATCTTGGTCAGGA
291) P F G H T P T M A Y I L K Q M K F K N M L I Q R V H Y A V K K Y L A G E
982 AAGTCTCTGGAATTCAGATGAGACAAATTCGGAATTCAGCTTCAGTACAGACATGATGCTCTCATCTCATGCTTCTTATCATATGATGTTCCCTCACTACTTGTGGCC
328) K S L E F R W R Q M W D S A S S T D M M C H L M P F Y S Y D V P H T C G
1091 CAGACCCCAAGATTTGCTGCCAGTTTCATTTGCTGCTTACCCCGGCAAGATAAATCCCATGAAAGTTCTCTCTGTTCCCATCACTCAATCATAGAAAT
164) P D P K I C C Q F D F A R L P G G K I T C P W K V P V A I T D S N V E T
1200 ACAGCTCGGAATCACTCTGCAACATATGACAAAAGTCAAAACTCTCAAAAGTGAACCTGCTTATATATAGCAGATCATTTCTTATTCGTCAGCAAGCA
409) R A G I L L D O Y R K K S K L F S D T L I I L G D D F R Y B L S K E
1308 ACCCAAGTCAGTTTCAAACTACCTCGAATATCTCTGATGTAATTCGACCCAGAGTTAAAGCCAAATCTCAGTTTGAACATATTCGAATTTATGATGCCA
437) T N O Q D F N Y A R I S Y V N S H P E L N A K L Q F G T L S E Y F D A
1418 TCAATATCTGAAGTGGGGGAGGAGAAAATCCAGCTTTAAGTGGTATTTCTTCACTTATGCTCATAGCAAGATCATATTTGGAGTGGTACTACCTTACCGGCC
473) M K S E V G G E E K L P A L S G D F F T Y A D R E D H Y W B G Y Y T S R F
1527 TTACCACAAAATGCGAGGACAGCTCTCGGAAGCCACTCTCGAGGACAGAAATGTTGTTTGGCTCTCATGCCCAAAATCCAGTGGCAGCAGCTTGGTGAACACTT
509) Y H K M O E R Y L S E S H L R G A E M L F A L S W P K I Q W T O L G E T F
1636 TCATGAACTTTACCTCACTGGTGGCAAGCATCAAAATCTGCTGTTTCTTCAACCAAGCATGCTGATAACAGGCAAGCAAGCATCATGTTTGGTCAATAGC
546) S H E L Y P L L V Q A R O N L G L F Q H N D G I T G T A K D H V V D Y
1745 GGAATAACTCATGAAGAGTGTATGGAATGCAAAAGCTAATTTATACAGTCCCAAGTCTCTTGCAGAAAGATGATCAGTTTCTCATTAACATACCATGCTACTTA
592) G N K L M K S V M D A K K V I S Y S A Q V L L Q E M I T D P N T M V L N
1854 CTATGTCAGGCTGTATCAAGCTCAGAACCAAACTCGCCCTGCTGTTTGAAGTACCAAGCAAGATTAAGAAAGCGGGCAAGCTCGTCTCTCAACTCTCTGGAT
618) Y D E V A T C Y G A O N O P A P V V V K L P T K N E E A R K V V L Y N B L D
1963 TACCACAAAATCGGTGCTGCTGCTCAATGTTATGCTGCTACCCCAAGCTGGTGTGATGTCAGAAAGCAAAAGCTGCTTCTCATGCAAAACAGTCCGATCTGGTCAGATT
655) Y D R T G V V R L I V T S P D V V V M S E N K N V P S Q T S P I W S D
2072 CGAGCGAGATCCGACAGACAGTTCGAATGCTTTCTTTCAATGTTTCCCGCATAGCACTCGGCTGTCAAGATATGGGAAGCAACGAGCTAGCAGACACAC
691) S T E I R T D Q F E L V F L S T V P A I G L A V Y K I W E D N D V A D T
2183 GCATCACTGTTAAAGTTTATCAACCCGAGATGGGTTTTCGAACCAAGCCGCAATGTTTGTACTCGAGCTTGAGGATACCGGGCAAGTTTACCATCATCAATGAC
727) H S T V K F I N P R V G F S K R T R B K F L D V E D S G E F T I M N D
2290 CAATGATTTGGCCATTTCTCTGGCAAAAGCGGATGCTCGAGTCAGTCACTGCTGCTGACACAGCTTAAAGCCAGCTCGGAATTCGAATTCCTGCTCTTACTTCTC
764) Q L V A H F S G O N G M L Q E V T T R D N V K T Q L O I E F V A T S
2399 GTAATAGAAAGACAGAGCGCGGCTTACTTGTCTGCTGCTGCGACAGCACAACCCATGTAAACAGAAATCCCAACCGCTTATGTAAGGATCATCAGGGCTCCAGT
800) R M K K D K S G A Y L F L P A G P A Q P H V T E S H R P L V R I R G P V
2508 GATGTCCAAGCTGCTGATTTCTACTACGAAAGCTTCGCAATAAGCTTACCTTATACACCGTACTCGTGCGAGCGCCAGCTCTTACGGCTCCAGCTCTCTAACCAAGCTC
826) M S T V N H V L L P N V L H K V T L Y T G T A G A T O S L G V H V B N D V
2617 CAGCTTAGAATCGGTACGACAAACAAAGACTCATGATGAAGTTAAACAGCAAGTTTATCGGAAGCAAAATCTTTACGGAATTTAAAGCGTTTCAAAATTCACCCC
873) D V R T G Y D N K E L S M R L N S E V L S G S K F F T D L N G Q I O P
2726 CAACCACTGATTTCAATCTGCCATCAACGAAACTCTTACCAATACCAAGTGGGTTTCATCAAGACGAAAAATCAAGATTAACTTGATGACCGCCCAACCT
909) R T T Y S K L P L Q A N F Y P I T M A F I Q D E K S R L T L M T A Q P L
2835 CGGTCTGCTCTCACTCAAGTCAGTCAACTTCAGGCTGGTTTGGATCGCTGTTTAAATCGACAGCAACAACAGGGGCTGGGTCAAGCTTGAGAGATTAATTTACCAAT
945) G V A S I K S G O L E V L D R R L M Q D D N R G V G Q G V K D N L P T
2944 CCTGAGAGTTTCTGATCATGCTCGAAAGATGCAACCTCATTCGACGCAAGAAAGCAAAATCTGACGCAAGCTCGGATTCATCATGCTGCTGATCATGTCATCAT
982) P E S F V I M L E R W T A I A A K E S B A K L A Y P E M A V Y O S
3053 GCGAATTCCTACACCCCAATGCTTCAATTCGCTTAAATCGCCCGCTACATTTGAAACAGAAATTAACGCTGCTGACACAGCTTTACCATCCCACTGCAAGCTGTTAAA
1018) W E L L H P I R P M S V N G P V H L K E D Y A C B R L B Q P L P C D V M V L N
3162 CTTCGGCGCAATTCATTTAAAGATTCAGTTCGCCCTACCCGCAATCGGCTGCTCTTACACACAGTTCGGGCGCAATGCTCTTTCGACGCGCAAGATTAATTCAC
1054) L R A I H S K D A V A P T D O S A L L L H T V G R E C S L D A D K Y F H
3271 CCAAGCTGCTCATGCAACCGGCTCGACAAAATTCGCTATCAGGATTCGAGCTGTTTACTAACTTCGCGATCGGCAAGCTCGCTGCTTCAACAAACAGCGGCTGCT
1091) P T C L M H G V E K L A I T I S L T F T H S G M R K T S L S L O H D G B
3240 TCTCGACCAACAGCCGCTTACAGCTTCCCCAATGGAGATACAGCTTACAAATATGATCATGACTAA
1127) L L D N Q G G I T V S P M E I O A Y K I V L T

1 ATCTGCGCAATACGTCGGCGGTCGCTTGGTAATTGCTCGCGGTCGCTGCTGTTTCTCAGCGCTGACATAATCTCAATTTTGGCGCGCGCGGAGCGCACTCCGA
2 MLRI RRRFALVICSGLLVFLSLYIILNFAPAATAQ
3 TAAAGCCCAATATGAGAACATGAGCAACGTCATGCTGGAATTCGTCAGCAGACGGGAGGAGTCCGGAATCTCAGCGCGGCTGCTGCCAAAATC
4 KP NYENIENKLEHLENGLOENGHEEMRLRLAKTS
5 CAATCGGACGATCCAAATAGACCTCCACTAAAGTGGCTGCTCCCGAGGCGAGCGAATGCAAGATGGTCCAGAGCTGCCCAATCTGCATGTACACAGTGTG
6 NRDDPIRPPPLKVARSPRPGQCDGVGVDPVNVVDVOML
7 GAGCTATACGATCGCATGCTCTCAAGCAGATAGATGGAGCGGTGCGAAACAGCGGTGCAACATTAAGTACCATCTCAAGCTACAAAGCCCAATCAAAATCAAAAG
8 ELYDRMSFKDIDGGVWKQGWNIKYDPLKYNAMHKKL
9 TCTCTGTGTGCGGCACTCGCAACAGCTCTGCATGGATTCAGAGCTTTCAGGAATATACACGACGACCAAGACATCTCTGCAATGCACTACGCCATCTGCA
10 VFVVPVPHSNNDPCPGWGTQTFEEYYQHDTKMLSLNHLRLH
11 CGCAATCTCCGAGATCAAGTTCTCTGCGCGGAATCTCTACTTCTGCTGCTTCTATCAGATTTGGGAGACACAAAAGCTGCGAGTCAAGTCAATGTAAAGAA
12 DNPENKFIWAEISYFARFYHDLGKLNKQMSIVKN
13 CGACATCTCGAATTTCTGACTCGAGCATGGCTGATCCCGGACGAGGCACTCTCACTCGGCAAGCACTCTGCTGCACTGACCGAAGCGCAAGCTGTTGAGCAAT
14 GLEFVTGGWMPDEANSHWRNLVLLQLTETEGOTWLKQ
15 TCATCAATCTCACCCACTGCTTCTCGGCACTGATCTCTGCGACACATCCCATATGCGGTACTTTCGACAGAGTGGTTTCAAGATATGCTTATCCAAAG
16 FMNVVPTASWAIIDPF:FGHSPTMPYIILQKSGFKMHLIQ
17 GAGCAGATTTCCGTTAAGAACGATGCGCCACACGACGAGCTGACTCTGCTGCGCGAGATCTGGCAGCAACAAAGGGGACAGAGCTCTTACCACCATCATG
18 THYSVKKELADQOROLEFLRWROIWDNKGDTALFTMM
19 CCTCTTACTGTAACCATCTCTCATACCTGTGGTCAGATCTCAAGGTTTCTGCTGAGTTCGATTTCAAAAGCAATGGCTCTCTCGGTTGAGTTGCTCATGGAAG
20 PFFSYDIPHTCGPDPKVCQDFKRMGSFGLSCFWK
21 TCGCGCGGCTACAATCAGTCACTCAAAATGTGGCAGCAGCTCAGATCTGCTGGTTCATCAGTGGAGCAAGGCGGCAAGCTGATCGCAAAAGCTGCTGCTGATTCC
22 VPPRTISDNNVAARSDDLVDQWKKAELVYRTNVLIP
23 GTTGGGTGACACTTCCGCTCAAGCAACAAACAGTGGGATGTGACGCGCTGAACTACAAAGGCTGTTGGAACACATCAACAGCGAGCGGCTCAATGTCCAG
24 LGDDFRFKONTENDVORVNERLFEHINSQAHFNVQ
25 GCGGCACTGCGCACACTGCGAGCAATACTTTCATGCACTGCGACAGGCGGAGGCGGCGACAGCGCACTTCCCACTAAGCGGCTGACTTTTCACATAGCGGCACT
26 AOFGLQEYFADVHWQAERAGAEFTLSODFFTYAD
27 GATCGGATAACTATTGGAGTGCTACTACACATCCCGCGGATCATAGAGCGGATGAGCGGCTCTGATGCACTATGACGTGCGACAGCAATGCTTTCGCGCTGCCA
28 RSDNYWSGYTSPRYNKHMRDRLVMHYVRAAEML'SAWH
29 CTCTCGGAGCGGTATGCGCGCGCATGAGCAAGCTCTGCGGACGCGCCGACAGGAGCTCTATTGTCAGGACCAAGAGCGGTATAAGTGGCAGCAAAAGCGCAGTA
30 SWDGMARIEERLEQARRELSLFQHHGDTGTAKTTHV
31 GTCGTGACACGAGCAACCTGTCAGGAAGCTTAAAGCGCTGTCAAAATGTAAGCAACAGTGGCTTACGAGTTGCTGACAAAGCGCTCCATCTACAGTCCGAGCT
32 VVDYEQRMQEAALKCOMVMOOSVYRLTKPSIYSYD
33 TCAGTTTCTCTGATTTACCTCGGACGACTCCGCTGCGCGAGGATCTGGTGTGGAGCAGCTCAACACCAATAATCTGGGCGAGGATATCTGCTTCCAGCACTV
34 FSYFTLDDSRWPGSGVEDSRTTILGLGEDILPSKHV
35 GGTGATGCAAAACACCTCGCCCACTCGGCGAGCAGCTGGTGCATTTTATGATTCAGCTCGGTTTGAAGGCTTACCGACTTGGCAAAACAAATCCGCTCGAGGCTCAG
36 VMHNTLPHWRQELVDFYVSSPFVSVTDLANNPVEAQ
37 GTGTCGCGGCTGCGAGCTGGCAGCAGCAGCACTACAAAGACTATCCACCCACAAGGCTCCACACCAAGTACCGCATCTTCAAGCTCGGCTCGGCGGCAATG
38 VSPVWSWHNDTLKTIHPQSGSTKYRIIFKARVPPM
39 GCTTGGCGCACTACGTTTAAACATCTCGGATCTCAAGCGAGGACCATCTGATGATGATCAATCTCTGCTCGGTAAGAAACCGCACTGCTTACCATGCGGCAATA
40 GLATYGLVTLTSDKPEHTSYASHNLLLRKNPTLSLPLCQOY
41 TCGGAGATGTGAATTTGGCGATCTCGACAGATCTCATTCGCGGTTGTAACCGCACACCTTGGCTTTTCGCAAGCGGCTGCTTAACTGCTTCACTTACT
42 PEDVKFGDPRLESLRVNGFTLAFSEGOQLLKSIQLT
43 CAGGATAGCCACATGTACCGGTGCACTCAAGTTCTCAAGTATCGGTTGATGCGATGGGATAGATCGGTCCTATCTGTTCTCGGCAATGGACCACTTCCG
44 QDSPHVPVHFVKFLKYGVRS·HGDRS·HGLFLPNPGAS
45 CAGTGCAGCTTGGCCGAGCTGCTGCTGACTAAGGCAAACTCGAGTCTGCTGTCGAGCTGGGACTTCCAGGCTGCTGCAACCAAGCAATCCGCGGCTGCTG
46 PVELGQPVVVLTKGKLEBSVSGVGLPSVHVQTIMRQGA
47 ACCTGAGATTCGAATCTGCTGGATATAGCTCTACTGGACAAACAGCAATCTGATGCGCTTCCGACAGCAATTCGACAGCGGCGATATCTTACAGCGATCTCAAT
48 PEIRNLVDIGSLDNTIEVMRLETHIDSGDIFYTDLN
49 GATTCGAATTTATCAAGAGCGGCGCTTGGACAAATACCTTTCAGGCGCACTATTATCCATACCTTCTGCTATCTTCATTGAGCATGCCAATACCGCACTCACTE
50 GLOFATIKRRRLDKLPLQANYPIPSGMFIENDATRLT
51 TCTCTCGGCTCAACGCTCGGTCGATCTTCTGCGCTCGGCGAGCTAGAGATTATGCAACATCTGCTGCTCGGCGGCTGATGACGCGGCTGGGACAGGCTG
52 LLTGGQPLGSSLASGELEIMODRLASDDERGLQDQV
53 TTTGGACAAAGCGGCTGCTGCATATTTATCGGTCGCTGCGAGAGGTAAACAACTCTGCTGCGACCTCAAGCTCATCTCGGCGCTATTGCAAGTCCGCGCA
54 LDNKPVLHLYRLVLEKYVNNVCRPSKHLHPAGYLTBA
55 CAAAGCAATCCGAGCTCACTGCTGATCTCACTGCAAGTTATATTCCTGAAATGAGTGGATCGGCGACAGGCGCAATTTGCTGCGCATCATCTTCCGCTCGTG
56 HKASQSLDPLDKXIFAEENEWICAGQGGFGGDHPSAR
57 AGCATCTCATGTCTGCTGCTGATCAGACGCTTAAACAGAGCTCGGCGAAACAGGCAAGTACGCTGCTGACGCAACCAATCTGATGCAATGCGGCACTGCA
58 EDLDVSVMRRLTKSASAKTORVOYVLHRTNLMQCGTPE
59 CGACATACACAGAGCTGATCTGTCACACTACTGCGCAATGTGCGGAGATCGGAGCGACGAGCGCTGACTTCTGCGAAGATTCGAGGACTTGCATGCGATGCTG
60 EHTQKLDVCHLLPNVARGERTTLFLONLENDGMV
61 GCGCGCGAAGTCTCGCCCATGGAAACCGCGCTTATGTGAGCAGCACTCAAGCTCA
62 APEVCYPMETAAYVSSNRS

40/47

FIG. 29

Human mannosidase II (U31520)

```

1 ATGAAGTTAAGCCGTCAGTTCAACGCTGTCGGGACTCCGATCTTCTGTGCTGATTCTCTCGCTCTACCTGATGCTGGACCGGGCTCACTTAGACTACCCACGAAAC
2 M K L S R Q F T V F G S A I F C V V I F S L Y L M L D R G H L D Y P R N
110 CCGCCGCGGAGGCTCTCTCCCTCAGCCGCGAGTCTCAATGTGCAAGAAAAATAGACCATTTGGAGCGTTTGTAGCTCAGAAATATGAGATCATCTCAAAATATTAG
120 P R R E G S F P Q G G O L S M L O E K I D M L E R L L A E N N E I I S N I R
219 AGACTCAGTCATCAATTTGAGTCAGTCTGTGGAGGATGCTCCGAAAGTTTCAACAAAGCAATTTCAAGCAAGGCTGCTGGCTCAATCTTCTGCCCCACAAATATCCCTC
73 D S V I N L S E S V E D G P K S S Q S N F S O G A G S H L L P S Q L S L
320 TCAGTCTGACACTGACGATCTCTGTTGCTTCAAAAGTCAAGCTCACAATTCAGATGTCGAGATGTTGGATGTTTACAGTCTAAATTTCTTTGACAATCCGACATGGTG
120 S V D T A D C L F A S Q S G S H N S D V Q M L D V Y S L I S F D N P D G
437 CAGTTTGGAAAGCAAGCATTTGACATTACTTATGAATCTAATCAATGGGACACTGAAACCCCTTCAAGTCTTGTGCTGCTCATTCCCATAACGACCCAGGTTGCTTGA
146 G V W K Q G F D I T Y E S N E W D T E P L O V F V V P H S H N D P G W L K
546 GACTTCAATGACTCTTACAGACAAAGCTCAGTATATTTTAAATCAATGGTCTTAAAGCTGAAAGAGAGCTCAGGAGGAACTTTATTTGCTCTGAGATCTCTTAC
182 T F N D Y F R D K T Q Y I F N N M V L K L K E D S R R K F I W S E I S Y
655 CTTTCAAACTGGTGGGATATTAGATATTCAAGAGAACGATGCTGTAAAGCTTAAATAGAAAATGGTCACTTCAAAATGTCACAGCTGGCTGGCTTATGGCTGATC
219 L S K W W D I I D I O K K D A V K S L I E N G Q L E I V T G G W Y M P D
764 AAGCTACTCCACATTATTTGCTTAAATGATCAACTAATGAAGGACATCAAGTGGCTGCAAAAATATATAGGACTGAAACCTCGGCTCGGCTATTCATCCCT
255 E A T P H Y F A L I D O L I E G H O W L E N N I G V K P R S G W A I D P F
873 TGGACACTCACCACAAATGGCTTATCTTAAACCTGCTGGACTTCTCACATGCTTATCCAGACAGTTCATTATGCACTTAAAAACACTTTCGACTGCAATAAAAA
291 G H S P T M A Y L L N R A G L S H M L I O R V H Y A V K K H A L N K T
982 TTGGAGTTTTTCGAGACAGAAATGGGATCTGGGATCTGTCACAGATATTTATGCCACATGATGCCCTTCTACAGCTATGACATCCCTCAGACTTGTCCACTCATC
320 L E F F W R O N W D L G S V T D I L C H M M P P F Y S Y D I P H T C G P D
1092 CTAAAAATATGCTGCCAGTTGATTTTAAACCTCTCTCGAGGACAGTTTGGTGTCTCTCGGAGTCCCCCAAGCAAAATACATCTGCAAAATGTCAAAAGCAGGCT
364 P K I C C O F D F K R L P G G R F G C P W G V P P E T I H P G N V Q S R A
1200 TCGGATGCTACTGATCACTACCGAAAGCAAGTCAAGCTTTTTCGAAACAAAGTCTCTCTGGCTCCACTAGCAGATGATTTCCGCTACTGTGAAACACCCAAATGGAT
400 R M L L D Q Y R K K S K L F R T K V L L A P L G D D F R Y C E Y T E W D
1309 TTACAGTTTAAAGAAATATCAGCAGCTTTTGAATATGAATTCCTCAGTCCAAGTTTAAAGTAAAGATAAGTTCGAACTTTATCAGATTTTTCATGCCCTGCCAFA
427 L O F K N Y Q O L F D Y M N S O S K F K V K I O F G T L S D F F D A L D
1438 AAGCAGATGAAATCAGAGAGACAAAGGCAATCATGTTCCCTGTTTAAAGTGACATTTTCACTTATGCCGATCGAGATGATCATTACTGGAGTGGCTATTTTAC
473 K A D E T O R D K G O S M F P V L S G D F F T Y A D R D D H Y W S G Y F T
1527 ATCCAGACCTTTTACAAACGAATCGACAGATCATGCAATCTCATTTAAAGGCTGCTGAAATTTCTTACTATTTCCGCTCGACAGCTCAGACAAATACAAAGATAAAT
503 S R P F Y K R M D R I M E S H L R A A E I L Y F A L R Q A H K Y K I N
1636 AAATTTCTCTCATCATCACTTTACACCGCACTCAGCAAGCCAGAGGAATTTGGAGCTGTTTCAACATCATGATGCTATCAGCAGAACTCCAAAGCACTGGCTGGTTC
546 K F L S S S L Y T A L T E A R R N L O L F Q H H D A I T G T A K D W V V
1745 TGGATTAATGCTACAGACTTTTTCATTCCTTAAATGCTTTGGAGAAAGATAATGGAAATTTCTGATTTCTTATTTGGGAAGCAAACTCAGATACGACTCTTACTC
582 V D Y G T R L F H S L M V L E K I I G N S A F L L I G K D K L T Y D S Y S
1854 TCGGATGCTTCTCTCGAGATCGATTTCAAAACAAAAATCACAAGATTTCTCTGCCCAAAAAAATATATATAGGCTGAGTCCGAGCCAAAGCTACTTGTGCTATAAAT
618 P D T F L E M D L K O K S Q D S L P Q K N I I R L S A E P R Y L V V Y N
1963 CTTTGAACCAAGACCCCAATCTCGTGGCTCTCAGTCTATGTGAGTCTCCCGCAGTCCCAAGTGTCTCTGCTTACGAAACCTGTGGAGTCAAGTCAAGCCAGCTTT
655 P L E Q D R I S L V S V Y S P T V Q V F S A S B G K P V E V Q S A V
2072 CGGATACAGCAAAATCTATTTTCAAGACAGCTATGAGATCTCTTTTCCAGCACATATATCCGCTATTGGCACTCAAACTGTATAAGATTTTGCATCAGCAAGTTCAAA
692 W D T A N T I S E T A Y E I S F R A H I P P L G L K V Y K I L E S A S N
2181 TTCACTATTTAGCTGATTATGCTCTGTATAGAAATAAAGTAAAGATACCGGAATTTTCAACATAAAGAAATATGATAAATCTGAAGCAAGCTTAAACACTAGCAACTCC
727 S H L A D Y V L Y K N K V E D S G I F T I K N M I N T E O G I T L E N S
2290 TTTGTTTACTTCCGTTTCATCAAACTCGCACTATGAAGCAAAATGATCACTAAAGAACATCGTAAACACCATCAAGTAAATGTCGCAATTTTCATGCTATGCAACCAAA
764 F V L L R F D O T G L M K Q M M T K E D G K H H E V N V Q F S W Y O T T
2399 TTAAGACAGACAAAAGTGGTGGCTACCTCTCTTACCTGATGGTAATGCCAAGGCTTATGTTTACACAAACACCGCCCTTTGTGAGAGTGACACATGGAAGCATTTATTC
800 I K R D K S G A Y L F L P D G N A K P Y V Y T T P P F V R V T H Q R I Y S
2508 GGAAGTGACTTGTCTTTTTCACCATGTTACTCTATAGACTCCGACTATACACATACAGCGGAATAGAACGACACTGTGGAAGTTTCCAATATTGTGGACATCCGAAAA
816 E V T C F F D O H V T H R V R L Y H I Q G I E G Q S V E V S N I V D I R K
2617 GTATATACCGTGCAGATGCAATGAAATTTCTTGTATATAAAGCCAAATAGATTTTATCTGACCTAAATCGGTACCGATCAAGCTAGAACTCAGACTCAGCA
872 V Y N R E I A M K I S S D I K S Q N R F Y T D L N G Y Q I Q P R M T L S
2726 AATGCTCTTCAAGCAAAATGCTATCCCATGACCAAAATGGCTTATATCCAGGATGCCAAACATCGTTTGACACTGCTCTCTGCTCAGTCAATAGCGGTTTCCGATTT
509 K L P L O A N V Y P M T T M A Y I O D A K H R L T L L S A O S L Q V S B L
2835 CAATAGTGGTCAGATGAACTTATCATGATCGAAGCACTCATGCAAGATGATAATCTGCGCTTGAGCAAGGATCCAGGATAAACAGATTACAGCTAATCTATTTCGA
945 N S G Q I E V I M D R R L M O D D N R O L E Q Q I O D N K I T A N L F R
2944 ATACTACTAGAAAAAGAACTGCTGTAATACGGAAGAAAGAAAGAACTCGGTCACTTATCTTCTCTCTTACGACATAAATCTTCTCTCATGAATCACTCAGTCA
982 I L L E K R S A V N T E E E K K S V S Y P S L L S H I T S S L M N H P V
3053 TTCAAATGGCAAAATGCTCTCTCACTACCTCTGAGCTGCAAGGTAATCTCTCAATTAAGTCACTCTTGGCTTGTGACATCTCTGCTTAAATTTGAGAAACAAAT
1018 I P M A M K F S S P T L E L O G E F S F L O S S L P C D I H L V N L R T I
3162 ACAGTCAAGGTCGGCAATGGGCACTCCAATGAGGAGGCTTATCTCTCACAGAAAGGTTGATTGTGGTCTCTAGCAAGCCACAGGCTGTTTGTGTTACT
1054 O S K V G N G H S N E A L I L H R K G F D C R F S S K G T G L F C S T
3271 ACTCAGGCAAGATATTGCTACAGAACTTTTAAACAACTTATTGTCGAAAGCTCAGACCTTCATCACTATCTTGTATGCAATCAGCTCCCGGCACTCAGAAATATAA
1091 T O G K I L V O K L N K F I S S E L T P S S L S L M H S P P Q T O N I
3380 CTCAGATCAACTTCACTCCAATGGAATCAGCAGATCCGAATCCAGTTGAGGTGA
1127 S E I N L S P M E I B T F R I Q L R

```

Mouse mannosidase II (X61172)

[illegible]

Rat mannosidase II (XM_218816)

[illegible]

Human mannosidase IIx (D55649)

[illegible]

Insect cell mannosidase III (AF005034)

[illegible]

Human lysosomal mannosidase II (NM_000528)

[illegible]

Human cytoplasmic mannosidase II (NM_006715)

[illegible]

[illegible]

Diagram illustrating the biosynthesis of the *Asn* core structure:

The diagram shows the central role of *Asn* in the biosynthesis of various branched structures. The central node is labeled *Asn*. Three arrows, each labeled *ManIIx*, point from the central *Asn* node to three different branched structures. A fourth arrow points from the central *Asn* node to a fourth branched structure. A final arrow, labeled *ManI, GnTs, GalTs, STs* and *nucleotide substrates transporters*, points from the fourth branched structure to the right.